



Hypertension and  
Hypertensive Disease

LONDON  
HUMPHREY MILFORD  
OXFORD UNIVERSITY PRESS

# Hypertension

AND

# Hypertensive Disease

WILLIAM GOLDRING, M.D.

*Associate Professor of Medicine New York University College of Medicine Chief Nephritis and Hypertension Clinic New York University Clinic Physician to the Adult Cardiac Clinic and Associate Visiting Physician Third (New York University) Medical Division Bellevue Hospital Visiting Physician Goldwater Memorial Hospital*


HERBERT CHASIS, M.D.

*Assistant Professor of Medicine New York University College of Medicine Associate Chief Nephritis and Hypertension Clinic New York University Clinic Physician to the Adult Cardiac Clinic and Assistant Visiting Physician Third (New York University) Medical Division Bellevue Hospital Cardiologist to the French Hospital*

NEW YORK  
The Commonwealth Fund

1944

COPYRIGHT, 1944, BY  
THE COMMONWEALTH FUND  
FIRST PRINTING, SEPTEMBER 1944  
SECOND PRINTING, JANUARY 1945  
THIRD PRINTING, AUGUST 1945  
FOURTH PRINTING, DECEMBER 1947



PUBLISHED BY THE COMMONWEALTH FUND  
41 EAST 57TH STREET, NEW YORK 22 N Y

---

PRINTED IN THE UNITED STATES OF AMERICA  
BY E L HILDRETH & COMPANY INC

*Dedicated to*  
**HOMER W SMITH**



## Foreword

THE studies presented in this volume, and many others touched upon only by reference represent fifteen years of collaboration between the Department of Medicine and the Department of Physiology of New York University College of Medicine. This collaboration has been the product of a broader plan whereby in successive years various junior members of the medical faculty have returned to physiology for a period of a year or more, during which time they have usually assumed the routine duties of instruction as well as the privileges of investigation. Facilities have been made available for certain of these men on their return to the Department of Medicine to carry on investigative work along the lines of their chief clinical interests and as certain phases of this investigative work have assumed increasing clinical importance, special effort has been made to aid it by supervision and criticism and above all by integration in relation to normal physiology.

The impetus to this cooperative program was afforded by the late John Wyckoff. As Associate Professor of Medicine then as full Professor and finally as Dean Dr. Wyckoff ever defended the thesis that those who would reap the maximal benefits from their medical training should return at some time during this training or shortly thereafter to one or more of the preclinical departments for additional experience.

If this policy has been profitable to medicine it has been doubly profitable to physiology for not one of the men who has performed this excursus has failed to bring to the preclinical department his share of practical experience and dynamic interpretation and, above all, of the vitality that springs from the responsibility for the care of sick human beings.

William Goldring and Herbert Chasis are two of the men who have brought their clinical experience to physiology and thus enriched this subject and whom physiology in turn has been able to help. For fifteen years they have given generously of their time to investigations on the physiology of the normal and the diseased kidney and it is a pleasure to acknowledge this indebtedness and to



acknowledge with them that the opportunities for these collaborative studies stem from the foresight of our mutual friend, John Wyckoff. It is largely because of the foundations which he laid that the authors are able to write this volume on hypertension in man from data obtained in man.

HOMER W. SMITH

*April 1944*

## Preface

IN THE preparation of this book we were faced with the choice between a full review complete with citations and a concise presentation of our concepts of hypertension and hypertensive disease. We chose the latter and the bulk of the material comprising this book is derived from our own clinical and experimental observations. We have presented as facts only those observations which our personal experience has led us to accept as established. Where current knowledge was inadequate to permit us to reach a definite conclusion, we subjected all pertinent evidence to a critical analysis and arrived at a tentative opinion. We caution the reader to recognize that such a presentation must contain some dogmatism. We are fully aware of the hazard involved in a discussion of hypertensive disease in man at a time when many questions remain unanswered.

Accumulation of the clinical material has been facilitated during the past fifteen years by an arrangement that permitted continuous observation of hypertensive patients in the Nephritis and Hypertension Clinic of the New York University Clinic and in the Adult Cardiac Clinic of Bellevue Hospital with periodic admission of these patients to the wards of the Third (New York University) Medical Division of Bellevue Hospital. Patients with hypertensive complications of pregnancy observed on the Obstetrical and Gynecological Service of Bellevue Hospital were referred to the Nephritis and Hypertension Clinic for follow up observation. In many instances it was possible to assess clinical appraisal at necropsy.

New renal functional and hemodynamic methods applicable to man were developed in this clinic. They yielded data of sufficient importance to throw new light on some aspects of hypertensive disease. The method of measuring renal blood flow in man permitted us to examine the question whether or not renal ischemia was the primary event in human hypertension and to assess the therapeutic value of certain surgical procedures currently used in the treatment of hypertensive disease. Methods for the measurement of the rate of glomerular filtration and for the measurement of maximal tubular excretory

capacity have made it possible to examine renal functions in a manner not possible heretofore. The use of the right heart catheterization method in estimating cardiac output combined with direct arterial blood pressure determination permitted us to measure over all peripheral resistance and to examine some of the fundamental hemodynamic alterations in hypertensive disease in man.

In the past decade there has been a vast amount of investigation in hypertension, and many of the conclusions derived from animal experiments have been arbitrarily transferred to man. The results of the application of new methods indicated to us that such transference in great part is not justified and strengthened our conviction that the hypertension experimentally induced in animals is fundamentally different in genesis from the hypertension that occurs spontaneously in man. For this reason we present only those conclusions that are based upon or confirmed by the study of the disease in man.

We stress the distinction between hypertension and hypertensive disease because it is important to distinguish between elevation of the blood pressure as a reversible hemodynamic alteration and hypertensive disease as an irreversible, progressive process.

We have been impressed with the relative benignity of increased blood pressure in the large majority of patients, and with the facts that increased blood pressure *per se* does not produce subjective symptoms and that the actual level of blood pressure does not necessarily reflect the severity of the disease. However, subjective symptoms and the phobia of high blood pressure are often created in patients when they are informed of the presence of hypertension, particularly when emphasis is placed upon the level of the blood pressure. While such patients require constant observation and advice, it is important for their well being that the significance of the level of the blood pressure be minimized rather than emphasized.

Our principal purpose in the clinical chapter is to present the life history of hypertensive disease. The clinical data, therefore, are presented broadly with little reference to detail. Our experience with the clinical manifestations of hypertensive disease does not differ from the general experience, and detailed repetition would serve no purpose.

The structural changes in hypertensive disease are referred to only

in those instances where they are necessary to establish a basis for discussion of alterations in hemodynamic and renal functions to evaluate the role of the kidney in the genesis of human hypertension, and to arrive at conclusions bearing on the rationale of certain forms of therapy. We have not included a discussion of the details of gross anatomical and histopathological changes since they are adequately presented by others.

It seemed desirable to present the renal functional material in two sections. The body of the book contains a composite description of the functional evolution of hypertensive disease, a detailed presentation and discussion of the quantitative observations in individual patients on which our conclusions were based is given in Appendix G. The appendix contains also detailed descriptions of the methods employed and the manner of their application in the study of the functional aspects of hypertensive disease as well as discussion of the limitations of these measurements.

We acknowledge with profound respect our debt to Doctor John Henry Wyckoff whose help and encouragement made possible the beginnings of this task.

We have been particularly fortunate in our association with Doctor Homer W. Smith, Professor of Physiology at New York University College of Medicine. The period of preliminary training with him and his constant guidance made this book possible. Collaboration between the Departments of Physiology and Medicine led to the application in hypertensive patients of the new measurements of renal function conceived by Doctor Smith. It further permitted us to interpret problems in hypertensive disease on the basis of functional alterations, a point of view which largely characterizes this book.

We are grateful to Doctors Hilmer A. Ranges, Jules Redish, and Catherine Welsh for their constant and invaluable assistance in the collection of data. Their close association with us in the clinic and on the wards and their aid in the analysis of the clinical and functional material contributed in large measure to the completion of this study.

We are indebted for assistance in the collection of the clinical data during various periods of this study to Doctors Albert Erdmann, Stanley E. Bradley, Henry D. Lauson, and James L. Whittenberger.

who served as Commonwealth Fund Fellows in the Department of Physiology, for technical assistance to Lucy Aliminosa, Martha Barrett, Betty Crawford, Nancy Eggleston, Norma Finkelstein, Helen Kiegher, Helen Claire Lawler, Anna Lublin, Frances E Marx, Anna Rosenthal, Willie W Smith, Katherine Tilson, and Christine Waples, for nursing assistance to Josephine Hearn, Ann Rivoire, and Agatha Evaskitis, for effective follow up of patients in the home to Miriam Cragin, for secretarial assistance to Winifred Gosline

We are indebted to the following members of the faculty of the New York University College of Medicine for assistance with special sections Doctors Clarence E de la Chapelle, Edward B Gresser, Morris Herman, Bernard Kaplan, Emery A Rovenstine, and Irwin Wellen, and for the surgical procedures involved in this study to Doctors Arthur M Wright, Hippolyte M Wertheim, John Mulholland, Samuel Standard, Howard Jeck, and Robert Hotchkiss

We are indebted to Doctors André Cournand, Stanley E Bradley, and Henry Lauson for permission to use unpublished data and for their help with the chapter on hemodynamics

Parts of the text and a number of the tables and figures appeared originally in *The Journal of Clinical Investigation*, *The Archives of Internal Medicine*, *The American Journal of Physiology*, and *The American Journal of Obstetrics and Gynecology* These journals have generously given us permission to include the material in this book

It is also a pleasure to acknowledge the generous support over the last five years of the Commonwealth Fund, whose interest has made possible a much more comprehensive program of investigation than could otherwise have been carried on

W G  
H C

April 1944

# Contents

I	DEFINITION OF HYPERTENSION	1
	Clinical significance of the level of blood pressure in hypertension	2
	Classification of hypertension	5
	Systolic hypertension	6
	Range of normal blood pressure	8
	Methods of measuring blood pressure	9
	References	13
II	CLINICAL ASPECTS OF HYPERTENSIVE DISEASE	14
	Hypertensive disease as a cause of death	14
	Concept of a prehypertensive phase	14
	The kidneys	18
	The heart	23
	The retinae	28
	The brain	29
	Hypertension in pregnancy	32
	References	36
III	SYSTEMIC HEMODYNAMIC ALTERATIONS IN HYPERTENSION	39
	Cardiac output	40
	Mean arterial blood pressure	42
	Effective peripheral resistance	43
	References	51
IV	RENAL FUNCTIONAL AND RENAL HEMODYNAMIC ALTERATIONS IN HYPERTENSION	53
	Rate of glomerular filtration	55
	Effective renal blood flow	59
	Filtration fraction	61
	Maximal tubular excretory capacity	65
	Maximal tubular reabsorptive capacity	67
	Excretion of urea	69




<i>Contents</i>	<i>xv</i>
<i>Clinical Implications</i>	200
VII SOME MECHANISMS IN ATHEROSCLEROSIS	203
Introduction	203
Pathogenetic Factors	205
Some Common Denominators of Hypertension and Atherosclerosis	208
The Role of Fat and Other Lipids	211
Clinical Implications	236
VIII PRACTICAL METHODS FOR MODERN THERAPY OF HY PERTENSION	238
Introduction	238
Evaluation of Patient for Drug Therapy	239
Evaluation of Generalized Vasospasm in Hyper tensive States	245
Specific Use of Drugs	248
Results Expected	268
IX A PRELIMINARY APPROACH TO THE TREATMENT OF ATHEROSCLEROSIS	277
Method	278
Results Expected	281
X SUMMARY AND INTERPRETATIONS	284
<i>Bibliography</i>	297
<i>Index</i>	329



Specific Effector Substances	68
Anatomical Causes of Renal Ischemia	78
Drugs Acting on Nephrogenic Mechanisms	82
Hydralazine and Other Chelating Agents	83
The Effect of Antihypertensive Agents on Nephrogenic Effector Substances	109
Clinical Implications	110
<b>V FACTORS INFLUENCING THE CONVERSION OF NEUROGENIC TO NEPHROGENIC HYPERTENSION</b>	116
The Transition from Intermittent to Permanent Vasospasm	116
Theory of Habitual Repetitive Stimuli	117
Theory of Depletion of Vascular Substances	117
Intrarenal Enzymatic Mechanisms	119
Clinical Implications	130
Adrenocortical Mechanisms	132
Clinical Implications	139
<b>VI TRACE METALS AND CARDIOVASCULAR DISEASE</b>	141
Introduction	141
Metals Concerned in Metalloenzymes	142
Possible Competitions Between Abnormal and Essential Trace Metals	150
Drugs as Chelating Agents	155
Essential Trace Metals in Man	166
Abnormal Trace Metals in Man	176
Metals of Possible Biological Significance in the First Transitional Group	185
Metals With Possible Harmful Effects	192

## **MECHANISMS OF HYPERTENSION**



## THE COMPLEX OF FACTORS IN THE HUMAN DISEASE

### INTRODUCTION

**A**RTERIAL hypertension is only a sign of disturbed hemodynamics. At the basis of this disturbance is generalized vasospasm. Without vasospasm the diastolic blood pressure would not rise significantly (1)

Generalized vasospasm is a condition common to a number of hemodynamic disturbances. Whenever effective blood flow through vital organs is reduced a series of reactions is set in motion aimed at restoring flow through those organs at the expense of other less essential ones. Thus vasospasm follows hemorrhage precedes and accompanies shock, severe coronary occlusion, heart failure and other states of circulatory embarrassment. It even accompanies the upright position to a small degree. In these conditions blood pressure is normal or low and effective circulating blood volume and cardiac output low. the vasospasm accompanying the reduction in circulation. Only in late irreversible stages of shock is vasospasm replaced by vasodilatation or its capillary counterparts. If the peripheral circulatory state of vasospasm remained constant and effective circulating blood volume or cardiac output were returned to normal hypertension would ensue.

Therefore when generalized vasospasm occurs in the presence of a normally functioning heart a normal blood volume and a normal blood viscosity (dependent on the



blushed rather widely over her face neck and shoulders (there were blotches) when he examined her heart. She appeared a bit timorous and tense but under good self control. Her axillae were wet (or would have been had she not used antisweating preparations) and her hands and feet were cold and moist. She admitted blushing easily in the past on the least provocation. She was excessively neat, regular in her habits almost compulsive but quite unassertive. Laboratory examinations were un revealing. Being curious he immersed her hand in ice water for 1 minute a painful experience she showed no emotion but her blood pressure rose to 168/99 mm Hg falling in 5 minutes to lower levels after it was removed.

This young woman's vascular response to the stress of an examination and to the pain of ice water was almost certainly mediated through the sympathetic nervous system. She was one of those individuals very common in the population who react to stress by vasospasm. Her blushing was characteristic of a diencephalic discharge.

The physician did nothing but suggest an annual physical examination for which she regularly returned. She had two uneventful pregnancies. At the age of 32 her previously labile blood pressure was found to be 160/100 mm Hg or thereabouts not returning to a normal diastolic with rest. As each year passed, a slightly upward trend was observed. At 40 it varied around 180/110 mm Hg. Her mother died of a stroke of apoplexy at the age of 62 which upset her emotionally. She went to another physician who found her blood pressure 200/116 and told her that she had high blood pressure. This was the first she knew of it and she became very agitated. saw her original physician in an excited state and he measured her blood pressure at 230/140 mm. Her fundi oculi showed spasm but no other changes. He put her in hospital upon which her pressure fell to 160/100 mm. measured

concentration of circulating red blood cells and plasma proteins) diastolic hypertension is inevitable. Hypertension, then, can be considered a form of generalized vasospasm, a variant of normal responses to circulatory stresses, characterized by healthy blood and heart and by its chronic nature. Any one of several of the mechanisms which produce vasospasm can be involved in causing hypertension, new mechanisms can also arise at a time long after the organism would be dead or recovered from shock, had that been the initiating cause.

While we do not know the exact causes of generalized vasospasm, we do know a great deal about the mechanisms which produce it. The causes themselves lie in biochemical alterations in blood vessels, nervous tissue and organs of high metabolic activity. It is not enough to say that we do not know and therefore we must not try to know. For there are not many areas which have been so well studied, and there is little need to invoke esoteric mechanisms to the neglect of known ones. If one asked any physiologist what influences he would think could raise diastolic blood pressure on the basis of experimental data he would choose autonomic nerves, kidneys and endocrine organs. He would not choose liver, thyroid, spleen or pancreas, however, but consider sympathetic nerves and their origins, renal blood flow and adrenal glands.

**Clinical Chronic Hypertension** We can transfer these thoughts of our physiologist immediately to our own clinical experiences, viewing each case in their light. Let us take some typical ones.

1. A woman of 25 was found on routine examination to have a blood pressure of 152/88 mm Hg which after a rest fell to 138/82. Her mother had hypertension with out sequelae. She had no symptoms, but her physician noticed that her heart rate was a little rapid and that she

at 56 At autopsy were found cerebral hemorrhage massive arteriosclerosis moderate of aorta renal arteries coronary arteries marked of circle of Willis with rupture arteriolar nephrosclerosis moderate cardiac hypertrophy (460 Gm) Her adrenal glands were normal

This sequence of events leading to early death can be reconstructed in the light of what is known For many years this woman reacted to stressful situations by neurogenic vasospasm Slowly the reversibility of this alteration became less and less some gradually increasing factor being added which maintained a basal blood pressure at higher and higher levels upon which was engrafted a widely fluctuating neurogenic component This added factor was what killed her Perhaps she would not have died so early were it not for another disease atherosclerosis which began probably after her menopause and affected her cerebral arteries to such an extent that one ruptured under the high pressure

2 A man of 25 was found to have a slightly elevated blood pressure and tachycardia when examined for the draft His mother was hypertensive and his father had died of a coronary occlusion at the age of 51 Enuresis until the age of 8 had occurred but he was free of further urinary symptoms and his urine showed no albumin He went to his family doctor who found a few bacteria in his urine with about 10 white blood cells per high power field in the centrifuged sediment repeated cultures showed non hemolytic streptococcus of the colon group in large numbers He was given phenobarbital and was accepted for duty in the Army He had a creditable career and won several decorations for bravery His discharge physical examination showed a blood pressure of 160/100 mm Not until the age of 33 did he consult a physician for severe headaches and blurring of vision which had appeared a month earlier His blood pressure was 236/160



every 4 hours, it was normal during sleep (140/90) and dropped to 122/88 when tetra-ethyl ammonium chloride was injected intravenously. She was given phenobarbital but was never the same. Investigative studies on the renal clearance of para aminohippurate and inulin revealed reduction of renal plasma flow and relatively increased glomerular filtration rate. The profile of efferent arteriolar spasm.

Emotionally induced vasospasm had added to it another factor. In the first place the neurogenic influence had increased. Secondly the reversibility of the vasospasm had lessened.

She had her menopause at 45. By the age of 48, she was suffering from headaches every morning, anxiety, increased nervous tension and an inner sense of excitement. Her blood pressure was now constantly over 200 mm systolic in spite of sedatives but fell with rest to 160/110 fluctuating widely. During sleep induced by heavy sedation it did not fall to normal. Her fundi now showed some sclerotic, tortuous arteries; her electrocardiogram indicated enlargement of the left ventricle, seen also in x-ray photographs. Occasionally she had a trace of albumin in her urine but she excreted 30 per cent of intravenously injected phenol red (PSP) in 15 minutes and her kidneys were able to concentrate urine to a specific gravity of 1.025. The blushing became more pronounced.

Now had appeared an irreversible component to the vasospasm, in that sleep did not completely abolish it. Signs of organic damage were developing. Rest, reassurance, sedatives, superficial psychotherapy and laying on of hands could not interrupt the vicious cycle.

She suffered her first stroke of apoplexy, a mild one, at 51 and recovered with little residual other than a limp. Hypertension persisted unabated and she died of another

kidney and cardiac hypertrophy (520 Gm) and dilatation His brain was edematous his adrenals normal

This man suffered from the 'accelerated phase' or what is more exactly and descriptively called malignant hypertension and died young He had the constitutional make up of the hypertensive person to which was added chronic low-grade smouldering pyelonephritis with an organism which does not produce pus but causes scar tissue These two factors operating together shortened his life By the time he died there was little evidence left of the primary renal disease in the kidney distorted by nephrosclerosis

3 An older man had a slightly elevated blood pressure at times of stress which had been normal on regular examinations all of his life At 49 however he was refused life insurance because of a blood pressure of 170/110 mm Hg He had no symptoms except nervousness but he was a tense dynamic individual with excessive drive and ambition somewhat of a perfectionist Examination in hospital revealed no significant abnormalities except minimal left ventricular enlargement studies on his renal plasma flow showed slight reduction with the calculated increased renal vascular resistance on the afferent side of the glomerulus His blood pressure varied moderately but did not fall to normal levels during sleep or the injection of tetraethyl ammonium chloride Renal "function" was normal He was well working hard and taking few vacations until he was suddenly seized at age 54 with a severe retrosternal pain and was admitted to hospital with an acute coronary occlusion Other than minimal cardiac enlargement a tortuous aorta and the usual signs of infarction there were no abnormalities He recovered slowly but his blood pressure normal or low during his illness became elevated again to 180/110 mm during rest and as high as 220/120 during activity In spite of rearranging his life he remained hypertensive until his second infarction at 57 from which

mm there was 3 plus proteinuria and microscopic hematuria, the ocular fundi showed early papilledema and soft cotton wool exudates but no hemorrhages, and his heart was slightly enlarged. He was able to concentrate urine to a specific gravity of only 1.019 and excrete only 15 per cent of the intravenously injected dose of phenol red in 15 minutes. Culture of the urine showed nonhemolytic staphylococcus, considered a contaminant but intravenous pyelography revealed blunting of one upper calyx in the right kidney. His blood pressure altered little during deep sleep and when tert-butyl ammonium ion was injected, his diastolic pressure fell from 158 to 145 mm Hg.

This man, unlike his predecessor, had rapidly reached an irreversible stage of vasospasm. His blood pressure was 'fixed' and his course was presumed to be rapidly progressive. Some organic renal component could be inferred from the earlier urinary findings and the pyelographic evidence, but this was asymptomatic. His family and early history suggested that he might be one of those persons who react to stress by vasospasm, added to this component was a chronically diseased kidney.

He refused admission to hospital but was examined frequently during the next year and took the new Rauwolfia drugs continuously without effect on his slowly rising blood pressure and deteriorating condition. Finally he was forced to seek help because of increasing dyspnea, but by that time the nonprotein nitrogen in his blood was 132 mg per cent, his diastolic pressure 160 mm Hg or more. He had suffered one attack of pulmonary edema and his ocular fundi showed many hemorrhages, hard exudates, soft exudates and papilledema. After a stormy downhill course he died of uremia complicated by congestive heart failure. At autopsy there was moderate generalized arteriosclerosis, advanced arteriolar nephrosclerosis with necrosis, a few depressed scars on the cortices of one

The curious thing about her obesity was its distribution over the trunk upper arms and thighs. Her lower legs and arms were not obese at all. There was a "buffalo hump" and her face resembled those seen after overdoses of cortisone. Measurements of the sodium and chloride in her sweat showed values of 10 mEq/L or less levels found in Cushing's syndrome. She bruised easily and her ankles had a tendency to swell in the evenings. She had a distinct mustache. Serum sodium was 145 chloride 101  $\text{CO}_2$  32.4 and potassium 2.8 mEq/L.

She did well but remained hypertensive at home as it was impossible for her to restrict her salt intake and her appetite. Not until she was 45 did her first episode of congestive heart failure bring her back into hospital. She died 2 years later a cardiac cripple in the interim. At autopsy were found arteriolar nephrosclerosis slight to none moderate generalized arteriosclerosis marked cardiac hypertrophy and dilatation (640 Gm.) There was a 1 x 1.2 cm adenoma in the left adrenal cortex.

In her case a functioning adenoma in her adrenal cortex was affecting both her salt and fat metabolism the former influencing her hypertension. Better diagnostic methods would have allowed surgical removal.

These four cases are illustrative of distinct types of arterial hypertension encountered clinically. In actual practice one sees wide variations in their courses and some times bizarre mixtures. If the first patient had contracted glomerulonephritis in childhood or pyelonephritis during her pregnancy or had by chance had a kink in her ureteropelvic junction due to an aberrant renal artery with stasis and infection she probably would have exhibited more severe hypertension at an earlier age. If the second had not contracted pyelonephritis in childhood he might have lived to become hypertensive in his 50's and died of heart failure or apoplexy in his 60's. If the renal arterial

he died At autopsy there was found cardiac enlargement with focal myocardial fibrosis a new infarct arteriolar nephrosclerosis slight, and generalized arteriosclerosis Careful cross sectioning of the mouths of the renal arteries revealed some encroachment of their lumina by atherosclerotic plaques

This man also probably had the constitution for hypertension When he developed atherosclerosis, the slight narrowing of his renal arteries interfered enough with renal hemodynamics to cause a moderate hypertension The elevated pressure worsened the atherosclerotic process, which in his case was lethal because it involved his coronary arteries Hypertension itself did little direct but much indirect harm for he died before his time

4 A woman of normal weight began to gain rapidly after her second pregnancy at age 22 Within 2 years her weight increased from 110 to 190 pounds and slowly increased thereafter At 35 she weighed 252 but on dietary restriction lost 23 pounds Her menses had always been somewhat irregular and frequent but in her 30's periods of amenorrhea for 3 to 6 months appeared She was found to exhibit hypertension at age 31 using the large (18 cm) cuff her blood pressure was 160/102 and using the normal (12 cm) cuff 186/122 Subsequently hypertension was moderate blood pressure seldom exceeding 200/130 mm and usually being about 200/120 Fundal changes were minimal Studied in hospital there was little evidence of vascular damage other than an enlarged heart Periods of decreased urinary output followed by polyuria were noticed when her fluid balance was measured Renal plasma flow and glomerular filtration rate were normal Weight was lost very slowly on severe dietary restriction of calories, but restriction of salt promptly lowered blood pressure to normal levels Her mother and one of three sisters were fat hirsute and hypertensive

The curious thing about her obesity was its distribution over the trunk upper arms and thighs Her lower legs and arms were not obese at all There was a "buffalo hump" and her face resembled those seen after overdoses of cortisone Measurements of the sodium and chloride in her sweat showed values of 10 mEq /L or less levels found in Cushing's syndrome She bruised easily and her ankles had a tendency to swell in the evenings She had a distinct mustache Serum sodium was 145 chloride 101  $\text{CO}_2$  32.4 and potassium 2.8 mEq /L

She did well but remained hypertensive at home as it was impossible for her to restrict her salt intake and her appetite Not until she was 45 did her first episode of congestive heart failure bring her back into hospital She died 2 years later a cardiac cripple in the interim At autopsy were found arteriolar nephrosclerosis slight to none moderate generalized arteriosclerosis marked cardiac hypertrophy and dilatation (640 Gm) There was a 1 x 1.2 cm adenoma in the left adrenal cortex.

In her case a functioning adenoma in her adrenal cortex was affecting both her salt and fat metabolism the former influencing her hypertension Better diagnostic methods would have allowed surgical removal

These four cases are illustrative of distinct types of arterial hypertension encountered clinically In actual practice one sees wide variations in their courses and sometimes bizarre mixtures If the first patient had contracted glomerulonephritis in childhood or pyelonephritis during her pregnancy or had by chance had a kink in her ureteropelvic junction due to an aberrant renal artery with stasis and infection she probably would have exhibited more severe hypertension at an earlier age If the second had not contracted pyelonephritis in childhood he might have lived to become hypertensive in his 50s and died of heart failure or apoplexy in his 60s If the renal arterial

atheromata in the third had piled up enough to cause serious encroachment on the lumina, he might have entered the malignant stage, unless heart or brain gave out first. If the fourth had contracted pyelonephritis as well as her tumor, her course would have been shortened. Renal disease of any nature to interfere with blood flow, when combined with the "hypertensive diathesis," can increase the severity and shorten the course. The fact that hypertension is absent before azotemia in approximately 30 to 40 per cent of patients with renal diseases, points up the necessity for the presence of another factor to explain pathogenesis.

**Pathologic Alterations** Dead house pathology does not always explain physiologic and biochemical alterations in disease. But it cannot be neglected. There are very few anatomic changes in hypertension, but they are characteristic.

1 Renal arteriolar and arteriosclerosis are almost universal in this disorder (2). Cases similar to our fourth are a notable exception (3, 4). The thickening, scarring and hyalinization of the afferent arterioles vary from slight to marked, with complete or almost complete occlusion of their lumina. Only in azotemia, and then only in half the cases, are the necrotizing arteriolar lesions seen (5, 6). These are called malignant nephrosclerosis, a term which has little to do with non azotemic malignant hypertension. What has been little described are the earliest changes seen in hypertension: a thickening of the basement membrane of the glomerulus, later an increase in ground substance of the tuft, well followed in dogs (7) and observed in man. This change may be the result of increased intraglomerular pressure which must occur when efferent arterioles are constricted more than afferent ones.

2 Cardiac hypertrophy, and often dilatation, are almost

universal although we have rarely seen normal sized hearts after sustained hypertension. This change is probably a work hypertrophy resulting from the increased cardiac work necessitated by the hypertension. It can be modified by associated atherosclerosis of the coronary arteries.

3 Generalized atherosclerosis is almost universal in this country although cases without it are common in China (8)

**Sequence of Development of Arteriolar Nephrosclerosis**  
This basic lesion which by its very nature can cause renal ischemia and hypertension, is a result of hypertension. In other words the altered hemodynamics of hypertension can lead to a pathologic change which further alters renal and therefore peripheral hemodynamics. The evidence is clear on this point, in rats rabbits dogs and man (Chapter V). Therefore at some point in two of our cases renal vascular disease appeared after hypertension had become well established. Whether or not this secondary disease is responsible for the loss of reversibility of vasospasm is not known, but presumably it is not wholly accountable.

*Comment* All biological phenomena can eventually be understood in terms of physics and chemistry. The remainder of this monograph is concerned largely with an examination of the biochemical alterations possibly operating to cause this disease which is so eventually fatal as a rule and which is so common to Western Civilization.

## MECHANISMS OF SOME OF THE EFFECTS OF CHRONIC ARTERIAL HYPERTENSION

**Degree of Peripheral Vasospasm in Chronic Hypertension**  
The vasospasm can be very intense in chronic arterial hypertension. In fact, it must be so in order to maintain the diastolic pressure at high levels. One can estimate the intensity of the vasospasm by measuring the pressure



atheromata in the third had piled up enough to cause serious encroachment on the lumina, he might have entered the malignant stage, unless heart or brain gave out first. If the fourth had contracted pyelonephritis as well as her tumor, her course would have been shortened. Renal disease of any nature to interfere with blood flow, when combined with the "hypertensive diathesis," can increase the severity and shorten the course. The fact that hypertension is absent before azotemia in approximately 30 to 40 per cent of patients with renal diseases points up the necessity for the presence of another factor to explain pathogenesis.

**Pathologic Alterations** Dead house pathology does not always explain physiologic and biochemical alterations in disease. But it cannot be neglected. There are very few anatomic changes in hypertension, but they are characteristic.

1 Renal arteriolar and arteriosclerosis are almost universal in this disorder (2). Cases similar to our fourth are a notable exception (3, 4). The thickening, scarring and hyalinization of the afferent arterioles vary from slight to marked, with complete or almost complete occlusion of their lumina. Only in azotemia, and then only in half the cases, are the necrotizing arteriolar lesions seen (5, 6). These are called "malignant nephrosclerosis," a term which has little to do with non azotemic "malignant hypertension." What has been little described are the earliest changes seen in hypertension, a thickening of the basement membrane of the glomerulus, later an increase in ground substance of the tuft, well followed in dogs (7) and observed in man. This change may be the result of increased intraglomerular pressure which must occur when efferent arterioles are constricted more than afferent ones.

2 Cardiac hypertrophy, and often dilatation, are almost

universal although we have rarely seen normal sized hearts after sustained hypertension. This change is probably a work hypertrophy resulting from the increased cardiac work necessitated by the hypertension. It can be modified by associated atherosclerosis of the coronary arteries.

3 Generalized atherosclerosis is almost universal in this country although cases without it are common in China (8).

**Sequence of Development of Arteriolar Nephrosclerosis**  
This basic lesion which by its very nature can cause renal ischemia and hypertension is a result of hypertension. In other words the altered hemodynamics of hypertension can lead to a pathologic change which further alters renal and therefore peripheral hemodynamics. The evidence is clear on this point in rats rabbits dogs and man (Chapter V). Therefore at some point in two of our cases renal vascular disease appeared after hypertension had become well established. Whether or not this secondary disease is responsible for the loss of reversibility of vasospasm is not known but presumably it is not wholly accountable.

**Comment** All biological phenomena can eventually be understood in terms of physics and chemistry. The remainder of this monograph is concerned largely with an examination of the biochemical alterations possibly operating to cause this disease which is so eventually fatal as a rule and which is so common to Western Civilization.

## **MECHANISMS OF SOME OF THE EFFECTS OF CHRONIC ARTERIAL HYPERTENSION**

**Degree of Peripheral Vasospasm in Chronic Hypertension**  
The vasospasm can be very intense in chronic arterial hypertension. In fact, it must be so in order to maintain the diastolic pressure at high levels. One can estimate the intensity of the vasospasm by measuring the pressure

in an artery peripheral to complete intermittent mechanical occlusion (9 11) In man only the brachial bed offers a convenient means of doing this In Figure 1 are shown 'asystolic arterial pressure gradients' in various types of hypertension Persons with diastolic pressures from 100 to 200 mm Hg have shown asystolic brachial pressures 18




FIG 1 Brachial asystolic arterial pressure gradient in man (9 10) A needle connected to a recording manometer was inserted into the brachial artery and a sphygmomanometer cuff placed about the upper arm After rapid occlusion of the cuff the fall of pressure in the distal segment (the forearm) was measured The level of pressure with no circulation is a measure of the degree of vasoconstriction opposing arterial run off Curves were obtained from a 46-year old normotensive woman a 54 year-old arteriosclerotic man without much diastolic hypertension a 56 year old severely hypertensive man treated with ganglionic blocking agents and hydralazine and a 37 year-old woman with untreated malignant hypertension The curves are a function of diastolic pressure (11)

seconds after occlusion from 30 to 122 mm Hg (average 65.8 normotension being 15 to 40 average 28.7 mm) a finding surprising on the surface but expected when due consideration is given to hypertensive hemodynamics. The smooth muscle of all arteries and arterioles must therefore be in a state of chronic spasm otherwise hyperemia would occur in those which are not.

**Pathogenesis of Hemorrhagic and Exudative Retinitis**  
The lesions found in the fundi oculi when the diastolic pressure is high are those of edema, hemorrhage, deposits of proteinaceous or lipid material and scarring. Many ophthalmologists consider that hemorrhagic and exudative retinitis is due to localized ischemia of the retina secondary to excessive vasospasm. From a hemodynamic and anatomic and physiologic viewpoint this concept is hardly tenable since a) ischemia of a part does not usually cause edema without infarction b) ischemia does not lead to hemorrhage c) the retinal arteries and arterioles have rather thin muscular coats and d) the lesions appear when the diastolic pressure is high, regress when it is lowered (sometimes to the point of producing retinal ischemia) and occur as a manifestation of a sudden worsening of the hypertension. A more logical explanation is that of plethora or excessive hyperemia. If the artery supplying an area of the retina were diseased so that it could not contract and 'healthy' vessels in the remainder of the body were made to constrict, hyperemia through that diseased vessel would result. Excessive flow and pressure would be transmitted to the capillary bed supplied by that artery. When venous outflow became insufficient to carry off the increased load, water, then plasma and finally red blood cells would be forced through the capillary wall. This concept explains what we find: edema, cotton wool exudates and hemorrhages. The hard

in an artery peripheral to complete intermittent mechanical occlusion (9 11) In man, only the brachial bed offers a convenient means of doing this In Figure 1 are shown 'asystolic arterial pressure gradients' in various types of hypertension Persons with diastolic pressures from 100 to 200 mm Hg have shown asystolic brachial pressures 18




FIG 1 Brachial asystolic arterial pressure gradient in man (9 10) A needle connected to a recording manometer was inserted into the brachial artery and a sphygmomanometer cuff placed about the upper arm After rapid occlusion of the cuff the fall of pressure in the distal segment (the forearm) was measured The level of pressure with no circulation is a measure of the degree of vasoconstriction opposing arterial run-off Curves were obtained from a 46-year old normotensive woman a 54 year-old arteriosclerotic man without much diastolic hypertension a 56 year old severely hypertensive man treated with ganglionic blocking agents and hydralazine and a 57 year old woman with untreated malignant hypertension The curves are a function of diastolic pressure (11)

*Comment* The secondary effects of hypertension are relatively unimportant to this discussion but they are of the utmost importance to the patient and to his therapy for it is by them that hypertension becomes a fatal disease. A further and often fatal effect is discussed in Chapter VII.

exudates may be the scars of old hemorrhages and the protein and lipid remnants of exudation of plasma

Since the arteries of the retina and brain are thin walled, weak structures compared to those in the remainder of the body, being in a media of higher external pressure, fairly generalized exudation and hemorrhage would be expected when systemic diastolic pressure rose to very high levels. It is probable that focal hemorrhages in the kidney, and perhaps in the gut, are the result of a high diastolic pressure through an artery or arteriole which is so diseased that it cannot constrict as much as the rest of the vascular bed. Therefore, many of the hemorrhagic and exudative lesions found in malignant hypertension are probably caused, not by excessive spasm proximal to the lesion but lack of enough spasm to compensate for that of the rest of the vascular bed.

**Pathogenesis of Necrotizing Arteriolar Lesions** In man, we find necrotizing lesions of the arteries and arterioles usually of the kidney only in nitrogen retention (5). Two influences are necessary, azotemia and a high diastolic pressure. Azotemia alone will not produce the lesions, for example, in uremia without much hypertension. On the other hand, hypertension alone will not usually cause the lesions in dogs (6) or in man. It is difficult to discover more than isolated cases in experimental animals without uremia (12). Both kidney (6) and a section of the small intestine can be protected from their occurrence by partial constriction of the main artery even in severely uremic animals (13). Necrotizing fibrinous arterial degeneration however has been caused by the injection of organ, notably renal, extracts into nephrectomized dogs (14-15). Therefore both pressure and severe renal disease seem to be required for their occurrence.

This form of reacting to stress may be common to some human beings in many environments and of many races although adequate studies have not been made. The old idea that a part of the population is sympathotonic and part parasympathotonic or vagotonic may have some basis of fact. Different species of animals show different types of reaction to stress rats cats guinea pigs and rabbits not only exhibit opposite types but respond in aberrant ways to known pressor and depressor agents. There are at least two kinds of dogs nervous overactive breeds which are hypertensive on the first and many subsequent examinations and more or less phlegmatic breeds or cross-breeds which exhibit normal blood pressures and bradycardia (21). There is little reason to believe that the human organism differs radically in its fundamental reactions from those of higher animals.

Sympathotonic people are supposed to be subject to vasomotor phenomena tachycardia and cardiovascular diseases especially hypertension. Parasympathotonic people are supposed to be subject to bradycardia a low blood pressure and gastrointestinal disorders especially peptic ulcer. Another type of individual develops allergic reactions. In any population all varieties and degrees of reactive ability can be expected depending probably on the amount of imbalance between sympathetic and parasympathetic nervous function and the amount of external stress to which individuals are exposed. There may be several different constitutional types we have not observed true extrinsic asthma in a hypertensive person and such allergic states as hay fever and urticaria are much less common than in the general population. duodenal ulcer is unusual in hypertension although it exists (4). Rheumatoid arthritis and most malignant tumors are seldom encountered in a hypertensive population (22).



## Chapter II

### BASIC OR CONSTITUTIONAL FACTORS

**T**HE BASIC factors in arterial hypertension are those broad and ill defined influences which cause a human being to become predisposed to the development of the disease. By arbitrarily separating basic traits from factors operating after the disease has become established one can outline the areas of therapeutic approach and predict, with some success, efficacy of various forms of therapy.

Reaction to Stress by Vasospasm The basic defect in persons predisposed to hypertension appears to be a reaction to stress by vasospasm or through vasomotor phenomena. Thus Levy, Stroud, White and Hillman (15, 18) found in Army Officers that transient hypertension, transient tachycardia and overweight each predisposed to the later development of hypertension, the last factor being the least significant. Long prior to these studies Hines found that when the stress of the first examination resulted in transient elevation of the systolic pressure to more than 140 mm Hg, 63 per cent of the patients would develop hypertension 20 years later; if more than 150, 78 per cent would exhibit it (19). Critical predisposing diastolic levels were above 85 mm. Furthermore, Hines has shown that persons reacting by vasospasm to pain (cold pressor test) later usually develop hypertension (20). This manner of reacting therefore probably constitutes the underlying etiology, which lies in the constitution of the individual and is described but not understood.

This form of reacting to stress may be common to some human beings in many environments and of many races although adequate studies have not been made. The old idea that a part of the population is sympathotonic and part parasympathotonic or vagotonic may have some basis of fact. Different species of animals show different types of reaction to stress: rats, cats, guinea pigs and rabbits not only exhibit opposite types but respond in aberrant ways to known pressor and depressor agents. There are at least two kinds of dogs: nervous overactive breeds which are hypertensive on the first and many subsequent examinations and more or less phlegmatic breeds or cross breeds which exhibit normal blood pressures and bradycardia (21). There is little reason to believe that the human organism differs radically in its fundamental reactions from those of higher animals.

Sympathotonic people are supposed to be subject to vasomotor phenomena: tachycardia and cardiovascular diseases especially hypertension. Parasympathotonic people are supposed to be subject to bradycardia, a low blood pressure and gastrointestinal disorders especially peptic ulcer. Another type of individual develops allergic reactions. In any population all varieties and degrees of reactive ability can be expected depending probably on the amount of imbalance between sympathetic and parasympathetic nervous function and the amount of external stress to which individuals are exposed. There may be several different constitutional types. We have not observed true extrinsic asthma in a hypertensive person and such allergic states as hay fever and urticaria are much less common than in the general population. duodenal ulcer is unusual in hypertension although it exists (4). rheumatoid arthritis and most malignant tumors are seldom encountered in a hypertensive population (22).

The ability, or habit, of reacting to stress by vasospasm does not cause hypertension. It merely predisposes those individuals so constituted to the slow development of the disease. Other influences are probably operative which change reversible into irreversible vasospasm.

### HEREDITY AND ENVIRONMENT

**Heredity** The manner of reacting to stress by vasospasm is apparently an inherited characteristic. Hines has shown clearly that persons who so react have parents who are either hypertensive or react likewise to painful stimuli (23). The gross hereditary nature of chronic hypertension is well established, although Pickering disagrees with this idea (24). What makes up this predisposition has been little understood.

Thomas has clearly shown that cardiovascular disease is an inherited trait in the United States (25).

**Personality** Patients suffering from chronic arterial hypertension in all stages of severity supposedly exhibit certain defects of personality, the qualities of which go to make mature and well integrated individuals. The deficiencies have been considered as a subnormal level of assertiveness and tendencies towards obsessive-compulsive traits (26, 4). Anxiety which may precede, or be a result of the illness, is also common (27). Whether these alterations are similar in the major psychosomatic disorders which result in irreversible organic changes (peptic ulcer, asthma) or are specific for one disorder, has not yet been clearly established. Likewise the effects of abnormal renal metabolites (primary amines and other substances) upon cerebral metabolism, which might enhance relatively minor functional derangements, are not known (Chapter III).

**Environment** Without stimuli to cause a reaction the reaction would not occur. The stresses, or stimuli, which

are a product of the environment and the attitude of the individual toward it can be considered as initiating factors in the reaction. These influences vary widely from one person to another involving the many faceted aspects of existence and adjustment to a prevailing social order. It is probable that the more complex society becomes the greater are the environmental stresses consequent to adjustment to that society and therefore the stimuli to somatic reaction increase.

Pickering lately summed up his concepts on the relation of heredity constitution and environment in hypertension (28). To get these conclusions in perspective it may be said that in its mode of inheritance blood pressure resembles height but that the size of the genetic factor is greater in the case of height. However the regression coefficient certainly underestimates the size of the genetic factor since we have been unable to allow for the day-to-day variability of blood pressure and we have had to allow for the effects of age by a device which is probably valid when it is applied to large numbers but not so accurate for individuals. By contrast, height shows quite insignificant variations from day to day and for a considerable span of adult existence is uninfluenced by age. The difference between the size of the genetic factor in blood pressure and height is probably less than regression coefficients suggest. Even so it would seem justifiable to conclude that environmental factors are more important than hereditary factors in the pathogenesis of hypertension.

These considerations lead to one further idea which is so revolutionary that I merely lay it before you knowing that your minds must instinctively reject it namely that the current concept of essential hypertension as a specific disease entity is largely an artefact. I venture to suggest that a restatement of the facts would define essen

tial hypertensives as that group of the population with arterial pressures exceeding a certain value arbitrarily selected and in whom no specific cause can be detected to account for the high pressure. It is suggested that the factors causing it are factors operating generally on the population. Of these factors the contributions of age, sex and inheritance can be defined approximately. The influence of environmental factors which would seem by exclusion to be of great importance, remains to be explored.

We do not believe that this idea is so revolutionary, having entertained it for many years (29, 31, 4). In Chapters V and VI will be discussed the factors operating generally on the population. In Chapter III this curious, ill defined but well known vasomotor manner of reacting which varies from individual to individual. These factors can now be examined separately.

### CLINICAL IMPLICATIONS

Since persons predisposed to hypertension emotionally react to environmental stresses through somatic pathways by vasospasm, in the very earliest stages of the disorder some reversal of the somatic response can be expected if reversal of one or more of the psychic components could be accomplished. Many attempts to do so have been made. Psychotherapy has been extensively employed in young individuals without organic disease it may teach the person either to avoid emotional stresses to sidetrack the reactions thereto along other pathways or to resolve them without somatic reaction by means of logic and insight. In patients of older ages, with somewhat more advanced hypertension or with organic changes, however little in the way of therapy can be expected. By analogy, while psychotherapy of peptic ulcer is useful to promote healing and to prevent further attacks it is useless in relieving

pyloric obstruction with scarring secondary to repeated attacks. These defects of personality however are probably so deep-seated and fundamental to the growth of the individual that complete rebuilding becomes most difficult except in young people. In our experience psychotherapy has failed to modify the course of severe hypertension sufficiently to allow us even to suspect some beneficial somatic effect and we have often watched patients deteriorate to eventual death in spite of the most vigorous forms available (an analyst reanalyzed by an analyst).

An environment considered unfavorable by the individual may be altered by moving to a new one. Temporary effects upon the course of moderate and mild stages have been observed. The familiar fall in blood pressure when patients enter the hospital is an example. How permanent this change can be is not known. Minor adjustments in adverse environments especially those caused by other individuals with whom the patient is in close contact may for a time alter emotionally induced stresses (Figure 2).

Drugs especially sedatives have been employed for many years for the purpose of suppressing the emotional tension and lowering the threshold of reactions to stress. As a general rule the more severe the hypertension the less effective are sedative drugs and other such influences upon the disease. Contrariwise the milder the hypertension the more effective are measures aimed at the psyche and the emotional disturbance.

The effects upon the course of hypertension of any one or combinations of the above approaches is directly proportional to the relative influence of these factors in the total picture. Psychosomatic diseases may start as functional derangements mediated through autonomic nerves and end as organic conditions causing death. Therefore while the beginning may lie in the psyche as exemplified by the

word, constitution, that factor becomes increasingly less important as somatic changes occur. In reversible early and very mild stages the disease may be controlled, as its somatic ravages progress less and less can be expected from attacks upon these etiological factors. Alterations of




FIG. 2 Typical rapid fall of blood pressure after hospitalization. E. E. was a 39 year-old woman who was first discovered to have an elevated blood pressure six years previously at the time of pregnancy complicated by pyelonephritis. During the intervening years her blood pressure was always elevated in a physician's office. Six months and one month prior to admission she suffered two attacks of severe headaches, numbness and weakness of one side of her body and loss of consciousness for one to three hours with gradual recovery during the following week. Her blood pressure was said to have varied between 230/130 and 210/110 mm. Hg for 2 years. She complained of dyspnea on exertion and dizziness. On examination there was one small retinal hemorrhage. Blood pressure was 236/136. Her heart was enlarged to the left in x-ray photographs. Renal function was excellent. No cause for the attacks was discovered on careful neurologic examination. The first pressure shown (230/130 mm. Hg) was measured by both the intern and assistant resident the night of admission; subsequent ones were measured by nurses beginning the following morning. (From Schroeder H. A. and Perry H. M. Jr. *Am Heart J*, 51:776, 1956.)

disturbed emotional and nervous functions cannot be expected to dissolve scar tissue

Although Bays and Scrimshaw disagree (32) from all the evidence available we can be fairly certain that hypertension not secondary to renal disease is a disorder fairly well confined to persons exposed to the influences of Western Civilization (4) For example it is unusual in parts of Africa (33) and China (8) very prevalent in American Negroes but rare in American Indians in the Southwest (34) In Uganda only 2.6 per cent of autopsied cases of heart failure were due to essential hypertension the same percentage to atheromatosis and none to coronary thrombosis renal hypertension however, accounted for 16 per cent (35) Surely one is led to conclude that environmental influences are of the greatest importance for in this country probably half the cases of heart failure are hypertensive in origin When viewed from this outlook many discrepancies in the geographic incidence of hypertension fall into line

*Comment* There are three apparent facts upon which one can speculate

- 1 The predisposition to hypertension is inherited
- 2 There is an emotional overlay in the disease which may be either primary or secondary
- 3 The disease is confined more or less to civilized or partly civilized people without any particular ethnic cultural or social pattern suggesting that environmental factors such as food habits or contact with industrialized society plays an initiating role



## Chapter III

# NEUROGENIC EFFECTOR MECHANISMS

## INTRODUCTION

WHILE yet unproven it seems clear that the sympathetic nervous system is somehow relatively or absolutely overactive in prehypertensive and hypertensive states, especially when there is no demonstrable organic renal component. The indirect evidence, suggesting rapid alterations in the nervous control of blood vessels is as follows

1 The blood pressure is labile and widely variable (Fig 3)

2 Traube Hering and respiratory variations in blood pressure are often marked (36-37) (Fig 4)

3 The vasospastic response to painful stimuli and to emotion is often exaggerated (20-38-41)

4 The pressor effects of central vasomotor stimuli such as inhalation of carbon dioxide and holding the breath is often increased (42-44)

5 Blocking sympathetic nerves by drugs or surgery abolishes many of these exaggerated vasospastic responses to pain and emotion (45, 46)

6 Drugs acting partly on the central nervous system lower the blood pressure more or less (*vide infra*)

7 Sustained hypertension can be produced in certain animals by interfering with sympathetic and cerebral nervous mechanisms (47-50)




FIG. 9. Daily and nightly fluctuations of supine blood pressure in an 18-year-old man in the prehypertensive phase. His kidneys and heart were normal by all tests. Note that the rise in pressure occurs only during the day. The divisions between each 24-hour period are at midnight.

The evidence against neurogenic effector mechanisms operating in sustained human neurogenic hypertension is poor and usually explicable by an analysis of the cases employed for experimentation or by an understanding of the processes concerned in neurogenic vasoconstriction.

"At present no one doubts the existence of neurogenically induced vasospasm in man. We must emphasize, however, that in chronic human arterial hypertension the relative parts played by neurogenic and other mechanisms vary considerably from patient to patient (Chapter IV). The contrary evidence follows:

1. Little or no increase in urinary catechol amines is usually found (1). Norepinephrine, however, is liberated at nerve endings and metabolized or conjugated *in situ* before its products reach the blood stream. Therefore overproduction must be great enough to saturate oxidative and conjugative enzymes in order to allow enough to spill

### Chapter III

## NEUROGENIC EFFECTOR MECHANISMS

### INTRODUCTION

**W**HILE yet unproven it seems clear that the sympathetic nervous system is somehow relatively or absolutely overactive in prehypertensive and hypertensive states especially when there is no demonstrable organic renal component. The indirect evidence suggesting rapid alterations in the nervous control of blood vessels is as follows

1 The blood pressure is labile and widely variable (Fig 3)

2 Traube Hering and respiratory variations in blood pressure are often marked (36, 37) (Fig 4)

3 The vasospastic response to painful stimuli and to emotion is often exaggerated (20 38 41)

4 The pressor effects of central vasomotor stimuli such as inhalation of carbon dioxide and holding the breath is often increased (42-44)

5 Blocking sympathetic nerves by drugs or surgery abolishes many of these exaggerated vasospastic responses to pain and emotion (45, 46)

6 Drugs acting partly on the central nervous system lower the blood pressure more or less (*cide infra*)

7 Sustained hypertension can be produced in certain animals by interfering with sympathetic and cerebral nervous mechanisms (47 50)








FIG. 4 Spontaneous variations in blood pressure measured photokymographically by direct arterial puncture W G normal and normotensive variation 9.6 mm Hg F T normotensive convalescent from severe acute poliomyelitis with probable slight involvement of the hypothalamus or medulla giving rise to neurogenic vasomotor instability variation 13.1/20 mm Hg W D fairly severe neurogenic hypertension variation 13.1/20 mm Hg I H severe neurogenic hypertension variation 3.2/2.2 mm Hg W D (repeat after several days rest) variation 7.3 mm Hg C O mild neurogenic hypertension variation 47.19/76.34 mm Hg B indirect measurement C O a systolic pressure when taken by a white coated physician varied from 180 to 240 mm and her diastolic from 120 to 100 mm nurses always obtained readings 20 to 30 mm lower The wide fairly regular tracings are those of respiration the smaller ones of a plethysmograph on the finger Camera speeds 12.5 and 25 mm per second



FT ♂



Several influences arising in the brain can cause experimental hypertension such as noise (54) internal hydrocephalus (46) puncture of the third ventricle (55) tying off the arterial supply (49) all of which may interfere with blood flow or nervous function in a regulatory area. Similarly in man increased intracranial pressure certain brain lesions of viral vascular or traumatic origin (fractures of the base of the skull encephalitis poliomyelitis) certain tumors and hypothalamic injury can lead to chronic neurogenic hypertension or its acute equivalent (56)

There are four possibilities to explain the cerebral role in human hypertension 1 The nervous temperament of the hypertensive person with the frequent finding of anxiety and frustration may initiate repetitive discharges through the sympathetic nervous system. Subnormal assertiveness obsessive-compulsive traits and anxiety are said to be common to the hypertensive personality (26 27). This hypothesis has always been an attractive one but is unproven and most difficult to investigate with the tools at hand.

2 The peripheral metabolic abnormalities associated with hypertension may cause stimulation of cerebral metabolism. It is known that many primary amines cause central excitatory effects. Amphetamine (Benzedrine) is a good example. In fact Mann and Quastel (57) suggested that the central stimulant action of *dl* phenylisopropylamine (Amphetamine) is related to its inhibition of tyramine oxidation by amine oxidase in brain. On this basis Fellows and Bernheim (58) examined a large number of structurally related salts in rats and found in many instances good correlations between central stimulation and cerebral amine oxidase inhibition. Clinically the excitatory actions of epinephrine and a number of derivatives are well known we have observed profound and

over into blood and be excreted in urine. Actually some patients do have moderately increased amounts in their urines (51b) about a third.

2 No increase in circulating catechol amines can be detected (38).

3 Many patients do not show all of the typical exaggerated pressor responses nor the marked depression of blood pressure induced by drugs or surgery (52). The logical explanation is that another vasospastic process is largely operative in such individuals.

"Although neurogenic pathways effecting vasoconstriction are intimately connected it is necessary to examine each component of the sympathetic nervous system in the light of its role and of specific effector substances and chemotherapeutic agents. Some of these are known some must be postulated. The brain and its appendages exert a profound effect upon normal vasomotor tone and are probably involved in many forms of generalized vasospasm." As Starling said (53) "No pathology will be adequate which does not take into account the sensitiveness of the vasomotor centers to the changes in the circulation. Considerable information on pathogenetic factors can be learned from the actions of specific drugs more perhaps than by direct experiments."

### CEREBRAL MECHANISMS

The areas within the brain initiating or transmitting sympathetic discharges or regulating vasomotor tone are three: the cortex, the hypothalamus, and the vasomotor center. Just how these areas are involved in the hypertensive process is not known. What is known, however, is that certain drugs modify their activities and partly affect the amount of peripheral vasospasm neurogenically induced.

the hypothalamus or vasomotor center may initiate somatic sustained neurogenic pressor responses. While such lesions have been found in some cases (64) and may account for the hypertension of some older persons there is no uniform correlation with all cases and this idea remains merely an attractive hypothesis.

### SPECIFIC DRUGS

Whatever the cause of the increased nervous excitability of hypertensive patients many agents have been used to counteract it and thus produce variable effects upon blood pressure depending upon a) the relative part played by the brain b) the effectiveness of the drug and c) the ability of the patient to tolerate side effects. Sedatives have been used for many years in an attempt to allay tension and anxiety. They will not be discussed since their employment is wide.

Serotonin Antagonists Reserpine causes depletion of cerebral serotonin in the experimental animal (65-66) platelet serotonin is also reduced to a low level. The net effect of this agent a chemical analogue of yohimbine is to produce an effect the equivalent of a prefrontal lobotomy (67). Its locus of action appears to be pre hypothalamic and subcortical the posterior hypothalamus wherein lie the sympathetic centers is partially blocked (68). The effect of the drug is cumulative requiring a week or two for oral doses to act maximally although rapidly excreted the drug itself leaves serotonin receptors in the brain blocked for long periods. Aside from its 'tranquilizing' action the net somatic effect is that of relative parasympathetic overactivity (Table I). Diarrhea and gastric hyperacidity can result peptic ulcer has appeared *de novo* or become activated in one of our cases chronic ulcerative colitis has developed (69). Various cerebral symptoms are



uncontrollable anxiety induced by intravenous isoamyl amine in laboratory workers, for example. Therefore, some circulating primary amines may induce cerebral stimulation. Fast diffuse dysrhythmias in the electroencephalograms are common in human neurogenic hypertension (4). This picture can be produced by certain amines (59). Thus, a vicious circle could be established, from periphery to brain to periphery, the initiating organ not being known.

Serotonin, a derivative of tryptophane, has received the greatest interest in this regard, since its isolation from platelets. This primary amine occurs in brain and may have a definite function in nervous tissue (60), as may other similar substances. It is interesting and perhaps more than coincidental, that malignant carcinoid of the appendix, a serotonin producing tumor, apparently causes a peculiar flushing phenomenon which is similar to the diencephalic blush which we associate with neurogenic hypertension (61, 62). Injection of serotonin in man causes a variety of subjective symptoms not apparently associated with anxiety but similar in some respects to those seen following other substituted primary amines (63). The role of several tertiary and quaternary nitrogenous compounds on nerve conduction and synaptic transmission is barely beginning to be appreciated.

3 There is either excessive production of stimulating substances *in situ* or generalized inhibition of those enzymes concerned with metabolizing such substances. For example, if every sympathetic nerve ending contained a molecule inhibitory to amine oxidase or to the enzyme conjugating norepinephrine the normal tone of sympathetic nerves would be enhanced. There are no proofs of this theory.

4 Local vascular lesions of an arteriosclerotic nature in

TABLE I—(continued)

	Reserpine (123 subjects)	Chlorpromazine (137 subjects)
Epistaxis	2 4	0
Blurred Vision	0	1 5
Dry Mouth	0	1 5
Heart Burn	0	1 5
Edema	7 3	5 1
Pruritus	1 6	1 5
Dermatitis	0	9 5
Jaundice	0	5 1
Hepatomegaly	0	2 2

also induced among them vivid dreams and nightmares. One of the most interesting of its actions is to cause, in a sizeable percentage of people nervousness insomnia agitated depressions and suicidal tendencies (70) used to treat these symptoms in psychotic individuals it can back fire and produce them. Truly this most interesting drug has begun to open up a wide field in our understanding of mental illness.

Chlorpromazine is also an antagonist to serotonin (73). Its locus of action has been presumed to lie subtentorially probably in the medulla. tranquilizing effects are seen as well and hypothalamic action has been postulated (74). While it can cause some depression of the sympathetic nervous system it can also produce symptoms of stimulation in some individuals (Table I) with hypertension and tachycardia. Likewise its antiemetic action may be reversed in other subjects.

Other antimetabolites to serotonin are not used in hypertension: yohimbine because of its nephrotoxicity and diisergic acid diethylamide which produces schizophrenic like states (63-66). The most interesting are the nitroindoles which are true competitive antagonists blocking

TABLE I  
RESERPINE AND CHLORPROMAZINE  
INCIDENCE OF SIDE REACTIONS AND TOXIC EFFECTS IN  
NORMOTENSIVE PATIENTS

	<i>Reserpine</i> (123 subjects)	<i>Chlorpromazine</i> (137 subjects)
<i>Sympathetic N S Inhibition</i>		
Hypotension	31.6	14.6
Bradycardia	17.0	3.7
Diaphoresis	1.6	0
Chilliness	3.3	0
Nausea	5.7	7.3
Vomiting	2.4	5.1
Diarrhea	7.3	0.7
Exacerbation of Peptic Ulcer	0*	0.7
<i>Sympathetic N S Stimulation</i>		
Hypertension	0	6.6
Tachycardia	0	8.8
Hyperthermia	0	3.7
<i>Cerebral Symptoms</i>		
Excessive Flushing	9.0	0
Dizziness	5.7	5.1
Fatigue weakness	9.7	2.2
Syncope	1.6	0.7
Excessive Drowsiness	17.8	12.4
Tremulousness	15.4	0.7
Myalgia	3.3	0
Ataxia	5.7	0
Parkinsonism	1.6	0.7
Vivid Dreams	2.4†	2.2
Agitated Depressive Psychosis	±5‡	
<i>Other</i>		
Nasal Stuffiness	27.6	1.5

\* We have seen 4 cases

† Higher in our experience

‡ Author's series

(From Zeller W W Graffagnino P N Cullen C F and Reitman H J Use of chlorpromazine and reserpine in the treatment of emotional disorders *J A M A* 160:179 1956)




FIG 5 Metabolism of serotonin, modified from Sjoerdsma *et al* (61)

phane and its decarboxylation (Fig 5) The hydroxylase has not been discovered but the renal decarboxylase (71) contains a pyridoxal metal complex as a coenzyme (72) like many other amino acid decarboxylases. Serotonin is metabolized by monamine oxidase (Chapter IV) an enzyme requiring oxygen and sensitive to oxygen tension. Therefore renal ischemia could allow the formation of serotonin by anaerobic decarboxylation but prevent deamination in situ due to oxygen lack. Serotonin would then escape into the blood and be deaminated either in the lungs or on arterial smooth muscle. While it is doubt

the action of serotonin on smooth muscle, they have not been employed more than sporadically with little effects

A newer sedative, 2 methyl 2 n propyl 1,3 propanediol dicarbamate (meprobamate) apparently selectively blocks interneurons primarily on the thalamus and caudate nucleus (75) There is little or no effect upon the autonomic nervous system This drug should therefore prove a tool for controlling anxiety in mildly hypertensive patients and thus estimating the role which nervous tension *per se* plays in minor elevations of blood pressure

*Comment* None of these agents are more than mild antihypertensive drugs One or another may control moderate or intermittent elevations of blood pressure, especially when associated with emotional tension, but they are relatively valueless, except as adjuncts, in more severe cases Obviously the sustaining mechanism for severe hypertension lies elsewhere than in the brain, although initiating mechanisms may be there, in cerebral edema, however, a large neurogenic influence may be exerted The most potent and specifically acting drug can do no more than inhibit the relatively minor role which the brain contributes to the process of generalized vasospasm Even after destruction of much of the brain by atherosclerotic disease, to the point of causing a vegetative existence, established hypertension may not disappear

Serotonin is one of the newest agents discovered to be involved in cerebral interneurone transmission Of great interest is the fact that this primary amine apparently has a specific affinity for cortical pathways to the posterior and lateral hypothalamus (Too much could stimulate and cause emotional tension a normal amount interest, initiative and drive, while too little could result in mental depression) Serotonin is found in quite primitive marine organisms, it is formed by the hydroxylation of trypto-




Fig 5 Metabolism of serotonin modified from Sjoerdsma *et al* (61)

phane and its decarboxylation (Fig 5). The hydroxylase has not been discovered but the renal decarboxylase (71) contains a pyridoxal metal complex as a coenzyme (72) like many other amino acid decarboxylases. Serotonin is metabolized by monoamine oxidase (Chapter IV) an enzyme requiring oxygen and sensitive to oxygen tension. Therefore renal ischemia could allow the formation of serotonin by anaerobic decarboxylation but prevent deamination *in situ* due to oxygen lack. Serotonin would then escape into the blood and be deaminated either in the lungs or on arterial smooth muscle. While it is doubt

ful that serotonin is concerned directly in hypertension, injections into hypertensive, but not normotensive animals and man are moderately pressor, and this interesting substance in slightly increased amounts could represent an abnormal metabolite causing some symptoms and a small portion of the vasospasm

### CAROTID SINUS MECHANISMS

There is no good evidence that the carotid sinus mechanism is underactive in the usual case of hypertension. Chronic sustained hypertension can be produced in dogs however, by ablation of the carotid sinus and aortic depressor nerves (76) while this state is true neurogenic hypertension, after several years the renal lesions of arteriolar nephrosclerosis develop (7). In our experience, this form of hypertension is not dependant solely upon increased cardiac output as there is intense peripheral vasoconstriction under anaesthesia (10). A clinical counterpart may be suspected in patients with atherosclerotic narrowing of the mouths of the innominate and left common carotid arteries. That an appreciable degree of narrowing is uncommon may be suspected from the clinical observations that symptoms of severe cerebral ischemia do not usually follow reduction of elevated blood pressure to normal that some degree of obstruction may occasionally be found is suggested by the vague discomfort accompanying normotension seen in many atherosclerotic hypertensive individuals (While hardening of the carotid sinus wall and local atherosclerotic narrowing have been suggested (77) these lesions are unproven as causes of chronic hypertension).

**Specific Drugs** There is a group of drugs from plants of the *veratrum* family which do affect the carotid sinus sensitizing the pressor receptors and thus increasing the activity of the depressor mechanism (78). Protoveratrine

A and B are the most purified alkaloids usually found in a mixture and most difficult to separate. They cause depression of blood pressure and bradycardia, nausea and vomiting may result from vagal stimulation (79). The pathway is through the glossopharyngeal nerve to the vasomotor center (78). When doses are adjusted properly, intermittent normotension can result from the careful use of protoveratrine and its impure derivatives (80). Apparently tolerance is quick to appear and disappear, so that sustained normotension will not result unless adjuncts operating on other mechanisms are used. Whether or not this drug is a true antihypertensive agent affecting the basic process is unclear, although the hemodynamic response is quite favorable (Table II).

**Baroreceptor Changes** McCubbin, Green and Page (81) have recently shown that the carotid sinus and aortic depressor mechanisms are set at a higher level of pressure in renal hypertensive dogs than in normotensive dogs. They propose (the ingenious theory that this higher setting maintains the hypertension) even when the initiating mechanism (renal ischemia, pheochromocytoma, toxemia of pregnancy) is removed. Thus (renal hypertension slowly becomes neurogenic,) buffer nerve hypertension as Ogden has suspected in rats (82). If this were so in man, one would expect that late chronic hypertension would respond to the use of drugs or surgery acting on nerves better than would early hypertension. Clinically the opposite holds true; therefore this attractive hypothesis necessarily can be discarded as applying to most human cases.

### SYMPATHETIC NERVOUS MECHANISMS THROUGH GANGLIA

All autonomic nerves after emergence from the spinal cord pass through ganglia. In general, sympathetic nerves form synapses in paravertebral ganglia, while parasympa-



TABLE II  
CARDIOVASCULAR EFFECTS OF PROTOVERATRINE AND GANGLIONIC  
BLOCKING AGENTS IN MAN

	Normal		Hypertensive	
	Epineph rine	Norepineph rine	Proto- veratrine	Gan- glionic Blockade
<i>Cardiac</i>				
Heart Rate	+	-	-	-
Stroke Volume	+	+	+	-
Cardiac Output	+	0	0	-
Coronary Blood Flow	+	+	?	?
<i>Blood Pressure</i>				
Systolic Arterial	+	+	-	-
Mean Arterial	+	+	-	-
Diastolic Arterial	-	+	-	-
Mean Pulmonary	+	+	?	-
<i>Peripheral Circulation</i>				
Total Peripheral Resistance	-	+	-	-
Cerebral Blood Flow	+	0~	0	0
Muscle Blood Flow	+	0~	+	+
Cutaneous Blood Flow	-	+	?	+
Renal Blood Flow	-	-	0	-*
Splanchnic Blood Flow	+	0	?	-

\* Transient

thetic nerves end in ganglia at more peripheral (organ) areas. The adrenal medulla receives preganglionic fibres which cause discharges of epinephrine, a sympathetic effector substance, into the circulation; therefore it may be considered a ganglion in the broadest sense of the term.

The chemical mediator of ganglionic transmission is a quaternary ammonium compound, acetylcholine. Whether or not other compounds containing tetravalent nitrogen

or choline esters can act as transmitters is not known. Acetyl choline (or its derivatives) apparently is essential for synaptic transmission in all ganglia both sympathetic and parasympathetic. Nicotine in small doses is a stimulant.

The ganglion itself governs the integrity of the post ganglionic fibres much as the spinal nuclei control the integrity of their neurons. Removal of a ganglion is probably followed by degeneration of the nerve after a few days sensitivity of the nerve ending to circulating vasoconstrictor substances develops. Therefore in order to perform an adequate sympathectomy preganglionic fibres must be cut.

**Specific Drugs** Chemical ganglionic blocking agents usually contain quaternary ammonium stabilized tetra covalent nitrogen competing with acetyl choline or other more labile nitrogenous substances. Numbers of such compounds exist. The simplest one of the group is tetraethyl ammonium ion known for many years as a vasodilating drug of short action. Longer action is achieved by lengthening the carbon chain and doubling the nitrogen group (pentamethonium pendiomide hexamethonium) or by adding cumbersome ring structures (pentolinium chlorisondamine). All act in a similar manner differing only in duration of action and degree of gastrointestinal absorption. A new blocking agent mecamylamine (Inversine) differs considerably in structure being a complex spatial molecule with trivalent nitrogen as a secondary amine. It has the advantage of virtually complete absorption from the gastrointestinal tract (83). Comparative doses are shown in Table III (Fig 6).

Since acetyl choline also mediates nerve transmission to striated muscle it may appear strange that curariform

paralysis does not result from ganglionic blocking agents. Some anatomical or chemical differences between ganglia and motor end plates undoubtedly exist, for hexame



Tetraethyl Ammonium (TEA)






Pentamethonium ( $\text{C}_5$ )Hexamethonium ( $\text{C}_6$ )

FIG 6 Structural formulae of ions of some ganglionic blocking agents. The salts are not shown. The last known as Arfonad is only used intravenously. Note the quaternary or tetravalent nitrogen groups which are the active ones and the camphane structure of those with trivalent nitrogen.

TABLE III  
COMPARATIVE DOSES OF GANGLIONIC BLOCKING AGENTS (SEVERE ADULT HYPERTENSION)

COMPARATIVE DOSES OF GANGLIONIC BLOCKING AGENTS (SEVERAL AGENTS)						
Ion	Usual Effective Oral Dose		Maximum Tolerated Oral Dose		Duration of Action of Oral Drug hrs	Usual Effective Parenteral Dose† mg
	Single Dose mg	Daily Dose mg	Single Dose mg	Daily Dose mg		
Tetraethyl Ammonium	†	†	†	†	1-1	500
Pentamethonium	500	2500	?	?	3	25
Hexamethonium	500	2500	1000	6000	4	25
Pentolinium (Ansoly sen)	100	500	800	4000	4-5	25
Chlorisondamine (Ecolid)	50	250	200	1000	4-6	15
Mecamylamine (Inversine)	10	50	25	150	4-8	10

\* When combined with hydralazine

† Sublingual dose effective oral not

‡ Initial dose much smaller

Wide variation as tolerance develops

thonium ion in large doses can exhibit curare like actions. Lengthening of the carbon chain to 10 atoms results in a curariform drug, decamethonium. Curare itself contains tetravalent nitrogen, and succinyl choline has a similar action (84). The longer the chain from 5 to 10 carbon atoms, the greater is the paralytic effect.

The cardiovascular effects of ganglionic blockade are summarized in Table II. Thus, ganglionic blockade while lowering blood pressure, does not act primarily upon all of the functions disturbed in hypertension. Furthermore, sympathetic nervous inhibition at the ganglionic level is also associated with parasympathetic nervous inhibition. Renal and splanchnic blood flow are altered in the wrong direction. Continuation of these disturbances could cause serious consequences, were it not for some unknown readjustments which take place within the organism counteracting the changes. While the effects of these agents in opposing the hypertensive process are real and offer evidence for the role of the sympathetic nervous system in pathogenesis, they are not all to be desired. Presumably they differ from the effects of surgical sympathectomy. The subject of the specificity of these drugs on the basic processes concerned in vasospasm is open and arguments pro and con the question of whether or not the observed effects are truly antihypertensive have validity on both sides.

### SYMPATHETIC NERVE ENDINGS

The chemical effector substance of the sympathetic nerves is norepinephrine. On stimulation of a nerve, this primary amine is released at the junction of nerve and organ or smooth muscle fibre. Infusion of norepinephrine intravenously mimics the cardiovascular profile seen in sustained arterial hypertension (Table II) and a similar

"picture is caused by norepinephrine secreting pheochromocytomata. Therefore the neurogenic component of hypertension can be considered to be mediated by this substance."

Norepinephrine is derived either from dihydroxyphenylserine by decarboxylation or from tyramine by hydroxylation of the benzene ring and the  $\beta$ -carbon. The first appears the most facile method for the nerve ending to make this substance rapidly. It is inactivated either through conjugation through oxidation of the amine nitrogen by monamine oxidase or by rearrangement of its molecule to form an indole nucleus through oxidation by polyphenol oxidase, a copper enzyme.


The ideal agent for counteracting norepinephrine has not been found. There are a number of sympatholytic drugs which inhibit its action on nerve endings and which are effective for short or longer periods in experimental animals. We list them only as directions for research. These may be grouped roughly as derivatives of benzylamine or phenethylamine or ergot or benzodioxane and of imidazole (Table IV, see page 48). All contain tertiary substituted nitrogen.

**Derivatives of Benzylamine** Dibenamine, a complex structure remotely related to norepinephrine, forms tight bonds at sympathetic nerve endings, preventing the action of this constrictor substance, probably by competitive inhibition. The action is prolonged for many hours. It is moderately effective by mouth, much more so intravenously. There are many side effects in man, especially on the brain. Dibenamine and its relatives are the most effective sympatholytic agents known at present, but their value in hypertension remains to be proven.


**Derivatives of Phenethylamine** We had an opportunity of testing a group of primary amines in rats for sympath

olytic qualities, some of which were given intravenously in man


Those blocking norepinephrine in the rat had the following formulae




SKF 1298 A



SKF 669 C




Mer 11




Norepinephrine


The nitrogen in these compounds was completely substituted all being tertiary amines. There was, however, no consistency in the results for the following gave no blocking action




SKF 690 A




SKF 1222







SKF 1297 A



SKF 1277 A



SKF 1299 A



SKF 1300-A

Renal hypertensive dogs responded by a lower diastolic pressure only when SKF 1298-A was given \* SKF 690 A was a powerful epinephrine like substance in man causing vasodilatation and an increased cardiac output with fall in diastolic pressure SKF 1298-A caused symptoms suggestive of cholinergic stimulation two others were without effect

The experiments of Furchgott are of interest Using the spirally cut rabbit's aorta as a source of smooth muscle he was able to show on this simple system how certain agents such as dibenamine block all constrictor amines others block some and others block only a few (85) Therefore it is likely that very specific agents can be found which will pick out one primary amine and not others for inhibition

---

None of these substances specifically depressed elevated blood pressure in the anaesthetized renal hypertensive rat without affecting normotensive rats.



TABLE IV  
ACTIONS OF ADRENERGIC BLOCKING AGENTS IN MAN\*

Function	Dihydrogenated Ergot Alkaloids			Phenolamine and Tolazoline		Ben odioxanes
	Diben- yline	Epinephrine	Both	Epinephrine	Both	Epinephrine
Principal Action on Epi or Norepinephrine	Both	Unchanged or Decreased	Unchanged	Unchanged	Decreased?	Decreased?
Cardiovascular	Unchanged	Increased	Increased	Increased	Increased	Unchanged ?
Cardiac Output	Unchanged	Decreased	Decreased	Decreased	Decreased transiently	?
Blood Flow—Femoral	Unchanged	Unchanged	Unchanged	Unchanged	Decreased	Constricted
—Mesenteric	Dilated ?	Constricted	Constricted	Dilated	Decreased ?	Variable
—Renal	Decreased	Decreased	Decreased	Decreased		
—Cerebral						
Coronary arteries						
Peripheral Resistance						
Principal Adverse Effects						
Central Nervous Stimulant	+	+	+	0	0	+
Tachycardia	+	+	+	0	0	+
Tissue injury local	+	+	+	0	0	0
Nausea and Vomiting	+	+	+	0	0	0
Duration of Action	Days	Hours	Minutes	Minutes	Minutes	Minutes

\* After Goodman and Gilman (84)

**Derivatives of Ergot** The dihydrogenated ergot alkaloids have the ability of blocking adrenergic impulses but their action is greater on epinephrine than on norepinephrine. Toxic effects limit the tolerable dose so that useful blockade is rarely produced. They must be given sublingually or parenterally their effects in hypertension vary but are usually inconsistent.

**Derivatives of Imidazole** Tolazoline (Priscoline) and Phentolamine (Regitine) are two short acting moderately effective adrenergic blocking agents containing both benzene and imidazole rings. Phentolamine while opposing the actions of both epinephrine and norepinephrine is useful for the most part only as a test substance for circulating catechol amines. It usually causes a transient fall of blood pressure in hypertensive patients suggesting that some sympathetic tone is present. In azotemia the effect may be prolonged and profound. Cardiac stimulation is the rule. Tolazoline is readily absorbed and excreted unchanged in the urine. Phentolamine is apparently metabolized up to 90 per cent of the dose. The short durations of action limit their use.

**The Benzodioxanes** Piperoxan (Benodaine) and pro-sympal first synthesized by Fourneau act transiently usually by vasoconstriction. They do oppose however the action of epinephrine probably by *competitive inhibition*. Norepinephrine is blocked only by toxic doses. Side effects are many especially smooth muscle stimulation and limit their use except in epinephrine producing pheochromocytomas.

**Comment** All of the known adrenergic blocking agents fail to block cardiac accelerator mechanisms. Tachycardia and increase in cardiac output of reflex origin limit their clinical uses. In all cases blockade of injected or circulating

vasoconstrictor amines is greater than is the blockade of nerve impulses, dibenamine has less differential activity in this respect. The ideal agent for chemical sympathectomy is one which prolongedly blocks norepinephrine at all vascular nervous endings including especially those in the heart. This agent has not been found, if it can be it should prove the best agent for controlling the neurogenic factor in human hypertension.

**Other Effector Substances** While the role of other sympathomimetic amines in hypertension is not established they are probably present in excessive amounts and may contribute to symptoms if not to vasospasm. Decarboxylation of amino acids by kidney is an anaerobic process (86, 87) while deamination is an aerobic one (88) the enzymes monamine oxidase and possibly diamine oxidase being sensitive to oxygen lack (89). Under these conditions any amino acid decarboxylated by the kidney could form amines by partial interrupted metabolism, altering the locus of deamination from kidney to peripheral smooth muscle or liver. The level of primary amines in hypertensive blood is usually high (4, 90, 91). This error of metabolism will be discussed at length in Chapter IV.

### CLINICAL IMPLICATIONS

In the absence of a good specific adrenergic blocking agent which also blocks the cardiac sympathetics we are forced to use combinations of drugs depend upon ganglionic blockade or affect the carotid sinus mechanism. Combinations of adrenergic blocking agents such as dibenamine derivatives and protoveratrine have been advocated the former to block nerve endings and the latter to slow the heart. In fact one such preparation also contains reserpine, which tends to cause bradycardia. Such

pousse café combinations are to be avoided all drugs give reactions and side effects and it would be difficult to assess the vomiting induced by dibenamine and that by protoveratrine in such a mixture

The toxic or side reactions of reserpine and chlorpromazine have been given in Table I The most serious late toxic reactions of reserpine are those of agitated depressive psychosis which are often accompanied by suicidal tendencies and may lead therefore to death Of chlorpromazine there are hepatic disease and granulocytopenia some 17 deaths have resulted (92) Chronic administration of any drug given to control not cure a chronic disease may back fire Furthermore in severe hypertension the use of mild drugs is potentially dangerous giving the physician a sense of security while the disease continues relentlessly on its ravaging course

There are no known late toxic reactions to protoveratrine Immediate side effects are those attributable to vagal stimulation i.e. nausea and vomiting The rapid development of partial tolerance in a few hours with restoration of sensitivity after a few hours rest is unexplained

Ganglionic blocking agents show many side effects most of them the result of parasympatholysis or sympatholysis (Table V) Only two serious ones of this nature have been encountered The first occurs when partial often asymptomatic obstruction to a hollow organ has been present Complete obstruction may result The second is concerned with the mode of excretion Absorbed blocking agents are excreted in the urine If severe renal disease is present ganglionic blockade may cause hypotension and anuria as the drug is then retained hypotension and anuria persist To set one pharmacologic thief to catch another pharmacologic offender is undesirable in modern chemotherapy

but sometimes it becomes necessary. The activity of cholinergic drugs is enhanced when ganglia are blocked, thus, urecholine and prostigmine provide useful tools in abating unwanted parasympatholysis (98). Likewise norepinephrine infusions combat the hypotension quite effectively.

TABLE V  
SIDE EFFECTS OF GANGLIONIC BLOCKADE

Carotid Sinus Reflex	Decreased
Cardioaccelerator nerves	Blocked
Cardiovascular reflexes (cold pres or etc.)	Blocked
Venous pressure	Decreased
Eye—Pupil	Fixed in mid position
—Accommodation	Fixed at normal resting point
Ptosis	Slight or absent
Ear—Eustachian Tube	Paralyzed?
Salivary secretion	Decreased
Gastric juice acidity and volume	Decreased
Gastrointestinal motility	Decreased
Gastric tone	Decreased
Colonic tone	Decreased
Defecatory Reflex	Decreased
Urinary Bladder tone	Decreased
Sweating	Decreased
Sexual potency (male)	Inhibited
Response to injected norepinephrine	Increased
Response to injected cholinergic drugs	Increased

Mecamylamine intoxication occurs in azotemic individuals and in others with poor renal function. It is characterized by gross, generalized coarse muscle tremor, increased with activity, disappearing with sleep, by nervous tension and sometimes by visual hallucinations. The state resembles delirium tremens. The flapping tremor, which involves all voluntary muscles in advanced stages, is not associated with cog wheel rigidity and only moderate hy

perreflexia is found. The tremor usually remains for many days after discontinuation of the offending drug even as long as two weeks. Severe hyperpyrexia without infection leading to death was observed once. Dilantin may partly ameliorate the condition. It is probable that this secondary amine of a camphor nature affects the central nervous system. Camphor itself is convulsant and high doses of mecamylamine cause gross tremors in dogs. We have observed fine tremors occasionally when hexamethonium ion was used. Meprobamate can cause leucopenia.

Ganglionic blockade disease occurs in poorly treated malignant hypertension (93-94-5). It is characterized by excessive tachypnea worsened in the sitting or standing position, diffuse or patchy roentgenologic changes in the lungs with few physical signs and interstitial pulmonary fibrosis at autopsy. Almost all cases have exhibited azotemia (5). The microscopic findings are indistinguishable from uremic pneumonitis. One patient recovered after the use of cortisone; the remainder died.

All of the antihypertensive agents with powerful actions can induce cardiovascular accidents due to the nature of the arterial disease (atherosclerosis) often encountered and too sudden alteration of hemodynamics. Arterial thrombosis is the most serious although it is rare. Such reactions are not true side effects of the drugs themselves but are inherent dangers in their overenthusiastic and careless use.

Summary Because drugs acting specifically on the autonomic nervous system may affect the elevated blood pressure in human hypertension we may assume that there can be a profound neurogenic component in some cases. This component probably is mediated via sympathetic nerves. Although the ideal counteracting agent is not avail-

able, certain tools can be used with varying results on the course of the primary disorder. All have side effects and most, late toxic reactions, which usually do not preclude their use provided careful attention is paid to the patient and his personal reactions.

## Chapter IV

# NEPHROGENIC EFFECTOR MECHANISMS

## EVIDENCE FOR EXISTENCE OF OTHER EFFECTOR MECHANISMS

**T**o this point we have inferred that mechanisms other than neurogenic account for much of the generalized vasospasm seen in severe hypertensive states. Although their natures are imperfectly understood, there is sufficient experimental and clinical data to warrant careful examination of several hypotheses which fit or do not fit the facts.

Most of the evidence for the existence of effector mechanisms other than neurogenic comes from experimental hypertension and from the wide variations in the acute or prolonged effects of drugs acting on sympathetic nerves. To take up the pharmacologic evidence, the following clinical observations are pertinent:

- 1 Early and mild hypertension responds well to simple measures and milder acting sympatholytic drugs; severe hypertension little or not at all.

- 2 Extensive surgical sympathectomy, either lumbo-sacral or subtotal, still leaves a sizeable proportion of patients as hypertensive as before; relieves a fair number completely; with the remainder improved to variable degree.

- 3 Full therapeutic doses of ganglionic blocking agents or protoveratrine cause intermittent or sustained normotension in a few cases; a modified response in many; and no appreciable effects (other than postural ones) in the more severe forms of hypertension.



able, certain tools can be used with varying results on the course of the primary disorder. All have side effects and most, late toxic reactions, which usually do not preclude their use provided careful attention is paid to the patient and his personal reactions.

## NEPHROGENIC EFFECTOR MECHANISMS

### EVIDENCE FOR EXISTENCE OF OTHER EFFECTOR MECHANISMS

TO THIS point we have inferred that mechanisms other than neurogenic account for much of the generalized vasospasm seen in severe hypertensive states. Although their natures are imperfectly understood, there is sufficient experimental and clinical data to warrant careful examination of several hypotheses which fit or do not fit the facts.

Most of the evidence for the existence of effector mechanisms other than neurogenic comes from experimental hypertension and from the wide variations in the acute or prolonged effects of drugs acting on sympathetic nerves. To take up the pharmacologic evidence the following clinical observations are pertinent:

1. Early and mild hypertension responds well to simple measures and milder acting sympatholytic drugs; severe hypertension little or not at all.

2. Extensive surgical sympathectomy, either lumbodorsal or subtotal, still leaves a sizeable proportion of patients as hypertensive as before; relieves a fair number completely; with the remainder improved to variable degrees.

3. Full therapeutic doses of ganglionic blocking agents or protoveratrine cause intermittent or sustained normotension in a few cases; a modified response in many and no appreciable effects (other than postural ones) in the more severe forms of hypertension.



## NEPHROGENIC EFFECTOR MECHANISMS

### EVIDENCE FOR EXISTENCE OF OTHER EFFECTOR MECHANISMS

**T**O THIS point we have inferred that mechanisms other than neurogenic account for much of the generalized vasospasm seen in severe hypertensive states. Although their natures are imperfectly understood, there is sufficient experimental and clinical data to warrant careful examination of several hypotheses which fit or do not fit the facts.

Most of the evidence for the existence of effector mechanisms other than neurogenic comes from experimental hypertension and from the wide variations in the acute or prolonged effects of drugs acting on sympathetic nerves. To take up the pharmacologic evidence, the following clinical observations are pertinent:

1. Early and mild hypertension responds well to simple measures and milder acting sympatholytic drugs; severe hypertension, little or not at all.

2. Extensive surgical sympathectomy, either lumbodorsal or subtotal, still leaves a sizeable proportion of patients as hypertensive as before; relieves a fair number completely; with the remainder improved to variable degrees.

3. Full therapeutic doses of ganglionic blocking agents or protoveratrine cause intermittent or sustained normotension in a few cases; a modified response in many; and no appreciable effects (other than postural ones) in the more severe forms of hypertension.

4 Injection of tetra ethyl ammonium ion causes transient falls of blood pressure to a floor, this level being low in milder cases and rising as the disease progresses into severe stages. Only in cerebral edema does the floor fall (95)

5 Injections of hexamethonium ion in full doses cause variable responses the estimate of the neurogenic component affected by the drug ranging from 100 to 15 per cent of the total elevation of blood pressure above normal. The less the fall after hexamethonium ion, the higher is the final blood pressure. There is a reciprocal relationship between neurogenic and humoral factors in maintaining the blood pressure high (53) (see Table XIX, p 110)

### THE NATURE OF THE OTHER MECHANISMS

Two processes can be hypothecated to explain these findings

1 The arteries and arterioles become so sclerotic that a mechanical increase in peripheral resistance accounts for the sustained hypertension in the absence of neurogenic mechanisms. This explanation is incompatible with the anatomic and pharmacologic facts. While hypertension causes vascular lesions, they vary in intensity and degree throughout the body. Only late hypertension is associated with these lesions. Reduction in blood pressure of a degree sufficient to cause local ischemia in areas of severe vascular disease usually can be accomplished without such ischemic manifestations.

2 The arteries and arterioles are in a state of spasm which is not mediated through nervous mechanisms. This is the only tenable hypothesis. If so several causes of the spasm must be examined

a) Some organ is forming and discharging into the circulation abnormal substances, which either are strong

vasoconstrictors themselves or which inhibit the destruction of normally circulating pressor substances

b) Some organ is not destroying or excreting pressor substances normally present, so that they accumulate to form a new homeostatic level

" c) Some organ is sensitizing the blood vessels to normally circulating pressor substances

d) For some reason the arterial and arteriolar walls become edematous thereby increasing peripheral resistance.

Probably all of these mechanisms can operate under different clinical circumstances

The vast experimental and large clinical experience with hypertension induced by renal ischemia focuses attention upon the kidney as a mediating mechanism for that component of elevated arterial pressure which is not neurogenic in origin. The posterior pituitary however forms a pressor substance and the adrenal cortex can sensitize blood vessels to vasoconstriction therefore endocrine mechanisms must also be considered (Chapter V). In this section we are concerned however with nephrogenic mechanisms

First the effects of sympathetic nervous discharges upon the renal circulation must be examined. Both emotional tension and catechol amines cause renal vasoconstriction abolished in the case of the former by sympathectomy. Curiously enough norepinephrine constricts in so far as is known only the renal circulation to a greater extent than other vascular beds. The hemodynamic profile is similar to that seen in hypertension with efferent arteriolar constriction being dominant. Epinephrine produces the same renal profile. Therefore increased neurogenic sympathetic tone can cause relative renal ischemia but ischemia of no other known organ

4 Injection of tetra ethyl ammonium ion causes transient falls of blood pressure to a floor, this level being low in milder cases and rising as the disease progresses into severe stages. Only in cerebral edema does the floor fall (95)

5 Injections of hexamethonium ion in full doses cause variable responses the estimate of the neurogenic component affected by the drug ranging from 100 to 15 per cent of the total elevation of blood pressure above normal. The less the fall after hexamethonium ion, the higher is the final blood pressure. There is a reciprocal relationship between neurogenic and 'humoral' factors in maintaining the blood pressure high (53) (see Table XIX, p. 110)

### THE NATURE OF THE OTHER MECHANISMS

Two processes can be hypothecated to explain these findings

1 The arteries and arterioles become so sclerotic that a mechanical increase in peripheral resistance accounts for the sustained hypertension in the absence of neurogenic mechanisms. This explanation is incompatible with the anatomic and pharmacologic facts. While hypertension causes vascular lesions they vary in intensity and degree throughout the body. Only late hypertension is associated with these lesions. Reduction in blood pressure of a degree sufficient to cause local ischemia in areas of severe vascular disease usually can be accomplished without such ischemic manifestations.

2 The arteries and arterioles are in a state of spasm which is not mediated through nervous mechanisms. This is the only tenable hypothesis. If so several causes of the spasm must be examined

a) Some organ is forming and discharging into the circulation abnormal substances which either are strong

4 No renin or angiotonin can be found after several weeks of hypertension although the enzyme is present at first VEM in blood however increases with time to a plateau (103)

5 The oxygen consumption of the kidney may be reduced (104)

In kidneys removed from hypertensive rats and dogs the following enzymatic alterations have been demonstrated

1 Amino acid oxidation is reduced (104 105) suggesting a general inhibition of oxidative enzymes

2 Transamination is reduced in the presence of adequate pyridoxal phosphate (104) suggesting a depletion from renal tissue of apotransaminase

3 Deamination of amines is reduced (104) suggesting depletion of monamine oxidase

4 Succinic dehydrogenase and possibly cytochrome oxidase are reduced (105) All of these enzymatic alterations can be explained by loss of renal tissue consequent to prolonged ischemia

✓ In man the following changes have been measured

1 Renal oxygen consumption is usually reduced (106 107) reflecting the ischemia

2 The urine is usually acid (108) reflecting perhaps the acidity of the cortex in ischemia

3 There is a tendency for renal loss of sodium and some chloride (109 110 4) caused in the case of sodium possibly by the acidity producing loss of base

4 The ratio of ammonia to titrable acid is lower than normal influencing possibly the sodium losing tendency of hypertensive kidneys (111)

5 Primary amines in arterial blood are usually elevated (90 91 112) a result perhaps of insufficient deamination from oxygen lack

Removal of one ischemic kidney before hypertension



Second, what metabolic abnormalities are present in renal ischemia? This subject is little understood and alterations little measured. We know of some functional changes in experimental animals. Certain urinary abnormalities occur, reflecting what appear to be minor renal derangements. The cause is reduced blood flow, but whether it is mediated through oxygen lack or through some other mechanism concerned with flow remains to be discovered. In anaesthetized experimental animals the following occur after acute mechanical constriction of a renal artery.

- 1 Cortical oxygen tension falls only to rise again without changing the constriction (96) suggesting intrarenal vasodilatation.

- 2 The same changes in blood flow take place. At this point the renal vascular bed becomes sensitive to injected epinephrine (97).

- 3 The cortex becomes acid (96).

- 4 Renin, the renal proteolytic enzyme, is released into renal venous blood where it reacts with a globulin to form hypertensin or angiotonin, a constrictor peptide (99). Likewise, a vaso excitator material (VEM) appears in blood (100). Angiotonin produced by the ischemic kidney, can constrict the vessels of the kidney making it more ischemic (101).

- 5 After several hours blood pressure may rise in the experimental animal (97), probably due to the release of renin and/or pressor amines.

In the dog made hypertensive by partial constriction of a renal artery the following changes have been seen.

- 1 Renal blood flow may be unchanged or decreased (102), but all of the increased resistance is not provided by the mechanical clamp; there is a component of intrarenal vasoconstriction as well, be it neurogenic or humoral (9).

- 2 Oxygen tension is lower than normal (96).

This is more than an academic point. If hypertension were the result of chronic inhibition of a renal enzyme, removal of the enzyme or removal of the kidneys would accomplish the same result. The next question is whether a precursor is altered by ischemic kidney into a pressor

G. J. P. W.




FIG. 7 Azotemic hypertension with reversal when azotemia regressed. Patient was a 45-year-old woman with abdominal lymphosarcoma which had involved both ureters causing bilateral hydronephrosis. It was impossible to pass a urethral catheter through the left. Radiotherapy was instituted, resulting in a shrinkage of the tumor, a return of renal function toward normal and a fall of blood pressure occasionally to hypotensive levels.

substance or whether normal kidney inactivates a pressor substance found normally in blood. This question cannot be answered except by reference to the hypertension existing in the presence of one ischemic and one normal kidney. The hypotheses of best fit include both processes: retention, hypertension developing with azotemia and

has persisted for long often relieves the elevated blood pressure. Such experiments suggest that the ischemic kidney was making something new, a pressor substance. At this point there are two apparently diametrically opposing viewpoints. Grollman's experiments show that totally nephrectomized dogs develop chronic hypertension when maintained by peritoneal dialysis or the artificial kidney. He therefore believes that healthy kidneys are necessary to maintain normotension (113). In other words the kidney destroys normally circulating pressor substances, and on its removal (or in ischemic states) these substances arising elsewhere accumulate. The other viewpoint is that the ischemic kidney makes pressor substances not normally present from precursors adding something new. These two opposing theories can be resolved by moving to a more fundamental level.

The kidneys can make vasoactive amines from the proper amino acids. Perhaps by decarboxylation, without deamination, vasoactive peptides can be formed. Obviously nephrectomized dogs cannot make these substances. In azotemia or in the absence of the kidneys however, vasoactive amines are probably formed elsewhere and retained. The humoral substances produced by renal ischemia and those accumulating in the absence of the kidneys are different although both are pressor. The latter are mainly catechol amines for increased quantities have been found in uremic blood and heart muscle urinary concentrations are low and regitine and benzo-dioxane lower elevated blood pressure (as in pheochromocytoma) (38). A clinical counterpart is seen in cases of azotemic hypertension where the blood pressure rises only with the blood nonprotein and falls when azotemia is relieved (Fig 7). Prostatic obstruction is the most common example.

TABLE VI  
AMINO ACIDS CAPABLE OF FORMING URINARY AMMONIA\*

Amino Acid	Renal Amino Acid Oxidase Present	Renal Diaminase Present	(Dog and Rat)	
			Renal Decar boxylase Present	Renal Amine Oxidase Present
Glycine	+			0
L-Alanine	+			+
L-Leucine			+	+
L-Cysteine			+	?
L-Methionine			?	?
L-Aspartic Acid	?		?	?
L-Asparagine				
L-Glutamine		+		
L-Histidine			+	+
Oxygen required for enzyme	+	0	0	+
No ammonia formed by glutamic acid lysine or arginine				

After Meister (432)

or diamine oxidase which also acts on other diamines such as cadaverine. The remainder are oxidized by monamine oxidase.

Both of these enzymes are found widespread throughout many tissues. The liver is a rich source. Smooth muscle and gut contain them. Their ubiquitous nature is all out of proportion to their known metabolic functions.

The most interesting aspect of monamine oxidase in reference to renal ischemia is its sensitivity to oxygen lack (Fig. 8). Small decrements of oxygen tension inhibit enzymatic activity considerably which is not always the case for other oxidases (89). If this relationship holds in

production hypertension of the ordinary renal or 'essential' variety

How are these often subtle changes made? What are the enzyme systems concerned? Very little is known, but speculation is rewarding

**The Amine Oxidase Theory** The kidney is an organ of high metabolic activity with one of the largest oxygen consumptions and blood flows of any in the body. Filtration is a passive process, tubular transport usually an active one. The kidney makes some ammonia from glutamine, thereby providing a base conserving mechanism. Other amino acids undoubtedly contribute their nitrogen groups as well, probably by transamination or deamination\*. There are many enzymes in kidney. Of them, decarboxylases of certain amino acids have been described of tyrosine, histidine, dihydroxyphenylalanine (DOPA), tryptophan, leucine and 5 hydroxytryptophan. Decarboxylation is an anaerobic process liberating carbon dioxide from the amino acid and leaving the amine residue.

We do not know for certain that amino acid metabolism takes place in the kidney primarily through decarboxylation (Table VI). The enzymes are found, however, and presumably must act. If they do, they can provide bicarbonate for tubular transport. Interestingly enough, most known decarboxylases are pyridoxal enzymes.

The amine residues of these amino acids are the vasoactive substances tyramine, histamine, dihydroxyphenyl ethylamine, tryptamine, isoamylamine and serotonin. Histamine is deaminated by a special enzyme, histaminase.

\* There is little or no L amino acid oxidase in mammalian kidney. Glycine oxidase is found, but for other amino acids to donate ammonia requires either transamination to form glutamine or the two phase reaction: anaerobic decarboxylation and then oxidative deamination by monoamine oxidase.

that passed would be distributed to all vascular organs and tissues including brain splanchnic bed and liver. In so doing they would be expected to show 1) vasoactivity before being deaminated and 2) some stimulatory or depressant actions on cerebral metabolism.

Bacteria in the colon have the proper decarboxylating enzymes for these amino acids and for several others. The resultant amines should theoretically act on the vascular system and brain in a similar manner if absorbed. That they do not usually so act can be explained by their destruction by amine oxidase in intestinal wall and in liver. For it is well known that primary amines and even epinephrine can be ingested in large quantities without systemic effects, adding one or more methyl groups to their side chains as in amphetamine or ephedrine however prevents oxidation by hepatic and intestinal amine oxidase allowing the drug to pass unchanged through liver and act on brain or blood vessels. No orally active amine vasoconstricting agent lacks this side chain. It is possible however that when bacterial flora are selectively inhibited by antibiotics products of intestinal putrefaction can be absorbed into the circulation from the lower colon and cause symptoms especially when the liver is damaged.

The fact that extracts of arterial hypertensive blood usually contain more primary amines than those of normotensive blood (90-91) and that certain new or abnormal amines appear in some hypertensive urine (114-115) lends support to the idea that renal amine oxidase is inhibited in most cases of severe hypertension. Presumably other renal ischemic states such as shock and congestive heart failure would be associated with the same metabolic abnormality.

This attractive theory first propounded by Holtz (87) has received considerable attention from our group.

the living animal, we may readily conceive of the consequences of renal oxygen lack.

The amino acids decarboxylated by kidney would continue to be so metabolized. Oxidation of the amine res




FIG 8 Relative rate of oxidation as a function of oxygen tension. Dotted circles are for tyramine or monamine oxidase; solid for xanthine oxidase. A reduction in oxygen tension of 50 per cent reduces the activity of the enzyme by about 50 per cent. Thus monamine oxidase as opposed to xanthine oxidase is extremely sensitive to oxygen lack. (From Kohn H I. Tyramine oxidase. *Biochem J* 31:1693, 1937.)

values would be diminished in proportion to the oxygen lack. Presumably these amines would reenter the circulation through the renal vein and be deaminated by monamine oxidase at other sites where there is adequate oxygen. First, the lung would take some of them out, those

amines (which is theoretically possible) a minor vicious circle could be induced. The result would be minor degrees of fluctuating neurogenic hypertension and many of the symptoms of the neurogenic hypertensive state.

✓ Since we are concerned primarily with the killing factor in hypertension and not with mild neurogenic vasospastic states, it is well to examine the properties of this enzyme system further. There are two which are of help in implicating a disturbance of amine oxidation. First of all, amine oxidase acts on hypertensin or angiotonin (4, 112). This pressor amine is a complex polypeptide (119). Second, the enzyme acts on pherentasin. This pressor amine is probably a polypeptide (120). If the enzyme can act on terminal amines of peptides, it is possible that the formation of such peptidic amines occurs through decarboxylation and destruction by terminal amine oxidation. Therefore, we cannot exclude monamine oxidase in any theory of pathogenesis.

This enzyme probably needs vanadium as a cofactor. Vanadium occurs in three valence states and is therefore a good metal for oxidation-reduction reactions, being used as such by certain ascidia which concentrate it from sea water. While not shown to be an essential trace element for man, vanadium is found in tissues of mammals and occupies a place in the periodic table where essentiality might be inferred. This subject will be discussed further in Chapter VI.

**Possible Role of the Lungs.** In order to cover other conceivable mechanisms of vasospasm induced by humoral pressor substances, we cannot neglect the pulmonary circulation. Any vasoactive material formed in an organ and discharged into the venous circulation must pass through the lungs before entering the area of action, the peripheral arterial bed. The lungs destroy at least one vasoactive



Partly purified but still crude amine oxidase, injected into rats, prevents the pressor action of both renin and pherentasin (*vide infra*) Furthermore, hypertensin or angiotonin is a good substrate for the enzyme (112, 116) indicating the presence of a primary amine group necessary for activity, for the reaction mixture is vascularly inert or depressor Renal hypertensive dogs can be maintained normotensive on daily injections of the active enzyme (117, 112) All naturally occurring pressor substances are amines Why, then does not this enzymatic disturbance account fully for the establishment and maintenance of hypertension?

Perhaps it does, but not through the mediation of the substances listed For all of them are relatively weak pressor amines when compared to norepinephrine Very large quantities would be required to cause hypertension amounts readily detectable in blood Furthermore, a mixture of these amines would be expected to produce a peripheral circulatory profile different from that seen in hypertension in so far as is known for many of them have selective actions on different vascular beds (112) although all, including histamine, constrict the vessels of the kidneys (118) Therefore, circulating primary amines from simple amino acids cannot be implicated as direct causes of generalized vasospasm They can be concerned however, with some of the minor manifestations of hypertension, such as headaches anxiety tension nervousness insomnia the diencephalic blush flushing sweating and the like If they can cause nervous and emotional tension (which some of them can) and if nervous tension can cause peripheral vasoconstriction through sympathetic nervous discharges (which it can) and if sympathetic discharges can cause neurogenic renal ischemia (which it can), and if renal ischemia can produce circulating primary

ably is associated with renal abnormalities (90 91 120 124) As far as is known it is the only pressor substance found so far in hypertensive blood but not in normotensive blood There is more in arterial than in venous blood

Pherentasin has a prolonged pressor action in rats especially those with renal hypertension (91) It also constricts the smooth muscle of the isolated rabbit aorta (120) Because of its strong pressor action and the small quantities present isolation and identification has been most difficult. Much of what is known of its nature comes from inactivation studies by known agents

Pherentasin probably contains a trace metal essential for activity the nature of which is unknown It is inactivated by many antihypertensive agents not acting on sympathetic nerves (Table VII) and disappears from the blood when hypertension is controlled No one knows how it is formed.

Renin Now largely discarded the mechanism for the formation of renin by ischemic kidneys supplied an attractive hypothesis to explain chronic renal hypertension When the kidney is made ischemic renin is released into renal venous blood from parenchymal tissues possibly the juxta-glomerular apparatus (125) This proteolytic enzyme acts on an  $\alpha$ -globulin made in liver partially hydrolyzing it to hypertensin or angiotonin \* a vasoactive polypeptide As with most other more simple substances this pressor amine does not produce the peripheral circulatory profile of the hypertensive state as does norepinephrine (126 127) Unfortunately for the theory renin and its effector substances have not been found in renal venous blood of dogs or human beings with chronic hypertension They do appear however in the acute vasospastic states of acute

---

\* Hypertensin and angiotonin are used interchangeably except when reference is made to a specific preparation One term should be dropped.

material, serotonin, and probably others, for over a hundred years physiologists have taken advantage of this property to free shed blood of "spatgift" and "fruhgift" constrictor and dilator substances in preparation for perfusion experiments. Presumably monamine oxidase is the enzyme which deaminates constrictor primary amines in the pulmonary circuit

Let us for a moment consider what might happen if all pulmonary monamine oxidase were inhibited. A portion of the pressor amines formed normally by kidney or tissues would be transported unchanged from venous to arterial circulations and would act on the peripheral blood vessels, the blood pressure would rise unless cardiac output were depressed. The remainder would constrict the pulmonary vascular bed, causing pulmonary hypertension. If extra quantities of primary amines were formed by kidney (or liver) and pulmonary monamine oxidase were inhibited or saturated beyond its capacity to oxidize them, further vasoconstriction would result. Therefore, the pulmonary circulation could play a part in hypertension.

In this respect it is interesting that the lungs were the only organs in which Tipton detected vanadium, the possible cofactor of monamine oxidase. The pulmonary circulation responds to hypoxia by constriction. The lungs contain many abnormal trace elements notably aluminum and titanium, a known enzyme inhibitor. This hypothesis to our knowledge has not been explored.

### SPECIFIC EFFECTOR SUBSTANCES

**Pherentasin** Although pherentasin has never been proven to come only from the kidney, this pressor amine of probable peptide nature is found in increasing quantities in the blood of patients with severe hypertension, is difficult or impossible to detect in mild stages, has been obtained from the renal vein of two patients and presum-

**TABLE VIII**  
**COMPARISON OF PROPERTIES OF ANIMAL HYPERTENSIN AND**  
**HUMAN PHERENTASIN**

Inactivation by	Hypertensin (1)	Pherentasin (2)	Method and Remarks
Drying	0	+	(1) can be lyophilized
Heat at pH 8.8	+	+	
Heat at pH 2.0	0	0	
Nitrous acid	+	+	
Ninhydrin	+	+	
Semicarbazide	?	±	(2) alters to a rapid reactant
Hydroxylamine	?	±	(2) alters to a rapid reactant
Amine Oxidase	+	+	
Tyrosinase	+	0	
Papain + cysteine	+	+	
Chymotrypsin	+	0	
Carboxypeptidase	+	0	
Trypsin	+	0	
Pepsin	+	0	
Mg <sup>++</sup>	0	0	
Mn <sup>++</sup>	+	+	(1) rapid (2) slow
Cr <sup>++</sup>	?	0	
Co <sup>++</sup>	+	±	(1) rapid (2) partial
Fe <sup>++</sup>	0	0	
V <sup>+++</sup>	~	~	Both enhanced
Cu <sup>++</sup>	0	0	
Zn <sup>++</sup>	0	0	
Hydralazine	+	+	(1) more sensitive
NaSCN	+	+	
8-Hydroxyquinoline	+	+	(1) slow (2) more rapid
EDTA Na <sub>2</sub> H <sub>2</sub>	0	±	(1) 50% in 22 hours (2) 50-100% in 3-6 hours
NaN <sub>3</sub>	+	+	
Na <sub>2</sub> Fe(CN) <sub>6</sub> NO	+	+	Rapid for both
1 benzyl 2 methyl 3 methoxy tryptamine	+	+	Serotonin antagonist

Note While distinct differences between these two substances are obvious the hypertensin used was probably principally hypertensin I (angiotensin) obtained from hog renin and serum Pherentasin may be hypertensin II of human origin with a slightly different structure since there is no reason to believe that the  $\alpha_1$  globulins of pig and man are identical.

TABLE VII

INACTIVATION OF PHERENTASIN BY METAL IONS AND METAL  
BINDING AGENTS (120)*Estimated Activity Per Cent of Control Values*

Substance	Immediate	4-5 hr	24 hr	Boiled after 24 hr	Color Developed
Mg <sup>++</sup>	91	130	61	0	0
Cr <sup>++</sup>	187	180	12	0	0
Mn <sup>++</sup>	45	17	0	—	Pink cloudy
Fe <sup>++</sup>	70	134	58	0	0
Co <sup>++</sup>	59	50	50	0	Faint pink
Cu <sup>++</sup>	96	107	27	0	0
Zn <sup>++</sup>	84	137	54	27	0
Hg <sup>++</sup>	168	51	115	0	0
None	100	100	100	80	0
Hydralazine	46	20 (2)*	0 (18)		Deep blue
NaSCN	110	0 (1)			Yellow-orange
Na Fe(CN) <sub>5</sub> NO	110	0 (2)			0
NaN <sub>3</sub>	89	0 (2)			0
8 Hydroxyquinoline	35	0 (1)			Pale green
NaH <sub>2</sub> EDTA	100	0 (3)			0
Cysteine	100		100 (120)		0

All metals were added to the active material in 0.01 M concentrations giving a final concentration in the 20 ml bath of 0.0005 M. The binding agents were added in 2-5 mg amounts per ml extract. None of the metal ions alone affected the test system at 0.0005 M concentrations. The test method was that of Furchgott (85).

Figures in italics represent more than 50% inhibition.

\* The figures in parentheses indicate the number of hours of incubation at room temperature when different from that shown at the top of the column.

renal ischemia, toxemia of pregnancy, shock, acute nephritis and congestive heart failure (128-131).

The validity of the renin mechanism is unquestioned as a defense reaction to acute and subacute circulatory changes. When these become chronic, renin is replaced by another vasospastic mechanism, probably that of pherentasin.

Pherentasin may be a form of hypertensin, for there are similarities between the two substances. There are also dissimilarities. The known properties of the two are listed in Table VIII. It is possible that metabolic alterations

animals to normal levels (132) It is not renin As a protein it probably acts enzymatically Possibly sustained pressor principle is a precursor of pherentasin or represents another renal pressor mechanism

**Vasoexcitor Material** This unidentified substance has the property of sensitizing blood vessels to epinephrine when the latter is topically applied It comes from ischemic kidney and is active in minute amounts Larger quantities appear in chronic hypertension and congestive heart failure (100) Other substances such as renin pherentasin sustained pressor principle and some primary amines also have this property which may be nonspecific

**Others** A great many vasoactive substances have been found in urine and blood most of them eventually showing up as primary amines or more complex structures They may represent metabolic by products of the basic renal abnormality No good case for any has been proven as directly concerned in chronic generalized vasospasm (133-135 112 4)

*Comment* When many different substances are discovered or suspected to cause a single recognized abnormality time usually leads to the abandonment of all but one as causative factors Let us attempt to gather all of these different substances together and fit them into one unified scheme To do so we must speculate

1 Renin may be involved in experimental renal hypertension The evidence for this statement is indirect in that anti renin prepared by immunization reduces the hypertension of renal hypertensive dogs (136) Anti hog renin neutralizes hog and dog renin and canine hypertension anti monkey renin neutralizes monkey and human renin and simian hypertension (137) These anti renins are therefore species specific to some degree

2 If anti monkey renin is found to affect human hyper

occurring with time from the former from the latter, or that both have a common precursor Hypertensin appears to require a metal as an activator

**Posterior Pituitary Factor** A pressor substance of polypeptide nature which has received some serious attention in hypertension is vasopressin While a smooth muscle stimulant in small doses, it also has such antidiuretic properties that little speculation concerning its role in hypertension has been aroused The direct relationship of the hypothalamus and the stalk of the pituitary, the known but minor electrolyte imbalances found and the peptide nature of the substance make it not inconceivable, as an effector substance, provided some minor alteration in its molecule negates its antidiuretic properties While not a nephrogenic substance one of its actions is on the kidney, if pressor, its release by the pituitary might be expected to cause widespread vascular constriction The antidiuretic dose, however, is very small compared to the pressor dose In our experience even large amounts do not constrict the smooth muscle of the isolated rabbit aorta, as pherentasin and hypertensin do Although it is possible that pherentasin may be a renal metabolic product of vasopressin, there is no proof or disproof of this idea Interestingly enough, however, pitressin has been used to treat hypertension, with most variable and inconclusive results \*

**Sustained Pressor Principle** A protein obtained from ischemic renal tissue or blood of animals in shock has the property of restoring the low blood pressure of pitied

\* Pitressin or vasopressin may require an activator for commercial preparations are inactive on the rabbit aortic strip It exists in a ring form with an S-S linkage (435) We have attempted to activate it by adding copper cobalt ferrous iron zinc manganese nickel and mercury without success save for an equivocal slight activation with copper Oxytocin or pituitrin is also inactive in this system

contain a terminal amine group necessary for activity. Both can act as a VEM. Renin is inactivated *in vivo* by crude monamine oxidase (112).

6 Alterations may occur by two mechanisms: decarboxylation of a terminal carboxyl leaving a peptide amine or preferably peptide splitting leaving a terminal amine.

7 The substrates as well as the renins from different species are obviously different in composition. Human and primate renin will react with the substrates from all mammals tested, while animal renin will not react with  $\alpha$ -globulins from primates. The exhibition of pressor activity of all hypertensins does not in any way mean that they are identical in chemical composition, but only that they have in common an active group, probably a terminal primary amine. Pepsin acting on casein produces a pressor peptide, pepsitensin, identical in action to hypertensin. There are thus many variables in species, the source of a renin, the source of serum  $\alpha$ -globulins which almost certainly differ in composition from one species of animal to another, and perhaps the nature of the plasma enzyme converting the inactive peptide into its vasoactive form. The different amino acids found by various workers can be perhaps explained by the different sources from which the renin and its substrate were obtained (Table IX). Since human renin is unique to primates and since human globulins are unique to man, human hypertensin can be expected to be unique in its composition of amino acids. Therefore, human hypertensin may have only a moderate resemblance to that obtained from horses, dogs, pigs, and cows, and could well be pherentasin.

8 There is no good evidence that renin or pepsin break down their protein substrates into substances having a terminal primary amine. Activation most likely occurs



tension, one can assume that renin or some similar protein is involved in human nephrogenic hypertension. But renin is found in renal venous blood only in acute vasospastic states and not in chronic hypertension, either experimental or clinical. Therefore, it must remain in the kidney, a highly speculative point.

3 Hypertensin or angiotonin is found only in acute vasospastic states. It has two forms, hypertensin I, inactive on isolated smooth muscle but active in blood,\* and hypertensin II, a much more highly constrictor and pressor substance (138, 139). An enzyme in plasma converts I to II (141). Apparently this is a metalloenzyme, requiring chloride and another metal which is tightly bound. Perhaps this enzyme is, or acts like, sustained pressor principle.

4 Pherentasin is found only in chronic vasospastic states. Perhaps pherentasin is a form of hypertensin or angiotonin, altered either by a slightly changed renin by a slightly different protein substrate, or by a new enzyme developing in chronic vasospasm, such as a peptide decarboxylase attacking the terminal carboxyl group.

5 Both of these substances are peptides inactivated by metal binding antihypertensive drugs and therefore probably contain a metal necessary for activity. Both are inactivated by monamine oxidase and therefore probably

---

\* Hypertensin I obtained from the action of hog renin on horse serum contains the single amino acids aspartic, proline, valine, isoleucine, leucine, tyrosine, phenylalanine, arginine and two molecules of histidine (139). Peart, using hypertensin from rabbit renin and beef serum, disagrees slightly in that there was no isoleucine and two molecules of valine (142). Obviously tyrosinase inactivates both through the tyrosine portion of the molecule; amine oxidase attacks the terminal primary amine, probably on aspartic acid. Manganese inactivates by pseudopeptidase activity (140). The sequence of amino acids in Peart's hypertensin is Asp Arg Val Tyr Val His Pro Phe His Leu (142b).

through a manganoous peptidase (295). Thus, we can postulate several theoretical alternate reactions based on all the evidence (Fig 9 the active materials are in italics)

Reaction A would thus occur in acute vasospastic states while reactions B, C, or D might take place in chronic states. *Pherentasin* needs no serum for activity; that it has at least six amino acids is based upon the findings of the active material showing six spots in chromatograms. A more unitary hypothesis is that *pherentasin* is actually *hypertensin II*, a matter on which we have no evidence as yet.

*Comment:* The pieces of the picture puzzle are falling into place, but there is need for much work to be done before the outlines are clear.

**Locus of Action of Pressor Substances.** While not directly established, it is reasonable to assume that all vascular smooth muscle is constricted by the pressor sub-




FIG 9

TABLE IX  
AMINO ACIDS IN VASOACTIVE PEPTIDES

Amino Acid	Hypertensin		Vaso- pressin (435)	Oxytocin (435)	Pepstatinsin (434)	Common to All
	(142)*	(139)†				
Histidine	2	2				
Arginine	1	1	1			
Aspartic acid	1	1	1	1	+	Aspartic acid
Proline	1	1	1	1	+	Proline
Valine	2	1			+	
Lysine						
Leucine	1	1				
Isoleucine		1		1	+	Leucine
Phenylalanine	1	1	1	1	+	
Tyrosine	1	1				
Alanine			1	1	+	Tyrosine
Serine					+	
Glutamic acid					+	
Glycine			1	1	+	
Threonine			1	1	+	
Cystine						
Methionine			2	2		
No amino acids	10	10	9	9	10+?	

NOTE: The differences in hypertensin may be due to the sources of the  $\alpha_1$  globulins from different species: hog, beef and horse. Vasopressin from hogs differs from that of beef in that leucine replaces arginine (435). Pepstatinsin was obtained from casein (434).

\* Rabbit renin + beef serum

† Hog renin + horse serum

to do more than detect the grosser lesions. A disease causing renal ischemia which then influences hypertension is often unsuspected because the cardiovascular manifestations of the elevated blood pressure may mask the underlying renal abnormality.

**Organic Parenchymal Renal Disease** The most common diseases of the kidney producing ischemia are pyelonephritis and glomerulonephritis. The former is often a low-grade smouldering fibrosing disorder without systemic manifestations and often without obvious urinary changes (143). The latter may be masked insofar as the urinary sediment is concerned by the superimposed hypertension. To list the other more unusual renal diseases congenital or acquired is hardly within the province of this discussion; most are often but not always associated with hypertension (144, 4).

**Organic Extra renal Arterial Disease** Atherosclerosis of the mouths of the renal arteries is common in generalized and in aortic atherosclerosis. The mechanism for the deposition of lipid in plaques about the orifices of bifurcating arteries is not known. Undoubtedly pressure changes play a part; possibly the presence of increased numbers of vasa vasorum at such bifurcations influence the lesions. Therefore when atherosclerosis involves the renal arteries partial renal ischemia may result with subsequent elevation of the blood pressure in predisposed individuals. With aortography becoming more common such lesions are more frequently demonstrated. According to Blackman they are the usual findings in hypertensive patients (145). It is possible that they represent the most common form of the disease in individuals beginning to be hypertensive over the age of 50. They are difficult to demonstrate at necropsy (146, 147).

Because the existence of these lesions has not been

stance (or substances) responsible for the humoral component of sustained hypertension. If this is so, the following physiological alterations in vascular volume can be expected

1 An increase in aortic volume, for the aorta is predominantly an elastic and not a muscular organ. As elastic limits are approached with increasing pressures the rate of increase of volume lessens

2 A decrease in the volume of blood in muscular arteries

3 If veins also took part in the process, venous volume in the smaller muscular veins should be decreased without, however, change in central venous pressure

It is often difficult to detect the high pulse pressure in hypertension by feeling the *dorsalis pedis* arteries or even the radials. When blood pressure is lowered by hydralazine, the pulses in these smaller arteries become full. Thus, as pulse pressure falls the detectable pulsations in muscular arteries increase. This seeming paradox is easily explicable on the basis that the muscles of these arteries are constricted in hypertension and that their volumes are diminished.

The high pulse pressure seen in most patients with hypertension is probably due to a relative loss of aortic elasticity because of stretching under pressure. Thus, the aorta becomes physiologically 'hardened'. In children and young adults we see low pulse pressures with diastolic hypertension probably because their aortas are more elastic than are those of older people.

### **ANATOMICAL CAUSES OF RENAL ISCHEMIA**

A variety of mechanisms and lesions can account for renal ischemia in man, many with experimental counterparts. Unfortunately our diagnostic methods are too crude

in the two groups Yuile (158) recently reviewed the literature on the relation of obstructive lesions of the main renal artery and hypertension and concluded that such a relationship does exist in certain cases. This author pointed out the desirability of closer anatomical and physiologic correlation.

**Organic Intra renal Arterial and Arteriolar Disease** The almost universal lesion found in the kidneys of patients with hypertension at necropsy is renal arterial and arteriolar sclerosis. This lesion is not the cause of the hypertension however but is the result. And a late result at that. About 50 per cent of patients having renal biopsies done during the operation of lumbodorsal sympathectomy had little or no arterial or arteriolar sclerosis (159). This lesion has been shown to result from hypertension produced by a variety of causes in rats (160-163) rabbits (164) and dogs (165-7). Serial renal biopsies in dogs over a seven year period have demonstrated the gradual development of the lesions only after 2 to 4 years of both neurogenic and unilateral renal hypertension the first sign being a thickening of the glomerular capsule and later an increase in material in the glomerular tuft staining with periodic acid (7).

None of these renal diseases alone can be said to cause hypertension in man until azotemia develops. Hypertension is absent in 30 to 50 per cent of patients with the first two types in non azotemic stages. The third type of course is the result of hypertension. They do however influence it profoundly and may often alter its course to a progressive and severe one. That quality which we call the ability to react to stress by vasospasm must apparently be present first and in conjunction in order for severe sustained hypertension to develop in patients with organic renal ischemia.

Why then are there no more cures of hypertension

emphasized in the recent literature, we quote from Braun Menendez *et al* in 1946 (148) "Goldblatt (149) was the first to show that hypertension was associated in some cases with sclerosis and narrowing of the orifice or of the lumen of the main renal artery Lester (150) somewhat later described a case of chronic hypertension associated with complete arteriosclerotic occlusion of the left renal artery and incomplete occlusion of the right Freeman and Hartley (151) almost simultaneously reported hypertension in a patient who was nephrectomized because of an accident At autopsy an atheromatous plaque was found to obstruct the mouth of the renal artery Similar cases were described later by Blackman (145), Stewart (152) Saphir and Ballinger (153) and Laas (154) The importance of unilateral narrowing has been emphasized by Oppenheimer, Klemperer and Moschkowitz (146) who showed that in 18 cases who anatomically showed unilateral narrowing of the renal artery, 15 had hypertension Blackman (145) found a narrowing of the renal artery at or near its mouth in 86 per cent of cases with hypertension Richardson (155) recently reported stenosis of one or both renal arteries by arteriosclerotic plaques in 25 of 32 hypertensive patients studied at autopsy

Kahn and Lipply (147) observed a high incidence of bilateral arteriosclerosis in 1 000 hypertensive patients studied pathologically Friedman Moschkowitz and Marrus (156) observed arteriosclerosis of the renal vessels in 23 of 28 hypertensive patients who were nephrectomized

Lisa, Eckstein and Solomon (157) reported that in 100 consecutive cases coming to autopsy in which blood pressure readings were available, hypertension was present in 56 while 44 were nonhypertensive No appreciable difference in the average diameter of the renal artery was found

matter of fact many effective drugs bind metals in one way or another (Chapter VI) This common property immediately focuses attention on metalloenzymes in kidney and vascular smooth muscle It also stimulates considerable thought about the role of trace metals in pathogenesis of severe hypertension in which the neurogenic component has become of minor consequence

The agents used in man are hydralazine and its derivatives thiocyanate ion sodium nitroprusside 2,3-dimer captopropanol (BAL) sodium azide and ethylenediamine tetra acetate Of practical interest for continuous use are only the first three the effects of the other three being short lived (Table X)

#### HYDRALAZINE AND OTHER CHELATING AGENTS

Hydralazine and its derivatives are unique drugs No other agents known produce the same actions on vascular smooth muscle Understanding of their mode of action is the key to understanding of pathogenesis and possibly etiology of severe hypertension While imperfectly understood a consideration of their pharmacological chemical and enzymatic actions is necessary

**Chemical Reactions** Hydralazine like other hydrazides is a strong chelating agent. It will form a complex with iron copper tin vanadium, manganese nickel silver and mercury The possible structure is



making a five sided ring with nitrogen a most stable chelate This property is shared by isonicotinic acid hydrazide (isoniazid) and probably its isopropyl derivative



in cases of unilateral renal diseases subjected to nephrectomy? The answer is obvious. If hypertension once long established, can cause bilateral renal arteriolar sclerosis removal of the one primarily affected kidney will not remove *all* of the ischemic renal tissue. On the other hand, nephrectomy done in time may result in temporary or semi permanent cure (166, 167). Experimental counterparts of this situation are known in rabbits, which get permanent hypertension after removal of an ischemic kidney which has been in place for three months or more (164), two of our unilateral renal ischemic dogs suffered autonephrectomy, without influencing their long established hypertension.

*Comment* These three types of organic renal disease can be considered as accessory factors in pathogenesis but not primary ones. They probably do not cause hypertension in themselves without the neurogenic factor being present.

### DRUGS ACTING ON NEPHROGENIC MECHANISMS

We can learn something about nephrogenic mechanisms from the actions of specific drugs, although the effective agents are few and have several actions. In experimental hypertension however, there are broader leads. Three types of agents are active: metal binding agents, hydralazine and some other hydrazides (also metal binding agents) and pyrogens. The latter apparently dilate the renal vascular bed in some unknown manner allowing greater blood flow and therefore counteracting renal ischemia.

**Metal Binding Agents** All of the antihypertensive drugs used in man which do not apparently affect neurogenic pathways, have in common the ability to bind trace metals. There are no known exceptions to this statement. As a

(iproniazid) whose pyridine bases in themselves weakly bind metals without the hydrazide group (Table XI). Distinct specificities for metals are exhibited however.

Hydralazine is also a carbonyl reagent as are some other hydrazides phenyl hydrazine for example which forms an ozonone with glucose. It will bind pyruvate acetate and acetaldehyde (168). Hydralazine has specific reactions in that no ozonone is formed with glucose or lactic acid. It does not combine with any of the steroids tested (168). It is 1 hydrazinophthalazine (Apresoline).

This agent also complexes with the sulfhydryl groups on cysteine glutathione 2,3-dimercaptopropanol (BAL) and other simple mercaptans. The complex can be dissociated readily by arsenic.

TABLE XI A  
ISONIAZID \* HYDRALAZINE AND METALS

	Isoniazid		Binding of Hydral- azine† + Me <sup>++</sup>	Similarities
	Destruction by Me <sup>++</sup> Auto- claving %	Destruction by Me <sup>++</sup> H <sub>2</sub> O <sub>2</sub> %		
Mg <sup>++</sup>	0	5	0	+
Ca <sup>++</sup>	0	5	0	+
Mn <sup>++</sup>	100	100	87	+ Greatest at pH 6.5-7.0
Fe <sup>++</sup>	50	80	22	
Fe <sup>+++</sup>	10	95	100	+
Co <sup>++</sup>	40	35	0	
Ni <sup>++</sup>	10	15	48	
Cu <sup>++</sup>	100	100	100	+ Greatest at pH 9.5-10.0
Zn <sup>++</sup>	15	15	0	+

Lewin E. and Hirsch J. G. Studies on the stability of isoniazid. *Am Rev Tuberc & Pulm Dis* 71:732 1955

† Perry H. M. Jr. and Schroeder H. A. Studies on the control of hypertension by Hyphex. III Pharmacological and chemical observations on 1 hydrazinophthalazine. *Am J M Sc* 228:396 1954

TABLE X

SUBSTANCES WITH METAL BINDING PROPERTIES SELECTIVELY AFFECTING ARTERIAL HYPERTENSION (312)

Substance	Rat	Dog	Man	Metals Bound	Reference	Remarks
Thiocyanate		+	+	Many	173	Used in industry soluble
Nitroprusside		+	+	Many	174	Zinc Reagent
Azide*	+	+	±	Many	175	Reactant
2 3-mercaptopropanol (BAL)*	+	+	+	See Text	182	Chelator
Hydralazine and other hydrazines	+	+	+	See Text	168	Reactant
Tetrasodium pyrophosphate†	±			Many	4	Detergent and Reactant
9 mercaptans**	+	+		Many	182	Sulphydryl binding
6 sulfur compounds	+	+		Several	182	SCNH most active
8-hydroxy quinoline	+	+		Many	183	Chelator
Perma Kleer	+	+		Many	183	Polyamino carboxylic resin
Ca <sup>++</sup> EDTA	+	+	±	Many	180	Slight effect in man
Cr <sup>++</sup> EDTA	+	+			183	But not chelates of Fe <sup>++</sup> Zn <sup>++</sup> Ni <sup>++</sup> Cu <sup>++</sup> , Fe <sup>+++</sup>
Mn <sup>++</sup> EDTA	+	+			183	
Co <sup>++</sup> EDTA	+	+			183	

\* Short acting

† Large doses Only active phosphate of 11 tested

\*\* Ten others inactive 5 nonspecific

TABLE XII

INHIBITION OF HISTAMINASE BY HYDRAZIDES

Substance	Concentration Producing 50% Inhibition (molar)	Antihyper- tensive Effect
Guanidine HCl	$10^{-3}$	0
Thiosemicarbazide	$10^{-3}$	+
Semicarbazide HCl	$5 \times 10^{-3}$	?
Hydrazine $\text{SO}_4$	$8 \times 10^{-3}$	?
Aminoguanidine $\text{HCO}_3$	$5 \times 10^{-3}$	0
1-4 dihydrazinophthalazine	$2.3 \times 10^{-3}$	+
1 hydrazino-4 methylphthalazine	$2.5 \times 10^{-3}$	+
1 hydrazinophthalazine	$6 \times 10^{-3}$	+

Gross F Schuler W Tripod J and Meier R Inhibition of diaminoxidase (histaminase) by phthalazine derivatives *Experientia* 8 229 1952

Schuler W Inhibition of diaminoxidase (histaminase) *Experientia* 8 230 1952

It binds strongly to arterial mash serum proteins egg albumin and some polypeptides possibly through carbonyl or sulfhydryl linkages It does not bind with casein nor with mixed amino acids

**Enzymatic Reactions** Hydralazine is also an anti-enzyme for several known systems It and its derivatives are strong antihistaminases theoretically preventing histamine formed from histidine from being destroyed rapidly but not necessarily causing release of histamine from histidine (Table XII) Histamine can come from the action of histidine decarboxylase believed to be a pyridoxal enzyme if so inhibition by hydralazine might be suspected Hydralazine is a potent inhibitor of DOPA decarboxylase in small concentrations also a vitamin  $\text{B}_6$  enzyme (Table XIII) There is some evidence that histaminase itself may be a pyridoxal enzyme (169)

TABLE XI B  
EFFECT OF METALS AND BINDING AGENTS ON HISTAMINASE (437)  
(Substrate Cadaverine)  
Inhibition of Reaction %

Concentration	No Drug			Hydralazine			Isoniazid			Ba 12 630		
	10 <sup>-3</sup>	10 <sup>-4</sup>	10 <sup>-5</sup>	10 <sup>-3</sup>	10 <sup>-4</sup>	10 <sup>-5</sup>	10 <sup>-3</sup>	10 <sup>-4</sup>	10 <sup>-5</sup>	10 <sup>-3</sup>	10 <sup>-4</sup>	10 <sup>-5</sup>
Mn <sup>++</sup>	8	0		0								
Fe <sup>+++</sup>		0		0								
Co <sup>++</sup>	0				50		0		50	0		
Ni <sup>++</sup>	0	0					0			0		
Cu <sup>++</sup>		25	7	50			20	0		33	50	50

Schuler W and Meier R. Releasing action of metals on the hydrazine inhibited enzymatic oxidation of cadaverine  
*Arch Exper Path* 223 169 1954

NOTE The enzyme is inhibited by hydralazine isoniazid and Ba 12 630 2,4-di hydrazinoquinazoline. The metals alone had little effect on the enzyme but inhibition of the enzymatic reaction by both hydralazine and Ba 12 630 was prevented by Co<sup>++</sup> and Ni<sup>++</sup> that by hydralazine by Cu<sup>++</sup> that by isoniazid only by Mn<sup>++</sup> and none by Fe<sup>+++</sup>. The reaction between drug and enzyme was irreversible once it had occurred. These results offer indirect evidence for metal binding capacities of the three agents although histaminase (diamine oxidase) is not known to require a metal for activity.

TABLE XIII—(continued)

TABLE XIII—(continued)								
Substance	DOPA Decarboxylase MmMolarity of agent				Monamine Oxidase (Substrate tryptamine) MmMolarity of agent			
	10	1	0.1	0.01	10	1	0.1	0.01
Isoniazid	41	84	99	100	75	98	103	101
Iproniazid	108	—	—	—	14	52	91	101
Pyridoxal Isoniazid	100	114	92	91 (90)	96	101	101	101
1,5 diphenyl 3 thiocarbo- hydrazide	100	97	—	—	—	—	—	—
8 hydroxyquinoline sulfonic acid	102	—	—	—	105	—	—	—
Reserpine	102	90	92	94	—	—	115	—
$\beta$ Mercaptopropionic acid	81	98	100	97	123	111	103	95
Tetrasodium pyrophosphate	86	101	97	—	95	—	95	97
Sodium cyanide	66	85	98	97	45	98	—	—
Sodium thiocyanate	89	98	100	110	100	—	—	94
Sodium azide*	91	94	—	—	115	116	98	101
Choline azide	100	—	—	—	112	104	101	101
Sodium Nitroprusside*	63	71	76	91	129	98	101	100

Italicized figures represent 20% change at 1.0 millimolar concentrations or less considered significant

Those in parentheses show further dilutions by 10

\* Antihypertensive in man. Note that some of these tend to depress one enzyme and enhance the other

TABLE XIII  
EFFECT OF METAL-BINDING AND ANTIHYPERTENSIVE AGENTS UPON TWO RENAL  
ENZYME SYSTEMS (GUINLEA PIG)  
(% Activity)

Substance	DOPA Decarboxylase MmMolarity of agent				Monamine Oxidase (Substrate tryptamine) MmMolarity of agent			
	10	1	0.1	0.01	10	1	0.1	0.01
1 hydrazinophthalazine	12	23	59	88 (99)	163	159	118	103
C 5968* (Hydralazine)								
1-4 dihydrazinophthalazine	5	21	21	66 (83) (100)	144	156	118	103
C 7441* (Nepresol)								
3 hydrazine 6-phenyl diazine	4	39	74	87 (89) (90)	87	118	95	93
C 6084*								
1-4 dihydrazinopyridazine	20	33	61	102	25	82	98	84
C 13504*								
Phthalazine	87	—	99	98	61	103	101	96
C-7182								
1 hydrazino isoquinoline HCl	20	42	76	97	49	103	98	102
C 7406								

TABLE XIV B

EFFECT OF ADMINISTRATION OF HYDRAZINE ON URINARY  
EXCRETION OF 4-PYRIDOXIC ACID (MG) (111)

	No Subjects	No Tests	Mean Before	No Tests	Mean During	Dose of Hydrazine
Began on Hydrazine	4	9	24.5 (17.3-33.3)	18	15.5 (11.2-23.2)	150-600
On Hydrazine for 1-3 Years	6			28	12.8 (5.5-18.7)	200-600
On EDTA†	3	10	22.1	13	24.0 (22.0-26.0)	
On EDTA and hydrazine	4			22	12.7 (4.4-18.8)	200-600
Normal	5	22	21.8			
Atherosclerosis	4	22	27.4			

Per 4 hours after 0 mg. orally 1 pyridoxal hydrochloride

† Calcium disodium ethylenediamine tetraacetate intravenously

The ranges for each group shown in italics are the mean excretion rates of each patient

chelate trace metals. The antituberculous hydrazides are not antihypertensive however with the possible exception of isoniazid. The key to antihypertensive activity lies in the specificity of the hydralazines for a reaction not exhibited by other hydrazides and similar agents.

The known actions of hydralazine are listed in Table XV. The actions of a large number of similar substances are shown in Table XIII as regards the two enzyme systems considered here.

**Other Metal Finding Agents** Thiocyanate ion is used in industry for making soluble salts of a number of metals. In man according to Sollmann (173) it hastened the elimination of metals perhaps by rendering the metal protein compounds more soluble. In Table XVI is a partial list of the soluble metallic salts of thiocyanate. Symptoms



Whether or not hydralazine causes excretion or deficiency of vitamin B<sub>6</sub> is not known. It does seem to interfere with the conversion of pyridoxal to its metabolite 4 pyridoxic acid (Table XIV). A relative, isoniazid (isonicotinic acid hydrazide), promotes the excretion of a pyridoxal isoniazid complex in urine and can cause peripheral neuritis in patients taking large amounts for tuberculosis; presumably the neuritis is due to vitamin B<sub>6</sub> deficiency (170). Isoniazid is a good inhibitor of DOPA decarboxylase and a poor one of monamine oxidase (Table XIII). Its derivative iproniazid (isonicotinic isopropyl hydrazide) does not affect DOPA decarboxylase but is a strong inhibitor of monamine oxidase. Both inhibit histaminase (171, 172). The latter cannot be used clinically because of its 'benzedrine like' reactions of euphoria and cerebral stimulation, believed to be due to cerebral and peripheral inhibition of this oxidase, thus allowing natural primary amines to circulate.

We are discussing these related hydrazides because of their similarities of structure, their antienzymatic activities, their affinities for vitamin B<sub>6</sub> and their abilities to

TABLE XIV A

EFFECT OF REPEATED ADMINISTRATION OF PYRIDOXAL HYDROCHLORIDE UPON EXCRETION OF 4 PYRIDOXYLIC ACID (MG) (111)

Subjects	No	Mean Total Dose Vitamin B <sub>6</sub> (mg)	Mean Days Given	Amount Excreted on Last Test	
				Mean	Range
Normal	5	250	5	22.3	9.8-27.8
Atherosclerosis	4	250	5	27.8	21.8-32.4
Patients on EDTA†	3	1470	18	21.0	18.0-24.2
Patients on Hydralazine	11	700	12	11.3	2.6-20.5

TABLE XIV B

EFFECT OF ADMINISTRATION OF HYDRALAZINE ON URINARY EXCRETION OF 4 PYRIDOIC ACID (MG) (111)

	No Subjects	No Tests	Mean Before	No Tests	Mean During	Dose of Hydral- azine
Began on Hydralazine	4	9	24.5 (17.3-33.5)	18	15.5 (11.2-23.2)	150-600
On Hydralazine for 1-3 Years	6			28	12.8 (5.5-18.7)	200-600
On EDTA†	3	10	22.1	15	24.0 (2.0-26.0)	
On EDTA and hydral- azine	4			22	12.7 (4.4-22.8)	200-600
Normal	5	22	21.8			
Atherosclerosis	4	22	27.4			

\* Per 4 hours after 50 mg orally of pyridoxal hydrochloride.

† Calcium disodium ethylenediamine tetraacetate intravenously.

The ranges for each group shown in italics are the mean excretion rates of each patient.

chelate trace metals. The antituberculous hydrazides are not antihypertensive however with the possible exception of isoniazid. The key to antihypertensive activity lies in the specificity of the hydralazines for a reaction not exhibited by other hydrazides and similar agents.

The known actions of hydralazine are listed in Table XV. The actions of a large number of similar substances are shown in Table VIII as regards the two enzyme systems considered here.

**Other Metal Binding Agents** Thiocyanate ion is used in industry for making soluble salts of a number of metals. In man according to Sollmann (173) it hastened the elimination of metals perhaps by rendering the metal protein compounds more soluble. In Table XVI is a partial list of the soluble metallic salts of thiocyanate. Symptoms

TABLE XV

## SUMMARY OF PROPERTIES OF HYDRALAZINE OTHER THAN CARDIOVASCULAR

<i>Basic Chemical Reactions In Vitro</i>	<i>Reference</i>
Metal binding	
complete for Fe <sup>2+</sup> , Cu <sup>2+</sup> , Sn <sup>2+</sup> , V <sup>5+</sup>	(168)
partial for Mn <sup>2+</sup> , Fe <sup>3+</sup> , V <sup>3+</sup> , Ni <sup>2+</sup> , Ag, Hg	
none for Na, K, Be <sup>2+</sup> , Mg <sup>2+</sup> , Ca <sup>2+</sup> , Zn <sup>2+</sup> , Co <sup>2+</sup> , Cr <sup>3+</sup> , Cd <sup>2+</sup> , Al <sup>3+</sup> , As <sup>3+</sup> , Pb <sup>2+</sup>	
Carbonyl reagent	
with pyruvate, acetaldehyde, acetate	(168)
not with glucose, lactic acid	
Complex with SH	
with cysteine, glutathione, BAL and other simple mercaptans	(168)
Protein binding	
with serum, arterial mash, egg albumin, polypeptides	(436)
not with casein, mixed amino acids	
Enhances	
monamine oxidase ( $10^{-4}$ )	(Table XIII)
Anti-enzyme	
for histaminase ( $10^{-4}$ ) stronger than guanidine, thio-semicarbazide, weaker than hydrazine, amino-guanidine, equal to semicarbazide	(172)
for DOPA decarboxylase moderate ( $10^{-4}$ )	(Table XIII)
for succinic dehydrogenase, cholinesterase, polyphenol oxidase, none	(111)
Combination with	
no primary amines or simple amino acids	
lyophilized angiotonin	(168)
<i>Blocking Actions In Vivo</i>	
Weak for epinephrine, norepinephrine, arterenone, tyramine, isoamylamine, angiotonin	(168)
Strong for pherentasin, pervanadyl, cadmium, barium, pitressin	(168, 438)
Variable for serotonin according to species (weak in rat and dog, strong in cat)	(168, 63)
<i>Blocking Actions on Rabbit's Arterial Strip</i>	
Strong for pherentasin, angiotonin	(120)
Weak for norepinephrine and other primary amines	(120)

TABLE XV—(continued)

Vascular Reactions in Animals	References
Dilates constricted vessels renal femoral coronary acts for many hours	(438)
Does not dilate dilated vessels further (as in spinal animal)	(438)
Abolishes constriction caused by Ba pitressin ephed rine ergotamine histamine Priyine	(438)
Reactions in Man	
Lowering of plasma cholesterol	(180)
? lowering of blood pyruvate or total carbonyl	(168)
Apparent loss of Ti in urine	
Mild anemia	(168)
? Histamine release	(172)
Increases cardiac output tachycardia	(425)
Increases renal plasma flow	(426 427)

and side effects due to this ion are variable but resemble in some respects those induced by hydralazine because of the dissimilarity of the chemical structures of the two

TABLE XVI  
SOLUBLE COMPLEXES OF THIOCYANATES IN WATER

Soluble	Partly Soluble	Insoluble
Mn	Pb	Cu
Fe	Hg	Ti ?
Co	Ag	Si
Zn		
Mo		
Ca		
Sr		
Ba		

Hodgman C D ed *Handbook of Chemistry and Physics* 33rd Ed  
Cleveland Chemical Rubber Publishing Co 1951

TABLE XV

SUMMARY OF PROPERTIES OF HYDRALAZINE OTHER  
THAN CARDIOVASCULAR

Basic Chemical Reactions <i>In Vitro</i>	Reference
Metal binding	
complete for Fe <sup>3+</sup> Cu <sup>2+</sup> Sn <sup>2+</sup> , V <sup>5+</sup>	(168)
partial for Mn <sup>2+</sup> Fe <sup>2+</sup> V <sup>3+</sup> , Ni <sup>2+</sup> Ag Hg	
none for Na K Be <sup>2+</sup> , Mg <sup>2+</sup> Ca <sup>2+</sup> Zn <sup>2+</sup> , Co <sup>2+</sup> Cr <sup>3+</sup> Cd <sup>2+</sup> Al <sup>3+</sup> , As <sup>3+</sup> Pb <sup>2+</sup>	
Carbonyl reagent	
with pyruvate acetaldehyde acetate	(168)
not with glucose lactic acid	
Complex with SH	
with cysteine glutathione B <sub>4</sub> L and other simple mercaptans	(168)
Protein binding	
with serum arterial mash egg albumin polypeptides	(436)
not with casein mixed amino acids	
Enhances	
monamine oxidase (10 <sup>-4</sup> )	(Table VIII)
Anti enzyme	
for histaminase (10 <sup>-6</sup> ) stronger than guanidine thio semicarbazide weaker than hydrazine amino-guanidine equal to semicarbazide	(172)
for DOPA decarboxylase moderate (10 <sup>-4</sup> )	(Table XIII)
for succinic dehydrogenase cholinesterase polyphenol oxidase none	(111)
Combination with	
no primary amines or simple amino acids	
lyophilized angiotonin	(168)
<i>Blocking Actions In Vivo</i>	
Weak for epinephrine norepinephrine arterenone tyramine isoamylamine angiotonin	(168)
Strong for pherentasin pervanadyl cadmium, barium pitressin	(168 438)
Variable for serotonin according to species (weak in rat and dog strong in cat)	(168 63)
<i>Blocking Actions on Rabbit's Arterial Strip</i>	
Strong for pherentasin angiotonin	(120)
Weak for norepinephrine and other primary amines	(120)

Sodium azide which has a strong affinity for metals is a rather transient vasodilator, as is its relative choline azide producing sharp reductions in blood pressure. It is said to show differential actions in normotensive and hypertensive rats not depressing blood pressure in the former (175). We have been unable to confirm claims for chronic effects in man.

British Anti Lewisite (2,3-dimercaptopropanol BAL) is used clinically to remove trace metals from the body. Much is known of its actions (176, 177, 178) which do not include affinities for all metals. It is a disulfide chelating agent. In our hands it has proven effective in causing lowering of blood pressure in American hypertensive patients for periods of a few hours. On the other hand British patients have responded with a rise. It is prolongedly pressor in normotensive subjects (177) but was depressor in one American hypertensive patient in the hands of others (176). BAL has little clinical use at present in hypertension. In cadmium poisoning it will mobilize the metal but binding is weaker than is that of kidney for the metal is deposited and cadmium nephritis results (179). Many other heavy metals are mobilized and removed in the urine.

Ethylenediamine tetra acetate is a mild antihypertensive agent in man. Given intravenously as the disodium calcium complex it either lowers elevated blood pressure or reduces the patient's requirement for ganglionic blocking agents (180). Not a strong chelating agent for many metals it has little clinical use at present. Prolonged oral use has led to no toxicity; intravenous use has produced signs of zinc deficiency (181) which resembles that of vitamin B<sub>6</sub>.

**Experimental Compounds.** In anaesthetized rats and other animals a number of compounds having the capacity for binding or chelating trace metals lower hypertensive

agents, a common denominator must be present in the actions of both (Table XVII) Little interest in its mode of action has been aroused It can inhibit a number of enzymes, such as zinc-containing carbonic anhydrase and amino acid oxidase (173b) It is antithyroid, all antithyroid agents except those which act by competitive inhibition bind metals

Sodium nitroprusside is an antihypertensive agent of considerable potency when given intravenously, alterations in the course of the disease have been described (174) A zinc reagent, it is a strong metal binder Its chronic toxicity is not known but should become apparent with continued use


TABLE XVII

SIDE EFFECTS OF TWO METAL BINDING ANTIHYPERTENSIVE  
DRUGS (84 108)




	<i>NaSCN</i>	<i>Hydralazine</i>
Action		
in normotension	0	±
in renal hypertension	+	+
enhanced by sympathectomy	+	+
Arthralgia	+	+
Lupus like syndrome		+
Cholesterolemia	+	+
Rhinitis	+	+
Conjunctivitis	+	+
Anti thyroid	+	0
Peripheral neuritis	+	+
Paraesthesias	+	+
Skin lesions	+	+
Headache	+	+
Flushing	0	+

both types of animals D Lowering of blood pressure in both types of rats and depression of the pressor action of norepinephrine E Lowering of the blood pressure of both normotensive and hypertensive rats without greater effect on the latter and without altering the pressor action of norepinephrine (Fig 11)

Mercaptan compounds which showed specific antihypertensive but not sympatholytic effects (Type A) in the rat were





Procaine Salt of  $\beta$  mercaptopropionic acid




1-ethyl 2 mercaptoimidazole

Compounds showing both antihypertensive and norepinephrine blockade (Type C) were



and to a less extent





blood pressure but do not affect or raise normal blood pressure

Theoretically there are five types of sustained depressor responses of the blood pressure of hypertensive and normotensive rats to the intravenous injection of various active compounds A Little or no effect on normotensive rats with specific lowering of the blood pressure of renal hypertensive rats, while the pressor action of norepinephrine is unaltered or little affected (Fig 10) B Little effect on blood pressure with depression of the pressor action of norepinephrine in both types of rats C Effect of type A with depression of the pressor action of norepinephrine in






FIG 10 Effect of intravenous EDTA on diastolic blood pressure of anaesthetized rats Note that the normotensive pressure varies little while the renal hypertensive falls with smaller doses Typical type A response

Certain mercaptans were depressor in both types of animals (Type E) although the last two showed significant differential activities

6-amino- $\alpha$  mercaptobenzothiazole2,3-dimercaptopropanol (BAL)  
(Fig. 12)



Only four mercaptans were sympatholytic (Type B) without depressor effects the last to a lesser degree



Acetonyl mercaptan



1 thio-2 hydroxy propane



Sodium 2 mercapto-5 benzothiazole  
sulfonate

Tri-decyl mercaptan

Five were inactive or pressor the last having a short lived differential action



Cysteine

2 mercaptoethyl hydrogen  
(carboxymethylmercapto) succinate


Mercaptosalicylic acid



Tapazole




## A-MERCAPTOPROPIONIC ACID



B

## CYSTEAMINE



A

FIG 11 Effect of intravenous sulphydryl compounds on the diastolic pressures of anaesthetized rats A Cysteamine 5.0 mg Only hypertensive pressure is depressed (Type A) B  $\beta$ -Mercaptopropionic acid Both types of pressures are depressed (Type E) The dose of cysteamine at 0 minutes was 5.0 mg the rises after 0.5  $\gamma$  norepinephrine

A group of sulfur-containing compounds were similarly divided. Type A activity was demonstrated by





FIG 12 A. Transient effect of 2,3-dimercaptopropanol (BAL) on systolic pressure of renal hypertensive rat. Blood pressure was measured by the foot cuff method using a photoelectric cell. The open circles are measurements made 2, 3, and 4 hours after the injection; the closed circles 24 hours later. Note increasing tolerance.


B. Effect of BAL on blood pressure of a 59-year-old patient receiving hydralazine (5968) and hexamethonium chloride ( $\text{C}_6$ ) in too low doses to produce normotension. Doses are indicated at the top. BAL, 50 mg every four hours intramuscularly was given for four doses. At the bottom urinary excretion of hexamethonium ion and hydralazine are shown. The solid black areas represent free urinary hydralazine; the open areas that bound to sulfhydryl. All excreted hydralazine was bound after BAL was given. (From Perry H. M. Jr. Schroeder H. A. and Morrow J. D. *Am J Med Sci* 228:405, 1954.)

## BAL IN CHRONIC RAT




A

L.H.d



B

There was no activity exhibited by oxidized glutathione nor by




One compound of interest contained three ethyl mercaptans on a quaternary ammonium nitrogen it was made on the possibility that ganglionic blockade as well as mercaptan effect might result. However it acutely raised the mean diastolic pressures of normal and hypertensive rats 36 and 15 mm Hg respectively producing the usual differential mercaptan effect of a depression of 6 and 32 mm respectively at the end of 2 hours. Another of special interest had the basic structure of hexamethonium ion with an ethyl thiopseudourea group on each quaternary nitrogen. Although listed as Type E it depressed the mean diastolic pressure of 5 normal rats 36 mm Hg and that of 5 hypertensive rats 86 mm in doses of 10 to 15 mg. Possibly ganglionic blockade was combined with another action on the renal pressor mechanism.



Examination of the structures reveals that antihypertensive or depressor activity was confined to those aliphatic compounds having a terminal sulfhydryl group or  $\text{SCNH}$  in the molecule unencumbered by a heavy salt aromatic compounds containing  $\text{SCN}$  were likewise active. Such compounds usually bind metals sulfur nitrogen binding being strongest with Cu Ni Ag Cd and contiguous heavier elements in the periodic table. These results suggest that possibly some copper enzyme was altered or inactivated causing the pharmacological activities of the compounds (182).

If this surmise be true the next step was obviously to test known chelating agents in the same system preferably those not metabolized. If they were active obviously a metalloenzyme was altered.



Type C activity was shown by only one




Partial sympatholytic with good antihypertensive activity was exhibited by



Type E activity occurred after the following the last two showing differential effects



2 Benzyl 2 thiopseudourea hydrochloride



In order further to control the studies various pyridoxylidene metal amino complexes were subjected to the same test. Selective Type A effects were observed with the copper tyrosine nickel arginine aluminum phenylalanine and possibly the cobalt phenylalanine complexes. No ef

DIVALENT METAL DISODIUM ETHYLENE DIAMINE TETRA ACETATE





FIG 19 The effects of a series of increasingly tightly bound metal ethylene-diamine tetra acetates on the diastolic pressures of groups of hypertensive (upper bars) and normotensive (lower bars) anesthetized rats. The first bar for each metal complex represents the change 20 to 30 minutes after one intravenous injection of 5 mg the second and third changes a like interval after subsequent injections. Mean changes are shown each group representing at least 3 and usually 4 or more rats. All complexes were dihydrogen metal except for ferric as shown on the right. Note the comparable differences in hypertensive (mean diastolic pressure 119 mm. Hg) and normotensive animals (mean diastolic pressure 77 mm Hg) as well as the small effects with sodium and magnesium complexes which can alter calcium levels in blood, and the decreased effects with nickel copper zinc and trivalent iron. Metals are listed in order of atomic number. The ferrous was probably partly ferric. (From Schroeder H. A. and Perry H. M. Jr. *J Lab & Clin Med* 46:416 1955)



Activities of Type A were shown by the strong chelating compounds



and Perma Klear a polyaminocarboxylic acid resin with chelating qualities. Pressor activity was exhibited by the weaker chelating agent, 16 tolylbiguanide. Therefore one or more metals must have been removed presumably from metalloenzymes, since EDTA, at least is not metabolized.

In order to ascertain which metal or groups of metals might be chelated advantage was taken of the different stability constants of EDTA and various metals of the first transitional series. Figure 13 shows the results and Table XVIII the stability constants. Any metal removed from tissues must have displaced one with a lower stability constant. Aside from the ferrous chelate which readily oxidizes to ferric in solution it is evident that those with higher constants than 16 l (for cobalt) are not active, these included the nickel zinc and copper chelates. Since nickel has no known function it is reasonable to assume that ferric iron zinc or copper was displaced from tissues by the chelating compound.

In order to determine whether or not the metal ions themselves showed activity small amounts of the chlorides were injected (Fig 14). Only ferrous, cobaltous, cupric and zinc were active. Cobalt is a known vasodilator and zinc salts cause flocculation of plasma proteins which may have accounted for the obscured effects. Suspicion therefore rests upon copper or zinc as being involved in the maintenance of renal hypertension in the rat.

pressure of 4 hypertensive patients monothio glycerol was apparently inactive a trithione (SKF 1717) given orally appeared inert BAL, however exhibited depressor activity in 6 hypertensive patients when given every 4 hours in doses up to 50 mg per kg the effects were relatively short lived (2 to 4 hours) We did not observe a pressor effect after this material was given (183)

*Comment* This common denominator of the antihyper




FIG 14 The effects of a series of metal ions on the diastolic pressures of groups of hypertensive (mean diastolic pressure 121 mm. Hg) and normotensive (mean diastolic pressure 81 mm Hg) anesthetized rats similarly treated. Doses were 0.2 mg. For obvious reasons sodium and calcium salts were not given. The pressor action of pervanadate is indicated as well as are the effects of cadmium and chromic chlorides. Note the differences between the ions and their complexes as shown in Figure 13 especially in regard to chromous manganous ferrous nickelous zinc, and ferric iron which was inert in large doses (From Schroeder H. A. and Perry H. M. Jr *J Lab & Clin Med* 46:416 1955)

TABLE XVIII

SIGNIFICANT EFFECTS ON DIASTOLIC BLOOD PRESSURE OF METAL CHELATES (15 MG) AND ION (0.6 MG) IN HYPERTENSIVE RATS

$Me^{++}$	Atomic No	$\log K_1$	$H_2MeEDTA$ (mm Hg)	$MeCl_2$ (mm Hg)
Na <sub>2</sub>	11	1.66	—	—
Mg	12	8.69	—	—
Ca	20	10.59	-63	—
Cr	24	13.00	-51	—
Mn	25	13.47	-31	—
Fe	26	14.22	—	-40
Co	27	16.10	-33	(-21)
Zn	30	16.58	—	-29
Ni	28	18.45	(-22)	—
Cu	29	18.38	—	-28
$Fe^{+++}Na$		25.00	+33	—

$\log K_1$  is an index of the stability of the chelate the higher values being more stable. The figures were taken from Sequestrene a publication of the Alrose Chemical Co. Providence quoting Scharzenbach *et al*. That for chromous is not exactly known.

EDTA—ethylenediamine tetraacetate

effects were observed with three glutamic acid and two phenylethylamine complexes. Copper again comes under suspicion.

These same effects were observed in renal hypertensive dogs, by the use of BAL and hydralazine (Fig 15). In renal hypertensive dogs BAL (5 mg per kg) injected intramuscularly produced definite but transient (2 to 6 hour) depression of blood pressure as did sodium thio glycolate intravenously. When BAL was injected with 1 hydrazinophthalazine a moderately active depressor substance, the effects were enhanced. Only four of these compounds were sufficiently studied to give to human beings. Cysteine caused no demonstrable alteration in the blood

tensive compounds not acting on nerves that is the ability to bind trace metals is not confined to this class of drugs. In fact most modern drugs have this ability. Their differences lie in their relative affinities for the metals in question their dispersing powers and their transport to other sites. The striking coincidence however of metal binding properties and effect lead to only one conclusion that one or more metals are bound and altered from metallo-enzyme sites and that abnormal trace metals may indeed be acting upon enzymatic mechanisms to produce hypertension. A consideration of how they may act will be discussed in following chapters.

#### THE EFFECT OF ANTIHYPERTENSIVE AGENTS ON NEPHROGENIC EFFECTOR SUBSTANCES

A method for screening antihypertensive agents involves the isolated rabbit aortic strip a spirally cut piece of smooth muscle which contracts when pressor substances are applied (120). Substances acting mainly on norepinephrine and other primary amines acting on more complex pressor substances and showing general inhibition of all types can be evaluated. While many agents tested cannot be applied to man their activities can be evaluated readily on isolated muscle and in the hypertensive animal. A substance which is nontoxic inhibits pherentasin and lowers the blood pressure of hypertensive rats while not affecting normotension is obviously of therapeutic interest.

**Pherentasin** Using the isolated rabbit aorta suspended in oxygenated Ringer's solution a number of these substances have been tested for their activities against pherentasin. The relative degrees of inhibition are indicated in Table VII. All of the *metal binding* agents are inhibitory. On the possibility that pherentasin may be an adrenergic agent a number of sympatholytic substances




FIG 15 Effect of various substances on the mean blood pressure of a renal hypertensive dog 035. The left renal artery was constricted in August 1949 causing moderate hypertension. *Upper* 1 Hydrazinophthalazine (5968) injected intravenously. Note the effect when given at less frequent intervals than daily: blood pressure falling for 24 hours and then rising in 48. Only small doses were required. During the subsequent year mean blood pressure rose. *Lower* Cysteine intravenously caused only insignificant variations; sodium thio glycolate more pronounced but transient ones; BAI intramuscularly alone and combined with intravenous cysteine similar depressions but BAL combined with 5968 produced marked responses. Both the immediate (2 to 6 hour) and late (24 hour) responses to these substances are shown. Only BAL and 5968 together produced significant depression for 24 hours. The dog's mean blood pressure consistently remained above 200 mm Hg for 5 months after this study when it was given 1.0 gm thiosemicarbazide by mouth and died of convulsions.

is not lowered or raised 2) renal plasma flow increases relatively more than peripheral blood flow 3) blood flow through other areas does not change 4) blood viscosity and volume are not altered and 5) there are no toxic manifestations Hydralazine does not fulfill all of these criteria and also causes late toxicity and some unpleasant side effects However it is probably the closest approximation available at the present time the others either being in

## APRESOLINE BLOCKADE OF PHERENTASIN




FIG 16 At 0 minutes after a control period of 20 minutes 10 unit of pherentasin previously found active was injected intravenously into a rat with the response of systolic and diastolic pressure shown. At 10 minutes 10 mg of hydralazine (apresoline 5968) was injected intravenously resulting in an immediate fall of blood pressure. A subsequent injection of 20 units of pherentasin caused little response however 10 unit of angiotonin was pressor. At 35 minutes 50 mg of 5968 was injected the response to another unit of angiotonin 5 minutes later was not inhibited (From Perry H M Jr and Schroeder H A. *Am J M Sc* 228 396 1954)

TABLE XIX  
ADRENERGIC BLOCKADE OF VASOACTIVE PEPTIDES  
(RABBIT AORTIC STRIP)

<i>Blocking Agent</i>	<i>Pherentasin</i>	<i>Hypertensin*</i>	<i>Serotonin</i>	<i>Norepinephrine</i>
Regitine	0	±		
Dihydroergotamine	0	0	+	+
Iproniazid	sl	sl		
Cocaine	0	0		
Dibenamine	0	0	+	+
Pyribenzamine	0			
Atropine	0			
Amine oxidase	+	+	+	+
Tyrosinase	0	+	0	+

\* Probably mainly hypertensin I

were also tested. None showed the characteristic alterations of pherentasin activity exhibited by primary amines (Table XIX). Pherentasin was actively inhibited by hydralazine in the intact rat (Fig. 16).

**Renin and Angiotonin.** On the isolated smooth muscle system, hydralazine in fairly high doses is antagonistic to angiotonin. In the intact animal this antagonism is not demonstrated by doses sufficient to inactivate pherentasin. A number of antihypertensive metal binding agents however inactivate angiotonin in the isolated system suggesting that a metal is essential for its activity.

**Others.** Hydralazine inactivates sustained pressor principle as does  $\beta$  mercaptopropionate. It also inactivates pressin.

### CLINICAL IMPLICATIONS

A true antihypertensive drug is one which lowers elevated blood pressure to normal without affecting normal blood pressure, in the process of which 1) cardiac output

is not lowered or raised 2) renal plasma flow increases relatively more than peripheral blood flow, 3) blood flow through other areas does not change 4) blood viscosity and volume are not altered and 5) there are no toxic manifestations Hydralazine does not fulfill all of these criteria and also causes late toxicity and some unpleasant side effects However it is probably the closest approximation available at the present time, the others either being in

## APRESOLINE BLOCKADE OF PHERENTASIN




FIG 16 At 0 minutes after a control period of 20 minutes 10 unit of pherentasin previously found active was injected intravenously into a rat with the response of systolic and diastolic pressure shown. At 10 minutes 10 mg of hydralazine (apresoline 5968) was injected intravenously resulting in an immediate fall of blood pressure. A subsequent injection of 20 units of pherentasin caused little response however 10 unit of angiotonin was pressor. At 30 minutes 50 mg of 5968 was injected the response to another unit of angiotonin 5 minutes later was not inhibited. (From Perry H M Jr and Schroeder H A *Am J M Sc* 228 396 1954)



experimental stages, or showing excessive toxicities or only transient effects

Toxic effects appearing late are those of the development of a syndrome indistinguishable from disseminated lupus erythematosus, reversible when the agent is omitted (93, 184 187) This syndrome has been characterized by 1) normotension, 2) arthralgia or arthritis, and 3) appearance of elevated cephalin-cholesterol flocculation and thymol turbidity of serum Continuation of the drug causes later manifestations which include anemia, leukopenia, splenomegaly, hepatomegaly, low plasma cholesterol, albuminuria microscopic hematuria, azotemia, pleuritis pulmonary lesions and the appearance of a positive LE test on peripheral blood These dire events appear only when the drug is continued at full doses The many bizarre findings of collagen diseases can occur The syndrome has a seasonal incidence appearing mainly in warm weather Coming on only after 5 months or more of administration of drug it is similar to late toxicity from several other metal binding agents

Since hydralazine is the only known drug which will produce disseminated lupus erythematosus in man and the dog (188) speculation as to its mode of action may help understanding of collagen diseases For some time we were attracted to the hypothesis that this syndrome and perhaps disseminated lupus itself represented a state of depletion from the body of some material important in the health of ground substance Loss of a trace metal or imbalance between essential and abnormal trace metals was considered, in view of hydralazine's known reactions Feeding of several trace metals failed to influence the disease The universal appearance of normotension or hypotension before symptoms appeared was in line with this hypothesis On the other hand, definite hypersensitivity has been observed,

fever, acute arthritis and prostration have occurred within a few hours of giving the drug or its analogues (185-189) both to patients recovering from hydralazine disease and to others never receiving the drug before. We have seen showers of L-E cells appear in one recovered person who had taken no drug for 2 years and was given small doses. In several other individuals reduction of doses has resulted in reversal of symptoms but not of all laboratory abnormalities. If the L-E phenomenon is one of hypersensitivity which is not known, this explanation for the disease is tenable. The question is open but we suspect that its answer will be fruitful of information on hypersensitivity, collagen disease and hypertension.

We do not know which substance is removed from the body by hydralazine or which enzyme system or group of systems is inactivated. The ability to produce this syndrome in man by a drug however suggests that lupus erythematosus itself is an enzymatic disturbance which might be affected by replacement therapy. A suggestion of what has been removed in the way of metals may be obtained from trace metal analysis of human urine when hydralazine was given and from cases of known hydralazine disease and known lupus erythematosus (Table XX). The abnormal urines are somewhat low in manganese, somewhat high in tin and zinc. While these findings may not be pertinent to pathogenesis, they deserve study. Blood copper levels were not reduced in this syndrome.

Of the other known functions of hydralazine, carbonyl binding is the most logical to explain the toxicity. It is difficult however to conceive of carbonyl binding as leading to depletion. There was no diminution in total carbonyl or pyruvate in blood of patients treated with hydralazine. Its other function, removal of sulphhydryl, is also a possible but not probable cause of hydralazine

TABLE XX  
URINARY TRACE METAL CONCENTRATIONS\* IN DISSEMINATED LUPUS ERYTHEMATOSUS (111)

T <sub>1</sub>	V	Cr	Mn	Ni	Zn	Mg	Ag	Cd	Pb	Sn	Comments
Ch.	<0.05	0.6	Inter†	1.8	Inter	>50	0.36	1.4	120	38	Lupus
Ev	<0.05	—	<5	5.7	180	21	0.29	1.8	15	5.0	Lupus
Sc.	4.0	0.41	<5	Inter	175	4.4	0.46	3.0	1.1	3.0	Lupus
Mean**	1.37	0.5	<5	3.75	177.5	25.1	0.37	2.07	45.4	15.3	
Dr	10	4.9	<5	2.0	175	6.1	0.58	6.0	170	6.8	Lupus
Ha.	3.6	1.3	<5	1.4	87.5	12	0.33	<0.3	5.3	17	Lupus
Mean	6.8	3.1	<5	1.7	131.3	9.0	0.46	3.15	87.65	11.9	
St	2.8	1.5	<5	1.1	159	2.4	2.0	70	0.90	8.8	Hydralazine Disease
Sa.	<0.05	0.11	<5	4.4	108	3.9	1.2	0.5	0.50	7.8	Hydralazine Disease
Mean	1.43	0.81	<5	2.75	133.5	3.1	1.6	35.2	0.70	8.3	
Normal											
Mean	<3.8	<0.63	<9.7	<2.8	<67	<14	0.80	<0.86	<5.7	<3.2	
Max.	11	2.2	37	12	135	29	1.4	4	28	5.6	
Mfn.	<0.05	<0.5	<5	<0.05	<5	<0.5	0.23	<0.5	<0.05	<0.5	

\*Results are expressed in parts per billion  
 \*\*Specimens supplied by Dr. A. C. Corcoran.  
 †Interference

disease. Its known antihistaminase activity and the relation of histamine to hypersensitivity is another possible explanation as is its affinity for pyridoxal.

Lest the reader refrain from using this potent agent when it is needed for the prolongation of life we can say that hydralazine disease occurs in less than 10 per cent of patients and then only when relatively large doses are given that it is readily detectable easily reversible and does no permanent harm if the drug is discontinued in time. There has been no mortality except in unwatched patients and the drug on the whole is hardly more toxic than many in continuous use for the control of chronic diseases. The method of use is discussed in Chapter VIII.

## Chapter V

# FACTORS INFLUENCING THE CONVERSION OF NEUROGENIC TO NEPHROGENIC HYPERTENSION

## THE TRANSITION FROM INTERMITTENT TO PERMANENT VASOSPASM

**I**F THE VASOSPASM resulting from emotional reactions to stress were confined to the reversible phenomena seen in hyperreactors to pain the net effects upon the cardiovascular system would be less important than those resulting from exercise (Unfortunately at some stage *permanent vasospasm*, at first of slight degree then more and more pronounced gradually develops engrafted upon which are the repetitive reversible episodes of neurogenic vasospasm) The key to the understanding of the pathogenesis lies in this change of reversible to irreversible vasospasm therefore we may be allowed to theorize for purposes of orientation The curve of incidence of chronic hypertension in the general population plotted against age (showing a rapid increase in the fifth decade) is consistent with several theories Since all biologic phenomena can eventually be resolved in terms of physics and chemistry we should examine possible basic disturbances in that light The physical explanation—organically induced increase in vascular resistance from sclerosis of all vessels—does not fit the facts although the effects of increased intra arterial tension which both cause cardiac overwork

and which increase the rate of development of atherosclerosis are beginning to be appreciated. Of chemical explanations we look for some disturbance of some enzyme system concerned a) in the relaxation of smooth muscle b) the destruction of potential pressor substances, c) the reactivity of blood vessels or d) the metabolism of the kidney

### THEORY OF HABITUAL REPETITIVE STIMULI

One idea is that the trigger mechanism for emotional discharge to vasospasm becomes more sensitive as the years pass lesser and lesser stimuli setting off the response. In other words an habitual pattern of reaction is set up which becomes more and more active and eventually leads to organic renal vascular disease thereby causing organic renal ischemia. This explanation begs the question and is inconsistent with the fact that demonstrable renal vascular disease may be *absent* in sustained hypertension.

### THEORY OF DEPLETION OF VASCULAR SUBSTANCES

Another theory is concerned with the depletion of substances or the wearing out of the mechanisms which cause reversal of vasospasm i.e. the relaxation of smooth muscle. In other words repetitive stresses accelerate the aging process in smooth muscle making it more reactive. There is no evidence for this theory although as Szent Gyorgi has pointed out (190) contraction of muscle involves loss of potential energy relaxation a build up of energy (phosphate) in the contractile elements. Therefore slight loss of some substance promoting the restoration of the energy for relaxation may occur with time or possibly inhibition of the mechanisms of energy storage by accumulation of another substance. In that event, permanent vasospasm

would result from normally circulating vasoactive substances. This idea has no present basis of fact, although the ions calcium, magnesium sodium and potassium are intimately concerned in muscular contraction and relaxation and it is not impossible to believe that imbalances occur with age.

The irritability of muscle and presumably smooth muscle depends upon the ratio in extracellular fluids

$$\frac{\text{Na}^+ + \text{K}^+ + \text{OH}^-}{\text{Ca}^{++} + \text{Mg}^{++} + \text{H}^+}$$

When the concentration in the numerator is increased irritability increases when that in the denominator is increased irritability decreases. The extracellular concentrations under most conditions can affect intracellular ones. Therefore vascular smooth muscle may become more irritable and therefore contract more either with higher sodium and potassium levels, by interference or displacement of calcium or magnesium by another inactive element or by their depletion (192).

### INTRARENAL ENZYMATIC MECHANISMS

If all nephrogenic hypertension (except azotemic) is dependent upon the same renal enzymatic alterations it is well to consider and search for reasons as to how this can come about. Hypertension has been produced experimentally in animals and resulted in man from a variety of methods of damaging the kidney most of them can be considered as producing ischemia. Hypertension has also been produced in dogs with no kidneys kept alive by hemodialysis, whether the mechanism is the same or not is unknown. Yet in man with permanent hypertension there

may be no vascular lesions no organic renal disease no organic renal ischemia but functional changes are found which are obviously dependent upon circulating vasoconstrictor substances provoking spasm In the dog spasm is even present distal to renal arterial constriction (10) What is the reason?

To find the answer we must delve deeper into those mechanisms affected by ischemia in order to think of similar ones altered in the functional state Something has happened to the kidneys of patients with sustained functional hypertension which may be similarly affected in organic renal ischemia We look to altered enzymatic mechanisms to supply us with a common denominator Because ischemia is related to oxygen tension and oxygen consumption oxidative mechanisms are the first to be considered Is it possible therefore that some renal oxidative enzyme in man is reduced in function by both organic ischemia and an exogenous accumulating substance? If this were so a population might be exposed uniformly to this substance but only certain members predisposed to hypertension i.e. those who react to stress by vasospasm might develop permanent disease

Pickering put forth this same idea that a whole population was contaminated but only certain persons developed the disease (Chapter II) This theory is the only one consistent with the known facts and which explains the virtual absence of the disease in many areas of the world For it is likely that a proportion of all human beings react to stress by neurogenic discharges through the sympathetic nervous system

There are two possibilities intimately related which should be explored in order to discover this basic disturbance Both could explain this most important factor One involves vitamin B<sub>6</sub> one trace metals.



**Theory of Local Vitamin B<sub>6</sub> Deficiency** Vitamin B<sub>6</sub> is a most prevalent coenzyme, causing reactions described before which are essential for life and health. Deficiency disease in man has been produced by desoxypyridoxine, a metabolic antagonist which may not compete with all the known functions of the vitamin, the principal lesions were of the skin and included cheilosis, chemosis, papular eruptions and dandruff (191) similar to deficiency of other B vitamins or to zinc deficiency (181). Peripheral neuritis has also been produced by isoniazid which causes excretion of this vitamin. In monkeys loss of hair, weakness, weight loss, muscular wasting, microcytic anemia and skin lesions occur. Obviously we cannot look to generalized vitamin B<sub>6</sub> deficiency for explaining human hypertension, nor any other disease since most patients lack symptoms and appear in the best of health. In young rats however hypertension has been produced by desoxypyridoxine (193-195). Since this coenzyme takes part in all amino acid metabolism, it is possible that a relative or marginal deficiency occurs in the tissues (or kidneys) of populations subject to hypertension, being a local deficiency general ized lesions would not occur.

Is there a deficiency of vitamin B<sub>6</sub> in the American diet? Authorities differ in their opinions. The need for vitamin B<sub>6</sub> in man has been established but the daily requirement has not, being estimated as more than 10 and less than 50 mg (191). The vitamin is heat labile (196) and destroyed by light (197). It is destroyed or removed during the processing of foods, which includes canning and cooking (198-199). Simple methods for its estimation, depending upon the growth of certain bacteria or yeasts, are considered as giving values too low (200) or too high (201) compared to rat growth curves. The answer is difficult to find.

The American diet composed as it is of many canned

and processed foods, may be marginal with respect to vitamin B<sub>6</sub> during certain seasons of the year, according to the best figures available (201-202). Furthermore all pregnant women appear to be somewhat deficient the growing fetus apparently removing the vitamin from the mother without causing skin lesions (203-205). Army combat rations were found deficient for monkeys and rats (206-207) and a brand of infant food was found deficient causing convulsions (208-209).

✓ As we have said there is obviously no generalized deficiency state which can be recognized in the American adult population. Marginal intakes however are possible especially during seasons of the year when the diet is composed largely of processed foods. Converting the values in foods described in the literature to include a daily diet we have found that the intake is barely adequate (202). About 0.2 mg per 100 Gm of food is necessary to promote the growth of rats. Not many foods contain this much when cooked and it was difficult to calculate a 2.0 mg intake in a sample hospital diet (202).

Why do not pronounced deficiency symptoms appear? Apparently this coenzyme has an affinity for systems where it is most needed for life and less for health. Its distribution in organs shows wide variations (201). Perhaps renal deficiency can exist without deficiencies elsewhere, perhaps overloading of one vitamin B<sub>6</sub> enzyme system by metabolic products can produce a state of local deficiency without it being manifest in other systems. The need for a coenzyme varies as the load placed upon the enzyme system as is so well known in the case of vitamin B<sub>6</sub> or thiamin. A third possibility is that specific antagonists accumulate with age.

✓ Trace Metal Imbalance. The second theory concerns metalloenzymes. There are many in the kidney. If deficiency of a metal were produced that enzyme would be

TABLE XXI  
URINARY EXCRETION OF TRACE METALS IN NORMOTENSIVE AND HYPERTENSIVE STATES ( $\mu/L$ ) (111)

URINARY EXCRETION OF TRACE METALS IN NORMOTENSIVE AND HYPERTENSIVE CASES												
	Mn	Zn	Mo	V	Cd	Ti	Pb	Cr	Vi	Sm	Ag	
Normotensive 15 cases	Mean Range	<9.7 <5-37	66.8 <5-135	14.0 <0.5-45	<0.6 <0.3-7.5	<1.1 <0.5-4	<3.75 <0.05-10.7	5.7 <0.05-28	<0.64 <0.05-1.0	<2.78 <0.05-12	<3.22 <0.5-10.25	0.80 0.4-1.4
Untreated hypertensive 16 cases	Mean Range	54.11 <5-305	106.3 31-355	2.1-26 2.1-26	1.95 <0.2-14.5	37.0 <0.5-3.0	5.83 <0.5-31	14.23 0.93-50	0.88 <0.05-4.4	5.53 <0.1-16.8	8.93 0.5-41	1.21 0.3-4.6
Untreated hypertensive 8 cases	Mean Range	62.6 <5-305	109.7 5-205	7.59 3.8-15.5	2.86 0.4-14.5	41.7 <0.5-370	3.21 1.8-5.3	10.3 0.06-50	0.67 <0.05-3.1	3.99 1.1-6.75	5.47 0.5-10.5	1.44 0.3-4.6
Same treated	Mean Range	12.14 <5-36	89.75 31.170	4.54 0.5-10.25	0.93 0.27-1.85	3.14 <0.5-18	3.97 0.8-11	2.19 <0.5-4.9	0.71 <0.05-2.6	5.78 0.3-28.5	2.64 0.3-9	0.73 0.24-1.7
Hydralazine disease 2 cases	Mean Range	<5 Range	108-159 2.4-3.9	0.11-1.5 0.5-70	3.54 <0.05-2.8	123.5 1.1-170	1.99 0.4-2.8	2.7 1.4-5.7	13.96 3.0-38	0.40 0.29-0.58		
Disseminated lupus 5 cases	Mean Range	<5 Range	154 87.5-180	18.7 4.4-50	1.80 0.5-4.9	2.5 0.3-6.0	3.54 <0.05-10	1.99 0.4-2.8	2.7 1.4-5.7	13.96 3.0-38	0.40 0.29-0.58	

By ganglion blockade and Hydralazine  
From data of Perry and Schroeder

come inactive until the metal were replaced. There is no evidence at the present time that specific metal deficiencies exist in man with the possible exception of zinc in under nutrition. On the contrary there are many trace metals in American tissues which perhaps are not only unnecessary but undesirable. The kidney is notable in this respect (Chapter VI)

(Because an undesirable metal can replace an essential one in an enzyme system and inactivate it *in vitro*, it is probable that such a consequence can occur *in vivo*) In order to determine where to look we must examine the essential and the presumably abnormal trace metals in American human adult tissues and urine (Table XVI) compare them with metals found in infants to discover which accumulate with age and also compare the tissue content of people from areas not exposed to hypertension. This subject will be discussed in Chapter VI but examples can be considered here.

Cadmium was found in large quantities in adult American kidneys but not in infancy. This metal is nephrotoxic. An examination of the inhibitory effects of a number of trace metals upon DOPA decarboxylase and monamine oxidase revealed the following. Some inhibition was exhibited by all in high concentrations but at low (0.1 millimolar) only cadmium and mercury significantly inhibited enzymatic activity of DOPA decarboxylase both inhibited monamine oxidase to less extent (Table XXIII). Both are nephrotoxic and will displace zinc (p. 146).

(Any disease which is a function of aging may be influenced by the gradual accumulation in tissues of those trace metals which appear to show organ selectivity and poor excretion). Any diseases appearing frequently as a function of Western Civilization which are virtually absent in uncivilized man may be influenced by accumula

## Mechanisms of Hypertension

TABLE XMI

CHANGE IN SEVERAL METALS WITH AGE (P P M ASH)\*

TABLE X\II CHANGE IN SEVERAL METALS WITH AGE (P P M Ash)*															
Decade Cases		Kidney						Lung		Liver					
		Ni	Zn	Cd	$\Delta Zn-Cd$	Pb	Sn	Al	Ti	Ti	Ni	Cd	Sn	Cr	Pb
0	5	6†	1850	0	1850	13	15‡	77	0	0	0†	0	3‡	22	34
1	2	0	2050	160	1890	36	134	60	0	0	0	0	103	15	45
2	1	10	4700	1450	3250	68	33	440	82	14	0	190	66	21	115
3	4	14	5800	2750	3070	130	17	>1540	220	7	12	174	38	16	171
4	3	10	5100	2500	2600	115	37	>2400	>740	19	<33	167	124	16	140
5	5	13	6300	3500	2800	96	91	>>2320	>660	22	0	186	33	35	115
6	6	16	7450	4200	3200	96	24	>>2660	>910	10	<4	282	27	17	77
7+	4	51	6050	2850	3200	71	44	>>3000	>900	10	37	385	36	17	77

\* After Tipton (231)

† Present in only 1 stillborn

‡ Absent to trace in stillborn

Note These values are indicative of concentration in wet weight of organ  $\pm 10\%$ 

The remarkable constancy of the differences between zinc and cadmium suggests that as cadmium is accumulated displacing zinc from enzymes, more zinc enzymes are formed. If they were not this amount of cadmium would cause overt renal toxic ty

tion of those abnormal trace metals to which civilized man is exposed. Cardiovascular diseases associated with aging therefore may be influenced by accumulation of trace metals in kidney, liver, blood vessels, adrenal or brain.

In Table XXII are shown evidences of accumulation of various trace metals or lack of it in American kidneys with age. Although the numbers in each decade are small, the trends are definite for nickel, titanium and cadmium, not so for tin. Zinc is accumulated in proportion to cadmium. One of these metals could be the culprit, although we suspect cadmium because of its prevalence (see p. 146).

Other oxidative metalloenzymes in kidney (or elsewhere) might be affected by abnormal exogenous trace metals. Two pertaining to the problem of hypertension are listed in Table XXIII. (Any enzyme containing free sulphhydryl groups can be inactivated by metal binding thereon; thus metalloenzymes are not essential for inactivation by metals.) Direct evidence for their participation is lacking, but they are shown to call attention to their role in nitrogen metabolism, direct or indirect, and to their metalloenzyme natures. Vanadium and cadmium have striking actions.

Theory of Electrolyte Imbalance. Small elevations in the serum sodium of hypertensive patients have been reported from time to time (210, 211). Their significance is unclear. The hypertensive kidney is a salt losing kidney; no functional or morphological alterations in adrenal cortex have been demonstrated in the usual case. There is evidence, however, that the sodium content of arterial walls may be increased, causing enough swelling to increase peripheral resistance (212). There is also evidence that the sodium in the body affects vascular irritability in that the peripheral vessels become less sensitive in sodium depletion and more sensitive in sodium repletion and the administration of desoxycorticosterone ac-

TABLE XXIII  
EFFECT OF METAL IONS ON TWO ENZYME SYSTEMS (GUINEA PIG) (% ACTIVITY) (311)

Metal	Bound by Hydrate	DOPA Decarboxylase Millimolarity of Metal ion			Monamine Oxidase (Substrate: tryptamine) Millimolarity of Metal ion		
		10	1	0.1	10	1	0.1
Mg <sup>++</sup>		103	—	—	94	99	96
Ti <sup>+++</sup>		24	82	98	87	101	103
Ti <sup>++++</sup>		52	92	98	100	101	99
V <sup>++</sup>	+	11	99	113	185	137	118
V <sup>++++</sup>	+	7	100	99	256	154	110
Cr <sup>+++</sup>		96	—	—	127	106	108
Cr <sup>++++</sup>		34	100	—	90	102	99
Mn <sup>++</sup>	0	26	77	86	110	111	104
Fe <sup>++</sup>	+	84	94	—	98	91	106
Fe <sup>+++</sup>	+	70	100	—	106	103	94
Co <sup>++</sup>	+	32	106	105	106	101	102
Ni <sup>++</sup>	0	69	91	94	144	104	103
Ni <sup>+++</sup>	+	33	100	—	110	107	107
Cu <sup>+</sup>		60	93	—	58	114	105
Cu <sup>++</sup>	+	8	13	91	18	110	96
Zn <sup>++</sup>	0	41	83	93	93	—	101
Cd <sup>++</sup>	0	2	9	54	89	86	—
Hg <sup>++</sup>	+	93	105	86(89)	1	82	94
UO <sub>2</sub> <sup>++</sup>	+	—	—	101	127	102	106
Me <sup>++</sup> Na <sub>2</sub> EDTA						98	97
Mg <sup>++</sup> Na <sub>2</sub> EDTA						100	—
Ca <sup>++</sup>		104	110	—	127	116	92
Mn <sup>++</sup>	"	103	101	—	108	102	91
Fe <sup>++</sup>	"	106	107	—	126	109	103
Na <sup>+</sup>	"	100	105	—	—	117	—
Na <sup>+</sup>	" (24 hr)	95	94	—	125	115	101
Na <sup>+</sup>	"	102	—	—	—	—	—

Italicized figures represent 20% change. Note the specific effects of Cd Hg V Co (cf Table XIII p 88).  
Those in parenthesis show dilutions by 10

\* Depressor in hypertensive rats as EDTA complex (Figs 13 and 14 pp 105 107)

tate. What change affecting sodium intake loss or shift occurs in hypertension is not known. There is no correlation with salt intake in man although moderately hypertensive rats choose to eat more. The alteration must be an esoteric one and may involve potassium and magnesium or possibly calcium as well.

**Theory of Mechanical Renal Arterial Obstruction.** In view of the above discussion it is highly possible that enzymatic alterations secondary to organic ischemia and those caused by one or more of the aforementioned factors may be similar. If so partial obstruction of a renal artery by atherosclerotic plaques could provide the necessary mechanism for permanent hypertension just as well as could intrarenal enzymatic changes from trace metals or coenzyme deficiency. Such obstructive lesions exist and may be more common than realized (145). One can imagine a hypothetical case: a man with the ability to react to stress by vasospasm passes through his first five decades only with tachycardia or transient hypertension under the stimulus of an examination. In his fifth decade in our civilization he begins to develop overt atherosclerosis; plaques of which are deposited by chance or by dynamic design at the mouths of his renal arteries. He then develops hypertension caused by some organic renal ischemia and some neurogenic vasospasm. As the hypertension increases the rate of development of atherosclerosis these plaques may become larger leading to further renal ischemia and hypertension but without much intrarenal arterial sclerosis. He dies in his sixth or seventh decade usually of an atherosclerotic complication. This sequence of events may be very common and does not necessitate trace metal imbalance or other enzymatic disturbance unless a common disturbance influences both hypertension and atherosclerosis (Chapter VII). Further



TABLE V  
EFFECT OF METAL IONS ON TWO ENZYME SYSTEMS (GUINEA PIG) (% ACTIVITY) (311)

Metal	Bound by Hydrate	DOPA Decarboxylase MmMolarity of Metal ion			Monamine Oxidase (Substrate tryptamine) MmMolarity of Metal ion		
		10	1	0.1	10	1	0.1
Mg <sup>++</sup>		103	—	—	94	99	96
Ti <sup>+++</sup>		24	82	—	87	101	103
V <sup>+++</sup>		52	92	98	100	106	99
V <sup>+++</sup>	+	11	99	113	185	137	118
V <sup>+++</sup>	+	7	100	99	256	154	110
Cr <sup>+++</sup>		96	—	—	127	106	104
Cr <sup>+++</sup>		34	100	—	90	102	99
Mn <sup>+++</sup>	0	26	77	86	110	111	104
Fe <sup>++</sup>	+	84	94	—	98	91	106
Fe <sup>++</sup>	+	70	100	—	106	103	94
Co <sup>++</sup>	+	32	106	105	106	104	102
Ni <sup>++</sup>	0	69	91	94	144	136	103
Ni <sup>++</sup>	+	33	100	—	110	107	107
Cu <sup>+</sup>		60	93	—	58	114	105
Zn <sup>++</sup>	+	8	13	91	18	110	96
Cd <sup>++</sup>	0	41	83	93	93	—	101
Hg <sup>++</sup>	0	2	9	89	86 (89)	82	—
UO <sub>2</sub> <sup>++</sup>	+	—	6	86 (89)	1	64	94
Me <sup>++</sup> Na <sub>2</sub> EDTA		93	105	101	127	98	106
Mg <sup>++</sup> Na <sub>2</sub> EDTA							97
Ca <sup>++</sup>		104	110	—	127	116	92
Mn <sup>++</sup>		103	101	—	108	102	106
Fe <sup>++</sup>		106	107	—	126	109	103
Na <sub>2</sub>		100	105	—	—	117	107
Na <sub>2</sub>		95	94	—	125	118	101
Na <sub>2</sub>	(24 hr)	102	—	—	—	—	—

Italicized figures represent 20% change. Note the specific effects of Cd Hg V Co (cf Table XIII p 88). Those in parenthesis show dilutions by 10.

\* Depressor in hypertensive rats as EDTA complex (Figs 13 and 14 pp 105 107)

guish between these conditions and functional neurogenic vasospasm they can be presumed to react in the same way. Therefore in late stages arteriolar nephrosclerosis caused by the hypertension produces organic renal ischemia which sustains the hypertension. As discussed previously we probably cannot use this mechanism to account for middle stages of sustained hypertension because organic lesions are often not present.

Similarly the tubular part of the nephron may be unable to distinguish the difference between organic arterial and arteriolar narrowing from these causes or from intra renal arterial obstruction by scars (pyelonephritis) and glomerular obstruction (nephritis and glomerulosclerosis). The locus of the mechanism reacting to renal ischemia may be postglomerular (tubular) or it may be in the juxta glomerular apparatus which lies around the afferent arteriole. In the latter case chronic glomerulonephritis might not be expected to cause hypertension until fairly widespread renal degeneration had occurred. This may be the usual situation.

*Comment* One can only guess at which factor operates in a given hypertensive patient. There may be several others not mentioned. The theory of vicious cycles or cybernetics is quite prominent in much of what has been said as it is in many pathologic states and normal metabolic pathways (which are far from vicious until disturbed). This mechanism which transforms intermittent neurogenic vasospasm into permanent nephrogenic and neurogenic hypertension, is the 'killer'. Therefore it becomes of foremost importance to understand it for treatment. If we could counteract this one mechanism and break the cycle perhaps hypertension would be a mild relatively nonfatal but interesting physiologic abnormality.

more, cholesterol emboli in the kidneys have occurred from plaques (213), associated with hypertension

The renal hemodynamic picture of hypertension in older persons is that of the major resistance being on the arterial side of the glomerulus (214) contrary to that seen in younger people where it is predominantly in the efferent arterioles. If the disease begins in the 50's and 60's such sequential events are likely pathogenetic features, although it is now impossible more than to guess which comes first. A vicious cycle of this sort involves the initiation of nephrogenic hypertension by local atherosclerosis and the progression of atherosclerosis by hypertension with the predisposing factor (neurogenic vasospasm) present, however, for the previous lifetime of the individual.

Sustained chronic hypertension causes arteriolar nephrosclerosis characterized in order of appearance by 1) thickening of the glomerular capsule 2) thickening of the glomerular intercapillary substance 3) thickening and hypertrophy of the walls of the arterioles 4) intimal thickening and 5) fibrosis and hyalin degeneration of the walls of arterioles and small arteries. In neurogenic hypertensive dogs these alterations take 2 to 4 years to develop (7). In man with chronic hypertension little or no changes are apparent in half of biopsies (159) while almost all show it at necropsy (2). When pheochromocytomata act as the neurogenic factor for long enough, arteriolar nephrosclerosis is the frequent result and nephrogenic hypertension may remain after removal of the tumor.


When arteries and arterioles are narrowed by permanent sclerotic changes blood flow to nephrons is obviously reduced at normal blood pressure levels. It matters little to a nephron whether its flow is cut down by a single aortic and renal arterial plaque or by organic narrowing of its afferent blood vessel. Perhaps its tubules cannot distin-

TABLE XXIV  
VARIOUS EFFECTS OF PYRIDOXINE IN MAN WITH ESPECIAL REFERENCE TO ANTAGONISM TO METAL-BINDING AGENTS

<i>Clinical Finding</i>	<i>Induced by Metal binding Drug</i>	<i>Relieved by Vitamin B<sub>6</sub></i>	<i>No Reports</i>	<i>Remarks</i>
Convulsions	Isoniazid	Yes	1	
Convulsions	Semicarbazide	Yes	1	
Peripheral Neuritis	Isoniazid	Partly	1	Local disorder
Leukopenia and agranulocytosis	Thiouracil	Yes	5	
	Sulfonamides	Yes	2	
Peripheral Neuritis	Arsenic	Yes	1	
Cheilosis Chertosis etc	EDTA	No	1	Zinc deficiency
Same	Desoxypyridoxine	Yes	2	
Same	Spontaneous	Yes	8	
Seborrhoeic Dermatitis	Desoxypyridoxine	Yes	2	
Same	Spontaneous	Yes	4	Applied locally

*Vitamin B<sub>6</sub> Selected Annotated Bibliography 1954 Merck & Co*

Can we bring some of these ideas together into one theory? In the case of enzymatic mechanisms, we can. For pyridoxal phosphate is believed to contain a metal necessary for activity chelated to the pyridoxal amino acid complex in the following manner (215)



We have demonstrated that cadmium and mercury can selectively inhibit at least one pyridoxal enzyme, probably by competing with the essential metal just as a number of strong metal binding agents also inhibit this same enzyme (Chapter IV) probably by removing the essential metal. Therefore, certain trace metals can be biochemically interrelated with certain pyridoxal enzymes. It is possible that not only the decarboxylases which produce the vasoactive and cerebroactive primary amines serotonin, tryptamine, tyramine, isoamylamine, dihydroxyphenyl ethylamine from amino acids but also transaminases may be inhibited by abnormal trace metals (Table XXIV).

### CLINICAL IMPLICATIONS

The existence of organic narrowing of renal arteries and arterioles must be in mind during every attempt to reverse or control hypertension whether by drugs or surgery. No available therapeutic measure known will dilate renal arteries and arterioles more than they can dilate through smooth muscular relaxation; scar tissue will not

mechanisms are unknown but the clinical and laboratory evidence that adrenal steroids cause hypertension in certain cases is clear. The reader should remember, however, that there is no evidence that the adrenal cortex is over active in most cases of neurogenic or nephrogenic hypertension but that isolated instances in which it plays a definite and perhaps primary role are known.

**Experimental Steroid Hypertension** For many years it has been recognized that desoxycorticosterone (DOCA) a salt retaining hormone will cause hypertension in rats when added salt is given (216-217). Likewise a syndrome similar to toxemia of pregnancy can also be produced relieved or prevented by hydralazine (218). Feeding of salt alone in excessive quantities can produce rat hypertension (219); vascular lesions result. The amount of steroid and the amount of salt necessary to produce this disorder are far beyond physiologic limits. DOCA is pressor in renal hypertensive dogs (220) and hypertensive patients (221). Salt restriction apparently induces adrenal cortical hyperactivity (222).

**Effect of Experimental Nephrogenic Hypertension on Adrenals** Adrenal hypertrophy accompanies experimental nephrogenic hypertension (223). Furthermore rats with moderate hypertension voluntarily drink more saline than do normals or their paired severely hypertensive mates (224). This increased requirement for salt may be a reflection of the salt losing tendencies of ischemic kidneys already discussed in Chapter IV.

**Relation of Adrenal Cortex to Medulla** It may not be a coincidence that the adrenal medulla concerned with the release of epinephrine and the cortex concerned with sugar, salt and sex, are enclosed in the same gland. There is an intimate relationship between the two hormones acting on vascular smooth muscle. There may be a further

become more elastic. This statement may not hold true however, for cholesterol filled atheromata, which probably can be partly absorbed under the proper conditions.

Fortunately, the cases of severe hypertension which become azotemic when the blood pressure is lowered are rare. When present azotemia may be worsened. The existence of renal arterial constriction can make therapy difficult, however, intrarenal constriction beyond the obstruction probably can be quite readily opposed.

The existence of organic narrowing of other major arteries to myocardium and brain must be in mind during every attempt to reverse or control hypertension, for a lowered peripheral pressure may cause ischemia beyond the obstruction. These circumstances are fortunately uncommon.

Because hydralazine and similar compounds appear to attack the factor converting intermittent into permanent vasospasm in time, this drug is indicated in all patients with sustained hypertension who are able to tolerate it without symptoms of sensitivity. Whether or not it helps to restore a disturbed enzyme system to normal function, or merely makes abnormality more abnormal, is not known at this time. Its reactions on DOPA decarboxylase suggest that amino acid decarboxylation would be suppressed by the kidney thus preventing the formation of amines. Its actions on monamine oxidase suggest that it can promote the destruction of amines. Its inhibition of pherentasin suggests that it specifically inactivates the one pressor substance found in the hypertensive state.

### **ADRENOCORTICAL MECHANISMS**

One possible factor which may influence the conversion of intermittent to sustained vasospasm lies in the adrenal cortex and in its influence on electrolyte balance. The

readily when deprived of sodium conductance is restored by a number of quaternary ammonium compounds (229) Whether or not increased conductance occurs when there is an excess of intraneuronal sodium is not known The decreased sensitivity and the sometimes lowered blood pressure seen when dietary salt is severely restricted may perhaps be explained on this basis

These interactions between nerve transmission salt vasoconstrictor substances and steroids can explain some of the clinical findings which appear on the surface to be inexplicable Normal vasomotor tone normal discharges of sympathetic fibres normal amounts of norepinephrine can produce generalized vasospasm when the vascular smooth muscle becomes hypersensitive through salt and steroids Removal of salt or steroids may restore sensitivity to normal Excessive vasomotor tone excessive discharges of sympathetic fibres excessive amounts of norepinephrine formed at nerve endings can produce a much greater degree of generalized vasospasm when the vascular smooth muscle becomes hypersensitive Removal of salt or steroids restores sensitivity to normal but does no more than partly reduce the vasospasm to a lesser level to achieve strict normality requires additional restoration of sympathetic activity to normal When the vasospasm is in part caused by circulating humoral pressor substances restoration to a normal state is impossible unless these substances are inactivated

**Clinical Findings** Many but not all patients with adrenal cortical adenomata or hyperplasia have hypertension Other steroid producing tumors may also be associated with hypertension Hypertension is uncommon but not unknown in virilizing tumors we have seen it regress on surgical removal of the tumor Cushing's syndrome is



more basic, relationship between salt retaining hormone and the transmission of nerve impulses along sympathetic fibres affected by sodium or potassium

1 The administration of DOCA increases the sensitivity of vascular smooth muscle to epinephrine and norepinephrine (38)

2 The vessels of the patient with Addison's disease show a relatively low reactivity to injected epinephrine and norepinephrine (225, 226)

3 Salt restriction decreases these sensitivities, salt repletion increases them

4 The hypertensive, but not the normotensive, individual responds to intravenous DOCA by a rise in blood pressure (221)

There are two possibilities to explain these findings. The first is concerned with the smooth muscle fibre the second with unmyelinated sympathetic nerve fibres. Certain adrenal cortical steroids apparently act at the cellular level regulating the amount of sodium, potassium and possibly magnesium within the cell (227-228). At least there are rather profound alterations in cellular content of cations when salt retaining hormones are given or are formed in excess. In extracellular fluid there is apt to be hypernatremia, hypokalemia and alkalosis of variable degrees. If smooth muscle cells were so affected, the result might be hyperirritability of the fibres with excessive responses to vasoconstricting impulses either neurogenic or mediated through circulating pressor substances. Perhaps the intracellular edema found in the arteries of some hypertensive individuals (212) is on this basis.

Another theory involves the effect of sodium or potassium on nerve transmission through unmyelinated fibres. The fibres of primitive animals do not transmit impulses




FIG 1. Central obesity, menstrual irregularities, low sweat salt ( $<20$  mEq/L) and hypertension. Rapid weight gain, mild hirsutism, easy bruisability and moderate diabetes were also present. This complex has been named the endocrine hypertensive syndrome for want of a more definitive word. The blood pressure was highly responsive to salt restriction (3, 3c).

They may be recognized by the presence of central obesity and hypertension; in women, menstrual irregularities are common (Fig 17). The condition has been seen in families (3). Presumably their hypertension is influenced by an overproduction of aldosterone or other salt retaining hormones which decreases the sodium in sweat to low levels. We must hypothecate the chain of events in the

not invariably associated with hypertension primary aldosteronism, in which there is overproduction of salt retaining hormone, appears to be

The administration of cortisone and adrenocorticotrophic hormone (ACTH) is sometimes followed by hypertension. In such cases, we must assume that sensitivity of vascular smooth muscle increased because of the mild salt retaining side effects of these agents which are not of themselves primarily concerned with salt. In the presence of a normal or decreased sympathetic tone cortisone should be inactive in this respect. Hormones with lesser salt retaining qualities hydrocortisone, metacortandren etc are less active. DOCA, on the other hand, produces hypertension in a fair number of Addisonian patients treated with large amounts of salt.

"Therefore, the pressure raising activities of steroids and salt, according to this theory are not primary qualities residing in the substances themselves but depend principally upon the state of the neurogenic control of vasoactivity. If sympathetic tone is elevated, they elevate pressure. If sympathetic tone is low, they do not unless excessive hyperphysiologic amounts are given. Abnormal amounts of any hormone can cause profound derangements which would not occur with physiological replacement.

There is a group of patients now being better described which appears clinically to show excessive adrenocortical activity of two or three types of the hormones concerned with salt, sugar and sex. There are many clinical variations from the normal, extending from minor degrees to the borderline of full blown Cushing's syndrome. So far, all have had either adrenal cortical adenomata often small, or pituitary basophilism with adrenal hyperplasia.




FIG 17 Central obesity, menstural irregularities, low sweat salt ( $<20$  mEq/L) and hypertension. Rapid weight gain, mild hirsutism, easy bruisability and moderate diabetes were also present. This complex has been named the "endocrine hypertensive syndrome" for want of a more definitive word. The blood pressure was highly responsive to salt restriction (3, 3c).

They may be recognized by the presence of central obesity and hypertension. In women menstrual irregularities are common (Fig 17). The condition has been seen in families (3). Presumably their hypertension is influenced by an overproduction of aldosterone or other salt retaining hormones which decreases the sodium in sweat to low levels. We must hypothesize the chain of events in the

absence of exact hormonal measurements. A small adenoma forming only aldosterone will produce hypertension by polydipsia and alkalosis. One forming both aldosterone and hydrocortisone or cortisone like hormones will produce hypertension and central obesity with the resultant muscular weakness thin skin and possibly menstrual abnormalities. One forming both hormones plus androgens will induce in addition hirsutism an enlarged clitoris menstrual irregularities muscular hypertrophy maleness and the like. There can therefore be seven clinical types only four of which are associated with aldosterone and hypertension four with central obesity and four with androgenic overproduction. While the distinctions between cases are not as simple as outlined here since a single hormone may have the minor side effects of another this idea is worth considering from clinical grounds and can explain the presence or absence of these different clinical manifestations. In aldosteronism the tumor is probably derived from cells of the zona glomerulosa. The severity of the manifestations naturally depends upon the amounts of hormones produced in excess.

**Hypertension and Hyperaldosteronism** Recent studies have shown that there is a mild hyperaldosteronism in severe and malignant hypertensive patients as evidenced by the salt retaining properties of urinary extracts in adrenalectomized rats (230). If this is so it is possible that vascular hyperactivity is dependant upon a slight excess of this hormone. However taking into consideration all of the data concerning the adrenal cortex in hypertension this theory is hardly tenable.

The hypertensive kidney loses salt under a load and the more severe the hypertension in terms of nephrosclerosis the greater is the tendency to lose salt. Since salt de-

pletion or some electrolyte abnormality may be the stimulus to the formation of aldosterone it is possible that the mild aldosteronism measured may be merely a reflection of this salt losing tendency which probably has its seat in the kidney. Slightly excessive production of aldosterone could be predicted from knowledge of chronic renal salt loss. Obviously this form of adrenal cortical hyperfunction would cause if a primary initiating factor salt *retention* by the kidney a phenomenon opposite to what is actually encountered.

### CLINICAL IMPLICATIONS

Obviously patients with hypertension influenced by adrenal cortical overactivity should respond to restriction of salt by a lowered blood pressure. They do. The fact that severe salt restriction will not influence severe hypertension secondary to organic renal disease argues against the role of the adrenal in this state. Severe salt restriction can occasionally influence neurogenic hypertension probably because vascular reactivity to sympathetic discharges is decreased. But these results do not mean that all human hypertension is dependant upon steroids and salt. on the contrary these cases are in a minority. The reader must remember the simple fact that dietary salt restriction of severe degree causes overactivity of the adrenal cortex and that the usual hypertensive kidney is a salt losing kidney to an extent dependant upon the degree of renal damage or renal ischemia.

The clinician does well to recognize cases of aldosterone hypertension for treatment of them may differ radically from that of the usual case of neurogenic or nephrogenic hypertension. Although eventually arteriolar nephrosclerosis develops a lesion dependant *only on diastolic hyper*

tension from any cause, it seems slow to occur in these cases and is apt to be less severe than in other types (3, 4). Salt restriction, antiadrenal hormones and adrenalectomy are logical methods to use if diagnosis can be accurate. None of these measures is necessary nor justifiable in other types. Therefore their recognition becomes of practical significance. The measurements of sodium in sweat (3) or saliva and of specific steroids in urine or blood are specialized diagnostic procedures for such cases.

## *Chapter VI*

# TRACE METALS AND CARDIOVASCULAR DISEASE

## INTRODUCTION

**B**ECAUSE of the strong suggestion that trace metal imbalances may be involved in some of the chronic diseases to which the people of Western Civilization are exposed a chapter on this subject is in order. To be considered are the relations of metalloenzymes to the problem, the concentrations of essential trace metals in human tissues, the presence and amount of abnormal metals and from whence they may come and the possibility of their interference with metalloenzymes to such an extent that they cause chronic diseases. Because this subject represents a new frontier in Medicine, vast gaps in knowledge exist but the pattern is clearing.

By trace metals we will consider only those present in small or relatively minute amounts and not discuss the bulk metals sodium, potassium, magnesium and calcium nor iron which has an intermediary position between ubiquitous elements and trace metals. All bulk metals probably take part in enzymatic reactions or in exchange mechanisms; trace metals are often confined to more specialized systems. If interference with one of the bulk metals occurred in the body, profound toxicity would result. For example, should all magnesium enzymes be inhibited, intermediary metabolism would cease; if calcium were displaced, muscular relaxation would cease. Partial



inhibition of some of these systems undoubtedly occurs in disease, but many can be recognized

There are many metalloenzymes in mammalian tissues but only five essential trace metals have been identified manganese cobalt, copper, zinc and molybdenum Deficiency of one of these trace metals in a metalloenzyme either by depletion or displacement by another more or less active metal can be expected to lead to a profound metabolic disturbance induced in a very basic and discrete level There is growing evidence that arterial hypertension and possibly atherosclerosis may be influenced by trace metal imbalances induced by exposure to and accumulation of abnormal trace metals resulting from products confined to Western Civilization

## METALS CONCERNED IN METALLOENZYMES

For a metal to be reactive in oxidation reduction mechanisms it must contain at least two valence states which are fairly readily transposed The essential metals iron manganese cobalt and copper fit the requirement as do titanium vanadium, chromium and nickel of the first transitional group For a metal to chelate\* readily a requirement for enzymatic activity (232), it should usually


---

\* The definition of chelation and complex formation can best be given by quoting from Martell and Calvin (233) When a metal ion combines with an electron donor the resulting substance is said to be a complex or coordination compound If the substance which combines with the metal contains two or more donor groups so that one or more rings are formed the resulting structure is said to be a chelate compound or metal chelate and the donor is said to be a chelating agent The electron pair bonds formed between the electron accepting metal and the electron-donating complexing or chelating agent may be essentially ionic or essentially covalent depending on the metals and donor atoms involved Without further considering the nature of bonds simple examples of complex formation and chelation are represented schematically as follows

have a coordination number of 4 or 6 an index of the number of donors of the chelate with which the metal will combine. Thus magnesium aluminum vanadium chromic ion manganous and manganic ferrous and ferric, cobaltous and cobaltic nickelous and nickelic tin and lead have coordination numbers of 6 while zinc cupric cadmium mercury silver gold have one of 4 and molybdenum of 8. Those of titanium and scandium have not been determined (233). Some functional groupings which bind metals are carboxyl hydroxyl carbonyl amino (primary secondary tertiary cyclic tertiary) sulfhydryl thioether sulfonate and phosphonate (232).

**Principles of Chelation** The general rules regulating the stability of metal chelates according to Bailar (234) are as follows:

- 1 Ring structures involving metals and organic configurations have increased stability
- 2 Five membered rings in the absence of double bonding and six membered rings in its presence are the most stable
- 3 Fused rings that is configurations in which two or more rings have a common side have a greatly increased



where M represents a metal ion, A represents a complexing agent and A—A represents a chelating agent.

stability, e.g., ethylenediamine tetraacetate (EDTA) is 50 times more stable than predictions would indicate

4 Maximum stability is achieved in the presence of a minimum charge. Thus inner salts are maximally stable.

5 Spatial factors are important. Thus primary amines are better than secondary amines which in turn are better than tertiary amines, probably because the methyl groups are cumbersome. Similarly water is better than alcohol which in turn is better than ether, methanol is better than ethanol, and *n*-propanol is better than isopropanol. In addition each internal angle of a five membered ring should approximate  $108^\circ$ . If the ring involves an aromatic nucleus and its resultant obtuse external angle no chelate is formed.

6 The active groups involved in chelation are (1) fluorine and oxygen (2) nitrogen (3) sulfur carbon (CN carbonyl) phosphorus (as phosphene) and the halogens. The first group has maximum binding capacity for beryllium with a secondary one for vanadium. The second group has a maximum binding for cobalt and the third for palladium and copper. In addition both sulfur and oxygen bind metals centering around tin and antimony in the Periodic Table (Table XXV).

7 Transition metals are the most strongly bound because their inner shells are unfilled and allow a shifting of electrons to meet the optimum chelating requirements whereas other metals are much more rigid in the way they can accept or donate electrons.

The spatial type of chelate is also of interest (Table XXVI). Beryllium and boron, zinc, cadmium and mercury form tetrahedral complexes. Presumably the first two could resemble magnesium chelates, the last three each other. Copper, silver, gold and nickel form square complexes while all of the other essential metals save molybdenum

TABLE XV  
AFFINITIES OF VARIOUS COMMON TRACE METALS FOR CHLORATION BY DIFFERENT ACTIVE GROUPS

Group IIA    IIIB    IVB    VB    VIB

Be    Mg    Ca    Sr    Sc    Ti    V    Cr    Mn    Fe    Co    Ni    Cu    Zn    Cd    Hg

Nitrogen

Fluorine

Oxygen

Sulfur

Se    Te    Pb    Bi    Sb    Sn    As    Se    Te

After Bailar (234)

TABLE XXVI

NORMAL AND ABNORMAL METALS IN CHELATES (233)

Coordination No	Tetrahedral	Square	Octahedral	Dodecahedral
4 4	Zn <sup>++</sup> Cd <sup>++</sup> Hg <sup>++</sup>	Cu <sup>++</sup> Ag <sup>++</sup> Au <sup>+++</sup> Ni <sup>++</sup>		
6 6	Mg <sup>++</sup> Be <sup>++</sup> B <sup>+++</sup>			
6 6 6			Mn <sup>+++</sup> Fe <sup>++</sup> Co <sup>++</sup> Co <sup>+++</sup> Cr <sup>+++</sup> Al <sup>+++</sup> Pb <sup>++++</sup> Sn <sup>++++</sup>	
8 8				Mo <sup>++++</sup> W <sup>++++</sup>

See footnote p 193

form octahedral ones, as do chromium aluminum, tin and lead. Thus possible interfering metals may be roughly grouped according to their chelate forms. Those of the first transitional group have the requisite outer shell unfilled a measure of reactivity.

**Trace Metals and Metalloenzymes** In Table XXVII is a partial list of some of the enzyme systems believed to contain a trace metal as a prosthetic group. The list is by no means complete and undoubtedly will be expanded in the future as enzymes are purified. According to Williams (235) and Najjar (236) there are two types. In one a specific element and no other is firmly combined or chelated with the protein apoenzyme for enzymatic activity, other metals may inhibit activity. The second is relatively less specific in that two or more metal ions usually in the first transitional series can be interchanged and the metal is more or less dissociable from the protein. Some of the peptidases were thought to have only partial specificity until the work of Emil Smith (140) strongly

suggested that metal ions considered interchangeable such as magnesium manganese and cobalt are specific for enzyme activity and cannot be interchanged in the strict sense of the term

Certain metalloenzyme systems need organic coenzymes (or vitamins) for activity. One possible example is pyridoxal phosphate which according to Snell requires a metal for the coenzyme to become activated (215). While the metal is not known, model systems constructed without the apoenzyme suggest that either copper, iron or aluminum could be the essential one (237). It is apparently so firmly bound that most metal binding agents will not remove it. Other well known examples are riboflavin where flavin adenine nucleotide is intimately bound with the oxidation and reduction of iron and the copper flavinoid in acyl Coenzyme A-dehydrogenase. Other members of the vitamin B group in some cases may require metals for activity; magnesium with thiamine and molybdenum with flavin adenine nucleotide are examples.

In general, the active essential metals are divalent and in the first transitional group of the periodic table. Copper is essential for phenolic and catecholic oxidation and for fat metabolism. Manganese is required for peptide splitting and for carboxylation. In view of the high concentrations of zinc in tissues and the very few zinc enzymes found, carbonic anhydrase being the most prevalent, it is possible that others exist. The metallo-porphyrins are good examples of chelates; heme, the prosthetic group of hemoglobin, has iron chelated to four methyl pyrrole rings; the iron porphyrins of the cytochromes and myoglobin; vitamin B<sub>12</sub> has cobalt chelated in a porphyrin structure and the porphyrin of chlorophyll chelates magnesium. There are several metalloproteins known; ceruloplasmin and hemocuprein contain copper; mercaptalbumins ap-

TABLE XXVII  
EXAMPLES OF SOME METALLOENZYMES MOSTLY MANGANESE\*

Enzyme	Essential Metal	Other Activators	Organic Co-en-yme	Remarks
<i>Copper Enzymes</i>				
Tyrosinase	Cu <sup>++</sup>			
Ceruloplasmin	Cu <sup>++</sup>			
Hematocuprein	Cu <sup>++</sup>			
Hemocuprein	Cu <sup>++</sup>			
Hemocyanins	Cu <sup>++</sup>			
Acyl Co A dehydrogenase	Cu <sup>++</sup>			
<i>Protolytic Enzymes</i>				
Leucine aminopeptidase	Mn <sup>++</sup>			
Glycylglycine dipeptidase	Co <sup>++</sup>			
Glycylleucine tripeptidase	Mn <sup>++</sup>			
Prolidase	Mn <sup>++</sup>			
Carboxypeptidase	Mg <sup>++</sup>			
Carnosinase	Mn <sup>++</sup>			
Dehydropeptidase	Zn <sup>++</sup>			
Arginase	Zn <sup>++</sup> (?)			
Polypeptidases	Mn <sup>++</sup>			
<i>Keto Acid Carboxylases</i>				
$\alpha$ ketoglutaric carboxylase	Zn <sup>++</sup> or Co <sup>++</sup>	Fe <sup>++</sup> Co <sup>++</sup> Ni <sup>++</sup>		
Pyruvic acid oxidase	Mg <sup>++</sup>			
Oxaloacetic carboxylase	Mg <sup>++</sup>			
Oxalosuccinic carboxylase	Mn <sup>++</sup>			
Carbonic anhydrase	Mn <sup>++</sup>			
<i>Phosphatases (most)</i>				
Acid	Zn <sup>++</sup>			
	Mg <sup>++</sup>			
	Mn <sup>++</sup> or K <sup>+</sup>			
			Diphosphothiamin Diphosphothiamin	0.31-0.34% Zn

\* After Lehninger (267) and others (307-245)

TABLE XVIII—(continued)

	Mg <sup>++</sup> Ca <sup>++</sup> Mg <sup>++</sup>	Zn + Co <sup>++</sup> Ni <sup>++</sup> Cd +		
Alkaline ATPase	Mg <sup>++</sup> Ca <sup>++</sup> Mg <sup>++</sup>			
Hexosediphosphatase	Mg <sup>++</sup> (+K <sup>+</sup> )			
Transphorylase	Mg <sup>++</sup>			
Flavokinase	Ca <sup>++</sup>			
Actomyosin	Ni <sup>++</sup>			
Arginine ATP transphorylase	Mg <sup>++</sup>			
Iso phoglucomutase	Mg <sup>++</sup>			
Hexokinase	Mg <sup>++</sup> or Mn <sup>++</sup>	Zn <sup>++</sup>		
I nolase				
Dehydrogenases	Mg <sup>++</sup>	Mn <sup>++</sup>		
Iso phogluconic acid	Mn <sup>++</sup>			
Isocitric	Zn <sup>++</sup>			
Alcohol				
Oxidases	Mo <sup>+vi</sup>			0.03% Mo
Xanthine	Mo <sup>+vi</sup>			Only activator
Aldehyde	V <sup>+iv</sup>			found†
Monamine				Metal not known
	?		Pyridoxal PO <sub>4</sub> ?	
Histaminase				
Decarboxylases	Zn <sup>++</sup>	Mn <sup>++</sup> Mg <sup>++</sup>	Pyridoxal PO <sub>4</sub>	Metal inferred†
5 hydroxytryptophan	Zn <sup>++</sup>		Pyridoxal PO <sub>4</sub>	
DOPA	?		Pyridoxal PO <sub>4</sub>	
Histidine	Mn <sup>++</sup>	Co <sup>++</sup>		
Oxalacetate				
Others	?			
Transaminase	Zn <sup>++</sup>		Pyridoxal PO <sub>4</sub>	Metal not known
Uricase				

† See Table VIII p 126 and p 154



parently transport zinc and copper by imidazole binding and gamma globulins contain various metals some possibly bound to sulfhydryl groups. The discovery of hexavalent molybdenum as essential not only drew attention to heavier metals but was also the first example of a high valency metal in an enzyme. Therefore, higher valency metals in the first transitional group are not excluded from essential functions (Ti, V, Cr) nor are heavier ones.

The practice of suspecting the presence of a trace metal in an enzyme system by attempting to inactivate it with metal binding agents (cyanide, sulfide, azide, mercaptans, thiocyanate, ethylenediamine tetraacetate) may lead to false assumptions if the metal is more tightly bound to the enzyme than it can be to the binding agent. In the case of carbonic anhydrase, a known zinc metalloprotein, many strong chelating agents apparently fail to inhibit activity although some binding agents do (238). Inhibition by sulfanilamide may be the result of zinc binding. Strange to say, zinc itself is a potent inhibitor as are silver, gold, copper, mercury and vanadium. The kinetics of such reactions have not been described sufficiently to allow predictions as to different metals involved. Purification of an enzyme now is the only real proof.

#### **POSSIBLE COMPETITIONS BETWEEN ABNORMAL AND ESSENTIAL TRACE METALS**

The validity of the Periodic Table appears established for physics, geology, chemistry and metallurgy but until recently there has been little application of these disciplines to the biochemistry of disease. Substitution of one element of a periodic group for another, however, has been often demonstrated in specific mammalian tissues.

**Substitution of One Element for Another** In group II B, radium, barium, strontium, calcium and beryllium all

have an affinity for bone both strontium and beryllium can cause rickets and beryllium displaces magnesium on phosphatases inactivating them. Therefore all but magnesium are concentrated by one tissue. Similarly two anionic and all cationic elements in group VII have been shown to be concentrated by the thyroid: iodine, astatine, manganese, technetium and rhenium; those of the halide sub-group quite specifically (239-242). Likewise in group V A bismuth, antimony and arsenic are believed to displace phosphorus in phosphates. Gold, silver and copper of group I B have strong affinities for each other as does cadmium for zinc in group II B. Complete separation of the two from ores is difficult and often too expensive for commercial purposes. Cadmium displaces zinc on human mercaptalbumin while lead does not, presumably because the former two ions bind the same molecular group (the 16 imidazole groups) while the latter binds at a different site. Cadmium therefore has a higher affinity than zinc for this protein. Similarly cupric ion is displaced from the sulphhydryl groups of bovine serum albumin by metals in the following order of affinity:  $\text{Hg}^{++} > \text{Pb}^{++} > \text{Cd}^{++} > \text{Zn}^{++}$  (243). Among the anions, fluorine, chlorine, bromine and iodine are biologically interrelated while selenium and tellurium of group VII A will displace sulfur in hair and nails, possibly in sulphhydryl groups. In group I A, radio-rubidium is used to measure potassium space (244).

**Metalloenzyme Inhibitions.** In spite of these obvious relationships in biological material, metalloenzyme competition by an extraneous metal has not been systematically studied. In Table XXVIII are shown examples of cases where an extraneous metal apparently displaces an active metallic prosthetic group. The list may be far from complete. At least two types of enzyme inhibition can occur

TABLE XXVIII  
SOME EXAMPLES OF INHIBITION OF METALLOENZYMES BY METALS

Enzyme	Activator	Inhibitor	References	Remarks
Alkaline phosphatase*	Mg <sup>++</sup>	Be <sup>++</sup> Cu <sup>++</sup>	298	Other inhibitors less effective
ATPase*	Ca <sup>++</sup> Mg <sup>++</sup>	Be <sup>++</sup> Cu <sup>++</sup>	298 299	
Arginase*	Mn <sup>++</sup>	Be <sup>++</sup>	267	
Carbonic anhydrase	Zn <sup>++</sup>	Cu <sup>++</sup> Ag <sup>++</sup> Au <sup>++</sup> Zn <sup>++</sup> Hg <sup>++</sup> V <sup>+++</sup>	238	
Tyrosinase*	Cu <sup>++</sup>	Au <sup>++</sup> Ag <sup>+</sup> Hg <sup>++</sup>	246	Other metals (Cd <sup>++</sup> ) forming in soluble bicarbonates or phosphates may compete
Leucine aminopeptidase	Mn <sup>++</sup>	Cd <sup>++</sup> Cu <sup>+</sup> Hg <sup>++</sup> Pb <sup>++</sup>	300	
Carnosinase*	Zn <sup>++</sup> or Mn <sup>++</sup>	Ca <sup>++</sup> Cd <sup>++</sup>	301	
Xanthine oxidase	Mo <sup>++</sup>	Cu <sup>++</sup> Hg <sup>++</sup> Ag <sup>+</sup> Pb As	302	
Aldehyde oxidase	Mo <sup>++</sup>	As	303	No other transition elements or Cd
Glutamic transferase	Mn <sup>++</sup>	Cu <sup>++</sup>	301	
Succinic dehydrogenase	Cu <sup>++</sup> }	Cd <sup>++</sup>	238	
Choline oxidase	?	Cd <sup>++</sup>	238	
Prolidase	Mn <sup>++</sup>	Co <sup>++</sup> Ca <sup>++</sup> Zn <sup>++</sup>	238	Metal not established
Glycylglycine peptidase	Co <sup>++</sup>	Zn <sup>++</sup>	305	
Phosphoglucomutase	Mg <sup>++</sup>	Cu <sup>++</sup> Ag <sup>+</sup> Hg <sup>++</sup> Zn <sup>++</sup> Pb <sup>++</sup>	306	
			238	

\*Probably by peptic displacement For other examples see Tables XVIII and XXVI

One is when a heavy metal combines with sulfhydryl groups to inactivate the enzyme. Mercury, copper and silver will inactivate many enzymes which do not contain a metal (245). Presumably the toxic effects of many heavy metals are due to this type of reaction. The second is when the essential metal is displaced by another, often of the same periodic group. Lerner has offered good examples of both types of reactions in respect to tyrosinase, essential for formation of melanin (246). Metals which compete with copper: Increased melanin pigmentation is frequently observed when heavy metals such as arsenic, bismuth, iron, gold, silver and mercury are deposited in the skin. Patients with hemochromatosis have relatively large amounts of iron and copper deposited in the skin. The most plausible explanation for these findings is that metals bind epidermal sulfhydryl groups and thereby release inhibition of tyrosinase. The increased tyrosinase activity results in increased melanin formation. However, if sufficient quantities of the metals mercury, silver or gold are present they can replace the copper of tyrosinase to produce an inactive enzyme with resultant depigmentation. It is possible that the slight decrease in skin color produced by ammoniated mercury freckle creams is achieved in this manner. Six copper binding agents have caused depigmentation *in vivo* (247); most of them anti-thyroid drugs.

Essential metals such as copper, manganese, cobalt and zinc can interact to inhibit the metalloenzymes of each. Excess enzymatic activity by a presumably abnormal metal can also occur. For example, chromium causes increased synthesis of cholesterol and fatty acids by rat liver (248); cadmium and cobalt enhance bacterial oxalacetic carboxylase, a manganous enzyme; vanadyl ion enhances monamine oxidase (Table XXIII). Thus both stimulation and depression by abnormal metal are possible.

The effects of a series of metals on two enzymes possibly concerned in arterial hypertension are shown in Table XXIII. At the highest concentrations it is probable that inactivation of dihydroxyphenylalanine (DOPA) decarboxylase by metals was nonspecific or caused by sulfhydryl binding. At low concentrations the specific inhibition by cadmium and mercury may be the result of displacement of another essential metal. Since the coenzyme is pyridoxal, probably with a metal displacement of the related essential metal is the most plausible explanation of the mechanism of inhibition. If so, zinc may be the essential one. Obviously, high concentrations of cadmium in the kidney might cause serious metabolic alterations in the decarboxylation of several amino acids.

If interference of a single metalloenzyme system can be caused by another competing and inactivating metal, certain chronic diseases could ensue. As a theoretical example, if the molybdenum in xanthine oxidase were replaced by another in the same periodic group, for example, tungsten or chromium, and the enzyme so inhibited, gout might be produced. There is no evidence whatsoever that gout is due to tungsten or chromium, but this is a theoretical possibility. Interference by an extraneous metal such as chromium, with manganous ion in the Krebs cycle would interfere with carbohydrate metabolism. Any one of these reactions could have profound and lasting results if a sizeable part of the total activity of the enzyme in the body were inhibited.

**Simple Chelating Compounds** A great many organic compounds possess the ability to bind metals in more or less dissociable complexes. Many others form chelates in which two or more electron donors combine with the metal to produce one or more rings (233). The importance of chelation has long been appreciated in industry, but only

lately in biology although the calcium citrate chelate is commonly used to prevent clotting of blood All metallo-enzyme reactions are believed to depend upon chelation

Each chelating compound differs widely in its affinity for different metals. In Table XXIX are shown the stability constants of a number of common oxygen and nitrogen chelators with divalent metals of the first transitional group and with cadmium. Ten of these compounds are present in biological fluids. In general an increase in tightness of structure is proportional to atomic number reaching a peak at copper (or nickel) and decreasing thereafter. This fundamental property of most chelating agents must be in mind whenever they are used, in effect this property means that a free ion having a higher stability constant with the chelator will displace a chelated metal with a lower constant. When the active groups are sulfur and other chelators the pattern of metallic affinity is different (Table XXV).

**Metal Binding.** Simple metal binding is dependent either upon the tightness of the bond, the lack of dissociation of the dissolved salt, or upon the insolubility of the complex. Thus complexes may be formed between metal and ammonia, metal and sulfhydryl, metal and cyanide, or metal and hydroxide. The stability constants for transitional metal complexes in solution are usually lower than for chelates, although mercury has a fairly high affinity for CN, NH<sub>3</sub>, OH and pyridine. The common law relating the stabilities of chelates of the first transitional group and atomic numbers appears to operate in the case of simple complexes of OH, CN, NH<sub>3</sub>, and pyridine.

### DRUGS AS CHELATING AGENTS

Most potent drugs may act through their abilities to chelate trace metals on metalloenzymes. Schubert states

(232) The action of many drugs probably can be explained, partly or wholly, by their possession of groupings capable of binding metals. The drug whether deleterious or helpful to the organism inhibits or activates a physiological function in which a metal is required. Inhibition or activation may come about in several ways:

1 The drug may chelate a metal ion needed for the activation or inhibition of an enzyme system and hence, indirectly necessary for survival.

2 The drug by its chelating action may facilitate the transport of a metal ion to its site of action, in some cases by the formation of a fat soluble metal chelate.

3 The chelating drugs may render available for metabolic purposes a metal ion which otherwise might remain in an inactive, insoluble form.

4 The metal chelate may be readily excreted, thus providing a means of detoxification.

Examples of drugs which may act through chelation by some of these actions are given below. Of further interest are the factors determining whether or not a metal chelating drug will be effective, since these same factors are responsible for chemical specificity in biological systems. Knowledge that metal chelation is the basis of a drug's action facilitates considerably the development of new drugs because it becomes possible to anticipate how the drug molecule can be modified to enhance its metal binding properties.

In the case of salicylic acid it is highly probable that metal chelation is important. This is shown by the fact that the *m* and *p* hydroxybenzoic acids which do not chelate are inactive as analgesic agents or against the fever and pain associated with rheumatic fever. It is not known which metal or metals are affected by salicylic acid, but it is known that the metals affected must belong to the

transition groups. Numerous derivatives of salicylic acid containing the o-carboxyl hydroxyl group are about as effective as salicylic acid although they differ in dosage required and side effects. It might be anticipated that physiologically cortisone would have some resemblance to salicylates as has been demonstrated experimentally. Terramycin and aureomycin reverse the Be inhibition of alkaline phosphatase through the formation of a complex ion with Be. He lists as examples salicylic acid, adrenalin, terramycin, aureomycin, a thiosemicarbazone and cortisone. Penicillin forms insoluble salts with heavy metals.

Many chelating agents are fungicidal, antiseptic or bactericidal (233). Thirteen of nineteen common organic chelators of one or more transitional metals are listed by Martell and Calvin as effective against growth of *B. subtilis* with seven against growth of *B. Coli*. Likewise 8-hydroxy quinoline of seven quinolines and 26 substituted quinolines of 35 are effective against the growth of *Clostridium welchii*, most of which inhibit *Streptococcus hemolyticus*, *Staphylococcus aureus* and *B. Coli*; less so *Proteus* and *Pseudomonas pyocyaneus*. Zinc and manganese appear to be bound although the other essential metals, iron and cobalt, may be involved. Apparently copper is not for copper reagents in general are inert. Few are effective against *pyocyaneus*, an organism resistant to most antibiotics. The fungicidal properties of the oxines, so widely used in industry, is believed to be the result of their chelation with zinc, an essential metal for growth. Therefore bactericidal and fungicidal activity of many antiseptics and antibiotics may be functions of metal binding or chelation.

The most popular and versatile of the recognized chelating drugs is ethylene diamine tetraacetate (EDTA, Sequestrene, Versene), stability constants for which are shown in



TABLE XXIX  
THE LOGARITHM OF THE STABILITY CONSTANTS OF SOME METAL COMPLEXES\*

Ligand	log K <sub>N</sub>									
	N	Mg	Ca	Mn	Fe	Co	Ni	Cu	Zn	Cd
NH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> (En)	2	Small	Small	4.8	7.5	10.7	13.8	19.6	10.4	10.0
Histidine	2	—	—	7.7	—	13.8	—	18.6	12.8	—
N(CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> ) (Tren)	1	—	—	5.8	8.8	12.8	14.8	18.8	14.6	12.3
CH <sub>2</sub> NH(CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> )										
CH <sub>2</sub> NH(CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> ) (Tren)	1	—	—	—	—	—	—	—	—	—
Glycine	2	—	—	4.9	7.8	11.0	14.0	20.4	12.1	10.7
Glycylglycine	2	6.5	1.4	6.6	8.0	8.9	11.1	15.4	9.7	8.6
N(CH <sub>2</sub> CO <sub>2</sub> H) (Triac)	1	1.1	1.2	—	—	3.5	4.5	6.0	3.8	—
CH <sub>2</sub> N(CH <sub>2</sub> CO <sub>2</sub> H)	1	5.4	6.4	7.4	8.8	10.6	11.3	12.7	10.4	9.5
CH <sub>2</sub> N(CH <sub>2</sub> CO <sub>2</sub> H) (EDTA)	1	—	—	—	—	—	—	—	—	—
Oxalate	1	8.7	10.6	13.5	14.2	16.1	18.5	18.4	16.1	16.5
Tartrate	1	3.4	3.0	3.9	—	4.7	5.3	6.2	4.9	3.9
Salicylaldehyde 5 Sulphonic acid	1	1.4	1.8	—	—	—	—	—	2.8	—
Salicylaldehydet	2	—	—	—	—	5.6	6.6	9.3	5.4	—
Acetyl acetonef	2	6.8	—	6.8	7.6	8.3	9.2	13.3	8.1	7.8
Polysulphate (N=2)	2	9.5	—	—	—	11.2	12.1	17.1	—	—
Hydroxyl ion	7	3.2	3.0	2.5	3.0	3.0	3.0	3.5	2.5	—
Dipyridyl	1	2.6	1.1	2.8	3.2	3.6	3.8	6.5	4.7	3.0
ortho-Phenanthroline	3	—	—	—	16.5	—	—	17.8	—	10.5
Riboflavin	3	—	—	—	21.5	—	—	—	17.0	15.2
Folic Acid	7	—	—	3.4	7.1	3.9	4.1	6.6	5.6	4.7
?	?	—	—	6.0?	7.9	8.1	9.0	7.8	7.5	6.7

\* After Williams (235)

† The measurement of these stability constants was made in a mixed dioxan/water solvent whereas the other measurements were all made in aqueous solution

**Table XXIX** In addition to the transitional metals many others have strong affinities lead (18.2) lanthanum (15.4) chromic (24.0) ferric (25.0) as well as beryllium vanadium titanium silver and many rare earths \* Because EDTA is not metabolized (249) and apparently enters cells (250) it provides a means for removing soluble ions from the body in the order of their stability constants. If an abnormal trace metal is to be removed normal ones will accompany it according to the relative amounts and stability constants of each. Thus EDTA is not specific for lead for example a current popular use but will remove other ions with a higher constant such as copper and nickel and especially ferric iron. EDTA will be inactive however if the metals in the body are more tightly bound or chelated to protein than to the drug. This relative chelating capacity of a sequestering agent and a metal in the body follows certain definite laws and explains the ineffectiveness of EDTA for removing most metals.

An example of the effects of EDTA given intravenously to two patients is shown in Table XXX. Zinc was removed in sizeable quantities other metals less so or not at all. The high excretion of zinc in the patient with the nephrotic syndrome found before the drug was given is probably explained by the excessive proteinuria which carries combined zinc. There was no mobilization of lead while

---

EDTA makes a good chelating agent for clinical use for the following reasons: 1 The stability constants ( $\log K_s$ ) for common but important loosely bound metals is low (Ba Sr Ca Mg = 7.76-10.96) 2 The constants for more tightly bound metals is moderate (Mn Fe<sup>++</sup> Co Cu Zn = 14.04-18.8) 3 The constants for several abnormal metals is high (Hg 21.8 V<sup>+++</sup> 25.9 Fe<sup>+++</sup> 25.1). Unfortunately several abnormal metals fall in the range of the essential ones (Pb 18.04 Al 16.15 Ni 18.6° Y 18.09 Cd 16.46) so that these cannot be removed without danger of essential metal deficiency notably zinc.

TABLE XXX

## RENAL EXCRETION OF 13 METALS BEFORE DURING AND AFTER INTRAVENOUS EDTA

Date	EDTA gm	Urine Volume l	Urine Protein gm/l	Ti	V	Cr	Mn	Ni	Zn	Mo	As	Cd	Pb	Sn	Fe	Cu
Normal Subjects																
Nephrologia																
11/ 3/54	0	1.55	—	<3.8	<0.63	<0.64	<9.7	<2.8	<6.7	<14	0.80	<0.86	<5.7	<3.2		
2/25/55	0	2.66	2.6	0.37	<1.0	0.14	<5.0	0.75	360	5.0	0.74	2.9	0.80	13	570	330
2/26/55	0	2.15	2.4	0.16	<1.0	<0.05	<5.0	1.8	170	3.6	0.59	1.3	3.4	22	560	—
2/27/55	0	1.80	2.2	0.88	<1.0	<0.05	<5.0	2.2	370	3.5	0.76	0.88	0.28	6.0	560	162
2/28/55	0	2.36	1.6	0.95	<1.0	<0.05	<5.0	2.2	240	4.1	0.57	1.4	0.60	14	660	230
Mean	0	2.24	2.2	0.59	<1.0	<0.07	<5.0	1.7	285	3.6	0.62	1.5	1.1	12	560	219
3/ 1/55	3	1.81	2.4	1.1	<1.0	0.11	21	2.4	1900	3.0	0.36	<0.5	0.27	2.5	1050	180
3/ 2/55	3	2.01	2.8	2.0	<1.0	0.35	12	4.0	1400	2.2	0.32	<0.5	0.07	2.2	1070	162
3/ 3/55	4	1.46	3.2	0.50	<1.0	7.3	15	16	2200	2.4	0.38	2.8	0.70	4.8	1930	187
3/ 4/55	0	1.97	2.4	0.73	<1.0	0.12	8.5	2.4	1200	1.2	0.37	4.0	0.04	3.4	1450	385
Mean	2.5	1.81	2.7	1.1	<1.0	2.0	14	6.2	1675	2.2	0.36	1.9	0.27	3.2	1375	229
3/ 5/55	0	1.73	3.2	1.3	<1.0	<0.05	<5.0	3.0	640	<0.5	0.43	3.6	0.13	3.9	—	385
Normal Female																
10/ 6/55	39			2.7	7.9	6.75	<6.0	1.15	17	7.0	0.4	<1.02	70.1	10.25		
10/ 8/55	0			1.8	7.4	4.0	<5.0	2.9	25	16	0.51	<0.5	2.0	14.25		
10/11/55	0			1.5	5.5	4.2	4.4	1.9	31	13.25	0.34	0.85	215	85		
Mean				0.65	<0.5	0.78	Tc	3.1	46	12.08	0.42	±0.79	95.7	36.5		
10/16/55	3			16	2.35	1.45	16	2.0	490	12	0.33	0.68	7.0	13		
10/17/55	3			8.25	1.8	1.75	17.5	1.75	650	9.25	0.43	0.9	26.5	3.0		
10/20/55	3			5.0	1.55	1.5	27	1.6	800	13.5	0.43	0.58	55	5.5		
Mean				7.46	±1.55	1.37	±15.1	2.11	496.5	11.0	0.41	4.04	44.0	6.69		

From data of Perry and Schroeder (181). The normal subjects were 15 laboratory workers. Note the increase in homolung manganese in the nephrotic patient in titanium, manganese and cadmium in the normal woman and the normal man. The high titration of lead in the patient represented by the obviously zinc deficiency. Note also the fall of lead to move. The high titration of lead in the patient. The lead on detection in nations was done by Dr. Reuben S. Dubach and the copper by Dr. Clark J. Gubler.

eight metals almost certainly present in a strongly bound form in their tissues did not change

BAL (2,3-dimercaptopropanol) a straight chain dithiol binds the following heavy metals in a chelate zinc chromium cadmium nickel, lead, antimony, arsenic, bismuth copper, mercury, gold (201) Substitution complexes on the sulphydryls are formed In the case of cadmium at least, these are dissociated in the kidney and may result in cadmium nephritis a reflection of the greater binding capacity of renal tissue for cadmium than BAL Citrate a chelating agent used for lead poisoning is metabolized by the body and is therefore relatively ineffective A list of some representative binding and chelating agents is shown in Table XXXI Their use in medicine is only beginning For example all antithyroid drugs have this common property suggesting their probable action

These considerations open up a wide field of thought on the mechanisms of disease and of drug actions Similar conclusions can be drawn when late toxic reactions of drugs are compared with structure The common denominator of the offending drugs appeared to be in chelation

**Drug Reactions** Late systemic reactions to drugs affect several organs and systems of which blood dyscrasias hepatitis and polyarteritis are the most serious (252) Most of the drugs causing fatal agranulocytosis as listed by Alexander (252) are metal binding agents (233-253) such as aminopyrine phenylbutazone antihistamines dinitrophenol Presidon procaine amide and Tapazole containing pyridines amines amides nitroso or sulphydryl groups (253) Their solubilities and specificities for heavy metals however are not known to our knowledge Nonfatal leucopenia has occurred with arsenical compounds gold salts thiouracils hydantoins salicylates sulfonamides streptomycin and thiosemicarbazone which can displace or bind

TABLE XXVI

SOME EXAMPLES OF CHELATING AND METAL-BINDING DRUGS (232 233 253)  
(OTHER THAN ANTIHYPERTENSIVE AGENTS)

<i>Drugs Used To Remove Metals</i>	<i>Reference</i>
EDTA	233
BAL	251
Citric Acid	235
<i>Antithyroid Agents†</i>	294
Thiourea	247
Thiouracil	247
2 Mercaptoimidazole* (Tapazole)	253
2 Aminothiazole*	253
P Aminobenzoic acid*	253
Sulfonamides	233
L-5 vinyl 2 thio-oxazolidone	294
<i>Antibiotics†</i>	
Sulfonamides	233
Penicillin (and penicillamine)	253
Chloramphenicol*	253
Streptomycin*	253
Isoniazid	296
Thiosemicarbazone*	253
P Aminosalicyclic acid	233
<i>Analgesics and Antipyretics†</i>	
Aminopyrene	233
Antipyrine	253
Phenylbutazone*	253
Phenacetylurea*	253
Salicylic acid	233
<i>Miscellaneous†</i>	
Bis(diethylthiocarbamyl) disulfide (antabuse)	297
2 Acetyl amino 1 3 4 thiadiazole 5 sulfonamide (Diamox)	233
<i>Drugs Containing Specific Groups†</i>	232 233 234
Pyridine	
Thiol or Mercaptan	
Carbazide	
Diazine	
Thiazol	

\* Contains metal binding groups affinities not known

† Drugs causing late toxic reactions

TABLE XXXI—(continued)

---

Nitrite	
Thiocyanate	
Pyrocatechol	
Quinaldine	
Hydantoin	
Hydrazine	
<i>Chelating Chemicals *</i>	
Phytic Acid	
2 ketogluconic acid	
Glycerophosphates	
Potassium gluconate	
Gallates	
Rubeanic acid and derivatives	
Guanidine carbonate	
Potassium ethyl xanthate	
Dimethyl glyoxime	
Uracils	
Oximes	
Diphenyl carbazide	
Diphenyl thiocarbazon	
Potassium thiocarbonate	
Cupferron	
Adipoin	
<i>Some Reagents for Analysis of Metals</i>	256
Zn Ferric cyanide	
8-hydroxyquinoline	
Quinaldinate	
Sn Dinitro-diphenylamine sulfoxide	
Toluene dithiol	
Ag P-dimethylamino-benzalrhodamine	
Ni $\gamma$ benzil-dioxime	
Dithiooxalate	
Dithiol	
Mo Thiocyanate	
Cu Quinosol	
Pyridine thiocyanate	
Cd $\beta$ -napthoquinoline	
Thiourea	
Benzoin-oxime	

---

From chemical catalogues

trace metals. The properties of the few other drugs causing this disorder are not known. Even the more unusual cases of leucopenia are due to such metal binding agents as barbiturates, chloramphenicol, isoniazid, demerol, phenothiazines, novalgin, pamaquine, penicillin and phenurone, which appear to possess the requisite metal binding groups or to form insoluble metallic salts.

Alexander's list of drugs reported to cause aplastic anemia contains eight of the above agents, with the addition of such possible metal binding agents as quinacrine, hydralazine, mercurial diuretics (both mercury and amide are present in mercurhydrin), novurone and para-aminosalicylic acid. The drugs causing thrombocytopenic purpura include eleven of the above with the addition of sedormid, procaine, quinine and quinidine containing either similar groups or quinoline. In the case of quinine and quinidine the quinoline structure is not such as to have chelating properties, the requisite group being on the 4 position while 8-hydroxyquinoline is a strong chelating agent. Unless the ring structure is broken in the body to form quinolinic acid the mechanism of action is probably not dependent upon chelation. Hepatitis has been caused by 17 of the above drugs and by acriflavine, cortisone and carbazone, all of which contain metal complexing or sequestering groups.

Aside from proteins and undefined extracts of plant and animal tissues many of the same drugs appear in the list of causes of what Alexander calls the serum sickness pattern (252). Twenty one of the above drugs are listed, with the addition of thiocyanate, ACTH (which may mobilize zinc and contain sulphhydryl), bismuth, two new antibiotics structurally unidentified and chlorpromazine, which obviously has metal binding properties when hydrolyzed. When a comparison is made with the substances

causing shock. 13 new ones appear which do not have this property and 13 of the above are represented. Bronchial asthma caused by 36 agents of which 19 are of plant or animal origin and unidentified structurally is caused by 14 containing possible metal complexing groups or metals. A similar situation appears among the agents causing severe late toxic skin reactions such as eczema urticaria exanthemata exfoliative dermatitis bullous eruptions and the like. Metals and binding agents appear frequently when the chemical structure is known.

Curiously enough serious local and systemic reactions are rare or absent among the drugs not containing metal reactive groups or producing them only on extensive hydrolysis. Sulfobromophthalein decholin paredrine ether boric acid Banthine menthol quetane diocaine chloral hydrate morphine opium codeine digitalis are examples. On the other hand barbituric acid the basic constituent of many sedatives and a pyridine compound forms salts with metals. Metal binding by sulfanilic acid is well known (233). The instability of hydantoin hydrolyzing to metal binding hydantoic acid the metal binding properties of pyridines nitroso groups (dinitrophenol is a good example) cyanides amine and sulphydryl groups semicarbazides dicarboxylic acids thiols and sulfur-containing structures appear to be related to many forms of drug sensitivity. Therefore it is possible that trace metals may be involved in many reactions of sensitization and perhaps even in some forms of allergy. BAL (2,3-dimercaptopropanol) for example is a potent contactant. Although drug reactions vary widely in frequency such agents as dinitrophenol being very active and amines relatively inactive metalloenzyme disturbances cannot be excluded as causes. It will be noted that the more metal binding groups on the soluble sulfonamides (pyridine thiazole succinate etc.) the more likely



the agent is to produce late generalized reactions. The interested reader can find many examples of this apparently general phenomenon by comparing structure (253), metal binding power (233) and ability to produce late reactions (252).

The author by no means wishes to imply that the phenomena of hypersensitivity, allergic and immune reactions, and anaphylactic shock are the result of trace metal chelation. The mechanisms of these reactions involving altered proteins have been studied extensively enough to exclude trace metals as being primarily responsible. Late toxic reactions to drugs, however, may well be caused either by metal imbalances or sensitivity. Thrombocytopenia induced by quinine is an example of the latter. Obviously, the problem should be studied further from this viewpoint.

### ESSENTIAL TRACE METALS IN MAN

To be essential for mammalian metabolism the trace metals under consideration should be able to form chelates and to be reactive. They should be demonstrable in human tissues both of infants and of adults. They should be found in sea water, for life began in the sea and in plants. They should demonstrate activity on enzyme mechanisms especially to accelerate reactions. We can apply these criteria to the metals actually found, examining the most logical ones (Table XXXII).

In Table XXXIII are shown the metals of interest found in sea water. In general those of highest concentration are more prevalent in plants and animal tissues. The relative composition of sea water, however, has probably changed since life began in the primitive ocean, only those elements present when amphibians left the ocean

TABLE XXXII  
TRACE METALS FOUND IN MAN AND THEIR PROBABLE ROLES

Essential	Possibly Essential	No Known Metabolic Function	Metabolic or Antimetabolic	Not Found in Antimetabolic
Cobalt	Aluminum	Barium	Bismuth	Antimony
Copper	Strontium	Boron	Cadmium	Arsenic
Iron	Vanadium	Cesium	Chromium	Beryllium
Manganese		Gallium	Gold	Thallium
Molybdenum		Lanthanum	Lead	
			Nickel	
			Silver	
Zinc		Tin	Titanium	

Those in *italics* may be implicated in chronic diseases especially cardiovascular because of their prevalence concentrations or known functions on enzyme systems.

and satisfying certain criteria for reactivity in enzyme mechanisms can be expected to have become essential for metabolism. We cannot say that living cells have learned to use new and less reactive elements in enzyme systems by a process of adaptation; the basic structures of atoms have not changed and life began by using the most suitable ones.

Because all food comes eventually from plants, an examination of the metallic content of plants is necessary. Local pastoral variations can be neglected. No metal can be expected to be essential for animals which does not occur in plants or in water. In Table XXXIII are the metals of interest in plants. Little aluminum, nickel, and no cadmium, tin, silver, gold, titanium, lead, or mercury is to be expected in animal tissues, while vanadium and the five known essential metals will be found. Obviously, if domestic animals or man show appreciable quantities of those which do not appear in plants, they must have come from unnatural sources.

To be classed as abnormal for our thesis, a metal

TABLE XXXIII  
TRACE METALS IN SEA WATER %  
(Also found in plants animals and man (256 257 231 254) )

Seawater	Essential for Plants		Found in American Tissues			Possible Contaminant			
	Factor	X10-	Plants	Infants	Adult's	Adult Urine	Essential for Mammals	from Soil	from Civilization
Mg	13	1	+	+	+	+	+		
Sr	13	3	?	+	+		+		
B	45	4	+	+	±		?		
Rb	20	5	?	?	+				
Zn	50	6	+	+	+	+	+		
Fe	50	6	+	+	+	+	+		
Cu	20	6	+	+	+	+	+		
Al	5	5	0	+	+	+	+		
Pb	50	7	0	+	+	?	?	+	+
Mn	40	7	+	+	+	+	0		
Ni	30	7	0	+	+	+	+	+	+
Sn	30	7	0	±	±	+	0	+	+
Co	10	7	+	+	+	+	0	+	
Mo	10	7	+	+	+	+	+		
Ti	<10	7	0	+	+	+	0?	+	
V	50	8	+	0	+	+	+		
Hg	30	9	0		+	+	0		+
Ag	n	8	0		+	+	0		+
Au	40	10	0	+	+	+	0		+
Cd	Trace		0	0	±		0		+
Cr	Trace		0	+	+	+	0	+	+

0=Strong evidence against element being essential ?=Cannot be excluded at present  
\* After V. I. Nogrodov (255)

0=Strong evidence against element being essential ?=Cannot be excluded at present  
\* After V nogradov (255)

a) should be found in human tissues from some areas of the world and not from others b) should not be found in plants or wild animals c) should affect some metallo-enzymes d) preferably should not be in the tissues of young infants e) should be introduced by the habits of Western Civilization into foods or beverages as a result of processing transportation or manufacture and f) should be poorly excreted cumulative and preferably showing organ specificity

**Concentrations of the Essential Trace Metals in Man**  
Although many analyses have been done by various methods for single or several elements in blood tissues and urine (254-257) the first extensive systematic investigation on the content of both essential and abnormal trace metals in human tissues was made by Tipton and her co-workers. Using spark spectrographic methods with indium as an internal standard and densitometric photoelectric recording of plates Tipton analyzed 258 tissues from 24 persons dying suddenly in various areas of the United States for 18 metals (almost 4500 analyses) (231). A preliminary analysis of 42 autopsies from various places in this country showed similar but less quantitative results (258) while in a later series the findings were essentially the same (259).

In Table XXXIV are the mean concentrations in various tissues of the essential elements manganese cobalt copper zinc and molybdenum calculated roughly for total bodily amounts. Zinc is the most prevalent of the normal group in several times the concentration of any of the others. Essential cobalt was found in only five bodies sparsely scattered in small concentrations probably because of methodological limits and its presence in very minute quantities. These results appear comparable to those of Griffith *et al* for copper zinc and manganese on

## Mechanisms of Hypertension

[illegible]

the basis of dry tissue in a much larger series (260)

Some organs concentrate certain metals others do not Zinc was found in every organ in concentrations of 4.4 to 300 mg/Kg being far highest in prostate then muscle liver kidney and heart and lowest in adrenal bladder brain testis lung and intestine Copper was concentrated in brain liver and spleen being lowest in muscle adrenal aorta intestine and testis Manganese in much smaller amounts was concentrated especially in liver with pancreas lung spleen and thyroid following quite far behind lowest organs were heart muscle testis and aorta Three of these four metals were found in all 258 specimens examined Molybdenum was absent in only half of the samples of muscle and testis a third of those of pancreas thyroid and lung most prostates and all but one brain but was found in concentrations of more than 0.13 mg/kg in all heart kidney and liver samples being by far the highest in liver In the concentrations detectable, molybdenum apparently is not essential for metabolism in all organs but three of the others may be

**Sources and Turnover of Essential Metals** All of the essential trace metals are found to a greater or less extent in plant and animal tissues (Table XXXIV) derived from the soil Cobalt is probably the least concentrated Soils vary widely in their contents of trace elements and disorders due to deficiencies or excesses have been recognized in both plants and animals Semi-quantitative trace mineral analysis is a recognized practice in the evaluation of soils for farming The following was summarized from Monier Williams (256) and Marston (261)

**Manganese** The largest sources are in the following foods with above 30 mg/kg oatmeal whole meal flour bran soy bean meal cocoa cloves chestnuts pepper maple sugar tea contains 150 to 900 mg/kg With lesser con



may also be important in hemoglobin formation. A copper enzyme ceruloplasmin is found in concentrations of about 34 mg per 100 ml of serum. Several phenolic oxidases depend upon copper. Pigmentation may be related to the content in skin and hair follicles. Copper is quite well retained by the body with some dependency upon intake being slowly eliminated by way of the feces. Gallstones contain large amounts. No chronic copper poisoning has been described in human beings. Human milk is extremely low in content 0.04 mg/kg. As a rule American foods contain adequate amounts, sometimes an excess since many insecticides and fungicides contain copper. The largest amounts 10 mg/kg or more are found in tea, coffee, cocoa, chocolates, nuts, liver, shell fish, especially oysters, tomatoes and yeast. The least is found in milk, butter, cheese, refined sugar, honey, margarine, lard and suet.

**Zinc** This most prevalent of the trace metals in the human body is present in large quantities in most organs as seen in Table XXXIV. It is found in foods and is a requirement of plants, bacteria and fungi. Most modern fungicides are zinc chelating agents. Deficiency in soils causes diseases of both plants and animals, although its prevalence makes animal diseases more uncommon. Foods with over 50 mg/kg are wheat germ, bran, oysters, beef livers, gelatin and dried eggs; those which contain the least amount are fruits, chestnuts, green vegetables and fish. Chronic poisoning in man is not known. There have been several outbreaks of supposedly acute poisoning from foods stored in zinc lined receptacles, but the contamination of zinc by cadmium makes it questionable that zinc itself was the cause. Symptoms of zinc and cadmium poisoning are identical, i.e. violent gastroenteritis and zinc poisoning is most difficult to produce in animals.



centrations are green vegetables, nuts, rice and barley of considerably less content are meats, legumes and many organ tissues. Dairy products and fish are low in manganese and coffee contains extremely little. It has been estimated that about half the intake of adults in Britain during the winter came from tea. The minimum daily requirement for man has been variously set at 4.6 to 10 mg, about 0.01 mg per day being excreted in the urine. In view of the small body pool, approximately 11 mg according to the method of analysis (Table XXXIV), this high requirement may reflect the poor absorption of manganese from the gastrointestinal tract. Large amounts may be given daily, up to 1.0 Gm per day of the citrate or glycerophosphate, without signs of toxicity and apparently without excessive absorption. While deficiency in man has not been described, a reasonable assumption that it might occur can be postulated, especially if conditioned by competing metals or affected by drugs. Toxicity from ingested manganese has not been described, although inhaled dust can cause Parkinsonian symptoms and occasionally cirrhosis of the liver.

**Cobalt** Present in vitamin B<sub>12</sub> as a porphyrin chelate, this element is essential for maturation of red blood cells but has no other known function in man. It is rapidly excreted both in urine and feces and apparently does not accumulate. It may not be readily absorbed in man. An excessive amount produces polycythemia in the rat, dog, frog, mouse, guinea pig and sheep. While the amounts in food are not well known, traces occur in vegetables, fruits and cereals, 0.5 mg/kg in legumes and as little as 0.003 mg/kg in white flour. In view of the small body pool, deficiency in man is possible but unproven. Cobalt is a vasodilator in man (262) and in the rat (183).

**Copper** An essential element in cell respiration, copper

high content of iron in their livers. Apparently the bacteria in the rumen synthesize vitamin B<sub>12</sub> when cobalt is present. High requirements are indicated by the large doses of the vitamin necessary to cure this disease. Horses and pigs raised in the same deficient areas are not affected as their requirements are lower. Bacterial synthesis in the colon, as occurs in man, apparently does not lead to absorption of this vitamin, therefore it must be ingested as such. Copper deficiency has been implicated in certain anemias in infancy but no known diseases in adults have been described. Anemia has been produced in laboratory animals along with a slow rate of growth, impaired absorption of ingested iron, impaired mobilization of iron from tissues, and impaired utilization of iron for hemoglobin synthesis have been found, as well as low cytochrome oxidase activity of the bone marrow. Cattle grazing on copper-deficient pastures show depigmented, abnormal hair, develop cachexia, anorexia, and anemia; their bones become fragile; reproduction and milk production is decreased, and they frequently die of cardiac failure. Young animals may become ataxic. Sheep show defective keratinization and hypochromic anemia; lambs born of copper-deficient ewes develop swayback and ataxic and paralytic diseases characterized by diffuse demyelination of the central nervous system. Depigmentation has been produced in many species. Excesses or deficiencies of other trace elements may influence the disorders in cattle and sheep, especially of cobalt and molybdenum. Molybdenum deficiency prevents fixation of nitrogen by soil bacteria, but diseases in higher animals have not been discovered. Zinc deficiency causes hyperkeratosis in pigs (264), hyperkeratosis and keratinization of the esophagus in rats (265), sterility (266), and signs suggestive of ariboflavinosis with vascularization of the cornea and lesions at the mucocutane

**Molybdenum** The newest of the essential elements to be found necessary in human and animal metabolism molybdenum plus a flavin are necessary for the metabolism of xanthine to uric acid by xanthine oxidase and the oxidation of aldehydes by liver. It is essential for the fixation of nitrogen in the soil by nitrogen fixing bacteria. Molybdenum is present almost universally in fertile soils and in plant and animal tissues. Its toxicity resembles that of selenium poisoning; excesses in soils affect ruminants rather than horses and pigs, producing a disease characterized by chronic diarrhea called teart. Copper fed to animals prevents molybdenum poisoning. An examination of the periodic table indicates that molybdenum is unique in that it is next to the heaviest element essential for mammalian metabolism and occurs in the hexavalent form. Whether or not deficiencies occur in man is not known, the body pool is small.

**Specific Metal Deficiencies (256, 261) \*** Actual deficiencies of some metals in man are not inconceivable, although no true deficiency (other than iron) has been described. Lack of manganese kills rabbits; deficiency in rats causes failure of male reproduction and a high mortality rate in the young. Hen's eggs do not hatch well, perosis or 'slipped tendon' with enlargement and malformation of the tibio metatarsal joint and arrested growth of long bones, possibly due to low bone phosphatase, is caused by deficiency of this element in growing chicks. Pigs and rabbits also show bone affections suggesting that it may be related to the growth or health of bone and joints.

**Cobalt** deficiency in soils causes enzootic marasmus or Bush Sickness in ruminants characterized by impaired growth, anorexia, weakness, emaciation and anemia with

---

\* The reader is referred to Moore's recent critical and inclusive discussion of this subject (263)

TABLE XXXV  
CONCENTRATIONS AND CONTENTS OF ABNORMAL TRACE METALS WITH ORGAN SPECIFICITIES  
(NET Wt. CHIT) (231)

Org	mg (Kt)	Total mg	mg (Kt)	Al	Total mg	mg (Kt)	Total mg	mg (Kt)	Pb	Total mg	mg (Kt)	P	Total mg
Ad. al	1.4	0.02	4.41	0.07	0.52	0.01	1.04	0.02	0.008	0.008	0.008	0.008	0.008
Aorta	2.09	0.19	9.09	0.5	0.75	0.04	0.39	0.08	0.05	0.05	0.05	0.05	0.05
Int. d. r	10.93	0.19	2.33	0.5	0.21	0.14	0.31	0.62	0.05	0.05	0.05	0.05	0.05
B. l.	0	0.52	3.55	0.75	0.43	0.03	0.98	0.0	0.0	0.0	0.0	0.0	0.0
St. int.	(1.74)	0.52	2.51	0.75	0.43	0.03	0.98	0.16	0.0	0.0	0.0	0.0	0.0
St. mach. & l. r. lin	1.20	0.40	3.25	0.50	0.44	0.04	0.14	0.38	0.0	0.0	0.0	0.0	0.0
Kid. ey	33.1	0.92	1.80	0.54	0.14	0.04	0.39	0.06	0.0	0.0	0.0	0.0	0.0
L. ver	2.60	0.40	2.55	3.81	0.20	0.39	2.04	0.05	0.0	0.0	0.0	0.0	0.0
L. r.	(1.73)	1.1	30.8	21.6	7.06	5.15	1.21	19.9	0.04	0.04	0.04	0.04	0.04
L. r. f	(1.73)	49.8	3.01	54.2	0.48	13.4	0.11	0.13	0.0	0.0	0.0	0.0	0.0
Muscl	2.10	0.21	2.67	0.27	0.15	0.02	0.32	0.01	0.0	0.0	0.0	0.0	0.0
P. v. os	(1.53)	0.03	5.53	0.18	1.51	0.03	0.29	0.01	0.0	0.0	0.0	0.0	0.0
P. l. to	(1.96)	0.39	3.34	0.67	0.51	0.06	1.33	0.27	0.24	0.24	0.24	0.24	0.24
Sple	(1.35)	0.03	3.87	0.08	0.21	0.004	0.67	0.02	0.0	0.0	0.0	0.0	0.0
T. tis	2.08	0.06	5.12	0.15	0.5	0.01	0.50	0.02	0.0	0.0	0.0	0.0	0.0
T. v. r. d	3.86	46.6	3.39	64.2	0.80	10.68	0.90	10.8	2.16	2.16	2.16	2.16	2.16
Skin	3.86	46.6	3.39	64.2	0.80	10.68	0.90	10.8	2.16	2.16	2.16	2.16	2.16
Adipose Tiss	3.86	46.6	3.39	64.2	0.80	10.68	0.90	10.8	2.16	2.16	2.16	2.16	2.16
Other Tiss e	3.86	46.6	3.39	64.2	0.80	10.68	0.90	10.8	2.16	2.16	2.16	2.16	2.16
a. b. Total known (mg)	70.24	0.0	96.56	0.0	0.0	20.46	0.0	0.0	0.0	0.0	0.0	0.0	0.0
c. Total unknown (mg)	31.14	0.0	31.14	0.0	0.0	31.14	0.0	0.0	0.0	0.0	0.0	0.0	0.0
d. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
e. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
f. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
g. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
h. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
i. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
j. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
k. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
l. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
m. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
n. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
o. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
p. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
q. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
r. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
s. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
t. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
u. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
v. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
w. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
x. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
y. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0
z. Total (mg)	101.38	0.0	127.70	0.0	0.0	51.60	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Figures in parentheses indicate 1 mg/ml of tissue or more sample  
a. b. Total known (mg)  
c. Total unknown (mg)  
d. Total (mg)  
e. Total (mg)  
f. Total (mg)  
g. Total (mg)  
h. Total (mg)  
i. Total (mg)  
j. Total (mg)  
k. Total (mg)  
l. Total (mg)  
m. Total (mg)  
n. Total (mg)  
o. Total (mg)  
p. Total (mg)  
q. Total (mg)  
r. Total (mg)  
s. Total (mg)  
t. Total (mg)  
u. Total (mg)  
v. Total (mg)  
w. Total (mg)  
x. Total (mg)  
y. Total (mg)  
z. Total (mg)

ous junctions. These signs are more like those of pyridoxine deficiency. It is doubtful that zinc deficiency ordinarily can be produced in man except on very low intakes or during excessive proteinuria, during which loss of protein bound zinc can occur. Some of the symptoms of beriberi have been thought to be manifestations of zinc deficiency caused by low intakes. The patient shown in Table XXX exhibited acute pyridoxine deficiency twice when EDTA was given intravenously (181) probably his excessive urinary loss of protein bound zinc added to the zincuretic effect of EDTA resulted in deficiency of the zinc chelated to some pyridoxal enzymes (Fig 20 p 231).

#### **"ABNORMAL TRACE METALS IN MAN**

In Table XXXV are the concentrations and contents of the five presumably 'abnormal' trace metals showing some organ specificity. We observe the following. Aluminum was not found in three hearts but was in every other organ examined almost always in concentrations of over 1 mg/kg and in all but six in over 3 mg/kg. It was selectively concentrated in lung (perhaps by inhalation) with a third as much in aorta and a sixth or less in prostate, stomach, thyroid and adrenal. Lowest values were in kidney. Amounts were higher than those of any essential metal save zinc. Cadmium appeared in kidneys in very high concentrations, with liver, pancreas, thyroid containing a tenth as much. Titanium appeared in lung (perhaps by inhalation) with prostate a poor second and a relatively even distribution in the other organs. Lead appeared highest in liver, pancreas, spleen, kidney, adrenal and aorta, lowest in stomach, brain and bladder. The less frequently found boron appeared to be concentrated in some spleens. On the other hand little evidence of concentration in any one organ was found in the cases of the

ubiquitous elements tin nickel, chromium and silver (Table XXXVI)

The obvious conclusions are that relatively large amounts of cadmium are in American kidneys and aluminum and titanium in lungs while other metals are more or less evenly distributed Furthermore there is weight for weight more of several abnormal metals in most organs than normal ones of high biological activity such as manganese copper and molybdenum On the basis of mass alone these three tables show the following when the metals are arranged according to the periodic table Silver is present in amounts equal to 2.2 per cent of copper cadmium equal to 12 per cent of zinc (50 per cent in the kidney) chromium equal to 61 per cent of molybdenum (and is more prevalent) nickel equal to 140 per cent of cobalt while there is more titanium tin and lead than manganese molybdenum and cobalt and there is more aluminum than copper Thus the order in decreasing amounts is *Zn Al Cu Cd Pb Ti Sn Mo, Ni Co, Cr Mn Ag B* according to the present estimate (essential ones in italics) Traces of gallium were found in most lungs of bismuth in 21 samples of gold in 72 samples and of thallium in 6 samples

In Tipton's second series of 24 autopsies from another (western) part of the United States (259) *the findings* were quite similar for the essential metals although there were somewhat less copper and zinc in most organs and molybdenum was largely confined to liver and kidney Of those now considered abnormal cadmium appeared in liver and kidney in the same concentrations as in her first series but a large majority of other organs were lacking in this element There was much less aluminum in all organs but lung (23 mg /Kg) and titanium was found in only a few bodies except for lung where its concentration

TABLE XXVI  
CONCENTRATIONS AND CONTENTS OF "ABNORMAL TRACE METALS WITHOUT ORGAN SPECIFICITY  
(WET WEIGHT) (231)

Organ	Cr		Ni		Sn		Ag	
	mg/Kg	Total mg	mg/Kg	Total mg	mg/Kg	Total mg	mg/Kg	Total mg
Adrenal	0.28	0.006	0.26	0.005	0.34	0.007	0.05	0.001
Aorta	0.01		0.20		0.42		0.07	
Bladder	0.42	0.08	0.23	0.06	0.19	0.04	0.07	0.01
Brain	0.36	0.76	(0.14)	0.29	(0.55)	1.16	0.04	0.08
Heart	(0.13)	0.04	(0.23)	0.07	0.36	0.11	(0.26)	0.08
Stomach & Intestine	0.18	0.36	(0.39)	0.78	0.48	0.96	(0.08)	0.16
Kidney	0.08	0.03	(0.22)	0.07	0.48	0.14	0.06	0.02
Liver	0.27	0.40	(0.32)	0.48	0.65	0.98	0.07	0.10
Lung	0.72	0.50	0.47	0.33	0.95	0.66	(0.15)	0.10
Muscle	(0.18)	3.04	(0.40)	11.2	(0.51)	14.3	(0.06)	1.68
Pancreas	0.20	0.02	(0.32)	0.03	(0.53)	0.05	(0.05)	0.008
Prostate	0.28	0.01	(0.48)	0.02	0.74	0.04	0.04	0.002
Spleen	0.63	0.13	(0.72)	0.14	(0.41)	0.08	(0.23)	0.05
Testis	0.39	0.008	(0.67)	0.01	0.22	0.004	(0.08)	0.002
Thyroid	0.42	0.01	(0.25)	0.008	1.0	0.03	0.03	0.0009
Skin								
Skeleton								
Adipose Tissue	0.32		0.37	4.44	0.53	6.36	0.085	1.02
Other Tissue								
Sub Total known (mg.)		7.394		11.738		18.561		2.294
Total with estimated skin and other soft tissue at mean value X 12 kg (mg.)		11.234		16.178		24.921		3.314
Specimens lacking metal	g		62		24		33	

Figures in parentheses indicate element ml ng in two o more sample

(256) There were 4 kidneys and livers 3 lungs 2 spleens and 1 aorta heart intestine and muscle In contradistinction to adult tissues kidneys and livers and lungs contained no titanium cadmium or tin Aluminum was not concentrated in lung although it occurred in amounts of 0.3-1.0 mg/kg in most tissues less than that of adults Titanium was found in only one body in intestine kidney and muscle Nickel occurred in one other kidney and liver tin was in both spleens and the sample of muscle and aorta On the other hand boron was in all tissues but one kidney and liver chromium and silver were ubiquitous in adult concentrations as was lead but in smaller amounts than in adults Organ specificity as determined by concentration was not found consistently \*

In the bodies of 3 older infants and children (7 weeks 10 months and 2 years) there was no titanium Nickel in traces was in 1 kidney tin was found in all tissues as was lead while silver occurred in 7 of 12 specimens Cadmium was present in the 10 month-old kidney (0.65 mg/kg) and in the 2 year-old (2.75 mg/kg) but not in the 7 week old one The essential metals were found in distributions and concentrations similar to those of adults Manganese was if anything more concentrated zinc less so while copper was comparable showing an affinity for liver Molybdenum was in all livers while cobalt was present in only two

Within the limits of these observations, and in view of what is known the following further conclusions can be drawn 1 Titanium nickel and cadmium are not essential to infant life but accumulate with age 2 Aluminum chromium silver and lead either qualify as essential trace metals or pass through the placental membrane Obviously titanium nickel cadmium and tin do not so pass

Analyses of 20 stillborn infants gave essentially similar results



was lower (2.8 mg/kg). Likewise lead was somewhat less frequent, being in all livers, kidneys, lungs, pancreases, bones, aortas and adrenals but missing in a few to many samples of other tissues. Chromium and silver were also absent in one or more samples of each tissue and were found in lower concentrations, while nickel was quite uncommon. Tin on the other hand, was widespread through most samples. There was less gallium, the same amount of bismuth and much less gold.

New elements added to the analysis were barium found in all samples of lung, bone, adrenal, aorta, gastrointestinal tract and thyroid and in most samples of the other organs; cesium in half the lungs (3.1 mg/kg); iron in all tissues in high concentrations especially spleen (280 mg/kg), lung (210 mg/kg) and liver (170 mg/kg); lanthanum in a third of spleens; strontium in every tissue (0.04-0.20 mg/kg) with much (20 mg/kg) in bone; and vanadium in two thirds of the lungs (0.27 mg/kg). No antimony, arsenic, beryllium, niobium, ruthenium, thallium or zirconium were found.

One can draw some tentative conclusions on Tipton's two series: the first obtained on autopsies from New York, Memphis and Chicago, the second from a Western city. 1. Minor regional differences in exposure or accumulation of some abnormal trace metals appear, especially as regards aluminum, titanium, chromium, silver, nickel and possibly lead. 2. Molybdenum is essential only for liver and kidney. 3. Chromium and nickel are probably not essential elements. These conclusions apply only to the concentrations detectable by the method.

**Trace Metals in Infant Tissues.** We can gain some idea as to which metals are essential for life and which are not by examining the tissues of babies. Analyses of 2 St. Louis stillbirths and 2 babies living 12 hours were revealing.

Some of these metals accumulate with age in Americans others do not In Table XXII Chapter V are shown examples Obviously cadmium titanium nickel and tin in all tissues and aluminum in lung increase from little or none in infants to relatively higher concentrations at older ages The striking examples are in cadmium and titanium

**Trace Metals in Tissues from Uncivilized People** In order to ascertain more definitely what trace metals are essential and what are not a small number of tissues from African natives in little contact with Western Civilization were obtained by Dr Perry from Uganda and analyzed by Dr Tipton (266) The ages ranged from 18 months to over 50 years there were three under 10 and four over 40 None showed any evidence of atherosclerosis in the aorta or elsewhere even fatty streaks were not seen The causes of death were several 6 patients died of acute infections No age trends in essential metals were apparent as is the case with Americans The interesting findings lay in the absence of those which might be guessed to be products of Western Civilization cadmium (in only one kidney) nickel and tin and the much smaller amounts of silver lead chromium and possibly titanium (Table XXXVII)

**Conclusions** Therefore it becomes apparent that nickel chromium cadmium lead silver and tin are not essential elements but results of civilization a conclusion which could be drawn from the analyses of children's tissues only for cadmium nickel and titanium The possibility of these six elements found in American tissues being toxic must therefore be considered Common sense excludes silver because of its low concentrations In addition we cannot rule out the possible essential nature of aluminium barium strontium and for lung of vanadium and ti

MEAN CONCENTRATIONS OF ESSENTIAL AND NONESSENTIAL TRACE METALS IN AMERICAN AND AFRICAN TISSUES  
(ANALYSES PERFORMED BY TIPTON *et al*)  
(mg/Kg Wet Weight\*)

Metal	Kidney		Liver		Lung		Spleen		American Child 0-2 Years	
	Africa	U S A	Africa	U S A	Africa	U S A	Africa	U S A	Kidney	Liver
No cases	10	24	24	24	4	23	24	2	7	7
Mn	0.39	0.43	0.56	0.57	0.49	0.58	0.19	0.27	0.55	0.98
Cu	0.26	2.76	2.9	4.47	2.8	4.49	1.4	1.7	2.89	9.0
Zn	24.5	67.2	48	65.3	39.5	18.3	17	33.8	18.4	63.0
Mo	0	0.63	0.33	0.55(1)	0	0.18(15)	0	0	0.85(3)	0.86
Al	5.95	1.80	0.67	5.77	2.55	0.7		4.83	2.1	0.64
Ti	0.64(1)	0.14	0.67(5)	1.6(2)	0.26(21)	0.5(2)		0	0.47(1)	0.69
Cr	0.037	0.09	0.04(4)	0.0	0.27	0.03(11)		0.009	0.30	0
Ni	0	0.22	0	0	0.32(13)	0.26(2)		0	0.17(2)	0.97
Pb	Tc(4)	1.27	0.94	0.24	2.04	1.5		0.25(1)	0.17(2)	0.13(1)
Su	0	0.48	0.27	0	0.65	0.56		0	0.17(6)	0.51
Ag	Tc(6)	0.06	0.02	0.015	0.07	0.03		0.41(22)	1.32(3)	1.6(3)
Bi	6.3(6)	0.49(6)	1.1(6)	1.25(1)	0.61(3)	0.9(3)		0.23(15)	0.06(5)	0.13(1)
Cd	±2(7)	3.1	3.0	0	3.60	3.3		0.25(1)	0.06(5)	0.15(6)
								1.96(6)	1.70(2)	0

Differences considered significant from American adults as italicized.

Numbers in parentheses indicate specimens with metal fall specimens did not show t.

† Two patients had 18 and 19 mg/Kg Bi in kidney probably the result of treatment

‡ In older children only not in babies.

§ Tipton's first series (231) 2-second series (259)

the fore increase in the sensitivity of the method.

tanium We can add to our list of possibly toxic metals bismuth and cesium

Are these extraneous elements biologically active or inert? Could one or more of these abnormal elements displace an essential metal and thus lead to metalloenzyme inhibition or combine with sulphhydryl enzymes and so inactivate them (Table XXVIII)? If so the possibility of inhibition causing dysfunction leading to disease is considerable

### METALS OF POSSIBLE BIOLOGICAL SIGNIFICANCE IN THE FIRST TRANSITIONAL GROUP

It is interesting that the transitional and nearby metals in the periodic table are those with most biological activity an expression perhaps of their structures (267) Other than the known essential trace metals of the first transitional group four might serve in metalloenzymes but have at present no known function i.e. titanium vanadium chromium and nickel Vanadium is found in all of the animal phyla is concentrated from sea water by tunicates as an essential oxygen carrier (268) is required by *aspergillus niger* (269) is concentrated in certain mushrooms (270) was probably an oxygen carrier in petroleum forming animals and appears in concentrations of about 10 mg/kg in all plants dry weight (271) The case for it having a function in mammals is good While chromium stimulates plant growth is present in all vegetables in concentrations of 10 to 1000  $\gamma$ /kg dry weight and is in many human tissues evidence for its essential nature is doubtful Nickel is probably not required by mammals although plants contain traces The role of titanium is not known although it is found in almost all human adult lungs Those concentrated in certain organs may be of more significance in metabolism or in causing diseases



turated fatty acids were oxidized very slightly. Further more they showed that vanadium exhibited two effects: dehydrogenation to produce unsaturated fatty acids and oxidation of the double bond (Table XXXVIII). The reaction was inhibited by the metal binding agents cyanide, pyrophosphate, fluoride, p-aminophenol and aminopyrine. Brain contained none of the enzyme, kidney little. When other metals were tested, manganese and to a less extent cobalt were found to inhibit the system, while nickel, iron, titanium and chromium had no effect (275). Manganese, cobalt and titanium inhibited the oxidation of cysteine to its sulfonic acid. Titanium in the form of sodium per titanate also inhibited hepatic oxidation of thioglycolic acid and ethyl mercaptan, but glutathione was not oxidized by this system (272).

*Evidence for Vanadium Being an Essential Trace Metal*

What evidence there is for vanadium being essential to mammalian metabolism is indirect but good. Aside from its use by ascidia which use it for oxidation-reduction reactions at a time when they are buried in mud, petroleum contains varying amounts of vanadium in a porphyrin form which has led to the hypothesis that animal organisms and not plants originated the formation of petroleum. It is found in mammalian tissues at a fairly good concentration, said to be 0.13 per cent dry weight, 12 mg/kg for invertebrates and 0.1 mg/kg dry tissue for vertebrates (268). While its occurrence may be a chance contamination, universal presence and three valence states ( $V^{+++}$ ,  $V^{++++}$ ,  $V^{+}$ ) with an ability to release energy similar to phosphorus make it likely that vanadium may be essential. Tipton found it only in the lung.

Vanadium is a powerful stimulant to monamine oxidase (Table XXIII). Only cobalt of the others tested exhibited this property to much less degree. This phenomenon

than those widespread in smaller concentrations (chromium, tin, nickel) We can supply our six rules of thumb to each

**Titanium** There is no evidence that titanium is necessary for normal function It can, however, act as an antimetabolite Titanium inhibits the oxidation of cysteine to its sulfonic acid (as well as thioglycolic acid) (272) but does not affect cholesterol and lipid synthesis in the rat (248) The antimetabolic action of this substance could but does not necessarily implicate it in chronic disease If involved, its only known effect is upon sulfur metabolism

When a patient with moderate hypertension was treated with hydralazine in increasing doses at four hour intervals up to 600 mg per day the only change in the urinary excretion of 11 trace metals was in titanium Taking the highest value of 4 control days this value was exceeded on 7 of 9 days of treatment on 5 it was twice as much or more on 2 6 times and on 1, 50 times greater No other trace metal so moved the control value for vanadium and chromium were exceeded three times, of lead twice and of manganese once of nine days Late results of hydralazine therapy on pairs of urine specimens before and after control of hypertension showed no essential changes in mean titanium excretion The values doubled twice and fell markedly once There were no significant changes in the urines of 5 patients with disseminated lupus (273)

**Vanadium** Bernheim and Bernheim have studied the oxidation of certain rat and guinea pig tissues as influenced by vanadium acetate or sodium metavanadate (274) They found that phospholipids were oxidized by the insoluble portion of liver proteins in the presence of vanadium brain and liver phospholipids and soy bean lecithin were good substrates for the vanadium enzyme system The oxidation of many other substances were unaffected Sa




FIG. 18 The effect of certain transition metal salts on the incorporation of  $C^{14}$ -carboxyl labeled acetate into cholesterol and fatty acids by surviving rat liver (From Curran G. L. *J Biol Chem* 210:765 1954)

adults and being ubiquitous in plants and animals (256) no role for chromium is known. It markedly stimulates the hepatic synthesis of cholesterol and fatty acid in rats. No other transition element save manganese had this property (Fig. 18) (248). It did not affect decarboxylase and monamine oxidase.

Normal urine contained less than 0.05 to 1.03  $\gamma/L$  (mean <0.46). Hypertensive urine less than 0.05 to 4.4  $\gamma/L$  (mean 0.88). Treatment did not change the means significantly (0.67 to 0.71  $\gamma/L$ ) nor did hydralazine or EDTA cause a consistent loss.

Chromium in liver could stimulate cholesterol and fatty acid synthesis in man. There is as much however in infants as in adults. Only by analyzing many more tissues from primitive areas can one determine whether or not chromium can qualify as an essential metal or if not play a part in chronic disease.



strongly suggests, but does not prove, that vanadium is an essential metallic component of monamine oxidase. Not until the enzyme is obtained pure and the metal identified can we say for certain that it is essential for amine oxidation.

The urinary output of vanadium in human beings is fairly constant, less than  $0.63 \gamma/L$  (range less than 0.5 to 2.15). In hypertension, however, it was increased to three times normal values,  $1.95 \gamma/L$  (range 0.4 to 14.5). Treatment appears to bring back the values toward normal (2.86 to  $0.93 \gamma/L$ ). However, only five of our values were initially greater than the highest normal.

The pharmacological effects of vanadium have been extensively studied by Jackson (276). It is a unique element in that it causes vasoconstriction in rabbits. The older literature contains equivocal reports of its effects in syphilis, tuberculosis, and skin diseases. Oral doses are well tolerated. In hypertensive states, giving sodium metavanadate by mouth sometimes caused transient reduction of blood pressure but also produced chills and fever. In rats it markedly depressed fatty acid and cholesterol synthesis by liver (248) (Fig. 18).

It is possible, therefore, that vanadium deficiency, either through lowered intake or exogenous abnormal metallic competitions, is one of the causes of the conversion of intermittent vasospasm into sustained vasospasm. Consistent with this theory are: 1. Stimulation of renal monamine oxidase only by  $V^{++}$  and  $V^{+++}$ , an enzyme which destroys norepinephrine and most other circulating vasoactive primary amines. 2. Reduction of pervanadate by hydralazine which also enhances monamine oxidase activity (277). Unfortunately, vanadium was acutely pressor for hypertensive rats but may be depressor in dogs.

**Chromium** Although found in all lungs of infants and

rier while its absence in many adults suggests that it is not necessary after full growth

Aluminum is almost absent from plant tissues although it represents seven to eight per cent of the earth's crust (256) Animal tissues with the exceptions of lungs and liver are said to contain less than plants (0.7 to 1.5 mg/kg in the dog and 0.5 to 3.3 mg/kg in the rat) (278-279) although a former study showed considerable amounts in human beings (brain 2.5 heart 2.1 liver 0.8 kidney 1.0 and spleen 0.7 mg/kg) but less than were found by Tipton *et al* Salts have been put into baking powders can be absorbed from cooking vessels and canning processes A considerable amount of investigation 25 to 50 years ago indicated the lack of toxicity of aluminum which is fed in antacid preparations to patients The large amount found in lungs probably comes from inhaled aluminum silicate from dust Having only one valence state in spite of its prevalence in the earth it has not been shown to have any essential role in human metabolism although by our criteria it cannot be excluded as an essential trace metal

Scandium and gallium are found in soils. The traces of gallium in human lungs probably have been inhaled since gallium is present in all aluminum minerals Both are relatively unreactive compounds with only one valence state

*Comment* If one were forced to choose a single trace metal to undo the harmful effects of degenerative cardiovascular diseases vanadium would be that choice for the following reasons

1 Vanadium stimulates monamine oxidase thereby probably increasing the destruction of pressor vasoactive and cerebroactive amines and affecting hypertension thereby (Table XXIII)

**Nickel** While found in all plants and animals tissues in traces, it has no known function (256) It is almost certain that this element is not essential for mammalian growth and development There is frequent exposure in processed and manufactured foods especially hardened vegetable oils (Chapter VII) where it is used as a catalyst (containing 0.012 mg/Kg), and from corrosion of nickel vessels No increase was noticed in human tissues after the second decade until the seventh Therefore, although present in small amounts we cannot state whether or not it is doing harm, although it probably has little direct action It did not affect the enzyme systems of interest to this discussion and is usually inert in others

Normal concentrations in urine averaged 2.78  $\gamma$ /L with a range of less than 0.05 to 12  $\gamma$ /L Hypertensive urine contained twice as much, 5.53  $\gamma$ /L with a range of less than 0.1 to 40 only a third however, contained more than the normal mean amount Hydralazine caused no essential changes, treatment did not alter the mean values significantly (3.99 to 5.78  $\gamma$ /L) EDTA caused no apparent changes Nickel cannot at the present time be implicated in cardiovascular diseases Excessive exposure causes dermatitis or eczema

**Elements of the Third Group** There is no evidence that any of the elements in the third periodic group are essential for mammalian life Boron, however, appears to be essential for plant life occurring in most forms and is necessary for reproduction (256) Only traces are found in dairy products and flesh foods, since this element is fairly rapidly excreted In man however in large amounts it causes weight loss albuminuria and gastrointestinal disturbances Its presence in most tissues of stillborn infants means either that it is essential or that it is a contaminant in the mother easily transported across the placental bar

185) After treatment the mean value diminished from 5.47 to 2.64  $\gamma$ /L. five of eight values declining. Hydralazine decreased the output to about a fourth as did EDTA. The possible role of tin is undetermined although its source lies in the products of Western Civilization i.e. tin plate traces dissolving in some tinned foods.

**Silver** Like tin silver is widespread occurring in every adult kidney and brain and in almost every other sample examined (225 of 258 specimens) (231). There was no tendency for accumulation with age and almost every young tissue contained it in adult concentrations (266). It was in all urine (0.8  $\gamma$ /L. range 0.23-1.4) hypertensive urine contained little more than did normal (1.4  $\gamma$ /L. range 0.3-4.6). Exposure to silver is constant in our society there is little or none in plants. Because of the small amounts found it is doubtful that enzymatic inhibition (on copper enzymes) if present is extensive enough to cause metabolic disorders.\*

**Lead** There is lead in all human tissues at birth and during life. This toxic metal accumulates especially in bone and liver. As far as is known it is not an essential constituent of any living organism getting into food mainly from the use of its compounds on plants and from vessels in which food is manufactured transported or stored. Shell fish may absorb lead from sea water contaminated with drainage from factories and animals from sprayed plants. African tissues had little.

A knowledge of the coordination number of a metal, the shape of its chelate and its periodic group allows a reasonably accurate *if indirect* method of predicting displacement of a known essential metal and inactivation of its enzyme. Conversely by inactivation studies unknown metals on metalloenzymes may be predicted (Table XXVI) cadmium and mercury displacing zinc, gold, silver, nickel displacing copper, tungsten displacing molybdenum. More basic chemical knowledge will lead to more accurate predictions.

2 Vanadium unsaturates fatty acids on phospholipids and oxidizes the double bond (274)

3 Vanadium depresses the synthesis of cholesterol and fatty acids (248)

4 Vanadium lessens the formation of atheromata in experimental animals (280)

If one were to choose a single abnormal trace metal as a contributing cause of hypertension, cadmium would be the choice for reasons discussed in Chapter IV

If one were to choose three abnormal trace metals as contributing causes of atherosclerosis, chromium cadmium and lead would be the choices Tin could not be excluded

#### METALS WITH POSSIBLE HARMFUL EFFECTS

With some certainty one can list the metals present in American human tissues which are contaminants and which may be potentially harmful, i.e. silver cadmium tin, antimony arsenic gold and lead Of these, known toxicities are found in the cases of cadmium arsenic and lead large amounts of the others are less harmful but will produce diseases or disorders Just as in the cases of transitional metals those which are evenly distributed throughout all tissues (tin silver) are under less suspicion for causing disease than are those concentrated in specific organs with high metabolic activities (cadmium lead)

**Tin** There is no evidence that the metal is essential for life (256) It is not essential for plants Little is known of its action as an anti enzyme It was present in almost all human adult American tissues and in the spleens of infants, older children showed quantities comparable to those of adults The mean normal urinary concentration was 3.22  $\gamma$ /L (range less than 0.5 to 10.0) the mean hypertensive concentration was 8.93  $\gamma$ /L (range 0.9 to

cause pulmonary fibrosis (from inhalation) (282-283) renal damage (286) this toxic metal is under considerable suspicion as a cause of chronic disease. Of all the exogenous abnormal metals found in adult American tissues cadmium appears the most toxic. It is obviously cumulative. Supposedly 40 mg by inhalation can cause death in man which is strange since the total content of adult bodies is about 120 mg and the lethal dose in rabbits by injection is 3 mg/kg ( $LD_{50}$ ) (84). Hepatic and renal lesions are prominent features of acute poisoning in rabbits and rats; cardiac hypertrophy is universal (286). Proteinuria and renal lesions occur in exposed workers (287). There must be obvious differences between acute and chronic effects in man especially when this metal accumulates for a life time. The protein in the urine is not albumin since it appears on the heat test but is not precipitated by Esbach's reagent (287). Cadmium causes aminoaciduria in man (288) \*

The source of the cadmium may lie in zinc for it is a constant contaminant of zinc ores. There is probably one per cent or more in the galvanizing grade (Prime Western) as indicated by the following specifications adopted in 1911 by the American Society for testing materials last

---

Cadmium causes increased excretion of the following amino acids in man exposed industrially: glycine, alanine, glutamine, tyrosine, lysine, histidine, methyl histidine. All of these except possibly lysine can act as donors of ammonia. Furthermore, serine excretion was increased 9.5 and threonine 33 times. The amount of cadmium in the urine was in the same range 12-33  $\mu\text{g/L}$  (average 20  $\mu\text{g/L}$ ) as we have found for hypertensive individuals (308). Cadmium was unique among four heavy metals (U, Pb, Cd, Hg) studied by Clarkson and Kench (288) who believed that it specifically inhibited the renal tubular reabsorption of these amino acids. An alternative and to us preferable explanation lies in the specific inhibition of decarboxylases by cadmium thus preventing the first step of renal amino acid metabolism.

There is no toxic metal which has received such concerted attention as lead (84). It has been proposed, and discounted, as a cause of many chronic diseases, including hypertension and atherosclerosis. The predilection of American lead for adrenal, aorta, bone kidney, liver, lung pancreas, prostate and spleen, but not for brain bladder, muscle and intestine, suggests that it might exert an anti metabolic function. The much smaller amounts in infantile and African tissues with a tendency to accumulate with age places it under suspicion. There are however, no good ideas as to its effects on enzyme systems in ordinary concentrations, although lead poisoning affects the nervous system and blood. It is well known that exposure to lead in industry produces definite slow accumulation. Tetra ethyl lead in gasoline is a fair source (84).

While we cannot implicate this toxic, accumulating metal in any chronic disease in our society we cannot discount it as a possible etiological factor. Workers in lead industries, however either develop clinical manifestation or suffer from no noteworthy disorder. The earliest symptoms of sub-clinical lead intoxication are those referable to emotional stability being irritability moodiness, restlessness, excitability, common complaints in this period of history. Lead salts are vasoconstrictor in perfused dogs legs and cause vascular smooth muscle to contract (281).

**Cadmium** The high renal concentrations of cadmium in American adults its absence in infants and in African native tissues focuses suspicion on this metal as an etiological agent in chronic disease. Since cadmium can displace zinc on mercaptalbumin (243) is a highly potent inhibitor of sulphhydryl enzymes (of which Coenzyme A is an example) and at least one vitamin B<sub>6</sub> enzyme, can

are no good examples) we could expect on the basis of mass alone the following enzymatic inhibitions Renal 55 per cent hepatic 6 per cent pancreas 5 per cent thyroid 5 per cent adrenal 8 per cent aorta 5 per cent intestine 5 per cent brain 0 per cent Obviously a 5 per cent reduction of metabolic activity would probably be unmeasurable while a 50 per cent would manifest itself in disorder which could lead to disease

Renal decarboxylase is inhibited *in vitro* at a lower concentration of cadmium than that present in adult kidney Other enzymes known to be inhibited *in vitro* are leucine aminopeptidase carnosinase succinic dehydrogenase choline oxidase (Table XXXVIII) possibly through sulfhydryl binding If other metalloenzymes are specifically inhibited such as vitamin B<sub>6</sub> enzymes it is obvious that effects of low concentrations could be profound and in the case of vitamin B<sub>6</sub> result in a conditioned local deficiency

As in the case of zinc and lead cadmium can be dissolved in slightly acidic media Therefore foods and waters coming in contact with cadmium could become contaminated by traces There are three possible sources 1) Water is usually piped in American houses through galvanized zinc coated iron pipes If soft aerated in municipal water stations to contain carbon dioxide and chlorinated appreciable quantities of zinc lead and presumably cadmium could be dissolved from the galvanized coat If hard however insoluble carbonates are laid down on the coating protecting it from solution and corrosion Water softeners probably would not soften water enough to corrode zinc Chlorinated water even when hard takes up zinc.\* 2) Carbonated beverages are acidic and will take up zinc lead and presumably cadmium from galvanized or zinc lined

\* A probable source of abnormal trace metals in some soft and acid water areas is in the corrosion of hot water heaters



revised in 1949 The maximum impurities allowable are (per cent)

	Lead	Iron	Cadmium	Total Not Over
Special High Grade*	0.006	0.005	0.004	0.010
High Grade*	0.07	0.02	0.07	0.10
Intermediate	0.20	0.03	0.50	0.50
Brass Special*	0.60	0.03	0.50	1.00
Selected*	0.80	0.04	0.75	1.25
Prime Western	1.60	0.08	—	—

\* It shall be free from aluminum

Since Prime Western zinc is the grade used largely in galvanizing and no limits for cadmium are provided, it is therefore probable that zinc coating so widely used in pipes and food processing and brass are likely sources of the cadmium found to accumulate in human tissues

Cadmium poisoning has been reported in human beings drinking acid beverages made in cadmium plated (yellow tinged) ice trays (289)

The high concentrations in adult human kidneys (33 mg/kg or about 10 mg of the metal) with secondary affinities for liver pancreas and thyroid and lesser amounts ( $\pm 1$  mg/kg) in adrenal aorta stomach and intestines suggests that antimetabolic activity could be exerted especially in those organs of greatest import to essential functions. Its absence in most hearts muscle tissue spleens and all brains is interesting indicating that proteins or enzymes in those areas do not chelate or bind this metal readily for cadmium is readily chelated by sulfur and nitrogen ligands (its affinity for EDTA, for example exceeds that of zinc cobalt ferrous iron and manganese). Its affinity for zinc suggests that it might interfere with zinc enzymes displacing the essential metal as it does on serum albumin (by displacement from indole groups). If zinc enzymes were inhibited by cadmium (although there

that zinc poisoning which does not occur in animals fed small amounts may be actually caused by contaminating cadmium

The source of cadmium which does not occur in plants is obviously in the products of Western Civilization \*

**Other Metals** Analyses for other commonly occurring possibly toxic metals such as arsenic antimony and bismuth of group V A have revealed no striking accumulations in human tissues There may be as much as 0.3 parts per million of arsenic in man much of it in hair and nails derived from fish and sea foods or from contaminants of food Arsenic displaces phosphorus in essential phosphate mechanisms but the amounts are probably too small to cause functional disorders and habituation or tolerance develops Antimony can gain access to foods from enamels solders tin foil rubber and insecticides The normal amounts in human tissues are not known but presumably it also displaces phosphorus Bismuth was found by Tipton in only a few bodies in small amounts in liver and kidneys (12 of 48 cases) and is probably not to be considered of universal import Mercury appeared in a surprisingly large number of kidneys analyzed by Griffith *et al* from patients with congestive heart failure who had supposedly never received diuretics containing this metal (260)

**Cardiovascular Implications** Aluminum and strontium were present in all samples of American heart muscle These metals plus lead and tin were found in all aortas In kidney there was the additional metal cadmium in liver these five and silver In adrenals were the same six and

---

Preliminary single analyses of five bottled drinks revealed a carbonated water 4.1 a popular carbonated drink 11 a citrus drink 1 a grape juice 1.5 a whiskey 5.5 in parts per billion. Three of these values are considerably higher than those of normal urine The grape juice contained relatively much nickel tin and lead.

containers in which they are piped, prepared or bottled Lemonade made in galvanized pails has produced acute gastroenteritis The widespread use of carbonated acidic drinks ("pop") in this country is a possible source which has not been explored 3) Acidic foods prepared in zinc lined containers, especially vegetables, can absorb cadmium and lead

According to Monier Williams (256) zinc is taken up by the following ingested products presumably cadmium is also dissolved Chlorides in water, chlorinated water, carbonated water, oxygenated water (from brass) soft acid water (from brass), milk (during pasteurization) milk (from bottle caps), alcoholic, acid or saline liquids, especially wine, vinegar soup orangeade lemonade, beer molasses (from zinc coated vessels in sugar refineries), maple sugar, honey, chocolate and candy (wrapped in zinc foil) gelatin (from zinc coated vessels and wire netting on which it is dried) dried fruit (from drying trays), jam (from pans) Poisoning resembling that from cadmium has been reported from soda water, rain water (collected from galvanized roofs or stored in tanks) stewed apples (from galvanized iron vessels) root beer, cider Coffee is floated and dried on galvanized trays All galvanized iron vessels are suspects since electrolytic action between the iron and the zinc may be initiated by moist foods

Cadmium is widely used for washing machines electric cooker parts and refrigerator trays It is absorbed by weakly acidic foods, sugars (jam) wine tomatoes, fruit fruit juice ice cubes (from acidic water?) coffee cooked food gelatin and attacked by lactic succinic citric and tartaric acids Possible sources of contamination besides galvanized zinc and cadmium plated vessels, are solders, fruit insecticides The similarity of known sources of acute poisoning and those of zinc are remarkable and suggest

presence in large quantities and its lower affinity for some proteins than other metals with a higher EDTA metal stability constant. Of course excessive quantities of metals obey the law of mass action and can be partly removed minor quantities cannot until better chelators are developed for fairly specific purposes

What good will it do our patients if the abnormal metals are removed from their bodies? We do not know. The subject of metals and chronic diseases is barely beginning to be appreciated. Forbes *et al* say for example. It is conceivable that the continuous ingestion of infinitesimal amounts of these metallic elements present in natural foods leading to their very gradual accumulation in the tissues may contribute to the processes of senescence in proportion to the degree with which they are combined with tissue proteins (apoenzymes) and the extent to which they inhibit or distort enzyme action in such combinations (290). While this may be true it is more likely that many of the diseases common only to our Civilization may be caused by the nonessential metals contaminating our foods, as a result of our industrial habits. We may be pleasantly surprised at the therapeutic results of their removal. Scleroderma has already been completely relieved in at least one instance by EDTA (291).

A logical therapeutic regimen within the limits of present-day vision is a concerted effort at removal by relatively nonspecific chelators followed by replacement of essential metals so removed. Generalized deficiency states of the essential metals iron cobalt copper and molybdenum is probably unlikely under such a regimen. manganese and zinc may require replacement. Too much of an essential metal however probably can cause as much disorder as too little. When deficiencies are recognized they can be treated.

Local deficiency states caused by abnormal metal com

boron chromium gold and nickel Barium was found in all tortas Cardiovascular organs, except the heart, appear to have the ability of accumulating at least four abnormal metals Several are known antimetabolites for man or living organisms (Table XXVII)

Many of these metals are found in normal and hypertensive urine (308-310), cadmium and manganese being increased in the latter Specific enzyme inhibition has been demonstrated for several which may play a part in cardiovascular (311) and other chronic diseases (312)

### CLINICAL IMPLICATIONS

At the present time, there are no known methods for removing from the human body one or more of these abnormal metals and leaving the essential ones Furthermore, the rules of chelation make such a procedure inconceivable Each metal probably has a different stability constant for different proteins and removal therefrom would require toxic amounts of very strong chelators which would complex or bind such essential metals as iron and magnesium The situation may be roughly analogous to that in argyria where silver is permanently deposited in the skin and cannot be removed by any known method

On the other hand certain metals might be eliminated from the body by the judicious use of chelators with specialized groups Thus aurointricarboxylic acid fairly selectively binds beryllium in a soluble lake reversing some of the actions of beryllium poisoning (232) A sulfur containing chelator might sequester cadmium although the affinity of this metal for renal tissue is high BAL giving up cadmium to kidney which it has displaced from other areas While such oxygen nitrogen containing chelators as EDTA and its relatives prefer copper and nickel to other elements in the first transitional group, in actual practice zinc is largely removed, probably because of its

## Chapter VII

# SOME MECHANISMS IN ATHEROSCLEROSIS

### INTRODUCTION

**A**LTHOUGH atherosclerosis is usually a disease of Western Civilization it has been observed in nomads. To begin to understand its pathogenesis one must consider the influences which civilization may contribute and those which can lead to the disease in uncivilized people. A brief discussion in a monograph on hypertension is justifiable for hypertensive patients are prone to develop the disease; treated hypertensive patients die mainly of its effects (319); hypertension accelerates its progress and there may be some basic factor common to both.

Atherosclerosis can occur without diastolic hypertension. Severe degrees of the disease in the aorta causing loss of elasticity produce systolic hypertension because the pipes are hard but do not of themselves cause elevated diastolic pressure. Contrariwise hypertension can persist without significant atherosclerosis especially in China (8, 313, 440).

In 1941 Snapper made some pertinent comments which are lately being appreciated (8). Another point which must be specially mentioned is the infrequency of arteriosclerosis in North China. The rarity of arteriosclerosis is proved by the scores of middle aged patients dying from all sorts of diseases showing hardly any sclerosis at autopsy. Extensive arteriosclerosis certainly does occur in North China but the thickened inelastic aorta with the widely

petition with metalloenzymes pose a more difficult problem of replacement, especially when the abnormal metal is more firmly complexed to enzyme than is the essential one. If a vitamin coenzyme is involved in the metalloprotein complex, it need be also replaced. Local enzymatic deficiencies have been postulated, for example, in the case of vitamin B<sub>6</sub> deficiency in the skin causing seborrheic dermatitis (292).

We may speculate on the results of such a therapeutic trial aimed at restoration of normal metallic balances. If the copper involved in the formation of melanin were partly displaced by an exogenous abnormal metal deposited in the skin, or were removed therefrom, the resultant grey hair and deficient tanning could be reverted to normal by removal of the offending metal and replacement of the copper. If the excessive cadmium, nickel, lead or titanium could be removed from human tissues, the part that one or more of these metals might play in hypertension, atherosclerosis, malignant tumors, arthritis, collagen diseases or allergic responses might be mitigated, none of these conditions can be excluded as not being influenced by abnormal trace metals. The field is wide and the frontier untrod.

Perhaps some day when these hypotheses are more firmly proven and specific metals strongly implicated in the causation of diseases, industry will prevent contact of foods with those metals shown to accumulate in American tissues such as nickel, cadmium, tin and lead. The subject would then enter the field of preventive medicine, rather than that of therapeutics where it now lies.

## PATHOGENETIC FACTORS

According to Friedman *et al* (314) the following schema invokes the multiple etiological factors and illustrates the pathogenesis of atherosclerosis

$$\text{Time} \times \begin{matrix} \text{Intrinsic (?) } \\ \text{Intimal} \\ \text{Derangement} \end{matrix} \times \begin{matrix} \text{Quantitative and} \\ \text{Qualitative Alter} \\ \text{ation of Plasma} \\ \text{Lipids Including} \\ \text{Cholesterol} \end{matrix} \times \text{Blood Pressure} = \text{Atherosclerosis}$$

We will consider each of these factors separately

1 Blood Pressure Rarely does long standing diastolic hypertension in Caucasians exist beyond the age of 40 without atherosclerotic lesions being found in aorta major arteries or coronaries Experimental hypertension is necessary to induce atherosclerosis in the rat a resistant animal and is desirable in the dog Fat in serum can be made to infiltrate the walls of arteries under high pressure especially if the intima is injured (315) Even in normotensive persons lesions develop at the sites of changes of pressure such as the mouths of the renal arteries in the Circle of Willis and at the bifurcation of the aorta (316 317) Atherosclerotic gangrene seldom occurs in the arm but is frequent in the leg where the hydrostatic pressure of the blood in the upright position is added to the blood pressure (318) These lesions are believed to be the result of pressure causing deposition of insoluble cholesterol or its esters subintimally either by forcing them into the vessel walls or preventing their diffusion out after entrance via the vaso vasorum

2 Intimal Injury Mechanical injury to the intima of dogs results in the formation of atheromata (320 322) It is difficult to understand how injury can occur at a normal pressure although acute hypertension in animals (323)



ulcerated intima so frequently found in autopsies in the Western part of the world, is decidedly rare here. This explains why the genuine angina pectoris syndrome, and also the picture of coronary thrombosis with myocardial infarction are only rarely encountered. During the past two years we saw three possible cases of this disease in the combined material of the common and private wards, the outpatient department, and the very busy emergency clinic of the hospital, although in every doubtful case repeated electrocardiograms with four leads are taken and scrutinized with utmost care. However in December 1940 one classical example of coronary thrombosis with typical findings at the autopsy was observed. The rarity of coronary thrombosis in North China is the more striking because the increase of the frequency of this affection in America and Europe is appalling. Even in diabetes mellitus extensive arteriosclerosis must be infrequent in North China because diabetic gangrene is as rare here as senile gangrene.

It is difficult to give an explanation of this characteristic feature of geographic pathology. One can, of course, fall back on the equanimity of the Chinese, but the differences in nutrition of Chinese and Westerners may give a better explanation. Arteriosclerosis begins as a fatty infiltration of the intima of the vessel walls. Quantitative and qualitative differences exist between the lipid content of the Chinese and the foreign diets as has been mentioned before. The Chinese diet contains only small amounts of cholesterol but considerable quantities of unsaturated acids especially of linoleic and linolenic acid. It is certain that the average cholesterol content of the blood of the Chinese is lower than that of Westerners and this gives perhaps an indication why the tendency to lipid infiltration of the vessel wall is so much smaller among the Chinese.

metal interference (with decarboxylases for example) that in liver by marginal concentration of vitamin B<sub>6</sub> excessive saturated fatty acid load and possibly metals. There is no evidence for a generalized deficiency state except for the high incidence of dandruff in the population believed by some to be dependent upon vitamin B<sub>6</sub> and fatty acid imbalance.

**3 Trace Metals** The synthesis of cholesterol and fatty acids by surviving rat liver can be influenced by metals of the first transitional group (Fig. 18). Chromium and manganese have a pronounced enhancing action, vanadium a depressant one (248). Vanadium also promotes unsaturation of phospholipid fatty acid and oxidation of the double bond, opposed by manganese (Table XXXVIII). There is no evidence, however, that chromium is implicated in the hypertensive process. In American tissues hepatic chromium is much less concentrated than manganese, a known lipotropic agent (231-259) (Chapter VI). Many metals directly affect oxidation of unsaturated fatty acids *in vitro*. Hydrogenation to harden or saturate them is accomplished commercially mainly by copper and nickel; sizeable quantities enter the fat during processing (256). Cadmium, however, inhibits at least one vitamin B<sub>6</sub> enzyme, DOPA decarboxylase (Chapter V), although it does not affect hepatic synthesis of cholesterol in the rat (331). Obviously we need to know much more about the effects of abnormal metals on the enzymes concerned in fatty acid and steroid synthesis.

A significant series of experiments were done by Curran and Costello in rabbits (280). Hypercholesterolemia was induced by feeding cholesterol at the 3 per cent level for 4 weeks. On resumption of a normal diet cholesterol levels usually fall slowly. Half the rabbits were fed vanadium as VOSO<sub>4</sub> (0.05 per cent) for 6 weeks. There were

and chronic hypertension in man will result in deposition of lipid in the high pressure areas. This process is hastened if lipid in blood is elevated (324)

Subintimal 'injury' from biochemical alterations in the mucopolysaccharides of collagenous tissue results from pyridoxine deficiency in the monkey (325, 326). The changes found resemble the earliest lesions of atherosclerosis (327-330). \* It is possible, therefore, that a conditioned vitamin B<sub>6</sub> deficiency not only affects the enzymes concerned in protein metabolism resulting in hypertension (Chapter V) but also initiates the arterial lesions in which cholesterol is deposited.

It should be emphasized that the vitamin B<sub>6</sub> deficiency postulated in this discussion is a local, conditioned deficiency state and not a generalized one, and that it involves enzyme systems in kidney and liver but not necessarily in brain, blood-forming organs or skin. The complex Schiff base of pyridoxal and amino acids is a strong chelating agent, for example, and could form a stable chelate with several abnormal metals. *Generalized* deficiency of vitamin B<sub>6</sub> is accompanied by low blood pressure and skin manifestations similar to seborrheic dermatitis and ariboflavinosis. A *local* deficiency in kidney could be induced by marginal concentrations of vitamin B<sub>6</sub> and especially trace

---

\* Rinehart and Greenberg state: Arteriosclerotic lesions develop regularly in the rhesus monkey subjected to prolonged pyridoxine deficiency. The initial lesion is characterized by the accumulation of a mucinous substance in the intima and to a less extent in the media of the arteries involved. This material exhibits the metachromatic staining property characteristic of mucopolysaccharides. Associated with the accumulation of this substance, cellular proliferation occurs and collagenous and elastic tissue fibers are formed. Studies of human arteriosclerosis indicate that basically similar sequences are seen in the evolution of the human disease. The morphologic features of the experimental vascular lesions and those occurring in man are similar. The possible role of pyridoxine deficiency in the etiology of human arteriosclerosis remains to be determined. (32)

examine the possibilities we can look at factors of suspicious import in hypertension which could conceivably influence the development of cholesterol-containing atherosclerotic plaques in arteries

There is no good evidence that the blood cholesterol is higher in American hypertensive than in normotensive people. Therefore the increase in the rate of progression of atherosclerosis in hypertension is probably largely due to intravascular filtration pressure causing deposition of lipids through the intima (319)

Hypertension and atherosclerosis however may be interrelated in a more fundamental fashion than by mechanical excessive filtration of cholesterol through intima by the high pressure when there are adequate cholesterol levels in blood. 1) A conditioned vitamin B<sub>6</sub> deficiency may involve both disorders. 2) abnormal trace metals may not only affect the hypertensive process but increase cholesterol synthesis. At this point the reader may wonder whether or not the author has an obsession with vitamin B<sub>6</sub> and its functions. Upon careful thinking in terms of enzymatic mechanisms this coenzyme continually obtrudes itself into possible schemata derived from experimental and clinical data both in hypertension and in fatty acid metabolism.

We must turn to epidemiologic data for evidence that there is no common denominator of these two diseases. Some atherosclerosis but no hypertension has been found in Alaskan Eskimau (332) the incidence may be smaller than in whites. Hypertension is extremely common in Hawaiian sugar plantation workers as is atherosclerosis but severe coronary sclerosis is less frequent than in Caucasians (333). Atherosclerosis is said to be prevalent in Kirghiz nomads as is contracted kidney (from hypertension?) (334). Snapper observed hypertension but little

no significant differences in hepatic cholesterol at the end of this time, but aortic and serum cholesterol values were about half the controls in the animals receiving vanadium. Likewise the livers of these rabbits incorporated  $C^{14}$  labeled acetate into cholesterol at a markedly reduced rate. Thus, both endogenous synthesis and aortic deposition of cholesterol were depressed considerably by vanadium.

Therefore, vanadium as a possible essential metal, manganese as a known one and chromium as an abnormal one can be implicated in cholesterol metabolism. As will be considered below, any metal interfering with renal enzymatic mechanisms also cannot be excluded as an indirect participant in vascular damage, initiating deposition of lipid in arteries.

### **SOME COMMON DENOMINATORS OF HYPERTENSION AND ATHEROSCLEROSIS**

One anatomical common denominator between the two diseases lies in the location of the lesions. When involving the renal arteries or their mouths, reduced renal blood flow may result in diastolic hypertension of sufficient degree to restore flow to normal (Chapter IV). These lesions have been demonstrated frequently in hypertensive patients and confirmed by physiologic measurements. It is also possible that chronic hypertension may influence deposition of lesions in the smaller renal vascular areas which of themselves cause further hypertension on a renal ischemic basis. Thus will one vascular disease worsen another in a vicious circle.

There may be chemical common denominators which predispose human beings to both hypertension and atherosclerosis. This is no new idea, for many people have wondered about the relationship. The geographic and racial distributions of the two are often quite similar. To

is probable that local deficiency of vitamin B<sub>6</sub> due to the interference of its trace metal by an extraneous one could probably have the same result. The intimal injury in vitamin B<sub>6</sub> deficient monkeys is exactly like the earliest lesions of atherosclerosis.

*Comment* Some derangement common to both diseases may be present but atherosclerosis with which the American public is riddled is more frequent in the population than is hypertension. Therefore while atherosclerosis can and does occur without hypertension the contrary is unusual in our civilization but frequent in others. Both abnormal trace metals and local pyridoxal deficiency may be implicated

### THE ROLE OF FAT AND OTHER LIPIDS

Let us review modern ideas on the pathogenesis of the lesions other than the factors already discussed. Most of the recent interest in the subject has centered on fats. Quite a case can be made for the role of cholesterol which is largely carried by lipoproteins as a strong link in the chain of reactions leading to the formation of plaques. The subject has had its ups and downs since 1914 but probably is here to stay. As Aschoff so aptly put it: "From plasma of low cholesterol content no deposition of lipoids will occur even though the mechanical conditions are favorable" (327).

**Normal Cholesterol Levels in Blood** What is the normal level of blood cholesterol? That is a difficult question to answer. The levels found in Europeans and especially Americans may not represent normal values but rather average values in a population subject to the disease. If so we should look elsewhere at healthy adults to determine our normal standards and thus our therapeutic aims in controlling and reversing the atherogenic tendencies of

atherosclerosis in poorer Chinese (8) sometimes the condition was malignant. Therefore, while the two diseases usually are found together in the same population, exceptions in both directions may exist. Coronary sclerosis however, is much more common in hypertensive than in normotensive people (335). Coronary sclerosis may be a different disease than aortic atherosclerosis or may be a different manifestation influenced by local cardiac factors. Likewise cerebral atherosclerosis may differ. Undoubtedly however, the underlying biochemical alterations are a common denominator. The epidemiological data does not prove the lack of association of the atherosclerosis seen in hypertensive states in Western countries but merely indicates that each condition can in some areas of the world, exist separately.

Experimental evidence, however, which points to a close association between the kidney and atherosclerosis is accumulating. Holman was the first to show that arteritis appeared in dogs fed butter only when the kidneys were damaged by uranium or mercury (336). Methods for producing experimental atherosclerosis have been developed which fit into Friedman's schema if kidney is substituted for blood pressure. Renal damage will produce atherosclerosis in rats and rabbits fed cholesterol (331, 332). Nephrectomy causes an increase in plasma cholesterol and low density lipoproteins especially when protein is fed (385). Unfortunately we have been unable to cause the disease by feeding rats and chicks stearate and any one of eleven metals.

One further factor which may be common to the two disorders is in pyridoxal deficiency. Olsen and Martindale were able to produce chronic hypertension in young rats by desoxypyridoxine, an antimetabolite for vitamin B<sub>6</sub> (194). While theirs was a generalized deficiency state, it

the populations with high values. Just because a disease is common does not make it or any one of its measurable parameters normal.

Considerable information comes from studies in other than Western countries (Table XXXIX). If these values for blood cholesterol be correct, as there is little reason to doubt, the normal range is 120 to 160 mg per cent. Higher values may be ascribed to dietary influences or their concomitants. That environment and an increasing standard of living may affect blood lipids was well shown by Toor *et al.* in their study of recent immigrants to Israel compared to immigrants living 20 years or more in that country (338) (Table XL).

In Table XLI are shown some wide variations in total cholesterol and other lipids in blood done by analytic methods which are considered quite accurate from various Western countries. The variations are unexplained. Page *et al.* tried to check the differences between their analyses done in New York (339) and Boyd's done in Ontario (340); they state "our results for cholesterol determined in the presence of the other lipids are likely to be low rather than high. For the fact that our normal cholesterol values range so much higher than those of Boyd (in Ontario) and of Gardner and Gainsborough (in England) we therefore lack an explanation. We can find no source of error for our results and none is obvious for theirs." Since Boyd's normal subjects were taking the standard high fat diet customary in this country (340) it is possible that an environmental factor not present in England and Ontario but influencing levels in New York was operating.

**Effect of Blood Levels of Total Cholesterol.** Most investigators believe that coronary atherosclerosis does not occur to any appreciable extent when blood cholesterol is low. Furthermore, some reversal of atheromata is in



TABLE XXXIV  
SOME BLOOD CHOLESTEROL LEVELS IN HEALTHY MALE SUBJECTS

Location	Rate	Mean Age	Mean mg %	Dietary Fat %	Method	Author
Calcutta	Hindu & Mohammedan*	—	140	—	Myers & Wardell (Whole blood)	Bose & De (1936) (378)
Calcutta	Indian	—	116	—	(Whole blood)	Boyd & Ray (1928) (379)
Calcutta	Indian	—	140	—	(Whole blood)	Ghose (1933) (380)
E Arctic	Esquimo	—	141	High	(Blood)	Corcoran & Rabinowitch (1937) (381)
					(Blood)	Rodahl (1954) (332)
Alaska	Esquimo	—	203	35	(Blood)	Walker & Arvidsson (1954) (382)
S Africa	Bechuana	21-38	149	<20	(Lieberman Burchard)	
	Basuto	21-40	153	<20		
	Bantu	21-40	167	<20		
	Bantu Westernized	21-40	178	20-25		
	Europeans	21-30	206	30-35		
	Europeans	41-50	238	30-35	(Lieberman Burchard)	Keys <i>et al</i> (1954) (383)
Spain	Laborers	45	210	27		
	Professional	45	254	40?		
Naples		45	231	20		
London		45	252	35		Toor <i>et al</i> (1954) (338)
Minnesota		45	247	40	(Blood)	Page <i>et al</i> (1935) (339)
Israel	Yemenites	45-54	160	—		
New York		20-91	232	—		

NOTE: In another survey Bronte-Stewart *et al* showed that in the Cape Peninsula Africa cholesterol values done by the same method were Bantu  $166.3 \pm 47.2$  Cape Colored  $201.1 \pm 54.8$  and European  $234.0 \pm 52.9$  mg per 100 ml serum (440)

\* Twenty for 1 women 76 men

TABLE XLI  
VARIATIONS OF PLASMA CHOLESTEROL LEVELS IN WESTERN COUNTRIES\*

Author	Location	Date	Total	Fibre	Phospholipids
Gardner and Gainsborough	England	1927	153 ♀ 169 ♂	54 50	
Man and Peters	Connecticut	1933	207 ♂		222
Boyd	Ontario	1935	177 ♂	52	185
Page <i>et al</i>	New York	1935	232 ♂	82	181
Peters and Man	Connecticut	1943	194	54	240
Gertler and Gorn	New York	1950	224		299
Gubner and Ungerleider	New York	1949	211		
Keys	Minnesota	1949	218		
Kornerup	Denmark	1950	203	55	172
Block <i>et al</i>	Minnesota	1951	181		234
Perry and Schroeder (Hyperten ive)	St Louis	1955	226		

NOTE The earlier determinations were done by digitonide precipitation and the later usually by acetic anhydride which tends to give lower values (439)

From Page *et al* (339) and Katz and Stamler (356)

TABLE VI  
COMPARISON OF SERUM LIPIDS CHOLESTEROL AND LIPID-PHOSPHORUS IN THE OLD AND NEW  
YEMENITE IMMIGRANTS IN ISRAEL\*

Age Group	Total lipids mg %		Relative Difference %	Total cholesterol mg %		Relative Difference %	Lipid phosphorus mg %		Relative Difference %
	Old Immig	New Immig		Old Immig	New Immig		Old Immig	New Immig	
Men									
35-44	639	558	11	188	146	28	93	84	100
45-54	695	602	15	195	160	22	96	89	78
55-64	654	603	8	191	158	20	104	95	98
Women									
35-44	688	620	11	196	172	14	98	98	0
45-54	731	607	20	213	170	22	106	87	210
55-64	732	615	19	220	205	7	109	103	03

For the purpose of this Table values of the

For the purpose of this Table values of the new immigrants group were considered as 100%  
 New Immigrants = living in Israel 3 to 5 years Old immigrants = living in Israel over 20 years  
 \* After Toor Agmon and Allalouf (338)

acid esters of cholesterol regardless of the length of the carbon chain melt at higher than body temperatures the lowest is for oleate ( $44.5^{\circ}\text{C}$ ) and linoleate ( $42^{\circ}\text{C}$ ) compare stearate ( $82.5^{\circ}\text{C}$ ) and palmitate ( $90^{\circ}\text{C}$ ) (348) Therefore variations in solubility and melting point may determine deposition of these esters in the lesions Solubilities of the cholesterol esters of  $\beta$ -lipoproteins believed to be of atherogenic importance (350) are not known

Since pyridoxal is concerned with hepatic desaturation of di and tri unsaturated fatty acids to tetra and hexa forms (349) this coenzyme could influence the type of ester Experiments in our laboratories however have failed to show that vitamin B<sub>6</sub> raises the iodine number of plasma lipids when given for a week or 10 days the tendency was for it to fall (Table XLII) Surprisingly enough the iodine numbers of blood lipids was found to be much higher in Chinese (8) than in American patients (Table XLIII) probably a reflection of their high unsaturated fatty acid diets

**Other Lipid Substances** We have not considered the phospholipids of plasma nor the chylomicrons containing neutral fat nor the lipoprotein fractions which carry cholesterol These are complicating parameters whose significance is unclear Their relations are shown in Table XLIV Keys has said At the present time (1951) it is entirely unjustified to attribute to G measurements any special virtues beyond that for simple cholesterol measurements for the prediction of atherosclerosis or the estimation of the activity of the atherosclerotic process (351) The type of lipoprotein its solubility and its physical characteristics however may have atherogenic properties These large molecules transport lipids and steroids in blood (352) Therefore an increase in  $\beta$ -lipoproteins may do something to the process directly or indirectly but at

ferred in patients dying of debilitating diseases (341) with depressed blood lipids. In the monkey, both vitamin B<sub>6</sub> deficiency and elevated blood cholesterol are necessary to induce atheromata, levels are higher in deficient than in normal monkeys fed cholesterol (324). Since not only cholesterol, but other suspended particles will filter through intact intima (342, 343), the blood level is the obvious factor in determining whether or not this sterol is deposited in the lesions. There is no evidence at present, however, to implicate vitamin B<sub>6</sub> in the synthesis of cholesterol.

The deposits in the aortic plaques are mainly esterified cholesterol (316, 344-347). Schoenheimer found that there was a steady increase with age of both free and cholesterol ester extractable from the aorta as atherosclerosis developed. The proportion of free cholesterol to bound cholesterol, however, was relatively constant (22.5 to 31.9 per cent) showing no age trend, while cholesterol ester calculated as oleate tripled at older ages with advanced lesions. In other words although the aortas contained more extractable fat, the cholesterol esters in atheromatous aortas were relatively greatly increased. Most of the esters were oleate, palmitate and stearate, with small amounts of unidentified unsaturated fatty acid esters. There was also a marked increase in aortic phosphorus and lecithin with atheromata and a decrease in free hexosamine (433).

**The Nature of Cholesterol Esters** Cholesterol is a very insoluble substance; how all of it is transported in blood is not known, but most is carried by lipoproteins. Esters of stearate, palmitate and oleate are found in human blood and tissues (348). Cholesterol linoleate is considerably more soluble and linolenate much more soluble than is the stearate ester. Solubility in tissues and tissue fluids may be of considerable importance. Although all fatty

acid esters of cholesterol regardless of the length of the carbon chain melt at higher than body temperatures the lowest is for oleate ( $44.5^{\circ}\text{C}$ ) and linoleate ( $42^{\circ}\text{C}$ ) compare stearate ( $82.5^{\circ}\text{C}$ ) and palmitate ( $90^{\circ}\text{C}$ ) (348) Therefore variations in solubility and melting point may determine deposition of these esters in the lesions Solubilities of the cholesterol esters of  $\beta$ -lipoproteins believed to be of atherogenic importance (350) are not known

Since pyridoxal is concerned with hepatic desaturation of di and tri unsaturated fatty acids to tetra and hexa forms (349) this coenzyme could influence the type of ester Experiments in our laboratories however have failed to show that vitamin  $\text{B}_6$  raises the iodine number of plasma lipids when given for a week or 10 days the tendency was for it to fall (Table XLII) Surprisingly enough the iodine numbers of blood lipids was found to be much higher in Chinese (8) than in American patients (Table XLIII) probably a reflection of their high unsaturated fatty acid diets

**Other Lipid Substances** We have not considered the phospholipids of plasma nor the chylomicrons containing neutral fat nor the lipoprotein fractions which carry cholesterol These are complicating parameters whose significance is unclear Their relations are shown in Table XLIV Keys has said At the present time (1961) it is entirely unjustified to attribute to G measurements any special virtues beyond that for simple cholesterol measurements for the prediction of atherosclerosis or the estimation of the activity of the atherosclerotic process (351) The type of lipoprotein its solubility and its physical characteristics however may have atherogenic properties These large molecules transport lipids and steroids in blood (352) Therefore an increase in  $\beta$ -lipoproteins may do something to the process directly or indirectly but at

TABLE XLII  
IODINE NUMBER OF SERUM LIPIDS BEFORE AND AFTER ORAL B<sub>6</sub>\*

Patient	Age	Sex	Iodine Number		Total Dose mg	Diagnosis
			Before Vitamin B <sub>6</sub>	After Vitamin B <sub>6</sub>		
T C	77	♂	87	58	250	Myocardial infarction Parkinsonism atherosclerosis
G E	76	♂	100	45	300	Myeloid leukemia tortic stenosis atherosclerosis
C H	61	♂	54	56	250	Metastatic carcinoma atherosclerosis
B H	53	♀	60	59	150	Metastatic fibrosarcoma
L J	58	♂	53	70	300	Myocardial infarction atherosclerosis
R LeG	19	♀	83	37	250	Fracture spine accident
M R	68	♀	42	69	250	Atherosclerosis diabetes mild
G S	74	♂	59	67	250	Atherosclerosis carcinoma of prostate
G B	58	♂	33	89	150	Hypertension atherosclerosis
T B	74	♀	78	77	350	Metastatic carcinoma of breast atherosclerosis
M J	50	♂	126	71	350	Pulmonary insufficiency and fibrosis atherosclerosis
E K	64	♀	124	34	350	Atherosclerosis lobar pneumonia convalescent
F S	55	♂	71	53	300	Atherosclerosis hypertension
Mean	61		74	61		
S D			27.6	15.0		

From data of Perry Schwartz Hager and Schroeder  
\* Fifty mg pyridoxal HCl per day

TABLE XLIII  
IODINE NUMBERS OF SERUM LIPIDS WHITE PATIENTS

Atherosclerosis  
Diagnosed

Patient	Age	Sex	Total Cholesterol mg / 100 ml	I <sub>2</sub> No	Atherosclerosis Diagnosed	Disease
I R	64	Q	96	71	+	Lobar pneumonia convalescent
P N	65	Q	101	94	+	Pulmonary insufficiency bronchiectasis
I I	59	Q	106	56	+	Rheumatic heart disease
M S	54	Q	111	70	+	Myocardial infarction
L J	68	Q	119	82	+	Myocardial infarction emphysema
J D	67	Q	124	89	+	Isthmic hypertrophy
J B	62	Q	131	63	+	Hypertrophic cardiomyopathy of stomach
R S	68	Q	133	97	+	Inferior vena caval obstruction
K S	49	Q	134	61	+	Cerebral thrombosis
B H	67	Q	148	70	+	Pulmonary fibrosis and insufficiency
M J	50	Q	182	124	+	Hypertension
I S	55	Q	191	61	+	Hypertension
G B	58	Q	206	78	+	Angina pectoris
I T	48	Q	210	88	+	Metastatic carcinoma of breast
T B	74	Q	231	126	+	Angina pectoris
G H	45	Q	242	73	+	Nephrotic syndrome
J M	60	Q	550	162	+	Amyloidosis nephrotic syndrome
I T	44	Q	>500	102	+	Cerebral thrombosis hypertension
J B	65	Q		84	+	Vascular tumor of brain
M C	53	Q		76	+	Hypertension aneurysm of Circle of Willis
J H	54	Q		70	+	Chronic cystitis
A H	63	Q		62	+	Diabetes Parkinsonism
V V	71	Q		76	+	Carcinoma of prostate
O W	70	Q		78	+	
Mean	60			81		

From data of Ferry, Schwartz, Hager and Schroeder

Note: The iodine number of human depot fat is 61 (348) and cholesterol is 65.8. The mean iodine number of fatty acids in plasma of normal Chinese is 156.6 (8).



TABLE XLIV

COMPARISON OF DESIGNATIONS OF LIPOPROTEINS SEPARATED BY VARIOUS TECHNIQUES\*

<i>Ultracentrifuge</i>		<i>Electrophoresis</i>	<i>Cohn Method Fraction 10</i>	<i>Barr Russ &amp; Eder</i>
<i>Solvent Density</i>				
1.063 (Gofman <i>et al</i> )	1.21 (Lewis Green & Page)			
<i>Symbol</i>				
$S_i$	$-S_{in}$			
20-100+	>70			
10-20	40-70			
3-8	25-40	Beta Globulin	I III	C
1-3	20-25	Alpha-2		
	2-8	Alpha-1	IV V VI	A

Note that the use of a solvent density of 1.063 does not permit alpha 1 lipoprotein to undergo flotation. It is not certain which Cohn fraction contains the lipoprotein identified ultracentrifugally as alpha 2.

\* From Furman (352)

best, these molecules are secondary invaders or carriers and probably are not as directly concerned with pathogenesis as is cholesterol and its synthesis. If the total amount of cholesterol to be carried were low, there would be little or none to be deposited. The nature of the fatty acids in phospholipids also may be more important in atherogenesis than the total quantity. We must go deeper into first causes than a consideration of carrier components.

in the blood. What they are and what they are made of is of the greatest importance.

The lipoproteins carry steroid hormones, cholesterol and its esters, carotene or vitamin A,  $\alpha$ -tocopherol and acetal lipid (containing hydroxyl groups) (352, 353, 387). Most (75 per cent) of the free cholesterol in serum is in the  $\beta$ -lipoprotein fraction as is the esterified fraction (73 per cent) while less (55 per cent) of the phosphorus is in this fraction. Barr found somewhat lower values in  $\beta$ -lipoproteins (354, 355). Thus, increase in the cholesterol/phospholipid ratio, suspected to be of atherogenic significance, means in terms of lipoproteins that with relatively less phospholipid than cholesterol, the  $\beta$ -lipoprotein fraction will be increased in the proportion of 1:1.35. Gofman finds that particles of the  $S_{10,20}$  classes have weight ratios of cholesterol to phospholipid as high as 1:1.3 (356).

**Exogenous Cholesterol.** There is no evidence that a diet containing reasonable amounts of cholesterol (up to 10 Gm per day or the equivalent of four eggs) influences the level of blood cholesterol (357). Feeding healthy volunteers (358) or patients (359) up to ten times that amount causes insignificant changes in plasma levels. \* Actually at 200 mg per 100 ml blood there is about 8 Gm in circulation with an additional 3 to 4 Gm in liver and a considerable amount in other tissues. While exogenous cholesterol probably little affects plasma levels in man, the reverse, i.e. restricting the dietary intake to very low values, does decrease plasma levels since all dietary cholesterol is contained in fatty foods which therefore need

---

\* It is possible to block some of the intestinal absorption of exogenous cholesterol by plant sterols such as sitosterol in large doses. The effect on plasma cholesterol, however, is either insignificant, or significant to a very minor degree.

TABLE XLIV

COMPARISON OF DESIGNATIONS OF LIPOPROTEINS SEPARATED  
BY VARIOUS TECHNIQUES\*

<i>Ultracentrifuge</i>		<i>Electro phoresis</i>	<i>Cohn Method Fraction 10</i>	<i>Barr Russ &amp; Eder</i>
<i>Solvent Density</i>				
1 063 (Gofman <i>et al</i> )	1 21 (Lewis Green & Page)			
<i>Symbol</i>				
$S_f$	$-S_{12}$			
20-100+	>70			
10-20	40-70			
3-8	25-40	Beta Globulin	I III	C
1-3	20-25	Alpha-2		
	2-8	Alpha-1	IV V VI	A

Note that the use of a solvent density of 1 063 does not permit alpha 1 lipoprotein to undergo flotation. It is not certain which Cohn fraction contains the lipoprotein identified ultracentrifugally as alpha 2

\* From Furman (352)

best these molecules are secondary invaders or carriers and probably are not as directly concerned with pathogenesis as is cholesterol and its synthesis. If the total amount of cholesterol to be carried were low there would be little or none to be deposited. The nature of the fatty acids in phospholipids also may be more important in atherogenesis than the total quantity. We must go deeper into first causes than a consideration of carrier components

usually contain unsaturated fatty acids. This is not true of fish oils which must be largely unsaturated or short chain because of the low melting point essential for mobility of the animal at low temperatures. Actually fish fat contains several very long chain unsaturated fatty acids.

There are three habits largely common to the U.S.A. and some European countries which tend to raise the dietary intake of saturated fats (202, 348, 360): 1) Since 1920 animals fattened for slaughter have been fed high carbohydrate diets in order to lay down a hard fat. Meat from animals eating unsaturated vegetable fats is oily and housewives do not like to buy it; the melting point is low. 2) For many years vegetable fats (unsaturated) have been commercially hardened, often by a copper or nickel catalyst, in order to provide shortenings or margarine which are solid at room temperatures. 3) The consumption of milk, butter and cheese has increased; milk fats contain shorter chain saturated fatty acids and are believed to be atherogenic (356).

**Relation of Dietary Fats to Cholesterol.** Why does an excessive intake of hard or saturated fats cause atherosclerosis? The following information is known:

1. Animals lay down in their tissues part of the fat ingested. This has been demonstrated in all mammals but man. Pigs fed very long chain high melting point fatty acids may crack in the cold. Unnatural fats (odd numbered carbon atoms or optical isomers of natural fats) can be recovered from the bodies of animals to which they are fed in amounts from 10 to 25 per cent (348).

2. Cholesterol esters can be formed of the type of fat in the diet. Thus stearic or even unnatural fatty acid esters of cholesterol can be recovered when a specific fat is fed (348).

3. The esters of cholesterol in blood usually contain

be severely restricted. In animals, however, especially rats, rabbits, monkeys and chickens, very high intakes (2 to 4 per cent of the diet) raise plasma levels markedly (356).

**Type of Fat Ingested** The weight of evidence at present is in favor of the idea that a diet high in fats of animal origin is atherogenic, while diets containing adequate but relatively smaller amounts of vegetable fat are not. Although there are many types of fat in both animal and vegetable sources, the number is somewhat limited by the digestibility of the fats with higher melting points. Natural fats contain an even number of carbon atoms and are usually found as triglycerides, the lengths of the chains vary from 4 to 24. Some are saturated, some contain one, two, three or four unsaturated ethylene linkages. Obviously an enormous number of possible combinations can occur; fortunately, in nature they do not (Table XLIV).

The melting points of the saturated fatty acids are directly proportional to the length of the carbon chain, short chain acids being liquid (348). Equal length unsaturated acids have lower melting points. Solubilities are directly related, the saturated acids being less soluble in water and alcohol. Furthermore, the specific gravities of saturated fatty acids are lower than their unsaturated relatives.

Insofar as is known, there is no difference between glyceryl tristearate obtained from animal sources and that derived from vegetable; the fatty acids are identical. Fully hydrogenated linolenic acid becomes stearic acid. What then are the differences? Unless vegetable oils contain some esoteric product which counteracts the atherogenic influence of animal fats, we must look to the composition of the fats themselves. In general, animal fats have more saturated fatty acids than vegetable fats, while the latter

usually contain unsaturated fatty acids. This is not true of fish oils which must be largely unsaturated or short chain because of the low melting point essential for mobility of the animal at low temperatures. Actually fish fat contains several very long chain unsaturated fatty acids.

There are three habits largely common to the U S A and some European countries which tend to raise the dietary intake of saturated fats (202 348 360) 1) Since 1920 animals fattened for slaughter have been fed high carbohydrate diets in order to lay down a hard fat. Meat from animals eating unsaturated vegetable fats is oily and housewives do not like to buy it the melting point is low 2) For many years vegetable fats (unsaturated) have been commercially hardened often by a copper or nickel catalyst in order to provide shortenings or margarine which are solid at room temperatures 3) The consumption of milk butter and cheese has increased milk fats contain shorter chain saturated fatty acids and are believed to be atherogenic (356)

**Relation of Dietary Fats to Cholesterol** Why does an excessive intake of hard or saturated fats cause atherosclerosis? The following information is known

1 Animals lay down in their tissues part of the fat ingested. This has been demonstrated in all mammals but man. Pigs fed very long chain high melting point fatty acids may crack in the cold. Unnatural fats (odd numbered carbon atoms or optical isomers of natural fats) can be recovered from the bodies of animals to which they are fed in amounts from 10 to 25 per cent (348)

2 Cholesterol esters can be formed of the type of fat in the diet. Thus stearic or even unnatural fatty acid esters of cholesterol can be recovered when a specific fat is fed (348)

3 The esters of cholesterol in blood usually contain

more unsaturated fatty acids than do neutral fats or phospholipids (360)

4 The metabolism of cholesterol and that of the essential fatty acids is closely interrelated. Essential fatty acid deficiency in rats is accompanied by storage of cholesterol in liver and adrenal. Diets low in fats may lower blood cholesterol but increase that in liver. Linoleate or linolenate either may be required to mobilize depots of cholesterol or be necessary for its catabolism (360, 361)

5 Blood and liver levels of cholesterol in rats are elevated in essential fatty acid deficiency when cholesterol is fed. Methyl linoleate lowers both values (360)

Cholesterol is synthesized in the liver, adrenal and presumably other tissues from acetate. The possible pathways are shown in Figure 19. Obviously it is impossible to avoid acetate, which is a metabolic product of fat, carbohydrate and amino acid metabolism. The immediate precursor of




FIG 19 Possible pathway of cholesterol synthesis. Entirely hypothetical intermediates are enclosed in brackets. (From Langdon. In *Fat Metabolism*, V A Najar, ed. Baltimore: Johns Hopkins Press, 1954)

TABLE XLV

COMPOSITIONS OF CORN COTTONSEED OLIVE OILS AND BUTTER\*

	Corn	Cottonseed	Olive	Butter
Iodine number	103-129	90-110	79-90	26-38
Saturated acids (%)	12-18	21-32	9-19	30-43
Oleate	21-49	19-36	64-86	28-41
Linoleate	34-61	34-56	4-15	
Linolenate	0-2.9	0	0	0
Arachidonate	0	0	0	0
Squalene (mg %)	28	8	383	0
Ergosterol	+	+	0	+
Sitosterol	+	+	0	
Stigmasterol	+			
Rate of enzymic hydrolysis	1	2	3	
Tocopherol (mg %)	87-250	83-110	3-30	

\* After Deuel (348) and Eckey (447) Contents vary with climate soil and seed

cholesterol has been shown to be squalene a hydrocarbon with six double bonds having the empirical formula  $C_{30}H_{48}$  (362). Squalene is found in the unsaponifiable fraction of several but not all fish oils and only one plant oil olive oil (0.41-0.54 per cent). Other vegetable oils contain only very small amounts (peanut oil 0.07 per cent). Animals fed labelled squalene synthesize cholesterol 50 times as efficiently as when given labelled acetate (362). Squalene is not converted to fatty acids as is acetate. An other precursor of cholesterol is provitamin D<sub>2</sub> or 7-dehydrocholesterol widespread in foods but in small quantities.

**Effect of Various Fats on Blood Cholesterol Levels in Man** One can gain some information on the relationship of the type of fat ingested to the level of cholesterol in plasma by human experiments in which dietary fat was markedly increased (Table XLVI). If these results are valid an examination of the table points at once to specific dietary factors or the lack of them which alter cholesterol



TABLE XLVI  
DIETARY FACTORS ALTERING PLASMA CHOLESTEROL IN MAN\*

<i>Factors Causing Increased Levels</i>	<i>Factors Causing Decreased Levels</i>
High fat intake	Low fat intake (386)
Starvation	Scurvy
Low carbohydrate intake	Vegetable fat (Diabetics)
Vitamin B deficiency	Soy bean oil (446)
Vitamin B <sub>6</sub> deficiency (monkey)	Sunflower seed oil (448)
Olive oil	Nuts (363 365)
Cottonseed oil	Corn oil (367 368)
Butter (368)	Brain extract (366)
<i>No change caused by</i>	
Obesity	
Cholesterol intake (357)	
(moderate)	

\* After Deuel (360) and others

levels in man Vitamin B deficiency starvation low carbohydrate intake high fat intake olive and cottonseed oils and butter move cholesterol values in the same direction, up while specific factors appear among those reducing it Because corn and olive oils act oppositely we must look to differences in content of specific factors in these two fats

The outstanding difference appears in the linolenic content which is absent in olive and cottonseed oils\* and is present to the amount of 0.6 per cent of corn oil This essential fatty acid is not found in butter unless it is fed to the cow it was present in one sample of American human fat and serum (348) (possibly influenced by diet) but was not found in one German (348) is in some lecithins and cannot be synthesized by the animal (Table

\* Oils may vary in their atherogenic properties possibly because of variations in essential fatty acid (linolenate?) content (440) Olive oil consumed in Spain is usually adulterated with soy oil

\LVII) Arachidonic acid a normal component of animal tissues lecithins cephalin phosphatides and fats is an other essential fatty acid formed from linoleic probably by a vitamin B<sub>6</sub> enzyme system (349)

Therefore the factor in certain vegetable fats (and not others) which lowers blood cholesterol may not lie in the presence or absence of unsaturated fatty acids themselves

TABLE \LVII

ESSENTIAL FATTY ACID CONTENT OF SOME EDIBLE OILS (%)

Food	Linoleic	Linolenic	Production†
Linseed	15-43	40-53	2.2
Peanut	47-72	0	3.9
Sunflower	44-75	0.1	2.0
Sesame	40-48	0	1.5
Soy bean	52.0	2.3-11	3.8
Coconut	1-2	0	4.6
Animal fats	+	0	17.8
Rapeseed	12-16	7-10	3.3
Palm	6-11	0	3.3

\* After Eckey (417) †Estimated World 1951 billions of lbs

but in the linolenic or other specific fatty acid content. The cholesterol lowering diets of Kinsell *et al* contain nuts in large amounts (363). The fat from some nuts especially walnuts contains linoleic and linolenic acids (348). In this respect Kinsell's diets (364-365) contained soybeans soy lecithins soy sauce corn oil and walnuts all containing linolenic acid while this fatty acid has not been found in peanuts almonds and cashew nuts (348). The hydrogenated oils in margarine Crisco and peanut butter as well as cottonseed peanut and olive oil which apparently do not contain linolenate were also given in spite of these fats at least two of which usually raise blood cholesterol. It fell. Brain extract probably cephalin which

contains arachidonic acid also has been reported to lower cholesterol (366). The common denominator of the effects of these various conflicting data appears to be in the tri or tetraethenoid acids similar to linolenic and arachidonic (367-369) (Table XLVIII).

TABLE XLVIII

FOODS CONTAINING LINOLEIC LINOLENIC AND ARACHIDONIC ACIDS\*

	<i>Linoleic</i> ( $C_{18}$ , 2 double bonds)	<i>Linolenic</i> ( $C_{18}$ , 3 double bonds)	<i>Arachidonic</i> ( $C_{20}$ , 4 double bonds)
Egg yolk lecithin	+	0†	+
Brain lecithin	0	0	+
Brain cephalin		0	+
Liver lecithin	0	0	+
Pig fat	+	0	2-1%
Butter fat	3-6-4-5%	?**	+
Fowl fat	21-3%	0	+
Fish	40±%	+	+
Soy bean lecithin	+	+	0
Phosphatidic acids	+	+	0
Walnut oil	73%	3-8%	0
Beechnut oil	38%	0-4-2-9%	0
Soy bean	52-0%	2-3%	0
Alfalfa	67-5%	20-8%	0

\* After Deuel (348)

† Only when fed to hens

\*\* Only when fed to cows

It is interesting that atherosclerosis is unusual in countries where soy beans are a staple article of diet. If these deductions are correct substances containing linolenic acid, either in fats or in phosphatides, should lower blood cholesterol\*. The relationship between pyridoxal and the formation of linolenate will be discussed below.

\* The practice of fasting by some religious groups during one day a week and the Lenten season may have logic in terms of essential fatty acid

**Pyridoxal and Trace Metals** The amount of vitamin B<sub>6</sub> in the diet has a definite influence on essential fatty acid metabolism in animals. Vitamin B<sub>6</sub> deficiency and essential fatty acid deficiency in rats resemble each other grossly and each factor will partly alleviate the other. There are however fundamental differences in enzymes in the two

TABLE XLIX  
COMPARISON OF ESSENTIAL FATTY ACID AND PYRIDOXINE  
DEFICIENCIES IN RATS (384)

<i>Function</i>	<i>Organ</i>	<i>Essential Fatty Acid</i>	<i>Pyridoxine</i>
Respiration	Liver	Increased	
Cytochrome oxidase	Liver	Increased	Increased $\pm$
Succinic oxidase	Liver	No Change	No Change
Phosphate esterification	Liver	Decreased	Decreased
Glutamic dehydrogenase	Liver	Decreased	Decreased
Butyric dehydrogenase	Liver	Decreased	No Change
Succinic dehydrogenase	Liver	Decreased	No Change
Glutamic decarboxylase	Brain	—	Decreased
Arachidonic synthesis	Carcass	Decreased	Decreased
Hexaenoic synthesis	Carcass	Decreased	Decreased
Octanoate oxidation	Carcass	—	Decreased

conditions (Table XLIX). Apparently vitamin B<sub>6</sub> is essential for desaturating partly unsaturated fatty acids such as linoleic further to synthesize arachidonic and in metabolizing linolenic to hexaenoic acids. Linoleic is a precursor of arachidonic and linolenic of the hexaenoic acids (349).

deficiency or saturated fatty acid excess. Thus the members of the Russian Orthodox Church eat nothing of animal origin during Lent. Advent and on Wednesdays and Fridays and use oils high in linolenic acid. Roman Catholics by custom supply themselves with adequate essential fatty acids on Fridays and during Lent but do not restrict other animal fats. Mohammedans have strict dietary laws during Ramadan. In terms of deposition of lipid these religious habits probably do no harm in maintaining or restoring the integrity of the intima.

In deficiency of this coenzyme, liver fat becomes more saturated (370)

Snell believes that vitamin B<sub>6</sub> as a coenzyme contains a metal for activity (215) If so, the interrelationships are obvious although whether or not such a metalloenzyme acts in the fatty acid cycle is not known The only one of these enzymes containing a metal is acyl Co enzyme A de hydrogenase which uses copper

Some further information may be obtained by the use of metal binding and chelating agents in lowering blood cholesterol Calcium disodium ethylenediamine tetraacetate (EDTA) is a good cholesterolytic agent in man (Figs 20 21) sometimes lowering values to the Indian normal (180, 371, 372) In rabbits (373) and rats (374) fed cholesterol however, it raises blood levels above the controls and in rabbits but not in rats it prevents deposition of this lipid in the liver Because EDTA is not metabolized in the body and diffuses readily (250) its sparing effect on liver but not on blood levels must be related to removal of one or more trace metals EDTA also raises lipid synthesis by rat liver while another agent 8 hydroxquinoline lessens it (375) EDTA causes marked loss of subcutaneous and depot fat (376) suggesting that a metal is involved in fat metabolism and synthesis Hydralazine another metal binding agent also lowers cholesterol in man (180) (Fig 22)

*Comment* These indirect but quite suggestive data are provocative of thought when viewed in pathogenetic and therapeutic terms Obviously normal cholesterol levels are lower in some countries than in others usually in those less touched by Western Civilization If we could reduce our own to these normal values by interfering with the processes which raise them to abnormal levels

## LT 44 NEPHROSIS




FIG. 20 Effects of oral hydralazine and intravenous EDTA on plasma cholesterol levels. L. T. 44 years of age was seen in October 1954 because of mild exertional dyspnea and ankle edema for six months. At 7 years of age he had Marie Strumpell arthritis and at 25 years of age migratory polyarthritis without urinary symptoms. Nephrosis was clinically evident and amyloidosis was proved by renal punch biopsy. To lower his plasma cholesterol hydralazine was begun without evident clinical improvement. In a further effort to lower his plasma cholesterol three courses of parenteral EDTA were given. On the sixth day of this first course of therapy slight inflammation of the mucous membranes and a magenta tongue were observed and he complained of soreness about his mouth and gums. By the final day cheilosis, chemosis, scrotal inflammation and pustular lesions over the face and trunk had appeared. Within a week the lesions had vanished and a second course of EDTA was begun. On the fourth day stomatitis reappeared and within 7 days the same syndrome was present again necessitating the discontinuation of therapy. The 3-day final course produced no such lesions, however fever immediately followed the dosage increase to 4 Gm. Cholesterol values for the second course were not plotted because such a low plasma level was attained that a laboratory error was suspected (303 mg per 100 ml on a single determination). The changes in cholesterol preceded clinical toxicity (From Perry H. M. Jr. and Schroeder H. A. J. Chronic Dis. 2:520, 1955). Metal excretion in Table XXX, p. 160.

# L S 28 DIABETES






FIG 21 Effect of intravenous EDTA on plasma cholesterol The material was given as the calcium disodium chelate L S The patient's diabetes controlled on 45 units of insulin a day worsened to the point that it needed 55 units possibly a result of pancreatic loss of zinc (From Perry H M Jr and Schroeder H A *J Chronic Dis* 2 520 1955) A M Hydralazine given in small doses appeared to maintain the lower values achieved with EDTA M B The rebound in a month is obvious

we would expect little or no atherosclerosis especially of our coronary arteries

There appears to be something in certain but not all vegetable fats which lowers blood cholesterol markedly in man while animal fats hydrogenated vegetable fats and other vegetable fats with a lower iodine number raise plasma cholesterol. As a first guess this substance may be linolenate an essential fatty acid. If that is so Europeans and Americans may be suffering from a relative essential






FIG 92 Effect of oral hydralazine on total fasting plasma cholesterol in 11<sup>0</sup> hypertensive patients. Changes in cholesterol concentrations before and after hydralazine are plotted against the length of therapy. Each large dot indicates a patient with an initial cholesterol level of more than 215 mg per 100 ml plasma. Each small circle indicates a patient with lower initial values below 211 mg per 100 ml plasma (From Perry H M Jr., and Schroeder H A J Chronic Dis 25:9 1955)



# LS #28 DIABETES



A.M.



M.B.



FIG 21 Effect of intravenous EDTA on plasma cholesterol. The material was given as the calcium disodium chelate L.S. The patient's diabetes controlled on 45 units of insulin a day worsened to the point that it needed 55 units possibly a result of pancreatic loss of zinc (From Perry H. M. Jr and Schroeder, H. A. *J Chronic Dis*, 2:520 1955). A.M. Hydralazine given in small doses appeared to maintain the lower values achieved with EDTA. M.B. The rebound in a month is obvious.

$$\begin{array}{l}
 \text{Intimal Injury due to} \\
 \text{me } \times \begin{array}{l} \text{a) Vitamin B}_2 \text{ deficiency} \\ \text{b) Excessive hypertension} \\ \text{c) Normal pressure differentials} \end{array} \times \begin{array}{l} \text{Increased Saturated} \\ \text{over Unsaturated} \\ \text{Fatty acid esters of} \\ \text{cholesterol lipo-} \\ \text{proteins and phospho-} \\ \text{lipids Increased} \\ \text{synthesis or decreased} \\ \text{destruction of cholesterol} \\ \text{due to metals or fatty} \\ \text{acid deficiency} \end{array} \times \begin{array}{l} \text{Blood} \\ \text{Pressure} \end{array} = \text{Atherosclerosis}
 \end{array}$$

The nature of the vitamin B<sub>2</sub> deficiency and its possible relation to trace metals has already been discussed. The plasma lipids under consideration include a) Cholesterol esters which are said to be usually of unsaturated fatty acids although esters of equal length saturated fatty acids are lighter and more insoluble. Dietary excess of the latter could influence their nature. b) Lipoproteins or protein fatty acid complexes the nature of which are unknown. The saturated fatty acid esters should be lighter and more insoluble than their unsaturated counterparts. If so they should centrifuge more slowly (or float more rapidly). A lipoprotein with a specific flotation rate of S<sub>1</sub> 0 10 if its fatty acid became saturated should theoretically change to the S<sub>1</sub> 10 20 class unless rearrangement of the molecule took place. c) Phospholipids the fatty acid components of which depend partly perhaps on dietary intake but usually are formed of unsaturated fatty acids in functioning tissue (brain and liver).

Effect of Sex For some unknown reason premenopausal women are quite immune from coronary atherosclerosis. The disorder however becomes as frequent in women after the menopause as in men. Coronary occlusion in a normotensive menstruating woman was formerly extremely rare although cases are now appearing. The degree of aortic atherosclerosis however shows little sex

fatty acid deficiency. There may be very little linolenic acid in the American diet. Pyridoxal is concerned with the utilization of essential fatty acids and a deficiency of one may enhance a deficiency of the other. Furthermore, trace metals can be involved since they affect fat synthesis and may be concerned in vitamin B<sub>6</sub> enzymes although their role is possibly of only secondary importance.

The differential effects of metal chelating agents must be explained. Let us assume that in the livers of human beings there is a metal (chromium, for example) which stimulates the formation of cholesterol and fatty acids or a metal (copper for example) which depresses catabolism of lipids, in addition to the normal metal (manganese for example) EDTA because of its higher affinity for the abnormal metal removes it allowing synthesis to revert from an accelerated to a normal rate or catabolism to rise itself to normal. In the animal fed cholesterol however there is no abnormal metal affecting synthesis therefore the normal one is removed. In that event the synthesis of cholesterol in liver might be lowered or catabolism raised preventing accumulation of endogenous cholesterol in liver but allowing exogenous cholesterol to remain in the blood. The latter would be the case if storage and synthesis were related. The differential effects of EDTA and 8-hydroxyquinoline in the rat can be explained by different affinities of the two substances for metals the former being the stronger chelating agent. That two antagonistic metals may influence an enzyme system is well known for actomyosin (Mg and Ca) and has been proposed by the Bernheims for lipid metabolism (Mn and V) (274).

These various factors can be substituted in Friedman's schema to include a more definitive but much more hypothetical one.

fluctuations can occur (377) A persistently high level is atherogenic a momentary low level may not reflect the true state of affairs in terms of intimal exposure There are conflicting opinions and data but the opposing views can be resolved by realization that a) cholesterol levels fluctuate and unless consistently elevated values may be meaningless 2) when a patient is sick the levels fall 3) the full lesions of atherosclerosis develop only after prolonged constant or intermittent hypercholesterolemia

In this chapter we have spoken of trace metal imbalances conditioned vitamin B<sub>6</sub> deficiencies and essential fatty acid deficiencies We have emphasized that these deficiencies are relative conditioned and local to one or at most a few enzyme systems There is no practical way however of reversing vitamin B<sub>6</sub> deficiencies at the present time The administration of 50 mg of pyridoxal hydrochloride daily to many patients has not resulted in a detectable fall in blood cholesterol The administration of at least two trace metals cobalt and manganese in large daily doses have not caused clinical changes detectable by ordinary laboratory methods Only by chelating agents have we been able to affect blood levels favorably (180)

The several pathogenetic factors outlined by Friedman *et al* should be affected simultaneously if we are to expect cessation of the process or at the best reversal Whatever is making the intima injured so that plaques are formed should be opposed as an approximation pyridoxine in adequate doses is required until more is known The abnormally high cholesterol levels in blood should be reduced by dietary influences and chelating agents if possible Elevated diastolic pressure should be controlled at normotensive levels Under these conditions some reabsorption of plaques which are not too scarred might be expected

difference (355) These differences cannot be explained by gross differences in plasma lipids, cholesterol or phospholipids but lower concentrations of beta lipoproteins higher ones of alpha lipoproteins and lower atherogenic ultra centrifugal lipoproteins are found in women The administration of estrogens to men alters these values to those of healthy young women, while methyl testosterone acts in the opposite direction Estrogen shifts an appreciable amount of cholesterol carried by beta lipoproteins into alpha lipoproteins while testosterone does the opposite The same sex immunity to coronary disease is found in chickens Although estrogen is carried in blood by lipoproteins this phenomenon is unexplained on a mass action basis by the small amounts administered

Clearing Factor Heparin will clear lipemic serum both in vivo and in vitro (444) Apparently this anticoagulant alters the physicochemical structure of chylomicra so that they become soluble These large fat filled particles carry almost all dietary cholesterol The rates of clearing are faster in young women than in men and slower in the aged Their relations to atherosclerosis are not known

### CLINICAL IMPLICATIONS

At present there are several available methods for lowering blood cholesterol in man Because the pathogenesis of atherosclerosis is a multivalent one the process must be attacked at different levels Obtaining a permanently lowered cholesterol level in blood might allow cessation of the deposition of cholesterol in plaques with probably some absorption in the presence of an altered gradient between plaque and plasma Practical methods will be discussed in Chapter IX

What the level is at any one instant of a lifetime of exposure to atherosclerosis is relatively unimportant Wide

3 Ischemia due to organic vascular disease which does not appear until the pressure is lowered is a clear and present hazard in actual practice it is rare

4 Diastolic normotension must be achieved and maintained whenever possible A compromise is hazardous merely modifies the disease promotes drug tolerance and does not allow eventual reduction of dosage

5 The use of any ganglionic blocking agent the action of which does not last for 24 hours requires that blood pressure be measured before each dose in order to prevent a) hypertension b) hypotension and c) to provide as constant a blood level as possible throughout the day and night Varying requirements and absorption necessitate varying dosages according to the prevailing levels of blood pressure

6 Arterial hypertension due to increased generalized vasospasm is a disorder or a disease The patient either has it or has not If he has severity varies widely from slight to marked Therapy should be applied when both patient and physician want to control the disease If therapy is not applied the responsibility rests on the physician that the disease is not doing or going to do harm

## **EVALUATION OF PATIENT FOR DRUG THERAPY**

The first question to be answered is Has the patient hypertension? A diastolic pressure of 90 mm Hg or over (measured by the disappearance of Korotkoff sounds) is strongly suggestive in fact usually indicative of generalized vasospasm in the absence of tachycardia polycythemia or coarctation of the aorta When persistent it suggests chronic hypertension when relieved by relaxation it suggests the prehypertensive state

The second question is How severe or sustained is the

## Chapter VIII

# PRACTICAL METHODS FOR MODERN THERAPY OF HYPERTENSION

### INTRODUCTION

**O**N THE BASIS of the various hypotheses and findings outlined in previous chapters and using the potent drugs discussed a practical method of controlling excessive vasospasm in man can be outlined and the therapeutic limits of a long term regimen can be predicted. While the use of this regimen requires care and precautionary measures, it is no more difficult in fact much less so than is the control of diabetes mellitus. Some simple but basic rules need be kept in mind, which any practitioner of medicine can follow. The results are often life saving in severe cases.

**General Rules** 1 Vasospasm alone is being treated. In no case are the results of atherosclerosis (coronary and cerebral arterial narrowing the loss of aortic elasticity, renal arteriosclerosis) being reversed as far as we know, although there may be slow changes with time. Therefore the most striking results will be seen in cases where the effects of vasospasm are the greatest (hypertensive heart failure cerebral edema), and the poorest in cases where the effects of atherosclerosis are the most advanced.

2 In all cases where two different factors are contributing to the generalized vasospasm two differently acting drugs must be used. When only one factor is operating, only one drug is necessary. In severe hypertension two factors almost always are functioning.

primary organic renal diseases adrenal dysfunction or emotional crises

For a thorough work up evaluation of the cardiac status requires a study of the symptoms electrocardiographic tracing for left ventricular hypertrophy strain patterns or old myocardial infarction and roentgen or fluoroscopic examination of the heart In actual practice only signs of a previous coronary occlusion are important indications for cautious therapy but physicians are often gratified to watch enlarged hearts slowly become smaller and abnormal electrocardiographic tracings revert to normal under continuous therapy

Renal status is evaluated most easily by routine urinalysis and the intravenous injection of phenol red (PSP) with urine specimens obtained 15 30 and 60 minutes after injection The test is simple and reliable The bladder need not be emptied before the test although the first specimen may show a somewhat smaller amount of PSP\* for unknown reasons (Reabsorption of PSP by bladder wall has not been ruled out) Adequate hydration is essential for accurate values The urinary concentration test is impractical on an outpatient basis owing to difficulties in restricting the amount of dietary water If the 15-minute PSP excretion is less than 10 to 15 per cent azotemia may be suspected

Retinoscopy is essential in all cases The appearance of exudative or hemorrhagic retinitis is often a poor prognostic sign making treatment mandatory The best method for grading fundal changes is that of Keith and Wagener

---

\* In a series of 39 medical students paired for the test with bladder empty the 15-minute excretion was 35.5 per cent with bladder full, 30.9 per cent The normal values with bladder initially empty were 1 minutes 35.5 per cent 30 minutes 21.2 per cent 60 minutes 17.0 per cent with a total of 73.7 per cent



*hypertension now? This can be answered only by repeated measurements of blood pressure sometimes complete bed rest is necessary to rule out emotionally induced vasospasm. The examining physician must be aware of the 'manometric reflex,' a psychosomatic response by vasospasm to the wrapping of the cuff about the arm (4). He also must keep in mind the wide spontaneous variations of blood pressure sometimes seen in hypertensive individuals (388, 37, 36).*

The third question is *How much harm, if any, is hypertension doing or has it done? This can be answered mainly by physical examinations and simple laboratory tests, bearing in mind the sharp division of what changes are atherosclerotic and what are the results of overwork and vasospasm. Systolic hypertension is not caused by vasospasm but by hard arteries or increased cardiac output, cerebral thrombosis and coronary occlusion are not directly hypertensive in origin.*

The fourth question is *How rapidly is it progressing? An accurate history and clinical judgment supplies the answer, often only after many examinations.*

**Office Practice** While partial answers to these questions can be obtained in office practice one can do better by a hospital work up (400)

The date of onset of hypertension should be determined if possible in order to get an idea of the rate of progression. The date of discovery may be less important. The effects of hypertension can be evaluated by inquiry into the cardiac status, dyspnea being the earliest symptom of insufficiency and renal status by polyuria and nocturia. The approach to the patient is divided into three parts a) estimation of the rate of progression b) estimate of the present status in terms of secondary organic damage and c) inquiry into possible definite etiologic factors such as

- 5 External compression of the renal artery
  - a Tumors of the pedicle\*
  - b Aneurysms\*
- 6 Diminution of the calibre of the renal arteries
  - a Congenital malformations hypoplasia\*
  - b Atherosclerosis, with atheroma of the main renal artery (common)\*
- 7 Disorders of the urinary tract
  - a. Obstructive disorders
    - (1) Lithiasis\*
    - (2) Hydronephrosis (usually infected)\*
    - (3) Pyonephrosis
    - (4) Congenital malformations\*
    - (5) Prostatic hypertrophy\*
    - (6) Uterine prolapse
    - (7) Pelvic tumors (fibromyomata)\*
  - b Pyelonephritis (common)\*
- 8 Venous obstruction
  - a External compression of renal vein
  - b Congestive heart failure\*

The following intrarenal diseases must be considered

- 1 Inflammatory vascular lesions
  - a Disseminated lupus erythematosus\*
  - b Polyarteritis nodosa\*
  - c Syphilis
  - d Thromboangitis obliterans
- 2 Inflammatory renal lesions
  - a Glomerulonephritis\*

The following endocrine diseases can influence hypertension

- 1 Hypophyseal tumors and hyperfunction\*
- 2 Adrenal cortical and medullary tumors and hyperplasia\*

(389), in simplest terms it means Grade I, spasm, Grade II, spasm and sclerosis Grade III, spasm and hemorrhage and/or exudate, Grade IV, spasm, hemorrhage and/or exudate plus papilledema Cases between grades are naturally encountered

The lability of the blood pressure can be tested by giving tetra ethylammonium chloride (Etamon) intravenously, thus blocking sympathetic ganglia This drug is not to be given in states of renal insufficiency excreted by the kidney, it may be retained and the patient may suffer from postural hypotension for several hours

Intravenous pyelography and repeated cultures of the urine are essential for revealing the presence of chronic pyelonephritis if active low grade infection is present Estimation of the numbers of bacteria per ml of urine (colony count) is of more value than merely finding organisms

The following renal conditions usually discovered by pyelography or aortic arteriography, can influence hypertension unfavorably by adding a renal factor to a neurogenic one The list was modified from that of Braun Menendez *et al* (148, 393, 394)

- 1 Reduction of renal parenchyma
  - a Polycystic kidneys\*
  - b Renal tumors (rare)
  - c Hydatid cyst of kidney (rare)
  - d Traumatic lesions\*
  - e Hypoplasia\*
- 2 Perinephritis, healed\*
- 3 Complete obstruction of main artery or branch
  - a Thrombosis and atheromata of the renal artery\*
  - b Emboli to the renal artery clot or cholesterol\*
- 4 Intermittent occlusion of the renal artery
  - a Renal ptosis\*

---

\* Personally observed

## EVALUATION OF GENERALIZED VASOSPASM IN HYPERTENSIVE STATES

It is of little more than academic interest what the underlying pathogenetic factors in a state of severe hypertension may be except when chronic pyelonephritis can be treated with antibiotics (often with little success) or recurrences of glomerulonephritis prevented by antibiotics designed to abort upper respiratory tract infections. It also matters little what the type of renal disease contributing to the vasospasm may be pyelonephritis glomerulonephritis secondary arteriolar nephrosclerosis or even polycystic disease. What do matter are the relative influences of neurogenic nephrogenic or adrenocortical factors in causing the vasospasm for the relative amounts of different drugs required will differ according to the amount of renal ischemia present. Therefore it is a good plan to group cases according to several stages of the disease dependent upon the amount of vasospasm one finds and its lability.

The degree of lability of the vasospasm is the factor which determines these stages. Complications such as cerebral vascular accident and coronary arterial occlusion can occur in any stage mild severe or normotensive as they are caused not directly by vasospasm but by an associated disease atherosclerosis. The fact that this other disease can be influenced by the severity of the hypertension i.e. the vasospasm has little to do with therapeutic measures aimed at vasospasm. Therefore classifications based partly upon atherosclerotic damage are valid for purposes other than the choice of drugs or procedures such as prognostic implications and for surgical risk. One would not use the most potent drugs in a patient with hemiplegia or congestive heart failure who exhibited severe atherosclerosis and mild hypertension one would use them however in a patient with severe but *asymptomatic*

- 3 Ovarian tumors\*
- 4 Toxemia of pregnancy\*
- 5 Testicular tumors with hyperfunction\*

The following nervous lesions can contribute to hypertension

- 1 Certain tumors of brain\*
- 2 Anxiety states\*
- 3 Expanding inflammatory lesions\*
- 4 Cerebral vascular lesions\*

**Hospital Patients** For further evaluation, the patient should be examined in hospital both for the purpose of determining the lability of blood pressure and for initiating treatment with ganglionic blocking agents. Blood pressure is measured every 4 hours by the nurses and is charted. The sodium amytal release test is performed (0.2 Gm sodium amytal given each hour for 3 hours, blood pressure being measured hourly during the night). The ability of the kidneys to concentrate urine also can be measured by giving the patient a dry diet and no fluids for 12, 18 or 24 hours; the last specimen shows the maximal specific gravity corrected for proteinuria or glycosuria.

The obvious disorders causing true or false hypertension must be ruled out before starting therapy. Pheochromocytoma is a rare disease requiring a high index of suspicion; it can be suspected by using phentolamine (Regitine) intravenously without prior sedation. Regitine can cause acute hypotension and renal shut down in azotemic states. Measurement of catechol amines in urine, either by bioassay (390) or chemical determination, is a specialized procedure done only in a few medical centers. Coarctation of the aorta is unusual; palpation of the femoral arteries or abdominal aorta will usually show its presence as will roentgenograms of the rib cage.

Serious secondary atherosclerotic complications may or may not be present if so about 30 to 40 per cent may be dead in 3 years. The ocular fundi are Grade I or II renal function is normal or nearly normal and the blood pressure is roughly 180/100 to 220/120 mm Hg during rest in bed. Reserpine plus fairly large doses of hydralazine (300 to 400 mg per day) will control about half of these cases eventually the remainder require the addition of ganglionic blockade. With time individuals in this stage uniformly exhibit reversal of the process and marked reduction of dosage in 2 to 3 years a majority can be maintained on reserpine alone and a few will be in a complete but probably temporary remission.

Stage III is made up of individuals with Grade II to III (Keith Wagener) ocular fundi with or without occasional hemorrhagic and exudative lesions with severe generalized vasospasm and hypertension not relieved by heavy sedation (sodium amytal). Renal function is adequate but usually reduced. Serious atherosclerotic complications may or may not be present. The blood pressure is usually 200/120 to 270/160 mm during rest in bed. In this stage which usually carries a poor prognosis (40 per cent dead in 3 years) ganglionic blockade plus adequate doses of hydralazine (500 mg or more per day) are essential for control. Reserpine may or may not be added mainly for its sedative action in smoothing out variations in blood pressure caused apparently by emotional lability in the presence of incomplete and irregular ganglionic blockade. Therapeutic results are good 95 per cent surviving 5 years with considerable eventual reduction in dosages in most.

Stage IV corresponds to Perera's accelerated phase or what is more commonly called the malignant stage. For therapeutic purposes it can be divided into three sub-

matic diastolic hypertension and retinitis without serious cardiovascular damage having yet occurred

We define normotension as levels below 140/90 mm Hg. It is at this diastolic level that vasospasm becomes slightly excessive. Definitions based on higher diastolic levels in older age groups pay lip service to the prevalence of the disease, avoiding realities. Actually in the absence of vasospasm the diastolic pressure falls slightly as atherosclerosis develops while the systolic rises.

*Prehypertensive* The blood pressure is slightly above 140 mm systolic or 90 mm Hg diastolic at times but falls with relaxation. There are no signs of secondary damage. Chronic pyelonephritis or hydronephrosis, however, may be found in young individuals (391).

*Stage I* comprises patients with elevated levels of blood pressure during a physician's examination but normal or lower levels part of the time corresponding to early stages of Perera's uncomplicated asymptomatic phase (392). Admission to hospital and frequent measurements by nurses combined with diagnostic procedures lower them to normal, often dramatically (400). Renal function is excellent and there are no findings suggestive of secondary damage. Emotional tension is present and continuous. Reserpine will effectively control about half of these cases in the remainder small doses of hydralazine (75 to 200 mg per day) may be necessary. We do not advocate the use of protoveratrine or available blocking agents in these individuals, for their irregularity and intermittency of action *may cause hypotensive symptoms*. A very long acting ganglionic blocking agent however should be effective.

*Stage II* comprises patients with elevated levels of blood pressure at all times except under heavy sedation (sodium amytal). It corresponds partly to Perera's symptomatic uncomplicated phase and partly to his complicated phase.

more theoretical benefits of dividing the dose or of using slowly absorbed increments such as are dispensed in some modern capsules than there is in dividing the dose of digitalis. It has been our practice to use 1.0 mg per day for 1 month reducing it then to 0.5 mg and further reducing it to 0.25 or 0.1 mg slowly if excessive sedation appeared. It is such a mild anti-hypertensive drug in most cases that it should not be depended upon if signs of cardiovascular damage are present. Its many side effects are listed in Chapter III, nasal congestion being the most prominent and paranoid depression with suicidal tendencies the most dangerous. This latter side effect places it among the agents indirectly hazardous to life; the self-satisfaction of a physician using it in severe and malignant stages who is afraid to employ more potent measures also makes it less directly hazardous. At the first sign of increasing nervousness, anxiety, insomnia, emotional tension and agitation it should be discontinued for agitated paranoid depression may develop (70-72). In our experience reserpine is not a very valuable agent for hypertension except as a curious kind of sedative with many side effects (Fig 24).

Reduction in dosage will often alleviate the usual depressive effects of the agent and may reduce the number of nightmares but nasal stuffiness can be most annoying. Epistaxis induced by the drug usually necessitates discontinuation. The time-tested sedatives are the only alternatives to replace reserpine if it cannot be used.


We have seen four patients whose severe hypertension was cured for several months in that all drugs but reserpine were slowly discontinued during 2 to 3 years. In one an ulcer developed in two inactive ulcers became active one having a massive hemorrhage and perforation into the pancreas requiring partial gastrectomy in the fourth




stages (a) early, in which hemorrhagic and exudative retinitis is present but not marked (Grade III to IV) and renal function is reduced but adequate, (b) severe, in which retinitis is advanced (Grade IV) and renal function is borderline, and (c) azotemic in which nitrogen retention has occurred. The diastolic pressure is usually 130 mm or more and fixed and albuminuria is usually present. Each sub stage carries a different prognosis, 3 year survivals of treated patients being roughly 100 per cent for (a), 80 per cent for (b) and 50 per cent for (c) without frank uremia. Ganglionic blockade plus adequate doses of hydralazine (500 to 1000 mg per day) are essential for reversal of the stage. In general control of hypertension is easier to achieve and is more even than with patients in Stage III, reduction of dosage is the rule after 12 to 18 months except in azotemic individuals. The systolic pressure can usually be maintained at or near former diastolic levels.

### SPECIFIC USE OF DRUGS

**Use of Reserpine** Reserpine is given in one dose a day usually at night (Fig 23). Since the effect of this drug is cumulative (although the drug itself is not), there are no



YOHIMBINE



RESERPINE

FIG 23 Chemical structures of Yohimbine and Reserpine according to Schlittler *et al* (442)

more theoretical benefits of dividing the dose or of using slowly absorbed increments such as are dispensed in some modern capsules than there is in dividing the dose of digitalis. It has been our practice to use 1.0 mg per day for 1 month reducing it then to 0.5 mg and further reducing it to 0.25 or 0.1 mg slowly if excessive sedation appeared. It is such a mild anti-hypertensive drug in most cases that it should not be depended upon if signs of cardiovascular damage are present. Its many side effects are listed in Chapter III, nasal congestion being the most prominent and paranoid depression with suicidal tendencies the most dangerous. This latter side effect places it among the agents indirectly hazardous to life; the self-satisfaction of a physician using it in severe and malignant stages who is afraid to employ more potent measures also makes it less directly hazardous. At the first sign of increasing nervousness, anxiety, insomnia, emotional tension and agitation it should be discontinued for agitated paranoid depression may develop (70-72). In our experience reserpine is not a very valuable agent for hypertension except as a curious kind of sedative with many side effects (Fig 24).


Reduction in dosage will often alleviate the usual depressive effects of the agent and may reduce the number of nightmares but nasal stuffiness can be most annoying. Epistaxis induced by the drug usually necessitates discontinuation. The time-tested sedatives are the only alternatives to replace reserpine if it cannot be used.

We have seen four patients whose severe hypertension was cured for several months in that all drugs but reserpine were slowly discontinued during 2 to 3 years. In one an ulcer developed in two inactive ulcers became active one having a massive hemorrhage and perforation into the pancreas requiring partial gastrectomy in the fourth


stages (a) early, in which hemorrhagic and exudative retinitis is present but not marked (Grade III to IV) and renal function is reduced but adequate, (b) severe, in which retinitis is advanced (Grade IV) and renal function is borderline, and (c) azotemic, in which nitrogen retention has occurred. The diastolic pressure is usually 130 mm or more and fixed and albuminuria is usually present. Each sub stage carries a different prognosis, 3 year survivals of treated patients being roughly 100 per cent for (a), 80 per cent for (b) and 50 per cent for (c) without frank uremia. Ganglionic blockade plus adequate doses of hydralazine (500 to 1000 mg per day) are essential for reversal of the stage. In general, control of hypertension is easier to achieve and is more even than with patients in Stage III, reduction of dosage is the rule after 12 to 18 months except in azotemic individuals. The systolic pressure can usually be maintained at or near former diastolic levels.

### SPECIFIC USE OF DRUGS

**Use of Reserpine** Reserpine is given in one dose a day, usually at night (Fig. 23). Since the effect of this drug is cumulative (although the drug itself is not) there are no



YOHIMBINE



RESERPINE

FIG. 23 Chemical structures of Yohimbine and Reserpine according to Schlittler *et al* (442)

serious mucous colitis and proctitis with ulceration and bleeding appeared and remained. Because reserpine produces relative parasympathetic overactivity it may be contraindicated in such individuals \* and complications such as these must be watched for.

**Use of Protoveratrine** One can begin this agent in doses of 0.2 mg three times a day increasing by 0.2 mg per dose until nausea or vomiting appears (395). The dose causing nausea is then reduced by 0.1 or 0.2 mg and the others gradually increased to the point of nausea. The emetic effect appears within an hour after the dose often sooner. Wide swings of blood pressure occur with a rise at night. This agent cannot be given effectively every 4 hours as tolerance soon develops only to disappear with a few hours rest. To be completely effective


---

These developments stimulate speculation. If psychosomatic influences are blocked in one somatic nervous pathway the sympathetic perhaps excessive outflow through the other the parasympathetic, has led to gastrointestinal disorders. The patient is determined to develop a psychosomatic disease when we do not allow him (or usually her) to have one kind he gets another. Reserpine may thus be an accessory etiologic agent.

---

been on treatment for 2 years with a fair response his pretreatment levels ranging between 200 and 250 systolic and 130 and 150 mm. Hg diastolic. Congestive heart failure had disappeared without drugs or dietary restrictions. Note the decreased intake of hexamethonium chloride required when reserpine was added the average level of blood pressure appeared to rise at end of the period. G.C. same in a 54-year-old man with severe aortic atherosclerosis who after 1 year achieved only a fair response from initial levels of 205 to 240 systolic and 120 to 140 mm. Hg diastolic. He preferred to maintain his blood pressure at levels higher than normal and to vary his dose of hydralazine his diastolic pressure was only slightly elevated. Note the reduction in average daily dosage of both agents without change in blood pressure when reserpine 10 mg a day was added. Control had been previously increased on two occasions by adequate doses (From Schroeder H. A. *Am J Med* 17:540 1954)

## DB 43. HYPERTENSION FOR SIX YEARS



CC #




FIG 24 Effect of added reserpine DB mean weekly blood pressure levels (each 35 measurements) and average daily doses of hydralazine (5968) and hexamethonium chloride ( $C_6$ ) as affected by reserpine (Serpasil) 10 mg per day in a patient with severe benign hypertension previously suffering from congestive heart failure. He had

to judge accurately the effective dose of a ganglionic blocking agent without knowing the level of blood pressure. It is most difficult to give increasing doses to maximal effect without overdosage unless the patient is under careful supervision of blood pressure and symptoms. Therefore it is our practice to begin ganglionic blockade by drugs in the hospital not only for convenience sake but also to achieve greatest benefit. We know of only one way to give oral ganglionic blocking agents effectively (Fig 26)

1 Blood pressure is measured by competent nurses every 4 hours day and night and charted

2 Initial dose is given every 4 hours if the blood pressure is above a chosen level usually 140 mm systolic. It is not given if the blood pressure is below that level. Slightly higher "omit" levels are used in the cases of atherosclerotic or azotemic patients: 150 to 170 mm Hg. Initial doses which are usually safe to give to patients with severe hypertension are: Hexamethonium chloride 125 mg, Pentolinium tartrate 20 mg, Chlorisondamine 10 mg, Mecamylamine 2.5 mg

3 If the desired normotension is not achieved, each dose is raised by increments amounting to the initial dose daily until 4 or 5 days have passed. Thus each dose given every 4 hours will be: Hexamethonium chloride 500 to 750 mg, Pentolinium tartrate 150 to 200 mg, Chlorisondamine 50 to 75 mg, Mecamylamine 15 to 20 mg. By this time intermittent normotension should have been achieved. (In order to change intermittency to more even control, hydralazine must be added at this point (Fig 27).) Each dip in systolic pressure gives the physician confidence in the lowest levels tolerable without cardiovascular accident.

4 Doses are then given on a sliding scale dependant on the level of blood pressure. If normotension is desired

protoveratrine must usually be supplemented by hydralazine (Fig 25)

**Use of Ganglionic Blocking Agents** It is impossible




FIG 25 Example of poor initial control of blood pressure by insufficient doses and excellent control later in a patient with malignant hypertension and renal insufficiency who also suffered from partial asymptomatic duodenal obstruction. Hypertension of 10 years duration had become severe and grade IV ocular fundi had developed. She had suffered a minor apoplectic stroke. Hexamethonium chloride induced intermittent subtotal obstruction and vomiting and was poorly tolerated after 2 months. After the initial excellent response a grade of only a fair response was achieved on large doses of hydralazine. 1 year later blood pressure slowly returned to control levels. The addition of protoveratrine caused a sharp decline to lower levels. The later addition of reserpine (serpasil) produced normotension. Each point represents the average of 150 measurements. Elevated nonprotein nitrogen in her blood of 40 mg per cent (Somogyi zinc method) had fallen to 16 mg per cent, an abnormal electrocardiogram had become normal and her ocular fundi had cleared. In our experience the effect of these two additional agents in severe stages is unusual. This case is illustrative of the point that control of hypertension is possible in almost all cases. (From Schroeder H. A. *Am J Med*, 17:540 1951)

to judge accurately the effective dose of a ganglionic blocking agent without knowing the level of blood pressure. It is most difficult to give increasing doses to maximal effect without overdosage unless the patient is under careful supervision of blood pressure and symptoms. Therefore it is our practice to begin ganglionic blockade by drugs in the hospital not only for convenience sake but also to achieve greatest benefit. We know of only one way to give oral ganglionic blocking agents effectively (Fig 26)

1 Blood pressure is measured by competent nurses every 4 hours day and night and charted


2 Initial dose is given every 4 hours if the blood pressure is above a chosen level usually 140 mm systolic. It is not given if the blood pressure is below that level. Slightly higher omit levels are used in the cases of atherosclerotic or azotemic patients 150 to 170 mm Hg. Initial doses which are usually safe to give to patients with severe hypertension are Hexamethonium chloride 125 mg, Pentolinium tartrate 20 mg, Chlorisondamine 10 mg, Mecamylamine 2.5 mg

3 If the desired normotension is not achieved each dose is raised by increments amounting to the initial dose daily until 4 or 5 days have passed. Thus each dose given every 4 hours will be Hexamethonium chloride 500 to 750 mg, Pentolinium tartrate 150 to 200 mg, Chlorisondamine 50 to 75 mg, Mecamylamine 15 to 20 mg. By this time intermittent normotension should have been achieved. (In order to change intermittency to more even control hydralazine must be added at this point (Fig 27)) Each dip in systolic pressure gives the physician confidence in the lowest levels tolerable without cardiovascular accident.

4 Doses are then given on a sliding scale dependant on the level of blood pressure. If normotension is desired



## H J ♂ 61 MALIGNANT HYPERTENSION.



## H O ♂ 60 MALIGNANT HYPERTENSION




FIG 26

the full dose is given if the systolic pressure is over 140 mm half the dose if between 140 and 130 mm one fourth the dose if 130 and 120 mm and none if 120 or below. Higher omit levels 10 mm apart are used in atherosclerotic and azotemic patients perhaps 150 140 and 130 or 160 150 and 140 depending upon where the diastolic pressure has settled or whether the azotemia has lessened or worsened. Measurements are then made with the patient seated in order to take advantage of some postural hypo-

## MB # 43 NEUROGENIC HYPERTENSION





FIG 26 Examples of adequate control of blood pressure by giving adequate doses of ganglionic blocking agents (hatched area pentolinium bitartrate  $C_9$ ) and hydralazine (solid black area 5968) In the case of H J in hospital control was poor at first until doses were raised sufficiently to achieve normotension. Each point represents the mean of six measurements Diastolic normotension was achieved. H O<sub>2</sub> Note increase in blocking agent required to maintain normotension in August. Hexamethonium chloride ( $C_8$ ) was used at first in hospital. M B Note automatically decreasing doses when blocking drug was given on a sliding scale Each point is mean of 35



## E D ♂ 48 SEVERE BENIGN HYPERTENSION




FIG 27 Examples of failure of control of hypertension by ganglionic blockade (pentolinium  $C_5$ ) alone E D Although normotension was achieved in hospital patient died of malignant hypertension in May 1955 Hydralazine should have been added to achieve control T P Hydralazine (5968) was discontinued because of late toxicity Although malignant hypertension was relieved and did not recur ganglionic blockade with hexamethonium chloride ( $C_6$ ) failed to maintain diastolic normotension High systolic pressures were necessary because of postural hypertension resulting from drug and surgical sympathectomy Each point is the mean of 150 measurements


tension Standing pressures are avoided The night dose is omitted leaving eight hours of uninterrupted sleep

5 Parasympatholysis should be treated A nightly laxative and magnesium citrate if the bowels have not moved by mid morning will usually promote a daily evacuation It is important to prevent distension of the intestines (404)

Precautionary measures against obstruction of a hollow viscus already partially obstructed should be taken Abdominal scars prostatic hypertrophy, frequent rhinitis are warning signs of possible trouble from this source They are usually less severe than the disease being treated When the drugs cannot be tolerated protoveratrine can be substituted with good results Surgical sympathectomy of course does not carry this hazard Prostatic obstruction may require surgery

Use of Hydralazine This drug is given almost always in conjunction with either ganglionic blockade (Fig 2) or another milder agent acting on nerves (423) Because of initial side reactions mainly attributable to its antihistaminase action which are lessened with nerve acting drugs it is begun at doses of 25 mg every 4 hours raised the dose to 50 75 and 100 mg every 4 hours on 3 successive days It is given with the blocking agent Thus 100 mg a day is the usual dose in severe hypertension Some have had to give as much as 10 Gm for short intervals These large doses may cause hydralazine disease in 10 per cent of patients after 6 months In general large doses are given for greater nephrogenic components the vasospasm smaller doses when the neurogenic component is large It is unreliable when used alone (189 3)

High fever aching and malaise appearing during the first few weeks of administration of hydralazine require discontinuation or marked reduction of dosage Fortunately such symptoms are usually



## E D # 48 SEVERE BENIGN HYPERTENSION.





FIG 27 Examples of failure of control of hypertension by ganglionic blockade (pentolinium  $C_5$ ) alone E D Although normotension was achieved in hospital patient died of malignant hypertension in May 1955 Hydralazine should have been added to achieve control T P Hydralazine (5968) was discontinued because of late toxicity Although malignant hypertension was relieved and did not recur ganglionic blockade with hexamethonium chloride ( $C_6$ ) failed to maintain diastolic normotension High systolic pressures were necessary because of postural hypertension resulting from drug and surgical sympathectomy Each point is the mean of 150 measurements

can be made worse (or relieved) by hydralazine. A compromise partial control of hypertension by neurogenically acting drugs plus perhaps restriction of dietary sodium may provide some measure of vascular safety which while not ideal may lengthen life. In our experience patients with *severe* hypertension are rarely intolerant to this agent when it is first given.

Hydralazine disease appearing after 6 to 24 months of ingestion of fairly large doses necessitates two courses. Stopping the offending agent entirely results in return of hypertension. In these patients the mortality rate from hypertensive causes is 10 per cent. Large doses of ganglionic and hypothalamic blocking agents with or without protoveratrine usually fail to control the hypertension adequately. Wide swings from high to low levels take place daily. This situation is about the most difficult to meet in therapy and we have no solution. Low salt diets or thiocyanate might be used. Sodium azide has been valueless (Fig 29). Closely related analogues of hydralazine have caused recurrences of the disease and chemically less related ones have been relatively worthless.

Hazards of severe restriction of dietary salt are well known. The nephrosclerotic kidney is a salt losing kidney to some extent and hyponatremia with renal failure (the low salt syndrome) can be induced by limiting the intake to a point less than obligatory urinary losses. Borderline renal function predisposes to this usually fatal condition (397-399) (Fig 30).

The second choice involves marked reduction of the dose and the possible addition of cortisone until symptoms subside. The disease resembles in part a phenomenon of depletion. By small doses blood pressure can be controlled although L.E. preparations may remain positive. The disease remains in a subclinical lupoid stage and



A.K. 49 SEVERE BENIGN HYPERTENSION.




FIG 28 Example of effect of pentapyrrolidinium bitartrate (hatched area) as compared with that of hexamethonium chloride in malignant hypertension quite resistant to the latter. Upper Curve: The patient suffered from Leriche's syndrome proven by previous operation which probably extended a year later to involve the right renal artery as shown by contrast aortograms. Each point is the average of six measurements made at four hour intervals during his hospital stay (Dec and Jan) and of five measurements as an out patient (a representative month Feb to March is shown). Large doses of hydralazine have been required. While the result can be considered only fair the patient worked full time on a railroad section gang without symptoms and his grade IV ocular fundi cleared. He died of uremia 2 years later. Lower Curve: Poor control of blood pressure in a patient taking adequate doses of hexamethonium chloride and insufficient doses of hydralazine after two years of good control. Each point is the average of 35 measurements. Pentapyrrolidinium bitartrate apparently altered a poor response into a good one. Such is not always the case.

creased the patient and his record are evaluated if relative normotension is not consistent and the fluctuations of pressure much less marked the dose of one or the other agent is adjusted upward until it is maintained. Maximal (but unusual) single doses of hydralazine can be as high as 200 mg of hexamethonium chloride 10 Gm of pentolinum bitartrate 300 mg or more of chlorisondamine 100 mg and of mecamylamine 20 mg.

Before discharge measurement of blood pressure with the patient seated causes the amount of ganglionic block





FIG. 29 Examples of hydralazine (collagen) disease with special reference to blood pressure and difficulty of achieving control without hydralazine (See also Fig 27) H D Control of systolic normotension was impossible by ganglionic blockade when hydralazine (596B) was stopped. Sodium azide ( $\text{NaN}_3$ ) had no demonstrable effect. I W Note strict normotension when hydralazine disease was once established. A sulfur containing pyridazine (13050) did not affect blood pressure nor did sodium azide W G represents the second choice that of continuing hydralazine in very much smaller doses. L-E cells appeared and disappeared several times in blood while this was done but normotension was maintained. Each point represents the mean of 35 or 150 measurements depending upon the time scale.



the patient's situation be potentially precarious. Discovery of a substitute for hydralazine which will not cause this phenomenon is the only solution to the problem (Fig 29).

**Combined Therapy with Ganglionic Blockade and Hydralazine** Hydralazine is given regardless of the level of blood pressure when the two agents are used together. It disappears rapidly from the blood. At the end of the four day period during which the dose was progressively in-

WG 54 SEVERE BENIGN HYPERTENSION



IW 93 MALIGNANT HYPERTENSION




FIG 29

→

ing agent automatically to adjust itself as postural effects occur. The usual result of omission of the night dose is a rise in the morning resting or basal pressure. The patient is taught to take his own blood pressure five times a day before each dose and record it on special charts. He is instructed on the actions of the drugs and their side effects. He leaves the hospital on the same schedule which was designed to prevent both hypertension and hypotension. By keeping a daily record trends can be observed which are invaluable for efficient therapy. In our clinic we examine a patient one month after discharge from hospital and then at 3 to 6-month intervals if he is doing well. Patients seldom complain of the inconvenience which takes about 15 minutes a day but they do object to the cost of the drugs.

**Treatment of Crises** In hypertensive crises (pulmonary edema, cerebral edema, toxemia of pregnancy) requiring parenteral administration, two lines 20 mm apart are drawn across the graphic chart at the level at which systolic pressure is to be maintained. After initial lowering of blood pressure by a small dose of a blocking agent, blood pressure is measured every hour and a subcutaneous injection of the full effective dose given if it is above the upper line, half the dose if between the lines, and none if below the bottom line. Changes in total dosage must be made often. The second day the two lines are drawn 20 mm lower. Thus a patient with encephalopathy (wet brain) may have his pressure reduced from 300 mm Hg to 220 to 200 mm the first day, 200 to 180 mm the second day, and 180 to 160 mm the third day. Usually oral medication becomes possible long before this time. The pressure must be reduced more drastically when there is pulmonary edema. We prefer parenteral ganglionic blocking agents to parenteral hydralazine because of their shorter




FIG 30 A woman aged 56 had rapidly progressive hypertensive vascular disease without retention of nitrogen but with diminution of renal function. When she was given a diet containing 0.5 Gm of salt (rice diet) oliguria developed 14 days later. This development was rapid and the patient complained of nervousness, apathy, loss of appetite and weakness. Her intake of fluids remained high in spite of the obvious overhydration which was developing. Plasma chlorides were low, as was sodium, and an attempt to reverse the oliguria by the use of intravenous hypertonic saline solution was to no avail. She died of uremia. (From Schroeder H. A. *J.A.M.A.*, 141:117, 1949)




FIG 31 Medication and vital signs during hospitalization of a 52 year-old white male with malignant hypertension and pre treatment azotemia. The upper bar graph indicates the daily dose of autonomic blocking agent. The open bars represent oral pentolinium tartrate (po  $C_5$ ). The cross hatched bars represent parenteral pentolinium tartrate (im  $C_5$ ) and the solid bars represent parenteral hexamethonium chloride (im  $C_6$ ). The potency of oral pentolinium tartrate approximates that of intramuscular hexamethonium chloride however the scale for intramuscular pentolinium tartrate has been expanded to allow for its greater effect. The lower bar graph indicates oral hydralazine intake per day. Daily blood pressure averages are shown each value being the mean of at least 6 and often as many as 24 readings taken with the patient in a sitting position. The stippled area to the left indicates the pre treatment range of blood pressure. The line graph at the bottom of the figure is a schematic representation of the vital signs. The solid line shows the temperature in degrees centigrade which was below 37.5 except for three bouts of pyrexia. The dotted line shows the pulse in beats per minute which was always below 80 except for two episodes of tachycardia. The figures indicate tachypnea with any daily average values above 30 breaths per minute being noted. The word failure denotes the three periods of cardiac decompensation. Note the very high doses necessary once escape has occurred. Patient died. (From Perry H. M. Jr., O'Neal R. M. and Thomas W. A., *Am J Med* in Press 1957.)

actions with less tendency to produce prolonged hypotension. In cerebral edema it may be necessary to avoid cerebral ischemia, as indicated by increasing coma by reducing cerebrospinal fluid pressure.

**Tolerance to the Action of Drugs** No tolerance seems to develop when both types of drugs are used correctly and continuously. On the other hand, tolerance is common when therapy is intermittent, an unexplained phenomenon. In the larger sense it resembles bacterial resistance to antibiotics given in less than therapeutic amounts.

One of the most difficult situations to meet is in the patient whose blood pressure has been lowered successfully, only to have the drugs discontinued because of undue alarm at side effects or the consequences of normotension (mental depression, malaise, lassitude, weakness). The hypertension which recurs immediately is much more resistant to therapy and requires much larger doses of drugs after a few days than it did initially, sometimes it seems impossible to treat (Fig. 31). We have encountered no resistance in fresh untreated cases; *the secret of successful therapy is continuous therapeutic pressure*. While we cannot account for this phenomenon, it is commonly observed and hazardous to the patient. Many lives have been lost by nervous and erratic therapy (Fig. 32).

**Changes Occurring with Time** If the dose of the ganglionic blocking agent automatically falls to negligible quantities (in 6 to 18 months) by reason of sustained normotension, the dose of hydralazine is then reduced to four times a day, three times a day, twice a day and finally halved at 2 to 6 month intervals. Reduction in dosage is made very slowly (Fig. 33). The amount of reserpine is halved in a month or two if drowsiness appears and then halved again until symptoms disappear (406).

**What to Do If a Patient Is Not Doing Well** The pa




FIG 31 Medication and vital signs during hospitalization of a 52 year-old white male with malignant hypertension and pre treatment azotemia. The upper bar graph indicates the daily dose of autonomic blocking agent. The open bars represent oral pentolinium tartrate (po  $C_2$ ). The cross-hatched bars represent parenteral pentolinium tartrate (im  $C_2$ ) and the solid bars represent parenteral hexamethonium chloride (im  $C_2$ ). The potency of oral pentolinium tartrate approximates that of intramuscular hexamethonium chloride however the scale for intramuscular pentolinium tartrate has been expanded to allow for its greater effect. The lower bar graph indicates oral hydralazine intake per day. Daily blood pressure averages are shown each value being the mean of at least 6 and often as many as 24 readings taken with the patient in a sitting position. The stippled area to the left indicates the pre treatment range of blood pressure. The line graph at the bottom of the figure is a schematic representation of the vital signs. The solid line shows the temperature in degrees centigrade which was below 37.5 except for three bouts of pyrexia. The dotted line shows the pulse in beats per minute which was always below 80 except for two episodes of tachycardia. The figures indicate tachypnea with any daily average values above 30 breaths per minute being noted. The word failure denotes the three periods of cardiac decompensation. Note the very high doses necessary once escape has occurred. Patient died. (From Perry H. M. Jr., O'Neal R. M. and Thomas W. A. *Am J Med* in Press 1957)




FIG 32 Example of logic of using both ganglionic blockade and hydralazine (5968). Neither drug was effective alone in large doses. Hexamethonium ( $C_6$ ), pentolinium ( $C_5$ ) or hydralazine failed to alter course of malignant hypertension until combined therapy was begun when relative normotension was achieved. These records were made in hospital and all readings are shown. Obviously in this azotemic patient (NPN 76) with heart failure death would have been the outcome had only one drug been used or had both been given in inadequate doses.

tients who do least well on combined therapy are usually men in the sixth decade with atherosclerosis, and not, as might be expected, those in malignant stages. Certain individuals, however, because of a too early reduction in dosage or because of a dosage schedule sufficient for the hospital but insufficient for the stresses of active living continually show hypertensive levels reaching as high as 180 or even 200 mm Hg systolic during one of the five measurements a day. Several choices are open: a) The dose of one agent is increased for a month. If not successful, the dose of the other agent is increased. b) Protoveratrine in amounts sufficient to cause nausea is begun. c) Dietary salt is re-

stricted moderately d) The patient is readmitted to the hospital and restabilized e) Pheochromocytoma is suspected in patients whose blood pressures fluctuate widely and cannot be controlled Reduction in dosage is not possible for those who keep themselves moderately hypertensive even after 3 years Those who do best are those who attain and maintain normotension (Fig 33) (406)

JC # 34




FIG 33 Blood pressure and oral medication for a 34 year-old white male with malignant stage of hypertension The range of pre treatment blood pressure is indicated by cross-hatching The bar graphs indicate the drug intake the open area representing hydralazine the dotted hexamethonium (C<sub>6</sub>) and the solid pentolinium (C<sub>5</sub>) Note that the scale is different for the two methonium compounds since the second is approximately five times more potent than the first. (From Perry H M Jr and Schroeder H A. *Circulation* 13 528 1956)



## RESULTS EXPECTED

Since this monograph is not primarily concerned with a report on the results of therapy, only a brief resume of what can be expected with adequate therapy can be given. The long term effects have been published (401-403 93 168 405 419). In general, those which could be predicted from an understanding of the disease occur, several unexpected and unpredicted effects appeared as well.

1 a) Heart failure due to left ventricular strain which accounts for over 50 per cent of the death rate is virtually

LM ♀ 47 MALIGNANT HYPERTENSION WITH HEART FAILURE FOR TWO YEARS




FIG 34 One of the first four patients to receive ganglionic blockade (hexamethonium  $C_6$ ) and hydralazine (5968). Severe left and moderate right sided heart failure disappeared in three days grade IV fundi regressed digitalis was discontinued and salt was added to her diet (in November 1951). She subsequently became sloppy in her habits omitted her drugs from time to time began to complain of dyspnea and hemorrhages reappeared in the ocular fundi. Hypertension was later controlled on larger doses of drugs and she remained symptom free. From being invalided, she has been able to work full time in her own restaurant for five years as long as she keeps her blood pressure down.

abolished this within a few days. Salt can be added to the diet in from 2 to 6 months time. Also in a few weeks digitalis can be eliminated (Fig 34). Only a rare individual continues to require digitalis and dietary restriction of salt. We presume that these patients suffer from myocardial fibrosis due to atherosclerosis. Heart failure with only a moderate hypertension and much coronary arterial disease however is only moderately affected.

1 b) Abnormal electrocardiographic patterns indicative of left ventricular strain revert to normal within several months. Patterns suggestive of left ventricular hypertrophy revert to normal in some but not in all cases. This may take 1 to 4 years. Enlarged hearts often but not always become smaller in roentgenograms. Time 1 to 5 years (406).

2 a) A few weeks after the start of therapy the progression of renal damage due to arteriolar nephrosclerosis is halted. Unpredicted was a gradual return of depressed renal function in many but not all cases. This occurs in from 1 to 4 years (405).

2 b) In from 1 to 6 weeks albuminuria diminishes or disappears. When caused by pre-existing organic renal disease it remains at lessened quantities.

2 c) In azotemic individuals nitrogen retention remains static or diminishes unless initial values are over about 60 mg per 100 ml of nonprotein nitrogen in the blood (Somogyi zinc precipitate corresponding to 75 to 90 mg per cent by the phosphotungstic acid precipitate method). Time weeks or months. In those with higher values azotemia usually but not always progresses to uremia rarely however we have seen relatively acute elevations to 130 to 160 mg per cent return to much lower levels. This may occur after 3 weeks or more (Fig 35 36).

2 d) Ocular fundi revert to normal. Hemorrhages are

**RESULTS EXPECTED**

Since this monograph is not primarily concerned with a report on the results of therapy only a brief resume of what can be expected with adequate therapy can be given. The long term effects have been published (401-403 '93, 168, 405-419). In general those which could be predicted from an understanding of the disease occur, several unexpected and unpredicted effects appeared as well.

1 a) Heart failure due to left ventricular strain, which accounts for over 50 per cent of the death rate, is virtually




FIG. 34 One of the first four patients to receive ganglionic blockade (hexamethonium C<sub>6</sub>) and hydralazine (5968). Severe left and moderate right sided heart failure disappeared in three days, grade IV fundi regressed, digitalis was discontinued and salt was added to her diet (in November 1951). She subsequently became sloppy in her habits, omitted her drugs from time to time, began to complain of dyspnea and hemorrhages reappeared in the ocular fundi. Hypertension was later controlled on larger doses of drugs and she remained symptom free. From being invalided she has been able to work full time in her own restaurant for five years as long as she keeps her blood pressure down.

D.M. #18. MALIGNANT HYPERTENSION WITH URICEMIA POLYCYSTIC KIDNEYS




FIG 36 Medication blood pressure and nitrogen retention during hospitalization. The solid bars represent oral hydralazine (5968). The cross hatched bars represent parenteral and the open bars oral hexamethonium chloride (C<sub>6</sub>). The parenteral dose has been multiplied by 10 in order partially to compensate for the much greater efficacy of this route of administration. Each of the points on the blood pressure curve is the average of at least six and initially as many as 24 determinations. All were made with the patient supine. Note that azotemia is shown in terms of blood urea nitrogen rather than total nonprotein nitrogen.

Except for life long enuresis this 18-year-old white male was entirely well until 3 days before he entered the hospital. His mother had died with polycystic kidneys. Pyrexia and malaise were the initial symptoms followed by lethargy, emesis, disorientation and coma. Physical examination revealed in addition papilledema, hemorrhagic retinitis, minimal cardiomegaly and a pre systolic gallop. Roentgenologic examination suggested polycystic kidneys and 3 plus albuminuria was found. After returning home the patient did very well. He was working when last seen in July 1955 at which time his physical examination including fundoscopic examination was normal. His urine contained no protein. His antihypertensive regimen called for a maximum dose of 750 mg oral hexamethonium chloride and a constant dose of 100 mg of hydralazine every four hours. His sitting blood pressure at home averaged 160/80 mm. Hg. (From Perry H. M. Jr and Schroeder H. A. *Circulation* 14:105, 1956.)




FIG 35 Medication blood pressure and nitrogen retention during hospitalization. The solid bars represent oral hydralazine. The open bars represent oral mecamylamine (Inversine Sharp & Dohme). Each of the points on blood pressure curve is the average of at least six and initially as many as 24 determinations. All were made with the patient supine. In addition to the medication shown 513 mg of intramuscular hexamethonium chloride were administered on November 22 without any effect on the blood pressure.

Except for probable pyelonephritis 10 years previously followed by the discovery of high blood pressure this 45 year-old Negro police man was essentially asymptomatic until 6 months before he entered Barnes Hospital. His initial complaints were progressive asthenia and increasingly frequent periods of syncope associated with vertigo and amblyopia. Urinary frequency and dyspnea appeared somewhat later finally nausea and vomiting became frequent. There was hemorrhagic retinitis with bilateral papilledema and cardiomegaly. Although cardiomegaly was present the lung fields were clear to percussion and auscultation and there was no edema. There was cylindruria and 3 plus albuminuria. Only 100 ml of blood contained 10 gm of hemoglobin. Both electrocardiograms and roentgenograms of the chest indicated left ventricular enlargement. The decrease in azotemia and blood pressure following the institution of oral mecamylamine and hydralazine therapy is indicated in the graph. This man was discharged from the hospital with a regular diet without digitalis and with no symptoms except amblyopia referable to his hypertension or to his therapy returning to work 3 weeks later (From Perry H M Jr and Schroeder H A. *Circulation* 14 105 1956).

absorbed in 2 to 6 weeks soft cotton wool exudates disappear in 1 to 4 weeks papilledema slowly regresses in 4 to 12 weeks and hard waxy exudates and scars shrink to nothing in 1 to 3 years

3 a) Atherosclerotic complications are less frequent In from 1 to 6 weeks angina pectoris usually disappears although rarely it becomes initially worse

3 b) The incidence of coronary occlusion appears somewhat lower (after 3 to 5 years) although this disease ac




FIG 37 Two directions of progress in azotemia and malignant hypertension Upper The condition of G. B. a 54 year-old man has been static or improving slowly and he has been able to return to full occupation Control of blood pressure has been deliberately only fair in order to avoid further azotemia which has varied from 48 to 79 mg per cent NPN (mean 59) Middle That of M. C. has remained fairly static or improved slightly weight and health have increased Lower That of L. T. a 48 year-old man improved at first but azotemia later rapidly progressed to death. Pyelonephritis was found at autopsy the kidneys together weighed 105 Gm.

## GB # 52 MALIGNANT HYPERTENSION





FIG 37

→

absorbed in 2 to 6 weeks soft cotton wool exudates disappear in 1 to 4 weeks papilledema slowly regresses in 4 to 12 weeks and hard waxy exudates and scars shrink to nothing in 1 to 3 years

3 a) Atherosclerotic complications are less frequent In from 1 to 6 weeks angina pectoris usually disappears although rarely it becomes initially worse

3 b) The incidence of coronary occlusion appears somewhat lower (after 3 to 5 years) although this disease ac




FIG 37 Two directions of progress in azotemia and malignant hypertension. Upper The condition of G. B., a 54-year-old man has been static or improving slowly and he has been able to return to full occupation. Control of blood pressure has been deliberately only fair in order to avoid further azotemia which has varied from 48 to 72 mg per cent NPN (mean 59). Middle That of M. C. has remained fairly static or improved slightly weight and health have increased. Lower That of L. T. a 48-year-old man improved at first but azotemia later rapidly progressed to death. Pyelonephritis was found at autopsy: the kidneys together weighed 100 Gm.



counts for a major part of the mortality in treated patients

3 c) In 3 to 5 years the incidence of cerebral hemorrhage is markedly lessened in those patients who have suffered one attack

3 d) Also in 3 to 5 years the incidence of cerebral thrombosis is considerably lowered, but by no means abolished

4 a) In patients for whom treatment is considered mandatory, continuation causes increased life expectancy while discontinuation results in early death (Fig 37)

4 b) When a patient has survived 6 months of therapy, his chances of surviving 5 years are excellent

**Surgery** This monograph is not the place to discuss the pros and cons of surgical sympathectomy an operation which has definitely altered the outcome and prolonged the life of many patients (420, 421) In our experience drugs faithfully taken and properly administered have been of considerably greater value than surgical sympathectomy for the following reasons 1 Cases too far advanced for surgery and unoperable cases with azotemia can often be salvaged 2 All patients can be treated regardless of the stage or degree of vascular damage 3 Failures after surgical sympathectomy can be salvaged when hypertension has recurred and become severe 4 The mortality rates of the most severe cases is considerably less than those following operation

In actual practice no patient should be denied the choice of drugs or surgical operation when hypertension is doing harm When a patient is unwilling or unable to take drugs regularly surgery should be urged in suitable cases We must remember however that surgical sympathectomy even the subtotal variety can never block as many nerves as does adequate ganglionic blockade Therefore, in cases resistant to ganglionic blockade surgical intervention can be expected to fail contrariwise cases re

sponding well to ganglionic blockade alone can be expected to respond to surgery even though the usual lumbodorsal sympathectomy only removes 50 to 60 per cent of the nerves. Operation therefore does not become the method of choice when medical measures fail for the opposite holds true i.e. drugs will work when surgery has failed. The one advantage of surgical over chemical sympathectomy is the lack of bother to the patient when the result is successful.

According to the data of White (421) when cardiovascular complications occur in hypertensive patients the mortality is high. Left ventricular weakness and failure cerebrovascular accidents angina pectoris and myocardial infarctions cause a 3 year mortality rate of 82 per cent and a 10 year mortality rate of 96 per cent with a mean survival time of 4.1 years. Surgical sympathectomy alters the 3 year rate to 24 per cent and the 10 year rate to 50 per cent with a mean survival time of 6.1 years for the deceased.

TABLE I

MORTALITY RATES AT FOUR YEARS OF PATIENTS SUBJECTED TO SURGICAL SYMPATHECTOMY USUAL MEDICAL MEASURES AND CHEMOTHERAPY (PER CENT)

Smithwick Group	Smithwick's Series (420) Age 38-47		White's Series (421) Age 30-60		Author's Series Age 34-76 Chemotherapy	
	Medical	Surgical	Medical	Surgical	Stopped	Continued
I	10	3			—	0
II	33	12			32	1
III	58	19	84	24	38	3
IV	87	52			100	20
Azotemia	(100)	†	(100)	†	100	45

\* Most patients were 40-60

† Not suitable for operation because of high operative mortality

patients. Chemotherapy properly maintained definitely decreases the mortality rate in 4 years to a point well below these figures (Table L)

Nephrectomy also can alter the course of hypertension when 1) unilateral renal disease is present 2) hypertension is early and not far advanced, and 3) the function of the opposite kidney is excellent. When the hypertension has produced arteriolar nephrosclerosis in the good kidney removal of the offending one will naturally not result in 'cure'. Cases favorable for nephrectomy are rare.\*

Bilateral adrenalectomy is indicated only in cases exhibiting evidences of adrenal cortical hyperfunction. Better diagnostic methods for overproduction of specific steroids may allow better selection for surgical therapy.

---

\* When any surgical operations are indicated patients long treated by drugs will usually respond by strict normotension without drugs for one to two weeks after which hypertension will recur. This phenomenon has also been seen after severe infections, gastro-enteritis and trauma. Apparently the ability of the peripheral vessels to respond to trauma is altered by these drugs for some days.

## Chapter IX

### A PRELIMINARY APPROACH TO THE TREATMENT OF ATHEROSCLEROSIS

OBVIOUSLY, control of a patient's hypertension will do no more than relieve cardiac strain prevent further nephrosclerosis prevent cerebral hemorrhage and relieve angina pectoris. Theoretically it will slow that part of the rate of progression of atherosclerosis which is dependant upon an elevated blood pressure. Since atherosclerosis is probably reversible (443) at least in so far as cholesterol-containing plaques are concerned (and possibly calcification (422)) treatment of the whole patient and his diseases becomes essential for prolongation of a life potentially shortened by cardiovascular damage. Therefore an outline of the method we have used is given here the method involves practical measures based on theoretical approaches of most promise. Since it is most difficult to measure alterations in this disorder for the better or worse until massive accidents occur only time will tell if the results are favorable.

The serial measurement of lipoprotein fractions in blood is a procedure confined to the larger specialized centers. Total plasma cholesterol however is readily measured in most hospital laboratories. Based upon the assumption that lowered plasma cholesterol will in part prevent deposition of esters in plaques one can attempt to lower these values by using some of the influences discussed in Chapter VII.

✓ The method is based upon three influences 1) removal of some trace-metals, 2) a diet low in animal fats but containing adequate vegetable fats, particularly linolenate, and 3) the provision of an adequate amount of pyridoxine. For it is the possible effect of these biochemically and metabolically interrelated substances which can contribute to the disease (446)

### METHOD

**I Diet** As discussed in Chapter VII, the most important factor in the development of atherosclerosis probably lies

TABLE LI

LIST OF FOODS TO BE AVOIDED AS HAVING A HIGH SATURATED  
LOW UNSATURATED FATTY ACID CONTENT (348)

<i>Food</i>	<i>Reason for Avoidance</i>
<i>Fats</i>	
Coconut	Short chain saturated
Margarine	Hydrogenated vegetable oils
Palm	Short chain saturated
Cocoa	Short chain saturated
Hydrogenated vegetable oils and frying fats	Long chain saturated
Lard tallow	Long chain saturated
Butter cream cheese whole milk	Short chain saturated
Hydrogenated peanut butter	Long chain saturated
<i>Proteins</i>	
Pork and pork products	Mainly saturated
Fat meats*	Mainly saturated
Sweetbreads	Not investigated
Domestic goose and duck	Fattened not investigated
Processed meats of all kinds	Contain much fat
Hamburgers	Contain much fat

**NOTE** The Pure Food and Drug Administration requires that all processed foods be labeled correctly. The labels should be read and those foods containing 'hydrogenated shortening' hydrogenated vegetable shortenings or pure meat products should be avoided.

\* The fat meats are beef rib roast, corned beef and tongue, lamb loin and shoulder and mutton.

in the kind of fat in the American and European diet. From 30 to 40 per cent of the caloric intake comes from fat mainly of animal origin. The purpose of the diet therefore is to restrict animal fat and hydrogenated vegetable oils and to provide an adequate intake of unsaturated vegetable fats containing linolenic acid. The basic rules are

- A No obvious fat of animal origin should be eaten. Modern methods of fattening cattle for slaughter make a saturated body fat.
- B No hydrogenated vegetable oils should be used since hydrogenation saturates an unsaturated fatty acid (Table LI).
- C Natural fat of vegetable origin containing the higher unsaturated fatty acids can be eaten in amounts as large as practicable since these contain the essential unsaturated fatty acids linolenic and linoleic.
- D In general reduce the fat content of the diet to about 20 per cent of the caloric intake.

The most available sources of essential fatty acids are in soy bean and corn oil with the following iodine numbers

	<i>Iodine No</i>	<i>Remarks</i>
Soy bean oil	130	Contains 11% linolenate
Corn oil	115	Contains 0.5% linolenate
Cottonseed oil	105	Contains no linolenate
Sesame oil	103	Contains no linolenate
Peanut oil	85	Atherogenic in animals

In order to obtain enough protein without animal fats the following are recommended

All kinds of fish and shellfish. Fish oils have a high iodine number.

Poultry and game avoiding the fat (except domestic goose and duck). Chicken fat is high in linoleate.

Lean beef lamb and veal. Most animal fat is low in

linoleate and linolenate There is fat in muscle fibres of cattle force fed on corn before slaughtering Legumes, such as peas, beans, lima beans soy beans and its products Their fats are largely unsaturated Skim milk and fat free buttermilk Butter cheese, cream and whole milk contain principally short-chain saturated fatty acids, butter raises plasma cholesterol

### Cereals

Some breads use hydrogenated vegetable oils for shortening

Eggs Yolks are fatty Fry or scramble in soy bean oil

Meat soups only if all fat is skimmed off at icebox temperature

Most canned soups contain butter, cream or fat

Salad dressings made of soy bean oil

All nuts, especially walnuts Seed oils contain unsaturated fatty acids

Curd cottage cheese and other fat free cheeses

The two vegetable oils should be used for shortening

Deep frying should be done only in corn or preferably soy bean oil

**II Vitamins** The second point of attack lies in the daily use of pyridoxine or pyridoxal, deficiency of which has caused the early lesions of atherosclerosis in animals and which is low in many processed foods About 5 to 10 mg per day is more than adequate

**III Trace Metals** Excessive amounts of certain trace metals in American human tissues may be concerned in cholesterol formation or the metabolism of fats One tablet, 0.5 Gm, of Calcium Versenate (EDTA) twice a day, or another similar compound, may chelate and remove these metals In some people, this substance alone will lower the cholesterol level in blood (Table LII)

Calcium If calcium deposits are demonstrable in blood

TABLE LII

CHANGE IN PLASMA CHOLESTEROL WITH ORAL EDTA (1.0 Gm /DAY)

Patient	Sex	Age	Control (mg %)	Chol (mg %)	Interval (weeks)	Major Diagnosis
W. H.	♂	54	293	-154	20	Angina pectoris
B. McD.	♂	54	275	-150	35	Peripheral vascular disease
I. S.	♀	70	276	-40	4	Arterial hypertension
E. B.	♂	61	253	-58	16	Coronary occlusion, convalescent
G. H.	♂	45	252	-36	25	Angina pectoris
G. S.	♀	49	237	-37	14	Arterial hypertension
E. S.	♂	77	225	-74	3	Arterial hypertension
E. S.	♂	43	210	+18	44	Angina pectoris
H. D.	♂	63	189	-49	8	Angina pectoris
R. S.	♂	54	177	-38	12	Angina pectoris
J. B.	♀	59	178	+14	4	Arterial hypertension
Mean			233	-55		

vessels and symptoms or signs are present the method of Clarke, Clarke and Mosher for removing metastatic calcium may be used (422). Trisodium EDTA, 5.0 Gm in 500 ml 5 per cent glucose solution is slowly infused intravenously over 2 to 6 hours. The patient is taught to slow the infusion at the appearance of unusual symptoms. Strangely enough hypocalcemic tetany does not appear under these precautions. Ionized calcium salts and calcium chelated to proteins and peptides at a weaker stability constant than 10.6 ( $\log K_2$  EDTA) are probably removed; the strongly chelated calcium in bone is probably not.

An injection is given daily for 5 days; 2 days are allowed for rest and the 5-day course repeated. After a month or more for evaluation of symptoms a second 5.0 Gm is administered.

### RESULTS EXPECTED

In Table LII are shown changes in blood cholesterol levels using calcium disodium ethylenediamine tetraacetate (Calcium Versenate) in doses of 1.0 Gm per day. In Table LIII are shown the changes produced by this agent.



TABLE LIII  
EFFECT OF REGIMEN ON PLASMA CHOLESTEROL (mg %)

Patient	Age Sex	Pre treatment		Range	2 Mo	4 Mo	Range After 3 Mo	No Samples	D agnosis and Remarks
		Mean	No Samples						
H Sch.	49 ♂	244	2	237	146	168	146-172	12	Normal
E Stu.	70 ♀	278	2	276	151	216	216-227	12	Atherosclerosis
C Cru	62 ♂	300	3	260	236	200	112-237	9	Hypertension
S Mat	61 ♀	240	2	207	146	198	190-234	6	Hypertension
K. Sch	59 ♂	217	4	200	120	141	117-154	8	Hypertension
G Nes.	45 ♂	234	4	213	178	180	159-197	7	Hypertension
D Blu	49 ♂	295	4	219	179	204	176-204	6	Hypertension
G Boa	55 ♂	272	4	233	155	137	137-272	6	Hypertension and Atherosclerosis
B McD	52 ♂	278	2	204	145	128	105-156	8	Peripheral Vascular Disease
C Grl	57 ♂	253	3	210	206	181	171-201	6	Hypertension and Leriche's Syndrome
A Han	60 ♀	207	3	174	168	171	171-200	5	Mild Hypertension
E Frl	69 ♀	231	2	217	128	185	161-196	3	Hypertension
E Shr	49 ♂	228	3	228	119	232	119-232	4	Angina Pectoris
M Bro	72 ♀	249	4	245	237	172	172 184	3	Atherosclerosis
L Bat	62 ♀	276	3	256	183	250	241-250	7	Atherosclerosis
R. She	55 ♂	300	5	162	121	131	114-140	8	Mild Hypertension
D L.L.	56 ♀	176	6	176	377	366	366-422	3	Xanthomatosis
A Bla.	48 ♂	624	6	481	216	287		4	Hypertension
G Hir	46 ♂	259	4	233	209	208	208-321	1	Angina Pectoris
R Ber	53 ♀	262	3	299	312	200		4	Hypercholesterolemia
Mean		323	2		279	208			
					181	200			
					258				

with diet and vitamin B<sub>6</sub> added. In general the cholesterol changes are downward although in some cases they are resistant to all three forms of therapy. Some depressed values did not rise when EDTA was discontinued an expected result if trace metals were being removed.

All patients with angina pectoris were relieved of attacks of pain either completely or partly in that they occurred less than once a month. No electrocardiographic changes in the direction of normal were observed. No signs of hepatocellular damage developed.

*Comment* While untried for periods long enough to evaluate these results on the disease there is little doubt that cholesterol values can become quite low by this form of treatment. Changes in the degree of atherosclerosis are difficult to measure but rough estimates of improvement in the disease can be estimated especially when it has advanced far enough to give local ischemic symptoms. In the coronary arteries relief of angina pectoris if it is real and not imaginary suggests resorption of plaques. In the aorta lessening of the widened pulse pressure suggests a return of aortic elasticity. In the legs relief of claudication indicates improvement in blood flow. In the cerebral area abolition of minor paraesthesias and paralytic episodes indicates reabsorption of plaques. Some changes may be expected in time except for a return of aortic elasticity.

Therefore if degenerative cardiovascular disease is to be treated as many predisposing parameters as possible must be altered favorably. Today these lie in blood pressure the health of vascular intima and the lipid esters of cholesterol.

## Chapter X

### SUMMARY AND INTERPRETATIONS

NATURE is not prodigal with biologic functions other than those for reproduction. Metabolic processes may have one or two alternate routes but Nature does not provide dozens of methods by which defenses of a single function are maintained, by which digestion and combustion of a single substance proceeds, or by which homeostasis is maintained. When an alternate pathway such as an anaerobic one, is substituted for an oxidation, malignant growth may result. It is proper, therefore to look at the many and complex mechanisms which Man in his erratic searchings has partly uncovered and try to unify them toward simplicity in an imitation of Nature. To do this we must depend upon evidence, in part factual and in part theoretical, delving into chemical causes.

**Psychosomatic** While the psyche may affect the soma, the reverse is also true. Realization that some areas of cerebral function may depend upon the valence of nitrogen in certain configurations, that one primary amine mediates one area of the brain and another can affect another and that the anatomic chemistry of phospholipids may influence healthy function, has opened up a wide field of investigation into the causes of mental derangements.

The psychic manifestations of arterial hypertension, when not due to organic cerebral vascular disease, are best explained by the effects of primary amines produced by intermittently or permanently ischemic kidneys. These

manifestations include emotional tension anxiety, excessive drive nervousness and the diencephalic blush The blush is induced by histamine and resembles that seen with excessive quantities of circulating serotonin tension nervousness anxiety result in some individuals from epinephrine isoamylamine tyramine and those synthetic or natural methylated analogues which inhibit cerebral monamine oxidase (ephedrine amphetamine etc.) thus preventing oxidative deamination of naturally occurring substances

From the huge amounts of tranquilizers sold the American public one might believe that chemically mediated nervous disorders were almost a national disorder That many individuals might be so affected could be inferred from the abnormal trace metal content of American tissues if one interfered with vanadium or monamine oxidase or there was deficiency of vanadium primary amines could be implicated as causes of a widespread cerebral disorder

**Hereditary** The ability to react to stress by vasospasm is an hereditary trait apparently transmitted as a Mendelian dominant

**Neurogenic** The sympathetic nervous system is over active most likely because of increased cortico-hypothalamic activity The posterior hypothalamus for which serotonin has a predilection is apparently stimulated more than is the anterior the chemical mediator of which is not known Cortico-hypothalamic activity is increased as a result of somatically formed primary amines Neurogenic vasospasm causes neurogenic renal ischemia

**Renal** Renal disturbances dependent upon ischemia produce humoral vasoconstrictor substances Trace metals both normal and abnormal are involved Two metabolic pathways may be considered

✓(I) Anatomic causes of ischemia usually depend upon intrarenal parenchymal disease, atherosclerotic narrowing of renal arteries, or arterial and arteriolar nephrosclerosis secondary to hypertension. When the ability to react to stress by vasospasm is combined in one individual with organic renal ischemia, hypertension becomes permanent. The first two renal disorders are anatomic accidents; the last is caused by hypertension.

Anatomic or intermittent functional ischemia produces enzymatic disturbances in the kidney. The expected biochemical alterations resulting are

- ✓A Reduction of oxidative deamination of amino acids capable of anaerobic decarboxylation. The results in the kidney
  - a) Less urinary ammonia formed per mol of bicarbonate (theoretical). Ammonia from glutamine however would continue to be formed anaerobically.
  - b) A change of pH in the cortex to the acid direction (found).
  - c) Substitution of sodium for ammonia in order to maintain acid base balance in tubule (theoretical but logically inferred).

The urinary results

- a) Urinary  $\text{NH}_3$ /acid ratio reduced (found)
- b) Acid urine (usually found)
- c) Sodium loss (found)

The expected remote results

- a) More primary amines in blood (found)
- b) Release of renin (found in acute states)
- c) Stimulation of the adrenal cortex to production of aldosterone in an attempt to prevent excessive sodium loss (found). Animals (and human beings) might therefore eat a little more salt in order to compensate (found in rats).

B Renin is released possibly because of the acidity secondary to the lessened formation of ammonia (renin is extracted from kidney only at acid pH) This postulate is unproven and not too sound but we have no better one Renin comes from the superficial areas of the cortex of the kidney which becomes markedly acid when the renal artery is constricted Adjustments take place with time—several weeks

### Result

- a) Hypertensin (angiotonin) is formed in blood at first through the physical release of renin (found)
- b) With time renin itself is no longer released into blood but continues to act *in situ* (not proven but renin disappears from blood) Perhaps renin is slowly modified into a somewhat different proteolytic enzyme
- c) Hypertensin I or its analogue formed in kidney is active on blood vessels becomes activated either 1) through decarboxylation leaving an active terminal  $\text{NH}_2$ , the decarboxylase being in blood and kidney or 2) through action of a specific peptidase splitting off one or two amino acids and leaving a terminal  $-\text{NH}_2$ . In this latter event the peptidase would necessarily be a manganous enzyme The second pathway is the more logical one as peptidases are known and peptide decarboxylases are not Ordinarily in the absence of renal ischemia the small amounts of renin released into the renal venous blood form hypertensin which is inactivated both in kidney and in blood In renal ischemia the shift of locus of catabolism of hypertensin is from kidney to peripheral vasculature (theoretical but monamine oxidase acts on both hypertensin and pherentasin both peptides and it probably occurs in smooth muscle of blood vessels)

- d) Pherentasin is actually human hypertensin II, the amino acid content of which could be expected to differ from that obtained from bovine, horse, or hog globulin (unproven but very likely)

✓ II Enzymatic disturbances somewhat different from those resulting from organic renal ischemia may be caused by the accumulation of abnormal trace metals, notably cadmium. Cadmium is a nephrotoxic substance. Mercury and cadmium are the only metals which can readily displace zinc on a specific chelate being in the same periodic group, having the same coordination number and making the same shaped complex. The expected results on renal acid base equilibrium

- A Inhibition of carbonic anhydrase by displacement of zinc (probable but not proven)

1 More acid in urine

2 More base needed to neutralize acid i.e. ammonia or sodium

- B Inhibition of decarboxylases by displacement of zinc on pyridoxal enzymes causing a local vitamin B<sub>6</sub> deficiency (one decarboxylase known to be inhibited. Zinc displacement logical but unproven)

1 Less decarboxylation of amino acids other than glutamine

2 Less primary amines formed

3 Less ammonia available for urine

4 Sodium wastage

- C Inhibition of transaminase a pyridoxal enzyme which probably contains a metal (unproven but possible)

1 Less transamination from glycine, aspartic, glutamic and other amino acids as a source of urinary ammonia (transamination not proven to be a source of urinary ammonia)

2 Sodium wastage

D Aminoaciduria (found) either because of process B or interference with tubular reabsorption by inhibition of a carrier metalloenzyme probably containing zinc

The net results would be cortical acidity less urinary ammonia and sodium wastage the same as those found in organic renal ischemia but appearing by somewhat different routes. Primary amines in blood, however would not be elevated (Fig 38)

(If cortical acidity is the stimulus for the action of renin hypertensin I would be formed *in situ* and released into renal venous blood where it would be converted to hypertensin II (pherentasin) by action of a specific manganous peptidase. Thus both organic renal ischemia and cadmium can cause the same end results. Naturally renal ischemia accompanying neurogenic or pherentasin vasoconstriction would call into action pathway I

Therefore trace metals can be involved in the hypothetical peptidase probably manganous which converts hypertensin I to hypertensin II in monamine oxidase which inactivates it in the decarboxylases and amine oxidases which are concerned in the hypertensive state and even in tyrosinase (copper) which can inactivate norepinephrine epinephrine hydroxytyramine and tyramine)

*Therapeutic Note* Drugs or procedures which block sympathetic nerve impulses will counteract only the neurogenic portion of hypertension. Drugs or procedures which a) act to dilate vascular smooth muscle b) increase renal plasma flow or c) inactivate hypertensin II or pherentasin will counteract the rephrogenic portion of hypertension. All known inactivators are metal binding or chelating agents /

The actions of hydralazine are fourfold /



- d) Pherentasin is actually human hypertensin II, the amino acid content of which could be expected to differ from that obtained from bovine horse, or hog globulin (unproven but very likely)

✓ II Enzymatic disturbances somewhat different from those resulting from organic renal ischemia may be caused by the accumulation of abnormal trace metals, notably cadmium. Cadmium is a nephrotoxic substance. Mercury and cadmium are the only metals which can readily displace zinc on a specific chelate being in the same periodic group, having the same coordination number and making the same shaped complex. The expected results on renal acid base equilibrium

- A Inhibition of carbonic anhydrase by displacement of zinc (probable but not proven)
  - 1 More acid in urine
  - 2 More base needed to neutralize acid, i.e., ammonia or sodium
- B Inhibition of decarboxylases by displacement of zinc on pyridoxal enzymes causing a local vitamin B<sub>6</sub> deficiency (one decarboxylase known to be inhibited. Zinc displacement logical but unproven)
  - 1 Less decarboxylation of amino acids other than glutamine
  - 2 Less primary amines formed
  - 3 Less ammonia available for urine
  - 4 Sodium wastage
- C Inhibition of transaminase a pyridoxal enzyme which probably contains a metal (unproven but possible)
  - 1 Less transamination from glycine, aspartic, glutamic and other amino acids as a source of urinary ammonia (transamination not proven to be a source of urinary ammonia)
  - 2 Sodium wastage

1 Decarboxylase inhibition with the result that renal amino acid metabolism is further suppressed and therefore less primary amine is formed

2 Monamine oxidase stimulation with the result that those primary amines which are formed are oxidized more readily These include pherentasin or hypertensin II

3 Hypertensin and pherentasin are both directly inactivated either through carbonyl linkage or what is more probable removal of a chelated trace metal necessary for the integrity of the peptides


4 Constricted vascular smooth muscle is dilated no matter what causes the constriction by some unknown process which could be dependent either upon carbonyl or sulfhydryl binding or upon metal chelation

In addition histaminase is inhibited a reaction common to many hydrazides

Adrenocortical Renal sodium wastage (or need as in heart failure) probably causes adrenal cortical production of aldosterone (theoretical but logical) This steroid probably sensitizes blood vessels to circulating vasoactive amines and sympathetic discharges through intracellular sodium potassium alterations (proven only for DOCA) Most cases of hypertension exhibit secondary aldosteronism because of renal sodium wastage

Primary aldosteronism by sensitizing vascular smooth muscle to normally circulating vasoactive amines and normal sympathetic tone can produce a moderate degree of hypertension with normal renal plasma flow Cases of this nature are not unusual This type of hypertension while benign can slowly develop into a more serious variety with congestive heart failure the usual end result

*Therapeutic Note* While dietary salt restriction may induce enough sodium loss to negate the sensitizing effect of cortical steroids and salt on blood vessels it stimulates



$\text{B}_6 = \text{Pyridoxal}$   
 $\text{Me}^{++} = \text{Metal}$

The reactions in italics have been demonstrated  
 shown for the sake of simplicity

FIG 38 Proposed intermediary metabolism in ischemic and cadmium loaded kidney

② Cholesterol has a predilection for making unsaturated fatty acid esters. When insufficient unsaturated fatty acids are available for esterification saturated fatty acids are used. These esters are quite insoluble and probably have lower specific gravities. Possibly breakdown metabolism or excretion of cholesterol is more easily accomplished when esters are unsaturated than when made of saturated long chain fatty acids.

These two ideas are highly speculative. The mechanism of lowering plasma cholesterol by essential fatty acids is not understood.

Factors which may influence the deposition of cholesterol esters in sub-intimal spaces are

C. Physical—Intra arterial pressure and changes of pressure (turbulence) at bifurcations of major vessels (Found)

D. Metabolic—Pyridoxal deficiency causes sub-intimal lesions identical microscopically to pre-atherosclerotic lesions observed in animals and man (Found)

a) Pyridoxal is necessary for the integrity of the mucopolysaccharides of sub-intimal ground substance (Inferred)

b) Pyridoxal affects fatty acid metabolism by promoting the synthesis of essential fatty acids from less unsaturated ones (Found)

c) Experimental pyridoxal deficiency and essential acid deficiency are quite similar in signs differing only in a few basic enzymatic disturbances (Found). Vitamin B<sub>6</sub> will partly relieve essential fatty acid deficiency; essential fatty acids will partly relieve vitamin B<sub>6</sub> deficiency.

The biochemical interrelationships of three of these influences are

1. Pyridoxal usually requires a metal for enzymatic activity. One abnormal metal (cadmium) can inhibit a pyridoxal metalloenzyme.

the adrenal zona glomerulosa to overactivity. The result is secondary hyperaldosteronism with salt depletion.

**Atherosclerosis** Treated hypertensive patients no longer die of heart failure or renal failure when treated soon enough. They die of the effects of atherosclerosis. In order to prolong life, both blood pressure and blood lipids must be reduced.

Factors which may affect cholesterol synthesis or degradation and therefore atherosclerosis are -

**A Trace Metals** 1) Chromium increases hepatic synthesis (in rats). Vanadium depresses hepatic synthesis. Manganese may be the normal metallic mediator of synthesis.

2) EDTA lowers cholesterol levels in man moderately or markedly, almost surely by chelation and removal of a metal from an hepatic enzyme concerned in synthesis or catabolism.

**B Essential Fatty Acids** Fats containing linolenic acid (and possibly arachidonic acid) lower plasma cholesterol in man even when given in excessive quantities. Fats not containing linolenic acid raise plasma cholesterol. The mechanisms are not known but two can be hypothesized.

1) **Squalene** is a probable precursor of cholesterol. Squalene ( $C_{30}H_{50}$ ) can be considered as a highly unsaturated  $C_{24}$  hydrocarbon chain with 6 extra methyl side groups and double bonds at the 2, 6, 10, 14, 18 and 22 positions or 4 carbon atoms apart. Linolenic acid ( $C_{18}$ ) has double bonds at 9, 12, 15 positions and arachidonic acid at 5, 8, 11, 14 positions or 3 carbon atoms apart. It would be impossible to use any combination of ethylene groups from these two acids in the structure of squalene. Degradation to acetate and subsequent synthesis would be required. No one knows much about this matter, except that squalene markedly accelerates synthesis of cholesterol.

application of therapy present and to come. Rapid improvements are expected.

① Reduce blood pressure of hypertensive patients to a mean level of 140/90 mm Hg (or as low as tolerable) and keep it there indefinitely. Two drugs are usually necessary given frequently, regularly and carefully; one should act on nerves and the other on vascular smooth muscle.

② Lower plasma cholesterol to 120 to 160 mg per 100 ml (or about the same levels in mg per cent as systolic pressure is in mm Hg!). This can be accomplished slowly in some individuals and soon will be in most by

a) Metal chelation probably removing from liver an abnormal trace metal affecting synthesis. Chelation and removal of metastatic calcium in blood vessels can probably be accomplished when desirable.

b) Diet based on Less total fat to about 20 per cent of caloric intake. Less animal fat especially saturated fatty acids. General dairy products and pork are avoided. Adequate linolenic acid (probably 0.5 Gm per day is enough) in oleic and arachidonic.

c) Enough pyridoxine or pyridoxal. Probably 5 mg per day is more than adequate. This coenzyme is given for logical but untested reasons.

It is a long step from a lowered cholesterol to absorption of plaques but the assumption is reasonable.

There are enough ideas now under experimental observation to strengthen the belief that atherosclerosis is a reversible disease at least in so far as the fatty and calcific deposits are concerned. Arterial hypertension in man can be controlled indefinitely and sometimes reversed. Application of therapy to both diseases in the same individual may be expected to reverse in part the lethal and disabling effects of each.

2 Pyridoxal affects unsaturated acid synthesis by promoting further desaturation to essential fatty acids (linoleic to arachidonic linolenic to hexaenoic)

3 Pyridoxal lowers plasma cholesterol in monkeys deficient of this coenzyme and fed cholesterol ✓

4 Metals affect synthesis of cholesterol and fatty acids

5 Removal of unknown metals lowers plasma cholesterol in man

6 Feeding essential fatty acids lowers plasma cholesterol in man

An hypothetical schema to include these influences is seen in Figure 39




FIG 39 Hypothetical interactions of metals essential fatty acids and pyridoxal

**Therapeutic Note** Thus it would appear that therapeutic tools are now available to control or treat cardiovascular renal diseases quite specifically. While these tools represent first approximations, they are powerful enough and practical enough to be effective in any individual who wants to be treated and is willing to give the time and energy to do so. Since cardiovascular renal diseases account for over half the American death rate, considerable increase in our national longevity can be expected from wide

application of therapy present and to come Rapid improvements are expected

(1) Reduce blood pressure of hypertensive patients to a mean level of 140/90 mm Hg (or as low as tolerable) and keep it there indefinitely Two drugs are usually necessary given frequently regularly and carefully one should act on nerves and the other on vascular smooth muscle

(2) Lower plasma cholesterol to 120 to 160 mg per 100 ml. (or about the same levels in mg per cent as systolic pressure is in mm Hg!) This can be accomplished slowly in some individuals and soon will be in most by

a) Metal chelation probably removing from liver an abnormal trace metal affecting synthesis Chelation and removal of metastatic calcium in blood vessels can probably be accomplished when desirable

b) Diet based on Less total fat to about 20 per cent of caloric intake Less animal fat especially saturated fatty acids General dairy products and pork are avoided Adequate linolenic acid (probably 0.5 Gm per day is enough) linoleic and arachidonic

c) Enough pyridoxine or pyridoxal Probably 5 mg per day is more than adequate This coenzyme is given for logical but untested reasons

It is a long step from a lowered cholesterol to absorption of plaques but the assumption is reasonable

There are enough ideas now under experimental observation to strengthen the belief that atherosclerosis is a reversible disease at least in so far as the fatty and calcific deposits are concerned Arterial hypertension in man can be controlled indefinitely and sometimes reversed Application of therapy to both diseases in the same individual may be expected to reverse in part the lethal and disabling effects of each



This book has attempted to give an orientation from biochemical abnormalities to clinical findings and specific therapy as the only satisfactory way to explain a disease and its control. As usual in scientific medicine, much more needs to be known than is known but the directions for research are clear.

# BIBLIOGRAPHY

- 1 SCHROEDER, H. A. The evidence that essential hypertension is not a single disease entity in *A Symposium on Essential Hypertension* Boston Commonwealth of Massachusetts 1951 pp 123-156
- 1b SCHROEDER, H. A. Generalized vasospasm and arterial hypertension in *Signs and Symptoms* 3rd Ed. edited by C. M. MacBryde Philadelphia Lippincott 1957
- 1c. SCHROEDER, H. A. Arterial hypertension. Veterans Administration Technical Bulletin TB 10-59 November 1949
- 2 MORITZ A. R., AND OLDT M. R., Arteriolar sclerosis in hypertensive and nonhypertensive individuals *Am J Path* 13:69 1937
- 3 SCHROEDER, H. A. AND DAVIES D. F. Studies on essential hypertension V An endocrine hypertensive syndrome. *Ann Int Med* 40:516 1954
- 3b SCHROEDER, H. A., DAVIES, D. F. AND CLARK H. E. A syndrome of hypertension obesity menstrual irregularities and evidence of adrenal cortical hyperfunction. *J Lab & Clin Med* 34:1746 1949
- 3c. DAVIES D. F. AND CLARK, H. E. A hypertensive syndrome with relative adrenal cortical overactivity *Circulation* 2:481 1950
- 4 SCHROEDER, H. A. *Hypertensive Diseases—Causes and Control* Philadelphia Lea & Febiger 1955
- 5 PERRY H. M. JR., O'NEAL, R. M., AND THOMAS W. A.. Pulmonary disease following chronic chemical ganglionic blockade A clinical and pathologic study *Am. J Med* 22:37 1957
- 6 GOLDBLATT H. *The Renal Origin of Hypertension* Springfield Thomas 1948
- 7 DAMMIN G. J. GOLDMAN M. L., SCHROEDER, H. A., AND PACE M. G. Arterial hypertension in dogs II The effects of neurogenic hypertension with a study of periodic renal biopsies over a seven year period *Lab Investigation* 3:72 1956
- 7b GOLDMAN M. L., SCHROEDER, H. A. AND DAMMIN G. J. Renal changes in experimental hypertension. *Am J Med* 14:751 1953
- 7c. DAMMIN G. J., GOLDMAN M. L., SCHROEDER H. A., AND PACE M. G. The effects of prolonged experimental hypertension in the dog with a study of periodic renal biopsies over a seven year period *Am J Path* 31:587 1955
- 8 SNAPPER, I. *Chinese Lessons to Western Medicine* New York, Interscience 1941
- 9 WILLIAMS A. H. AND SCHROEDER, H. A. The systolic arterial pressure gradient as a measure of local peripheral resistance. *Am J Physiol* 154:132 1918

- 10 WILLIAMS A H AND SCHROEDER H A Regional vasomotor tone in normotensive and hypertensive dogs *Circulation* 4706 1951
- 11 COMENS P AND SCHROEDER H A Brachial systolic arterial pressure gradient in man *Am J Physiol* in press 1957
- 12 CHILP C G Observations on the pathological changes following experimental hypertension produced by constriction of the renal artery *J Exper Med*, 67 521 1938
- 13 HOPKINS E L JASON R S AND HAWTHORNE E W Effect of arterial pressure level on site of development of arteriolar necrosis in dogs with malignant hypertension *Federation Proc* 1596 1956
- 14 WINTERITZ M C MYLON E., WATERS L. L. AND KATZENSTEIN R Studies on the relation of the kidney to cardiovascular disease *Yale J Biol & Med* 12623 1910
- 15 LEVY R L HILLMAN C. C STROUD W D AND WHITE P D Transient hypertension Its significance in terms of later development of sustained hypertension and cardiovascular renal disease *J.A.M.A.*, 126 829 1944
- 16 LEVY R L WHITE P D STROUD W D AND HILLMAN C C Transient tachycardia Prognostic significance alone and in association with transient hypertension *J.A.M.A* 129 585 1945
- 17 LEVY R L WHITE P D STROUD W D AND HILLMAN C C Transient hypertension The relative prognostic importance of various systolic and diastolic levels. *J.A.M.A* 153 1059 1945
- 18 LEVY R L. WHITE P D., STROUD W D AND HILLMAN C. C. Overweight Its prognostic significance in relation to hypertension and cardiovascular renal disease *J.A.M.A* 131951 1946
- 19 HINES E. A JR Range of normal blood pressure and subsequent development of hypertension A follow up study of 1,322 patients *J.A.M.A* 115271 1940
- 20 HINES E. A JR The significance of vascular hyperreaction as measured by the cold pressor tests *Am Heart J* 19 408 1940
- 21 SCHROEDER H A AND GOLDMAN M L Arterial hypertension in dogs I Methods *Circulation* 5 730 1952
- 22 ZONDEK S G Inhibiting influence of essential hypertension on malignant growth and rheumatoid arthritis *Acta med Scandinav* 152231 1955
- 23 HINES E. A JR Hereditary factor and subsequent development of hypertension *Proc Staff Meet Mayo Clin* 15 145 1940
- 24 PICKERING G W *High Blood Pressure* New York Grune & Stratton 1955
- 25 THOMAS C B., AND HIRSCHHORN B The familial occurrence of hypertension and coronary artery disease with observations concerning obesity and diabetes *Ann Int Med* 4290 1955
- 26 GRESSEL G C SHOBE, F O., SASLOW G DuBois P H AND

- SCHROEDER H. A.. Personality factors in arterial hypertension  
*J.A.M.A.* 140:265 1949
- 27 BOGGE, C. A. ACKERMAN N. W., COHN A. E., SCHROEDER, H. A.,  
AND STEELE, J. M.. *Personality in Arterial Hypertension* (Psychosomatic Medicine Monographs) New York, Robert Brunner 1913
- 28 PICKERING C. W.. The genetic factor in essential hypertension *Ann  
Int Med* 43:457 1955
- 29 SCHROEDER H. A. "Essential" hypertension A concept of its  
Mechanism *Am J M Sc* 204:734 1942
- 30 SCHROEDER H. A.. The pathogenesis of hypertension *Am J Med*  
10:189 1951
- 31 SCHROEDER H. A., AND STEELE J. M. Studies on "essential" hyper-  
tension I. Classification *Arch Int Med* 64:927 1959
- 32 BAYS, R. P., AND SCRIMSHAW N. S. Facts and fallacies regarding the  
blood pressure of different regional and racial groups. *Circulation*  
8:655 1953
- 33 WILLIAMS, A. W.. Heart disease in the native population of Uganda.  
Part IV Hypertensive heart disease *East African M J*, 21:328  
1944
- 34 COHEN B. M. Arterial hypertension among Indians of the south  
western United States *Am J M Sc*, 225:505 1953
- 35 WILLIAMS, A. W. BALL, J. D. AND DAVIES J. N. P. Endomyocardial  
fibrosis in Africa Its diagnosis distribution and nature *Tr Roy  
Soc Trop Med & Hyg* 48:290 1954
- 36 JANeway T. C. *The Clinical Study of Blood Pressure* New York  
Appleton 1904
- 37 SCHROEDER, H. A., AND MENHARD E. M. Spontaneous variations of  
blood pressure in hypertensive and normotensive individuals  
*Am Heart J*, 51:577 1956
- 38 RAAB W. *Hormonal and Neurogenic Cardiovascular Disorders*  
Baltimore Williams & Wilkins 1953
- 39 GUNTER, R., SILVERSTONE F., AND UNGERLEIDER, H. E. Range of blood  
pressure in hypertension. *J.A.M.A.* 130:32, 1946
- 40 SMITHWICK, R. H., AND ROBERTSON C. W. The phenomenon of  
hyperactivity Definition *Angiology* 2:143 1951
- 41 REISER, M., AND FERRIS E. B. JR. The nature of the cold pressor  
test and its significance in relation to neurogenic and humoral  
mechanisms in hypertension *J Clin Investigation* 27:156 1948
- 42 HED W. R. *Die Regulierung des Blutkreislaufs* Leipzig G. Thieme  
1930
- 43 HEYMAN, C., NOWAK J. G., AND SAMAN, A. Sur l'action vasomo-  
trice réflexe centrale et périphérique de l'acide carbonique de  
l'hyperoxémie et de l'asphyxie *Compt rend Soc biol Paris* 117:248  
1934.

- 44 GELLHORN E AND LAMBERT E H *The Vasomotor System in Anoxia and Asphyxia* Urbana Ill Univ Illinois Press 1939
- 45 LYONS R H MOE G K NELICH R B HOOBLE S W CAMPBELL, K N BERRY, R L AND RENNICK B R The effects of blockade of the autonomic ganglia in man with tetraethylammonium *Am J M Sc* 213 315 1947
- 46 FREEMAN N E AND JEFFERS W J Effect of progressive sympathectomy on hypertension produced by increased intracranial pressure *Am J Physiol* 128 662 1940
- 47 DIXON W E AND HELLER H Experimentelle Hypertonie durch Erhöhung des intrakraniellen Druckes *Arch exper Path u Pharmacol* 166 265 1932
- 48 NOWAK J G AND WALKER J J Experimental studies concerning the nature of hypertension *New England J Med* 220 269 1939
- 49 FISHBACK H R DUTRA F P AND MACCAMY E T Production of chronic hypertension in dogs by progressive ligation of arteries supplying the head *J Lab & Clin Med* 28 1187 1943
- 50 TAYLOR R D AND PAGE I H Production of prolonged arterial hypertension in dogs by chronic stimulation of the nervous system *Circulation* 3 551 1951
- 51 VON EULER U S AND HELLNER S Excretion of noradrenaline and hydroxytyramine in urine *Acta physiol scandinav* 22 161 1951
- 51b VON EULER U S HELLNER S AND PURKHOLD A Excretion of noradrenaline adrenaline in urine in hypertension *Scandinav J Clin & Lab Invest* 6 54 1954
- 52 DOYLE A E AND SMIRK F H The neurogenic component in hypertension *Circulation* 12 543 1955
- 53 STARLING E H The physiologic factors in hyperpiesia *Brit M J* II 1163 1925
- 54 FARRIS E J YEAKEL E H AND MEDOFF H S Development of hypertension in emotional gray Norway rats after air blasting *Am J Physiol* 144 331 1945
- 55 WALTER C W AND PIJOAN M J Persistent hypertension due to hypothalamic injury *Surgery* 1 282 1937
- 56 MCLEAN P D FLYNN J P AND KIM C Experiments Bearing on the Role of Limbic System in Cardiovascular Function Condition ing and Reserpine Studies *Proc Council For High Blood Pressure Research* Am Heart A New York 1955
- 56b BROCA P Anatomie Comparée des Circonvolutions Cérébrales Le grand lobe limbique et la scissure limbique dans la Série de Membrées *Rev Anthropol* Ser 2 1 395 498 1878
- 56c RAAB W Central vasomotor irritability (contribution to the problem of essential hypertension) *Arch Int Med* 47 727 1931
- 56d BAILEY P AND SWEET W H Effects on respiration blood pressure

- and gastric motility of stimulation of orbital surface of frontal lobe *J Neurophysiol.*, 3:76 1940
- 56c. POOL, J L. The visceral brain of man. *J Neurosurg.*, 11:45 1954
57. MANN P J G AND QUASTEL, J H.. Benzedrine ( $\beta$  phenylisopropyl amide) and brain metabolism. *Biochem J.*, 34:314 1940
58. FELLOWS E. J., AND BERNHEIM F. The effect of a number of aralkylamines on the oxidation of tyramine by amine oxidase. *J Pharmacol & Exper Therap* 100:94 1950
59. TOMAN J E. P., AND DAVIS J P. The effects of drugs upon the electrical activity of the brain *Pharmacol Rev.*, 1:425 1949
60. BRODIE, B. B., FLETCHER A., AND SHORE, P. A. Evidence that serotonin has a role in brain function *Science* 127:968 1955
- 60b. UDENFRIEND S., WEISSBACH H., AND BOGDANSKI D F.. Biochemical findings relating to serotonin action. *Ann New York Acad Sc.*, 66 Art 3 1956
61. SJOERDSTMA A. WEISSBACH H. AND UDENFRIEND S. A clinical physiologic and biochemical study of patients with malignant carcinoid (argentaffinoma) *Am J Med.*, 20:570 1956
62. SCHROEDER H A., AND GOLDMAN M L.. A test for the presence of the hypertensive diencephalic syndrome using histamine. *Am J Med* 6:167 1949
63. PAGE, I H. Serotonin (*o*-hydroxytryptamine) *Physiol Rev.*, 34:363 1954
64. BORDLEY J III. AND BAKER, B M. JR. A consideration of arteriosclerosis of the cerebral vessels and the pathogenesis of hypertension *Bull Johns Hopkins Hosp* 39:229 1926
65. FLETCHER A. SHORE, P A AND BRODIE, B B. Serotonin release as a possible mechanism of reserpine action. *Science* 122:374 1955
- 65b. SHORE, P A. Role of brain serotonin in reserpine action. *Ann New York Acad Sc* 66 Art 3 1956
66. SHORE, P A. SILVER, S L., AND BRODIE B B.. Interaction of reserpine serotonin and lysergic acid diethylamide in brain *Science* 122:284 1955
67. SELLING L. S. AND SELLING P H. Clinical study of a new tranquilizing drug *J.A.M.A* 157 1594 1955
68. WEISKRANTZ L., AND WILSON W A., JR. The effects of reserpine on emotional behavior of normal and brain-operated monkeys *Ann New York Acad Sc.*, 61:76 1955
69. SCHROEDER, H A. Hypertensive vascular disease. Therapy with modern drugs and its limits *J Chronic Dis* 1:497 1955
70. SCHROEDER, H A., AND FERRY H M. JR. Psychosis apparently produced by reserpine. *J.A.M.A* 159:839 1955
- 70b. MILLER, J C. FAYOR, W W., GIBBONS J E., AND ORGAIN E. S.

- Depression and anxiety occurring during rauwolfia therapy *J.A.M.A.* 159 836 1955
- 70c. ACHOR R W P HANSON N O AND GIFFORD R W JR Hypertension treated with rauwolfia serpentina (whole root) and with reserpine *J.A.M.A.* 159 841 1955
- 71 CLARK C T WEISSBACH H AND UDNENFRIEND S 5 hydroxytryptophan decarboxylase Preparation and properties *J Biol Chem*, 210 139 1954
- 72 BEILER J M AND MARTIN G J Inhibition of 5 hydroxytryptophan decarboxylase *J Biol Chem* 211 39 1954
- 72b BUXTON J AND SINCLAIR, H M Pyridoxal phosphate as a coenzyme of 5 hydroxytryptophan decarboxylase *Biochem J* 62 27 1956
- 73 BEADITT E P AND ROWLEY D A Antagonism of 5 hydroxytryptamine by chlorpromazine *Science* 123 24 1956
- 74 ZELLER W W., GRAFFAGNINO P N CULLEN C F AND RIETMAN H H Use of chlorpromazine and reserpine in the treatment of emotional disorders *J.A.M.A.*, 160 179 1956
- 75 BORRIS J C Study of effect of miltown (2 methyl 2 n propyl 1,3 propanediol dicarbamate) on psychiatric states *J.A.M.A.* 157 1596 1955
- 76 HEYMANS C. Experimental arterial hypertension *New England J Med* 219 154 1938
- 77 VOLHARD F (a) Über die Pathogenese des roten (essentiellen) arteriellen Hochdruckes und der malignen Sklerose *Schweiz. med Wchnschr* 78 1189 1948 (b) On the pathogenesis of red (essential) arterial hypertension and of malignant nephrosclerosis *Stanford M Bull*, 6 13 1948
- 78 ABREU B E. RICHARDS A B ALEXANDER W M AND WEAVER L C. Cardiovascular and emetic properties of veratrum alkaloids *Federation Proc* 12 297 1953 13 397 1954
- 78b SCHNEIDER J A Central Action of Anti Hypertensive Drugs *Proc. Council For High Blood Pressure Research Am Heart A New York* 1955
- 79 MEILMAN E AND KRAVER O Clinical studies on veratrum alkaloids *Circulation* 6 212 1952
- 79b MEILMAN E AND KRAVER O Clinical studies on the pure veratrum alkaloids protoveratrine and veratridine *J Clin Investigation* 28 798 1949
- 79c. DAWES G S Studies on veratrum alkaloids VII Receptor areas in the coronary arteries and elsewhere as revealed by the use of veratridine *J Pharmacol & Exper Therap* 89 325 1947
- 80 HOOBLER S W., CORLEY R. W KATZA T G AND LOYKE, H F Treatment of hypertension with oral protoveratrine *Ann Int Med.*, 37 465 1952

- 81 McCUBRY J W., GREEN J H., AND PAGE, I H.. Baroreceptor function in chronic renal hypertension *Circulation Res.*, 4:205 1956
- 82 OGDEN E. The relation of the nervous system to acute and chronic experimental hypertension in *Factors Regulating Blood Pressure Transactions of the First Conference* ed by Zweifach B W., and SHOTT E., New York Macy 1947 p 12.
- 83 ZAWOISKI E. J BAKER J E., BRUANSCHWIG L. W., PATLSON S F., AND SHERMER, A.. Gastrointestinal secretion and absorption of 3 methyl aminoisocamphane hydrochloride (mecamylamine) *Federation Proc* 15:205 1956
- 84 GOODMAN L. S. AND GILMAN A. *The Pharmacological Basis of Therapeutics* 2nd Ed New York, Macmillan, 1955
- 85 FURCHGOTT R. F., AND BHADRAKUM S. Reactions of strips of rabbit aorta to epinephrine isopropylarterenol sodium nitrate and other drugs *J Pharmacol & Exper Therap* 103:129 1953
- 85b FURCHGOTT R. F. The pharmacology of vascular smooth muscle *Pharmacol Rev* 7:183 1955
- 86 RING R. J. AND ZUCKER, M. B. Renal hypertension produced by amino acid. *J Exper Med.*, 74:235 1941
- 87 HOLTE P. CRONVET K. AND WALTER, H. Über die Spezifität der Aminosäuredecarboxylasen. *Ztschr physiol Chem.*, 262:111 1959
- 88 BLASCHO H., RICHTER, D., AND SCHLOSSMANN H. The oxidation of adrenalin and other amines *Biochem J* 31:2187 1937
- 89 KOHN H. I. Tyramine oxidase *Biochem J* 31:1693 1937
- 90 STOCK C. C., AND SCHROEDER, H. A.. Pressor substances in arterial hypertension. Activity and amine content of crude extracts of blood. *Am J Physiol* 160:409 1950
- 91 SCHROEDER H. A. AND OLSEN N. S. Pressor substances in arterial hypertension II. Demonstration of pherentiasin a vasoactive material procured from blood *J Exper Med* 92:545 1950
- 92 COUNCIL ON PHARMACY AND CHEMISTRY. Blood dyscrasias associated with chlorpromazine therapy *JAMA* 160:287 1956
- 93 MORROW J. D., SCHROEDER, H. A., AND PERRY H. M., JR. Studies on the control of hypertension by Hyphex. II. Toxic reactions and side effects *Circulation* 8:829 1953
- 94 MORRISON B. Parenteral hexamethonium in hypertension. *Brit M J* 1:1291 1953
- 95 BALST A. A. AND FERRIS F. B. Varying patterns of blood pressure response to autonomic blockade. Implications concerning the interplay of neurogenic and humoral factors in control of vascular tone. *Proc. Annual Meeting Council For High Blood Pressure Research, Am Heart A.*, Nov 1955
- 96 OLSEN N. S., AND SCHROEDER, H. A.. Oxygen tension and pH of the



- renal cortex in acute ischemia and chronic hypertension. *Am J Physiol*, 163 181 1950
- 97 SCHROEDER H A AND STEELE J M The behavior of renal blood flow after partial constriction of the renal artery *J Exper Med* 72:707 1940
- 98 CANNON W B AND ROSENBLUTH A *The Supersensitivity of Degenerated Structures* (Experimental Biology Monographs) New York Macmillan 1949
- 99 BRAUN MENÉNDEZ E FASCILOLO J C LELOIR L F AND MUÑOZ J M The substance causing renal hypertension *J Physiol* 98 283 1940
- 99b PAGE I H, AND HELMER O M A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator *J Exper Med* 71:29 1940
- 100 SHORR E Participation of hepatorenal vasotropic factors in experimental hypertension *Am J Med* 4:120 1948
- 101 CORCORAN A C KOHLSTAEDT K G AND PAGE, I H Changes of arterial blood pressure and renal hemodynamics by injection of angiotonin in human beings *Proc Soc Exper Biol & Med*, 46 244 1941
- 102 KATZ L N Hemodynamics of the circulation in hypertension in *Factors Regulating Blood Pressure* Transactions of the Third Conference ed by Zweifach B W and Shorr E New York Macy 1949 p 82
- 103 SHORR, E Comparative study of experimental renal and human essential hypertension with respect to the participation of the hepatorenal vasoactive factors ven and vdm in *Factors Regulating Blood Pressure* Transactions of the Fourth Conference ed by Zweifach B W and Shorr E New York Macy 1950 p 165
- 104 OLSEN N S Oxidation by normotensive and hypertensive tissues *Federation Proc*, 10:99 1951
- 105 RASKA S B The metabolism of the ischemic kidney I The respiratory and the oxidase activity of the ischemic kidney *J Exper Med* 79:75 1943
- 106 CARGILL W H AND HICKHAM J B The oxygen consumption of the normal and the diseased human kidney *J Clin Investigation* 28 526 1949
- 107 REUBI F C AND SCHROEDER H A Can vascular shunting be induced in the kidney by vasoactive drugs? *J Clin Investigation*, 28 114 1949
- 108 SCHROEDER, H A Personal observations
- 109 THOMPSON J E SILVA T F KINSEY D AND SMITHWICK R H The effect of acute salt loads on the urinary sodium output of normotensive and hypertensive patients before and after surgery *Circulation* 10:912 1954

- 109b. Ex J The influence of heavy hydration on the renal function in normal and hypertensive man *Scandinav J Clin & Lab Invest.*, 7-Suppl 19 pp 177 1955
- 109c. FRIEDMAN S M., HARDWICK D F AND HINKE, J A M.. The effect of pitressin on sodium tolerance in experimental hypertension *Circulation Res* 3:490 1955
- 109d. FRIEDMAN S M HINKE J A M., AND HARDWICK D F Sodium tolerance in experimental hypertension *Circulation Res* 3:297 1955
110. FARNSWORTH E B Renal reabsorption of chloride and phosphate in normal subjects and in patients with essential arterial hypertension *J Clin Investigation* 25:897 1946
- 110b. GREEN D M., JOHNSON A D BRIDGES W C. AND LEHMAN J H Stages of salt exchange in essential hypertension *Circulation* 9 416 1954
- 110c. COTTER P T HOORLER S W AND WELLES J M.. Effects of a sodium chloride load on renal hemodynamics and electrolyte excretion in essential hypertension *J Clin Investigation* 35:698 1956
111. PERRY H M Jr AND SCHROEDER, H A Personal observations from our laboratories
112. SCHROEDER, H A AND OLSEN N S Humoral pressor substances and their relation to arterial hypertension *Am Chemical Soc. "Advances in Chemistry Series No 2 Chemical Factors in Hypertension* May 23 1950
- 112b. GOLDMAN M L KASS J P FUTCHER, P H AND SCHROEDER H A The transfusion of arterial hypertensive and normotensive blood into hypertensive subjects *Am J M Sc* 217:637 1949
- 112c. OLSEN N S SCHROEDER, H A AND MENIARD E M Effect of certain amines on the blood pressure of normotensive and hypertensive rats *Proc Soc Exper Biol & Med* 74:581 1950
113. CROLLMAN A The Pathogenesis of Experimental and Clinical Hypertensive Cardiovascular Disease *Proc Council For High Blood Pressure Research* Am Heart A. New York 1955
114. EDVIGER, E. F JR. AND OLSEN N S Urine amine levels in normotensive and hypertensive subjects *Federation Proc* 9:36 1950
115. DAVIES D F WOLFE, K. M AND PERRY H M Jr Studies on primary amines II Their natural occurrence in urine of normotensive and hypertensive subjects *J Lab & Clin Med* 43:620 1954
116. CROXATTO H AND CROXATTO R.. Inhibitory action of amineoxidase and tyrosinase upon vasoconstrictor effect of hypertensin. *Proc Soc Exper Biol & Med* 48:392 1941
117. SCHROEDER, H A.. The effect of a preparation of amine oxidase on experimental hypertension *Science* 95:306 1942.
118. REUBI F C. AND FUTCHER, P H The effects of histamine on renal

- function in hypertensive and normotensive subjects *J Clin Investigation* 28 440 1949
- 119 SCHIALES O Kidney enzymes and essential hypertension in *Advances in Enzymology* Vol 7 F F Nord ed New York Interscience 1947 (pp 513 556)
- 120 SCHIROEDER H A PERRY H M JR DENNIS E G AND MAHONEY, L E Pressor substances in arterial hypertension V Chemical and pharmacological characteristics of pherentasin. *J Exper Med* 102 319 1955
- 120b SCHIROEDER H A AND PERRY H M JR Characteristics of a long acting vasoconstrictor procured from human hypertensive blood *Federation Proc* 14 134 1955
- 120c SCHIROEDER H A AND PERRY H M JR. Inactivation of pherentasin by antihypertensive drugs *Circulation* 12 772 1955
- 121 OLSEN N S SCHIROEDER H A AND MENHARD E M Pressor substances in arterial hypertension III Chemical studies on pherentasin *J Exper Med* 92 561 1950
- 122 DAVIES D F OLSEN N S, AND SCHIROEDER H A Pressor substances in arterial hypertension IV Quantitative and qualitative studies of pherentasin *Circulation* 5 380 1952
- 123 SCHIROEDER H A OLSEN N S AND GOLDMAN M L. Pressor substances in human hypertensive blood in *Factors Regulating Blood Pressure* Transactions of the Second Conference New York Macy 1948 pp 118 130
- 124 SCHIROEDER H A AND STOCK C C On the pressor activity of extracts of hypertensive blood *J Clin Investigation* 21 527 1942
- 125 MARSHALL, J., AND WAKERLIN G E Purification and possible histochemical localization of renin *Federation Proc* 8 106 1949
- 126 BARCROFT H AND KONZETT H On the actions of nor adrenaline adrenaline and isopropyl nor adrenaline on the arterial blood pressure heart rate and muscle blood flow in man *J Physiol* 110 194 1949
- 127 GOLDENBERG M PINES K L BALDWIN E F GREENE D G AND ROH C E The hemodynamic response of man to nor epinephrine and epinephrine and its relation to the problem of hypertension *Am J Med* 5 742 1948
- 128 DEXTER L FRANK H A HAYNES F W AND ALTSCHULE M D Traumatic shock VI The effect of hemorrhagic shock on the concentration of renin and hypertensinogen in the plasma in unanesthetized dogs *J Clin Investigation* 22 847 1943
- 129 DEXTER L Mechanisms of human hypertension *Am J Med* 4 219 1948
- 130 DEXTER L AND HAYNES F W Relation of renin to human hypertension with particular reference to eclampsia preeclampsia and

acute glomerulonephritis *Proc Soc Exper Biol & Med* 33:288 1934

- 131 MERRILL, A J MORRISON J L., AND BRANNON E. S. Concentration of renin in renal venous blood in patients with chronic heart failure. *Am J Med* 1:468 1946.
- 132 SHIPLEY R E., HELMER O M AND KOHLSTAEDT K G.. The presence in blood of a principle which elicits a sustained pressor response in nephrectomized animals *Am J Physiol* 149:703 1947
- 133 DAVIES D F., WOLFE K. M., AND PERRY H M., JR., Studies on primary amines I Methods. *J Lab & Clin Med* 41:802 1953
- 134 DAVIES D F WOLFE, K. M., PERRY H M., JR., SCHROEDER H A., AND MENHARD E. M. Chemical characteristics of pressor amines extracted from urine. *Federation Proc.* 12:467 1953
- 134b DAVIES D F MILLER, H AND SCHROEDER H A.. Association between primary amines and pressor substances in urine *Am J Med* 11:240 1951
- 135 PERRY H M JR AND GOLDSTEIN G. Studies on primary amines III. Limiting and optimum conditions for quantitative determination by the ninhydrin method *J Lab & Clin Med* 43:963 1955
- 136 WAXERLIN G E AND JOHNSON C. A. Reductions in blood pressures of renal hypertensive dogs by hog renin *Proc Soc Exper Biol & Med* 46:101 1941
- 137 FRANK M H GRAHAM L., AND WAXERLIN G E. Treatment and prophylaxis of experimental hypertension in monkeys with renins and antirenins *Federation Proc* 15:66 1956
- 138 SKEGGS L. T JR., MARSH W H., KAHN J R., AND SHUMWAY N P.. The existence of two forms of hypertensin. *J Exper Med* 99:275 1954
- 138b HELMER, O M. Use of rabbit aortic strips to biologically differentiate two forms of angiotonin. *Federation Proc* 15:273 1956
- 138c BUMPUS F M., AND SCHWARTZ H J. Evidence for existence of pressor and oxytocic active peptides in angiotonin preparations *Federation Proc* 15:226 1956
- 139 SKEGGS L. T., JR MARSH W H KAHN J R. AND SHUMWAY N P. Amino acid composition and electrophoretic properties of hypertensin I. *J Exper Med* 107:435 1955
- 140 SMITH E. L. Aspects of the Specificity and Mode of Action of Some Peptidases in *Enzymes and Enzyme Systems* Edsall J T., ed Cambridge Harvard 1951
- 141 SKEGGS, L. T JR., KAHN J R. AND SHUMWAY N P. The purification of hypertensin II *J Exper Med.* 103:301 1956
- 141b. SKEGGS L. T JR. KAHN J R., AND SHUMWAY N P.. The preparation and function of the hypertension-converting enzyme *J Exper Med* 103:295 1956

- function in hypertensive and normotensive subjects *J Clin Investigation* 28 440 1949
- 119 SCHALES O Kidney enzymes and essential hypertension in *Advances in Enzymology* Vol 7 F F Nord ed New York Interscience 1947 (pp 515-556)
- 120 SCHROEDER H A PERRY H M JR DENNIS E G AND MAHONEY L E Pressor substances in arterial hypertension V Chemical and pharmacological characteristics of pherentasin *J Exper Med* 102 319 1955
- 120b SCHROEDER H A AND PERRY H M JR Characteristics of a long acting vasoconstrictor procured from human hypertensive blood *Federation Proc* 14 134 1955
- 120c SCHROEDER H A AND PERRY H M JR Inactivation of pherentasin by antihypertensive drugs *Circulation* 12 772 1955
- 121 OLSEN N S SCHROEDER H A AND MENHARD E M Pressor substances in arterial hypertension III Chemical studies on pherentasin *J Exper Med* 92 561 1950
- 122 DAVIES D F OLSEN N S AND SCHROEDER H A Pressor substances in arterial hypertension IV Quantitative and qualitative studies of pherentasin *Circulation* 1 380 1952
- 123 SCHROEDER H A OLSEN N S AND GOLDMAN M L Pressor substances in human hypertensive blood in *Factors Regulating Blood Pressure* Transactions of the Second Conference New York Macy 1948 pp 118-130
- 124 SCHROEDER H A AND STOCK C C On the pressor activity of extracts of hypertensive blood *J Clin Investigation* 21 627 1942
- 125 MARSHALL J AND WAKERLIN G E Purification and possible histochemical localization of renin *Federation Proc* 8 106 1949
- 126 BARCROFT H AND KONZETT H On the actions of noradrenaline, adrenaline and isopropyl noradrenaline on the arterial blood pressure, heart rate and muscle blood flow in man *J Physiol* 110 194 1949
- 127 GOLDENBERG M PIVES K L BALDWIN E F GREENE D G AND ROH C E The hemodynamic response of man to nor epinephrine and epinephrine and its relation to the problem of hypertension *Am J Med* 5 742 1948
- 128 DEXTER L FRANK H A HAYNES F W AND ALTSCHULE M D Traumatic shock VI The effect of hemorrhagic shock on the concentration of renin and hypertensinogen in the plasma in unanesthetized dogs *J Clin Investigation* 22 847 1945
- 129 DEXTER L Mechanisms of human hypertension *Am J Med* 4 279 1948
- 130 DEXTER L AND HAYNES F W Relation of renin to human hypertension with particular reference to eclampsia, preeclampsia and

- 158 YULZ, C. L. Obstructive lesions of the main renal artery in relation to hypertension. *Am J M Sc* 67:394 1944
- 159 CASTLEMAN B and SMITHWICK R. H. The relation of vascular disease to the hypertensive state *New England J Med* 239:732, 1948
- 160 WILSON C. AND BYROM F. B. Renal changes in malignant hypertension. *Lancet* 1 136 1939
- 161 SCHROEDER H. A. Arterial hypertension in rats I. Methods *J Exper Med* 75:513 1942
- 162 SCHROEDER H. A., AND NEUMANN C. Arterial hypertension in rats. II. Effects on the kidneys. *J Exper Med* 75:527 1942
- 163 SPITZNAGEL, J. K., AND SCHROEDER, H. A. Experimental pyelonephritis and hypertension in rats *Proc Soc Exper Biol & Med.* 77:762 1951
- 164 FLASHER J. AND DRURY D. F. Effects of removal of "ischemic" kidney in rabbits with unilateral renal hypertension as compared to unilateral nephrectomy in normal rabbits. *Am J Physiol* 153:438 1949
- 165 SCHROEDER, H. A., AND GOLDMAN M. L. Arterial hypertension in dogs. I Methods *Circulation* 5:730 1952
- 166 SMITH H. W. Hypertension and urologic disease *Am J Med* 4:74 1948
- 167 SCHROEDER, H. A. AND FISH G. W. Studies on "essential" hypertension. III. The effect of nephrectomy upon hypertension associated with organic renal disease *Am J M Sc* 199:601 1940
- 168 PERRY H. M., JR. AND SCHROEDER, H. A. Studies on the control of hypertension by Hyphex. III Pharmacological and chemical observations on 1 hydrazinophthalazine *Am J M Sc* 773:396 1954
- 168b PERRY H. M. JR., AND SCHROEDER, H. A. The chemistry and pharmacology of 1 hydrazinophthalazine *Am J Med* 16:606 1954
- 168c. PERRY H. M. JR. AND SCHROEDER, H. A. Pharmacology of hydrazine. *Proc. Second World Congress of Cardiology and Am Heart A* 1954 p 442
- 169 SINCLAIR H. M. Pyridoxal phosphate as coenzyme of histaminase. *Biochem J* 51:1 1952.
170. BIEHL, J. P. AND VILTER, R. W. Effect of isoniazid on vitamin B<sub>6</sub> metabolism its possible significance in producing isoniazid neuropathy *Proc Soc Exper Biol & Med* 85:339 1954
- 171 SCHULZ, W. Inhibition of diaminooxidase (histaminase) *Experientia* 8:230 1952.
- 172 CROSS F. SCHULZ, W. TRIPON J. AND MEYER, R. Inhibition of

- 142 PEART W S The isolation of a hypertensin *Biochem J* 61:50 1956
- 142b ELLIOTT D F AND PEART W S Amino acid sequence in a hypertensin *Nature* 177:527 1956
- 143 SAPHIR O AND TAYLOR B Pyelonephritis lenta *Ann Int Med* 36:1017 1952
- 143b BROD J *Chronická Pyelonefritis* Praha Statní Zdravotnické Nakladatelství 1955
- 144 BELL E T *Renal Diseases* 2nd Ed Philadelphia Lea & Febiger 1950
- 145 BLACKMAN S S JR Arteriosclerosis and partial obstruction of the main renal arteries in association with essential hypertension in man *Bull Johns Hopkins Hosp* 65:353 1939
- 146 OPPENHEIMER B S KLEMPERER P AND MOSHKOWITZ L Evidence for the Goldblatt mechanism of hypertension in human pathology *Tr A Am Physicians* 54:69 1939
- 147 KAHN J R AND LAIPPLY T C Frequency of bilateral renal disease in persistent hypertension *Am J M Sc* 203:807 1919
- 148 BRAUN MENÉNDIZ E FASCIOLA J C LELOIR L F MUNOZ J M AND TAQUINI A C translated by L Dexter *Renal Hypertension* Springfield Thomas 1946
- 149 GOLDBLATT H Experimental hypertension induced by renal ischemia The Harvey Lectures *Bull New York Acad Med* 14:523 1938
- 150 LEITER L Unusual hypertensive renal disease 1 Occlusion of renal arteries (Goldblatt hypertension) 2 Anomalies of urinary tract *JAMA* 111:507 1938
- 151 FREEMAN G AND HARTLEY G JR Hypertension in a patient with a solitary ischemic kidney *JAMA* 111:1159 1938
- 152 STEWART C F Arteriosclerosis of the renal artery orifices with severe hypertension *JAMA* 114:2099 1940
- 153 SAPHIR O AND BALLINGER J Hypertension (Goldblatt) and unilateral malignant nephrosclerosis *Arch Int Med* 66:541 1940
- 154 LAAS E Die Wirkung einer Nierenarterienverlegung auf Niere und Blutdruck *Virchows Arch path Anat* 305:638 1940
- 155 RICHARDSON G O Atherosclerosis of main renal arteries in essential hypertension *J Path & Bact* 55:33 1943
- 156 FRIEDMAN B MOSHKOWITZ L AND MARRUS J Unilateral renal disease and renal vascular changes in relation to hypertension in man *J Urol* 48:5 1942
- 157 LISA J R ECKSTEIN D AND SOLOMON C Relationship between arteriosclerosis of the renal artery and hypertension Analysis of 100 necropsies *Am J M Sc* 205:701 1943

- Rheumatic and febrile syndrome during prolonged hydralazine treatment. *J.A.M.A.* 154:23 1954
- 185 PERRY H M JR. AND SCHROEDER H A.. Syndrome simulating collagen disease caused by hydralazine (Apresoline) *J.A.M.A.*, 154 6:0 1954
- 186 COMENS P., AND SCHROEDER H A.. The L. E. cell as a manifestation of delayed hydralazine intoxication *J.A.M.A.*, 160 1151 1956
- 187 SHACKMAN N H SWILLER A. L., AND MORRISON M.. Syndrome simulating acute disseminated lupus erythematosus Appearance after hydralazine (Apresoline) therapy *J.A.M.A.*, 155 1492 1954
- 188 COMENS P.. Experimental hydralazine disease and its similarity to disseminated lupus erythematosus *J Lab & Clin Med.*, 47 44 1956
- 189 SCHROEDER H A.. The effect of 1 hydrazinophthalazine in hypertension *Circulation* 5:28 1952
- 190 SZENT GYORGI A. *The Contraction Cycle and Its Regulation* Proc. Annual Meeting For High Blood Pressure Research Am Heart A., 1954
- 191 VILTER, R. W., MUELLER, J F GLAZER, H S., JARROLD T., ABRAHAM J THOMPSON C., AND HAWKINS, V R. The effect of vitamin B deficiency induced by desoxypyridoxine in human beings *J Lab & Clin Med.*, 42:335 1953
- 192 SINGH S I. AND SINGH L. The action of calcium on blood vessels and its relation to hypertension. *Proc Indian Acad Sc.*, 42 191 1955
- 192b SINGH S I. AND SINGH L. The action of sodium and potassium on blood vessels and its relation to hypertension. *Proc Indian Acad Sc* 42 172 1955
- 193 OLSEN N S., AND MARTINDALE, W E.. Hypertension and pyridoxine deficiency in the rat. *J Clin Investigation* 31:682 1952
- 193b OLSEN N S., AND MARTINDALE W E. Relation of pyridoxine deficiency and hypertension in the rat. *Federation Proc* 11 115 1952
- 194 OLSEN N S AND MARTINDALE, W E. Studies on chronic vitamin B<sub>6</sub> deficiency in the rat. I. Changes in the intact animal *J Nutrition* 53 317 1954.
- 195 OLSEN N S AND MARTINDALE, W E. Studies on chronic vitamin B deficiency in the rat. II. Changes in tissue metabolism *J Nutrition* 53 329 1954
- 196 HARRIS S. A.. Chemistry of vitamin B<sub>6</sub>. IV Reactions in solutions at elevated temperatures *J Am Chem Soc* 63 5563 1941
- 197 GYORGY P. Investigations on the vitamin B<sub>6</sub> complex. III The inactivation of lacticflavin and vitamin B by visible light. *Biochem J.*, 29:767 1955



diaminoxidase (histaminase) by phthalazine derivatives *Experientia* 8 2294 1952

- 173 SOLLMANN T *A Manual of Pharmacology* 7th Ed Philadelphia Saunders 1948
- 173b OLSEN N S Inhibitory effect of thiocyanate upon oxidations mediated by liver and kidney *Arch Biochem* 26:269 1950
- 174 PAGE I H CORCORAN A C DUSTAN H P AND KOPFANT T Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients *Circulation* 11 188 1955
- 175 BLACK, M M ZWEIFACH B W AND SPEER F D Comparison of hypotensive action of sodium azide in normotensive and hypertensive patients *Proc Soc Exper Biol & Med*, 85 11 1954
- 176 MODELL W GOLD H AND CATTELL MCK Clinical uses of 2,3-dimercaptopropanol (BAL) IV Pharmacologic observations of BAL by intramuscular injection in man *J Clin Investigation* 25:480 1946
- 177 SULZBERGER M B BAER R L AND KANOF A Clinical uses of 2,3 dimercaptopropanol (BAL) III Studies on the toxicity of BAL on percutaneous and parenteral administration *J Clin Investigation* 25:474 1946
- 178 CARLETON A B PETERS R A STOCKEN L A THOMPSON R, H S AND WILLIAMS D I Clinical uses of 2,3-dimercaptopropanol (BAL) VI The treatment of complications of arseno therapy with BAL (British Anti Lewisite) *J Clin Investigation* 25:497 1946
- 179 GILMAN A L PHILIPS F S ALLEN R. P AND KOELLE, E S The treatment of acute cadmium intoxication in rabbits with 2,3 dimercaptopropanol *J Pharmacol & Exper Therap* 87:85 1946
- 180 PERRY H M JR AND SCHROEDER H A Depression of cholesterol levels in human plasma following ethylenediamine tetraacetate and hydralazine *J Chronic Dis* 2 520 1955
- 181 PERRY H M JR AND SCHROEDER H A Lesions resembling vitamin B complex deficiency and urinary loss of zinc produced by ethylenediamine tetraacetate *Am J Med*, 22 168 1957
- 182 SCHROEDER H A MENHARD E M AND PERRY H M JR. The antihypertensive properties of some mercaptans and other sulfur containing compounds. *J Lab & Clin Med* 45:431, 1955
- 182b SCHROEDER H A The antihypertensive influence of certain sulfhydryl compounds *Science*, 114 441 1951
- 183 SCHROEDER H A, MENHARD E. M AND PERRY H M JR. Anti hypertensive effects of metal binding agents *J Lab & Clin Med* 46:416 1955
- 184 DUSTAN H P TAYLOR R. D CORCORAN A C AND PAGE I A

tous embolization with emphasis on an etiology of renal hypertension *Am J Med* 20:366 1956

- 214 CORCORAN A. C. TAYLOR, R. D., AND PAGE, I. H.. Functional patterns in renal disease *Ann Int Med* 28:560 1948
- 215 SWELL, E. E.. Summary of known metabolic functions of nicotinic acid riboflavin and vitamin B<sub>6</sub> *Physiol Rev* 33:509 1953
- 216 SELYE, H.. The role of the adrenal cortex in the pathogenesis of experimental hypertension in *Hypertension a Symposium* edited by Bell E. T Minneapolis Univ Minnesota Press 1951 pp 119-132.
- 217 BRAUN MEXÉNDEZ E.. The mechanism of hypertension due to desoxycorticosterone in *Hypertension a Symposium* edited by Bell E. T Minneapolis Univ Minnesota Press 1951 pp 133-146
- 218 MASOV G. M. C. LEWIS L. A. CORCORAN A. C. AND PAGE I. H. Desoxycorticosterone in rabbits. Simulation of rabbit "toxemia of pregnancy" *J Clin Endocrinol* 13:500 1953
- 218a RENZI A. A. AND GAUNT R.. Effect of Apretoline (1-hydrazinophthalazine) on the experimental eclampsia like syndrome and on related aspects of water metabolism *Federation Proc.* 12:360 1953
- 218c. RENZI A. A. AND GAUNT R. Apretoline (1-hydrazinophthalazine) in the experimental eclampsia like syndrome and related aspects of water metabolism *Am J Physiol* 175:313 1953
- 218d. GAUNT R. ANTONCIAR N. MILLER G. J. AND RENZI A. A. Effect of reserpine (serpasil) and hydralazine (apresoline) on experimental steroid hypertension. *Am J Physiol* 187:63 1955
- 219 SAPIRSTEIN L. A. BRANT W. L. AND DRURY D. R. Production of hypertension in the rat by substituting hypertonic sodium chloride solutions for drinking water *Proc Soc Exper Biol & Med* 73:89 1950
- 220 GOLDMAN M. L. KRIS J. P. SCHROEDER H. A. AND DAVIES D. F. The relation of the kidney to the acute pressor action of desoxy corticosterone *Am J M Sc* 222:257 1951
- 221 GOLDMAN M. L. AND SCHROEDER, H. A. The immediate pressor effect of desoxycorticosterone acetate *Science* 107:272 1948
- 221b GOLDMAN M. L. AND SCHROEDER, H. A. Immediate pressor effect of desoxycorticosterone acetate in arterial hypertension. *Am J Med* 5:33 1948
- 222 GOLDMAN M. L. RONZONI E. AND SCHROEDER, H. A. The response of the adrenal cortex of the rat to dietary salt restriction and replacement. *Endocrinology* 38:57 1956
- 222b SCHROEDER H. A. Edema in *Signs and Symptoms* edited by C. M. MacBryde Philadelphia Lippincott 1951

- 198 HOCHBERG M MELNICK, D AND OSER B L On the stability of pyridoxine *J Biol Chem* 155 129 1944
- 199 IVES M POLLARD A E ELVEHJEM C A AND STRONG F M The nutritive value of canned foods XVII Pyridoxine biotin and folic acid *J Nutrition*, 3P 347, 1946
- 200 TOMARELLI R. M SPENCE E. R AND BERNHART F W The biological availability of vitamin B<sub>6</sub> of heated milks *Agric and Food Chem* 3 338 1955
- 200b DAY, P L. AND DINNING J S Vitamin E Deficiency in the young Rhesus Monkey Resume of Communications Third International Congress of Biochemistry 1955 p 116
- 201 Studies on the Vitamin Content of Tissues II The B Vitamin Content of Foods Austin University of Texas Pub 4237 1942
- 202 SCHROEDER H A Is atherosclerosis a conditioned pyridoxal deficiency? *J Chronic Dis* 2:28 1955
- 203 WACHSTEIN M AND GUDAITIS A Disturbance of vitamin B<sub>6</sub> metabolism in pregnancy *J Lab & Clin Med* 40 550 1952
- 204 WACHSTEIN M AND GUDAITIS A Disturbance of vitamin B<sub>6</sub> metabolism in pregnancy II The influence of various amounts of pyridoxine hydrochloride upon the abnormal tryptophane load test in pregnant women *J Lab & Clin Med* 42:98 1953
- 205 WACHSTEIN M AND GUDAITIS A Disturbance of vitamin B<sub>6</sub> metabolism in pregnancy III Abnormal vitamin B<sub>6</sub> load test *Am J Obst & Gynec* 66 1207 1953
- 206 REGISTER U D LEWIS U J RUEGAMER W R AND ELVEHJEM C A Studies on the nutritional adequacy of army combat rations *J Nutrition* 40:281 1950
- 207 TAPPAN D V AND ELVEHJEM C A Observations on the nutrition of rhesus monkeys receiving highly processed rations *J Nutrition* 51 469 1953
- 208 MOLONY C J AND PARMELEE A H Convulsions in young infants as a result of pyridoxine (vitamin B<sub>6</sub>) deficiency *J.A.M.A.*, 154 405 1954
- 209 COURSIN D B Convulsive seizures in infants with pyridoxine deficient diet *J.A.M.A* 154 406 1954
- 210 HOLLEY H L ELLIOTT H C JR AND HOLLAND C M JR Serum sodium values in essential hypertension *Proc Soc Exper Biol & Med* 77 561 1951
- 211 JOHNSON L L SHAW C W GALEN W P AND HOLLEY H L Cerebrospinal fluid sodium values in essential hypertension *J Lab & Clin Med* 41 287 1953
212. TOBIAN L JR AND BINION J Tissue cations and water in arterial hypertension *Circulation* 5:754 1952
- 213 HANDLER F P Clinical and pathologic significance of arterioma

234. BAKER, J. *Chemistry of Coordinate Compounds* New York Reinhold, 1956
235. WILLIAMS R. P. J. Metal ions in biological systems *Biol Rev.* 25 381 1953
236. NAJJAR, V. The role of metal ions in enzyme systems in *Phosphorus Metabolism* Vol. I McElroy W D and Glass B., editors Baltimore Johns Hopkins Press 1951 pp 500-520
237. METZLER, D. E., ILAWA, M. AND SNELL, E. E. A general mechanism for vitamin B<sub>12</sub>-catalyzed reactions *J Am Chem Soc* 76 648 1954
238. VALLEE, B. L. Zinc and metallo-enzymes in *Advances in Protein Chemistry* Vol. X. New York Interscience 1955
239. HAMILTON J. G. AND SOLEY M. H. Comparison of metabolism of iodine and of element 85 (eka iodine) *Proc Nat Acad Sc* 6483 1940
240. BAUMAN E. J., ZIMMER, V., OSHRY E., AND SEIDLIN S. M. Behavior of thyroid toward elements of seventh periodic group rhenium. *Proc Soc Exper Biol & Med* 72 502 1949
241. BAUMAN E. J., SEARLE N. L., YALOW A. A., SIEGEL E., AND SEIDLIN S. M. Behavior of thyroid toward elements of seventh periodic group technetium *Federation Proc* 11 184 1952
242. RAY T. W. AND DEYSACH L. J. Storage of manganese by thyroid. Effect on oxygen consumption of guinea pig *Proc Soc Exper Biol & Med.* 51 228 1942
243. GURD F. R. N. The specificity of metal protein interactions in *Ion Transport Across Membranes* edited by H. T. Clarke New York Acad Press 1954
244. RAY C. T., THREEFOOT S., AND BURCH G. E. A study of the use of Rb<sup>86</sup> as a tracer for measurement of Rb<sup>86</sup> and K<sup>40</sup> space and mass in intact man with and without congestive heart failure *J Clin Investigation* 33 957 1954
245. COLOWICK, S. P. AND KAPLAN N. D. *Methods in Enzymology* Vol. I New York Acad Press 1955
246. LERNER, A. B. Metabolism of phenylalanine and tyrosine in *Advances in Enzymology* Vol. 14 Nord F. F. editor New York Interscience 1953 pp 73-124
247. LERNER, A. B., AND FITZPATRICK, T. B. Biochemistry of melanin formation *Physiol Rev.* 30-91 1950
248. CURRAN G. L. Effect of certain transition group elements on hepatic synthesis of cholesterol in the rat. *J Biol Chem* 210 763 1954
249. FOREMAN H. VIER, M. AND MAGEE M. The metabolism of C<sup>14</sup>-labelled ethylenediaminetetraacetic acid in the rat. *J Biol Chem* 203 1045 1953

- 222c. SCHROEDER H A Studies on congestive circulatory failure III  
The relation of edema to urinary chlorides *Circulation* 1481  
1950
- 222d SCHROEDER H A Low salt diets and arterial hypertension *Am J  
Med* 4578 1948
- 222e FUTCHER P H AND SCHROEDER H A Studies on congestive heart  
failure II Impaired renal excretion of sodium chloride *Am J  
M Sc* 204 52 1942
- 223 OLSEN N S Chemical changes in experimental renal hypertension  
*Am J Physiol* 161 448 1950
- 224 LANDIS E AND ABRAMS M I Salt choices by hypertensive rats  
in *Factors Regulating Blood Pressure* Transactions of the First  
Conference edited by Zweifach B W and Shorr E New York  
Macy 1947 p 68
- 225 ROWNTREE L G AND SNELL, A M *A Clinical Study of Addison's  
Disease* Philadelphia Saunders 1931
- 226 RAMEY E R GOLDSTEIN M S AND LEVINE R Action of nor  
epinephrine and adrenal cortical steroids on blood pressure and  
work performance of adrenalectomized dogs *Am J Physiol*  
163 450 1951
- 227 DAVIS A K BASS A C AND OVERMAN R R Comparative effects  
of cortisone and DCA on ionic balance and fluid volumes of  
normal and adrenalectomized dogs *Am J Physiol* 166 493  
1951
- 228 GAUBINO M AND LEVITT M F Influence of the adrenal cortex on  
body water distribution and renal function *J Clin Investiga  
tion* 28 1487 1949
- 229 LORENTE DE NÓ R On the effect of certain quaternary ammonium  
ions upon frog nerve Parts I & II *J Cell & Comp Physiol*  
(Supplement) 33 July 1919
- 230 GENEST J LEMIEUX G DAVIGNON A KOIW E NOWACZYNSKI W  
AND STEYERMARK P Human arterial hypertension A state of  
mild chronic hyperaldosteronism? *Science* 123 503 1956
- 231 TIPTON I H STEINER R L FOLAND W D MUELLER J AND  
STANLEY M Spectrographic analysis of the tissues from autopsies  
of twenty four instantaneous deaths Oak Ridge National Lab  
oratory Report C F 54 12 66 Dec 10 1954
- 232 SCHUBERT J Interactions of metals with small molecules in rela  
tion to metal protein complexes in *Chemical Specificity in Bio  
logical Interactions* edited by Gurd F R N New York Acad  
Press 1954
- 233 MARTELL, A E AND CALVIN M *Chemistry of the Metal Chelate  
Compounds* New York Prentice Hall 1952

- 257 LERNINGER, A. L. Role of metal ions in enzyme systems *Physiol Rev.* 30 393 1950
- 268 BERTRAND D. Distribution of vanadium among the invertebrates and vertebrates *Bull Soc chim biol* 25:36 1943
- 269 BERTRAND D. Vanadium as an essential trace element for aspergillus niger *Ann Inst Pasteur* 63:226 1942.
- 270 BERTRAND D. Vanadium in fungi especially amanita. *Bull Soc chim biol* 25 194 1943
- 271 BERTRAND D. Distribution of vanadium in plants. *Compt rend Acad sc.* 212 11 0 1941
- 272 BERNHEIM F. AND BERNHEIM M. L. C. The effect of titanium on the oxidation of sulphhydryl groups by various tissues. *J Biol Chem* 127:69, 1939
- 273 PERRY H. M., JR. SCHROEDER H. A., AND PERRY B. F.. Abnormally high urinary cadmium and manganese in hypertensive patients *Proc Soc Exper Biol & Med* 1957 (In press)
- 274 BERNHEIM F., AND BERNHEIM M. L. C. The action of vanadium on the oxidation of phospholipids by certain tissues *J Biol Chem* 127 353 1939
- 275 BERNHEIM F., AND BERNHEIM M. L. C.. Note on the action of manganese and some other metals on the oxidation of certain substances by liver *J Biol Chem.* 129:79 1939
- 276 JACKSON D. E. The pharmacologic actions of vanadium *J Pharmacol & Exper Therap* 3 477 1912
- 277 PERRY H. M., JR. TETTELBAUM S. AND SCHWARTZ P. L. Effects of antihypertensive agents on amino acid decarboxylation and amine oxidation *Federation Proc* 14 113 1955
- 278 MYERS V. C. AND MULL J. W. The influence of the administration of aluminum upon the aluminum content of the tissues and upon the growth and reproduction of rats *J Biol Chem* 78:605 1928
- 279 MYERS V. C., AND MULL, J. W. The aluminum content of human autopsy tissue *J Biol Chem* 78:625 1928
- 279 MYERS V. C., AND MORRISON D. B.. The influence of the administration of aluminum content of the tissues of the dog *J Biol Chem.* 78:615 1928
- 280 CURRAN G. L., AND COSTELLO R. L. Reduction of excess cholesterol in the rabbit aorta by inhibition of endogenous cholesterol synthesis *J Exper Med* 103 49 1956
- 281 SINGH S. I., AND SINGH I. The action of lead on unstriated muscle and blood vessels and its relation to hypertension *Proc Indian Acad Sc* 42:62 1956
- 282 BARRETT H. M., LAWEN D. A., AND SEMMONS F.. Studies on the

- 250 FOREMAN H AND TRUJILLO T T The metabolism of C<sup>14</sup> labeled ethylenediaminetetra acetic acid in human beings *J Lab & Clin Med* 43 566 1954
- 251 STOCKEN L A AND THOMPSON R H S Reactions of british anti lewisite with arsenic and other metals in living systems *Physiol Rev* 29 168 1949
- 252 ALEXANDER H L *Reactions with Drug Therapy* Philadelphia Saunders 1955
- 253 *The Merck Index of Chemicals and Drugs* 6th Ed Rahway NJ Merck & Co 1952
- 254 *Bibliography of the Literature on the Minor Elements and Their Relation to Plant and Animal Nutrition* 4th Ed Vols I II III. New York Chilean Nitrate Educational Bureau Inc. 1948
- 255 VINOGRADOV A P *The Elementary Chemical Composition of Marine Organisms* Memoir 2 Sears Foundation For Marine Research New Haven Yale 1953
- 256 MONIER WILLIAMS G W *Trace Elements in Food* New York, Wiley 1949
- 257 MITCHELL R L The spectrographic analysis of soils plants and related materials Commonwealth Bureau of Soil Science Tech Com 44 Harpendin England 1948
- 258 TIPTON I H FOLAND W D BOBB F C AND McCORKLE, W C Spectrographic determination of trace elements in human tissues Oak Ridge National Laboratory Report C F 53 84 March 11 1953
- 259 TIPTON I H COOK M J STEINER R S FOLAND W D BOWMAN D K AND McDANIEL, K K Spectrographic analysis of tissues for trace elements Oak Ridge National Laboratory Report C F 56 3 60 March 12 1956
- 260 GRIFFITH C G BUTT E M AND WALKER J The inorganic element content of certain human tissues *Ann Int Med* 41 501 1954
- 261 MARSTON H R Cobalt copper and molybdenum in the nutrition of animals and plants *Physiol Rev* 32 66 1952
- 262 LEGOFF J M Cobalt as a vasodilator *J Pharmacol & Exper Therap* 38 1 1930
- 263 MOORE C V A Iron and the essential trace elements in *Modern Nutrition in Health and Disease* edited by M G Wohl and R S Goodhart Philadelphia Lea & Febiger 1955 pp 220 255
- 264 TUCKER H F AND SALMON W D Parakeratosis or zinc deficiency disease in the pig *Proc Soc Exper Biol & Med* 88 613 1955
- 265 HOVE E ELVEHJEN C A AND HART E B Physiology of zinc in nutrition of rat *Am J Physiol* 119 768 1937
- 266 TIPTON I H Personal communication

- 297 DOMAR, G. FREDGA, A., AND LINDERHOLM, H. A method for quantitative determination of tetraethylthiuram disulphide (antibuse abstunyl) and its reduced form diethyldithiocarbamic acid as found in excreta *Acta chem scandinav* 3 1441 1949
- 298 DuBOIS, K. P., COCHRAN, K. W., AND MAZUR, M. Inhibition of phosphatases by beryllium and antagonism of the inhibition by manganese. *Science* 110 470 1949
- 299 BOWEN, W. J., AND KERWIN, T. D. A study of the effects of ethylene diaminetetraacetic acid on myosin adenosinetriphosphatase *J Biol Chem.* 211:237 1954
- 300 SMITH, E. L., AND SPACKMAN, D. H. Leucine amino-peptidase. V. Activation, specificity and mechanism of action *J Biol Chem.* 212:771 1955
- 301 HANSEN, H. T., AND SMITH, E. L. Carnosinase. An enzyme of swine kidney *J Biol Chem.* 179:789 1949
302. WERLAND, H. AND MITCHELL, W. Uber den Mechanismus der Oxydationsvorgange XXIX. *Liebigs Ann Chem.* 494 156 1932.
- 303 MAHLER, H. R., MACLEER, B., GREEN, D. E., AND BOCK, R. M. Studies on metalloflavoproteins III. Aldehyde oxidase. A molybdo-flavoprotein *J Biol Chem* 210 465 1954
304. WIELSCH, H.. Certain aspects of intermediary metabolism of glutamine, asparagine and glutathione in *Advances in Enzymology* Vol. 13 Nord, F. F., editor New York Interscience 1952 pp 437-515
- 305 SMITH, E. L. The specificity of certain peptidases in *Advances in Enzymology* Vol. 12 Nord, F. F., editor New York, Interscience 1951 pp 191-207
- 306 SMITH, E. L. The glycylglycine dipeptidases of skeletal muscle and human uterus. *J Biol Chem* 173:571 1948
- 307 VALLEE, B. L. AND ALTSCHULE, M. D.. Zinc in the mammalian organism with particular reference to carbonic anhydrase *Physiol Rev* 29:310 1949
- 308 PERRY, H. M. JR., SCHROEDER, H. A., AND FREDERICKSON, A. F.. Urinary trace metals from normal and treated and untreated hypertensive patients *J Lab & Clin Med* 44:907 1954
- 309 PERRY, H. M. JR. AND SCHROEDER, H. A. Concentration of trace metals in urine of treated and untreated hypertensive patients compared with normal subjects *J Lab & Clin Med* 46:936 1955
- 310 PERRY, H. M. JR., AND SCHROEDER, H. A. Comparison of the concentration of several trace metals in the urine of treated and untreated malignant hypertensive patients as compared with normal individuals *Circulation* 1 738 1955



toxicity of inhaled cadmium I The acute toxicity of cadmium oxide by inhalation *J Indust Hyg & Toxicol* 29:279 1947

- 283 BARRETT H M AND CARD B I Studies on the toxicity of inhaled cadmium II The acute lethal dose of cadmium oxide for man *J Indust Hyg & Toxicol* 29:286 1947
- 284 PATERSON J C Studies on the toxicity of inhaled cadmium III The pathology of cadmium smoke poisoning in man and in experimental animals *J Indust Hyg & Toxicol* 29:294 1947
- 285 HARRISON H E BUNTING H ORDWAY N A AND ALBRINK W S The effects and treatment of inhalation of cadmium chloride aerosols in the dog *J Indust Hyg & Toxicol* 29:302 1947
- 286 WILSON R. H DeEDS F AND COX A J Jr Effects of continued cadmium feeding *J Pharmacol & Exper Therap* 71:222 1941
- 287 FRIBERG L Proteinuria and kidney injury among workmen exposed to cadmium and nickel dust *J Indust Hyg & Toxicol* 30:32 1948
- 287b FRIBERG L Health hazards in the manufacture of alkaline accumulators with special reference to chronic cadmium poisoning *Acta med scandinav* 240 Supplement pp 7-124 1950
- 288 CLARKSON T W AND KENCH J E Urinary excretion of amino acids by men absorbing heavy metals *Biochem J* 62:361 1956
- 289 FRANT S AND ALEEMAN I Cadmium food poisoning ~ *JAMA* 117:86 1941
- 290 FORBES R M COOPER A R AND MITCHELL H H On the occurrence of beryllium boron cobalt and mercury in human tissues *J Biol Chem* 209:857 1954
- 291 KLEIN R AND HARRIS S B Treatment of scleroderma sclerodactylia and calcinosis by chelation (EDTA) *Am J Med*, 19:798 1955
- 292 SCHREINER A W SLINGER W HAWKINS V R AND VILTER R W Seborrhoeic dermatitis a local metabolic defect involving pyridoxine *J Lab & Clin Med*, 38:948 1951
- 293 FORBES R M COOPER, A R AND MITCHELL, H H The composition of the adult human body as determined by chemical analysis *J Biol Chem* 203:359 1953
- 294 PITT RIVERS R Mode of action of antithyroid compounds. *Physiol Rev*, 30:194 1950
- 295 CALVIN M KLOTZ I M SMITH E L DAVIS N C., ADAMS E AND SPACKMAN D H *The Mechanism of Enzyme Actions* Mc Elroy W D and Glass B editors Baltimore John Hopkins Press 1954 pp 221-320
- 296 LEWIN E. AND HIRSCH J G Studies on the stability of isoniazid *Am Rev Tuberc*, 71:732 1955

## Bibliography

- relationship to human arteriosclerosis *Arch Path* 304 1935
- 374 GREENBERG L. D., AND RIVERHART J. F. Plasma cholesterol fed control and pyridoxine deficient monkeys *Soc Exper Biol & Med.* 76, 80 1951
- 375 RIVERHART J. F., AND GREENBERG L. D. Arteriosclerosis in pyridoxine-deficient monkeys *Am J Path.* 25 481
- 325 RIVERHART J. F. AND GREENBERG L. D. Pathogenesis of arteriosclerosis in pyridoxine deficiency With notes to human arteriosclerosis *Arch Path.* 31 12 1951
- 326 MURPHY C. W., AND EMERSON G. A. Arteriosclerosis deficient monkeys and dogs *Federation Proc* 15-5
- 327 ASCHOFF L. *Lectures on Pathology* New York Hoeber
- 328 MORAY H. Z. AND MORAY, R. H. Morphologic and studies on the development and progression of *Circulation* 1 484 1953
- 329 STRONG J. P. MCGILL, H. C. JR., CARTER O. R., R. L. Natural history of aortic atherosclerosis, *Federation Proc.* 15 535 1956
- 350 ANDRUS S. B. MARY G. V. FILLIOS L. C., AND SYB histologic changes in experimental atherosclerosis *Proc* 15-542 1956
- 351 CURRAN G. L., AND CLUTE, O. L. Effect of cation synthesis by surviving rat liver *J Biol Chem*
- 352 ROBAHL, K. Studies on the Blood and Blood Eskimo and the Significance of Ketosis under A *Norsk Polarinstittutt Skrifter* Nr 102 Oslo 1954
- 353 LARSEN N. P. Stress and the aging circulation *Am Treatment* 6 1681 1955
- 354 KICZYNSKI B., Pathologische-geographische Untersuchungen in der Kurgusuchungsansicht. *Klin Wochenschr*
- 355 CLAWSON B. } The heart in essential hypertension A Symposium edited by Bell E. T. Minneapolis Press 1951 pp 439-453
- 356 GOLDSTEIN F. JENSEN W. K. WALSHOV J. M. AND The relationship between hypertension and co *Ann Int Med* 44 446 1956
- 356 HOLMAY R. L., Necrotizing arteritis in dogs produced by high fat diet

- 311 SCHROEDER H A AND PERRY H M JR. Essential and abnormal trace metals in cardiovascular diseases in *Proceedings of the Annual Meeting Council For High Blood Pressure Research American Heart A.*, 1955
- 312 SCHROEDER H A Trace metals and chronic diseases in *Advances in Internal Medicine* edited by Dock W and Snapper I Chicago Yr Bk Pub 1956 Vol VIII pp 259-299
- 313 PERRY H M JR. Personal communication
- 314 FRIEDMAN M ROSEMAN R H AND BYERS S O Deranged cholesterol metabolism and its possible relationship to human atherosclerosis A review *J Gerontol* 10:60 1955
- 315 DE SUTONAGY G I AND WATERS L L The effect of altered lipid metabolism on experimental lesions of the coronary arteries. *Circulation* 4 468, 1951
- 316 COWDREY E V *Arteriosclerosis* New York Macmillan 1933
- 317 KATZ L N Studies on experimental atherosclerosis and hypertension in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 174
- 318 WILENS S L Orthostatic influences on the distribution of atheromatous lesions in the cerebral and other arteries *Arch Int Med* 82 431 1948
- 319 CORCORAN A C PAGE I H DUSTAN H P AND LEWIS L A Atherosclerotic complications of hypertensive disease Relation to therapeutic response and to serum protein and to lipoprotein concentrations preliminary report *Cleveland Clin Quart* 23 115 1956
- 319b Dock, W Blood flow blood pressure and intimal thickness as factors in localizing atheroma formation in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 129
- 320 ANITSCHKOW N Experimental arteriosclerosis in animals in *Arteriosclerosis* Cowdrey E V New York Macmillan 1933 pp 271-322
- 321 WISSLER R W ALLEN R F MOY R H AND BRADFORD W L Role of arterial and renal injury in production of atheromatous lesions in coronary arteries of the rat under various dietary conditions *Federation Proc* 15 539 1956
- 322 WAKERLIN G E MOSS W G NEVILLE J B AND BOURQUE J E. Effect of experimental renal hypertension on experimental cholesterol atherosclerosis in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 193
- 323 DUFF G L Experimental cholesterol arteriosclerosis and its re

- ships in human plasma atherosclerosis and related conditions.  
*Am J Med* 11 480 1951
- 355 BARR, D P Influence of sex and sex hormones upon the development of atherosclerosis and upon the lipoproteins of plasma *J Chronic Dis* 1 63 1955
- 356 KATZ, L. N., AND STAMLER, J *Experimental Atherosclerosis* Springfield, Thomas 1953
- 357 KEYS A The physiology of the individual as an approach to a more quantitative biology of man. *Federation Proc.* 8 523 1949
358. KEYS A ANDERSON J T., MICKELSEN O Serum cholesterol in men in basal and nonbasal states *Science* 123 29 1956
- 358b LYN T M., KARVINEN E., AND IVY A. C. Absorption of dietary cholesterol in man *Federation Proc* 15 120 1956
- 359 TURNER, K. B AND STEINER, A A long term study of the variation of serum cholesterol in man. *J Clin Investigation* 18 45 1939
- 360 DEUEL, H. J JR. *The Lipids* Vol 2 New York Interscience 1955
- 361 AFTERGOOD L., ALFON SLATER, R. B., AND DEUEL, H J., JR. Comparative effect of cottonseed oil and lard on cholesterol metabolism in the rat. *Federation Proc* 15 541 19 6
362. LANGDON R. G III Some aspects of cholesterol metabolism related to atherosclerosis in *Fat Metabolism* edited by Najjar V A Baltimore Johns Hopkins Press 1954 pp 162 181
- 363 KINSELL, L. W MICHAELS G D COCHRANE G C., PARTRIDGE J W., JAHN J J AND BALCH H E. Effect of vegetable fat on hypercholesterolemia and hyperphospholipidemia. *J Am Diabetes A.* 3 113 1954
- 364 KINSELL, L. W Personal communication
- 365 FRISKEY R. W., MICHAELS G D AND KINSELL, L. W Observations regarding the effects of unsaturated fats *Circulation* 12 492 1955
- 366 JONES R. J AND REIS O K. The hypocholesteremic effect of a hot alcoholic extract of brain in hypercholesteremic patients. *Circulation* 12 496 1955
- 367 ANDREWS E. H., JR. TAALAS T T., HIRACH J., AND INSULL, W., JR. Effects of dietary fats on the serum lipides of human subjects *J Clin Investigation* 34 918 1955
368. BEVERIDGE, J M R., CONNELL, W F AND MAYER, G. Further studies on dietary factors affecting plasma lipid levels in humans. *Circulation* 12 499 1955
- 369 PETERSON D W., NICHOLS C. W., JR., PEEK, N F AND CHAIKOFF I L. Depression of plasma cholesterol in human subjects consuming butter containing soy sterols. *Federation Proc* 15 569 1956
- 370 TULPULE, P G., AND PATWARDHAN V N The effect of fat and

- 338 TOOR M AGMOY J AND ALLALOUF D Changes of serum total lipids total cholesterol and lipid phosphorus in Jewish yemenite immigrants after 20 years in Israel *Bull Res Council Israel* 4 202 1954
- 339 PAGE I H KIRK E LEWIS W H JR THOMPSON W R AND VAN SLYKE D D Plasma lipids of normal men at different ages *J Biol Chem* 111 613 1935
- 340 BOYD E M Diurnal variations in plasma lipids *J Biol Chem* 110 61 1935
- 341 WILENS S L Bearing of general nutritional state on atherosclerosis *Arch Int Med* 79 129 1917
- 342 HUEPER W C Experimental studies in cardiovascular pathology thesaurosis and atheromatosis produced in dogs by repeated intravenous injection of sodium cellulose glycollate *Am J Path* 21 1021 1945
- 343 HUEPER W C Atheromatosis in dogs following repeated intravenous injections of hydroxy ethyl cellulose *Arch Path* 41 139 1946
- 344 WINDAUS A Über den Gehalt normaler und atheromatöser Aorten an Cholesterin und Cholesterinestern *Ztschr physiol Chem* 67 174 1910
- 345 SCHÖNHEIMER R Zur Chemie der gesunden und der atherosklerotischen Aorta Über die quantitativen Verhältnisse des Cholesterins und der Cholesterinester *Ztschr physiol Chem* 160 61 1926
- 346 LEARY T Crystalline ester cholesterol and atherosclerosis *Arch Path* 47 1 1949
- 347 MORRISON L M AND JOHNSON K D Cholesterol content of coronary arteries and blood in acute coronary artery thrombosis *Am Heart J* 39 31 1950
- 348 DEUEL H J JR The Lipids Vol 1 New York Interscience 1951
- 349 WITTEN P W AND HOLMAN R T Polyethenoid fatty acid metabolism VI Effect of pyridoxine on essential fatty acid conversions *Arch Biochem & Biophys* 41 266 1952
- 350 GOFMAN J W Lipoproteins and atherosclerosis in *Factors Regulating Blood Pressure* Transactions of the Fifth Conference ed by Zweifach B W and Shorr E New York Macy 1951 p 46
- 351 KEYS A Giant Molecules and Cholesterol in Relation to Atherosclerosis *Bull Johns Hopkins Hosp* 88 473 1951
- 352 FURMAN R H Atherosclerosis and lipoproteins *South M J* 48 6 1955
- 353 HACK M H Some properties of human serum lipoproteins *Proc Soc Exper Biol & Med* 91 92 1956
- 354 BARR D P RUSS E M AND EDER H A Protein lipid relation

- cholesterol changes in nephrectomized dogs maintained by peritoneal dialysis *Federation Proc.* 15 118 1956
- 336 ANDERSON J T., TAYLOR H L. AND KEYS A. Serum cholesterol in subjects on reducing diets high and low in fat. *Federation Proc.* 15 54<sup>o</sup> 19 6
- 337 KENNEY V L., CORNWELL, D G., AND OXLEY J L. Vitamin A carotenoids and plasma lipoproteins *Federation Proc* 15 115 1956
- 338 SCHROEDER, H A. Rapid spontaneous variations in blood pressure *Federation Proc* 8 1 1949
- 339 WAGENER, H. P., AND KEITH N M. Diffuse arteriolar disease with hypertension and the associated renal lesions. *Medicine* 18 317 1939
- 340 HELMER O M. Estimation of catechol amines in urine by means of a rabbit aortic strip as an aid to the diagnosis of pheochromocytoma *J Lab & Clin Med* 46 871 1955
- 341 SCHROEDER, H A. Studies on essential hypertension IV Early arterial hypertension *Am J M Sc* 204 62 1942.
- 342 PERERA, G A. Hypertensive vascular disease: Therapeutic principles and objectives *J Chronic Dis* 1 472 1955
- 343 SCHROEDER, H A. STEELE, J M. Studies in "essential" hypertension II The association of hypertension with organic renal disease *Arch Int Med* 68 261 1941
- 344 SCHROEDER, H A. AND STEELE, J M. Abnormalities of the urinary tract in "essential" hypertension. *Proc Soc Exper Biol & Med* 39 107 1938
- 345 GROPPER, A L. SURTSYN S. AND HEDRICK, J T. Effects on essential hypertension of veroid. A new derivative of veratrum viride *Arch Int Med* 87 789 1951
- 346 SCHROEDER, H A. Hydralazine (Apresoline) in the control of severe hypertension *Practitioner* 173 195 1954
- 347 SCHROEDER, H. A. Renal failure associated with low extracellular sodium chloride The low salt syndrome *J.A.M.A.*, 141 117 1949
- 348 SCHROEDER, H A. GOLDMAN M L. FUTCHER, P H., AND HUNTER, M. Low sodium chloride diets in hypertension. *J.A.M.A.*, 140 458 1949
- 349 SCHROEDER, H A. FUTCHER P H., AND GOLDMAN M L. The effects of the "rice diet" upon the blood pressure of hypertensive individuals *Ann Int Med* 30 713 1949
- 400 SCHROEDER, H A. AND PERRY H M JR. Errors in the evaluation of hypertension *Am. Heart J.*, 51 716 1956
- 401 SCHROEDER, H A. The effect of 1 hydrazinophthalazine and hexamethonium on hypertension *J Lab & Clin Med* 38 949 1951
- 402 SCHROEDER, H A. Control of hypertension by hexamethonium and

- pyridoxine deficiencies on rat liver dehydrogenases *Arch Biochem & Biophys* 39 450 1952
- 371 SCHROEDER H A AND PERRY H M JR. Cholesterol lowering action of metal binding agents in man *Circulation*, 12 494 1955
- 372 PERRY H M JR AND SCHROEDER H A The effect of two metal binding agents on plasma cholesterol in man *Circulation* 12 759 1955
- 373 UHL, H S M BROWN H H ZLATHIS A ZACK B MYERS G B AND BOYLE A J Effect of ethylenediamine tetraacetic acid on cholesterol metabolism in rabbits Preliminary report on effect of parenteral and oral administration of disodium and calcium salts *Am J Clin Path* 23 1226 1953
- 374 ROSENMAN R H AND SMITH M K The effect of certain chelating substances (EDTA) upon cholesterol metabolism in the rat *J Clin Investigation* 35 11 1956
- 375 CURRAN G L Metal chelating agents and hepatic cholesterol synthesis *Proc Soc Exper Biol & Med* 88 101 1955
- 376 RUBIN M MARTELL A E AND BERSWORTH F C *The Biological Actions of the Versenes* Framingham Mass Versenes Inc. 1954
- 377 WILKINSON C F JR, JACKSON R S BOZIAN R C BENJAMIN M R LEVERE A H CRAFT G AND DAVIDSON N W II Clinical experience with sitosterols" *Tr New York Acad Sc* 18 119 1955
- 378 BOSE J P AND DE U N Cholesteremia in normal and diabetic Indian subjects *Indian J M Research* 24 489 1936
- 379 BOYD T C AND RAY A C Notes on cholesterol content of Indian blood in health and leprosy *Indian J M Research* 15 643 1928
- 380 GHOSE A C Cholesterol content of blood in Indians and its significance in jaundice *Indian J M Research* 20 883 1933
- 381 CORCORAN A C AND RABINOWITCH I M A study of the blood lipoids and blood protein in Canadian Eastern Arctic Eskimos *Biochem J* 31 343 1937
- 382 WALKER A R P AND ARVIDSSON U B Fat intake serum cholesterol concentration and atherosclerosis in the South African bantu Part I Low fat intake and the age trend of serum cholesterol concentration in the South African bantu *J Clin Investigation* 33 1358 1954
- 383 KEYS A VIVANCO F RODRIGUEZ MINON J L KEYS M H AND MENDOZA H C Studies on the diet body fatness and serum cholesterol in Madrid Spain *Metabolism* 3 195 1954
- 384 *Vitamin B<sub>6</sub>—Selected Annotated Bibliography* Rahway N J Merck & Co Inc. 1954
- 385 LEWIS L A KOLFF W J AND PAGE I H Serum lipoprotein and

- cholesterol changes in nephrectomized dogs maintained by peritoneal dialysis *Federation Proc.* 15 118 1956
- 386 ANDERSON J T., TAYLOR H L. AND KEYS A Serum cholesterol in subjects on reducing diets high and low in fat. *Federation Proc* 15:512 1956
- 387 KRINSKY N I., CORYWELL, D G., AND ONCLEY J L. Vitamin A carotenoids and plasma lipoproteins *Federation Proc* 15 113 1956
- 388 SCHROEDER, H A. Rapid spontaneous variations in blood pressure *Federation Proc* 8 1 1949
- 389 WAGENER, H P AND KEITH N M. Diffuse arteriolar disease with hypertension and the associated retinal lesions *Medicine* 18:317 1949
- 390 HELMER, O M Estimation of catechol amines in urine by means of a rabbit aortic strip as an aid to the diagnosis of pheochromocytoma *J Lab & Clin Med* 46:871 1955
- 391 SCHROEDER, H A Studies on essential hypertension IV Early arterial hypertension *Am J M Sc.*, 204:67 1942.
- 392 PERERA G A Hypertensive vascular disease: Therapeutic principles and objectives *J Chronic Dis.*, 1 472 1955
- 393 SCHROEDER H A STEEL, J M Studies in "essential" hypertension II. The association of hypertension with organic renal disease *Arch Int Med* 68:261 1941
- 394 SCHROEDER, H A., AND STEEL, J M Abnormalities of the urinary tract in essential hypertension *Proc Soc Exper Biol & Med.*, 39 107 1938
- 395 CROPPER, A L SCHRISIM S AND HEDRICK J T Effects on essential hypertension of veratrid A new derivative of *veratrum viride* *Arch Int Med* 87:789 1951
- 396 SCHROEDER, H A Hydralazine (Apretoline) in the control of severe hypertension *Practitioner* 173 195 1954
- 397 SCHROEDER H A Renal failure associated with low extracellular sodium chloride The low salt syndrome *J.A.M.A.*, 141 117 1949
- 398 SCHROEDER H A., GOLDMAN M L, FUTCHER, P H AND HUNTER M Low sodium chloride diets in hypertension *J.A.M.A* 140 458 1949
- 399 SCHROEDER, H A FUTCHER, P H AND GOLDMAN M L The effects of the rice diet upon the blood pressure of hypertensive individuals *Ann Int Med* 30:713 1949
- 400 SCHROEDER H A AND PERRY H M., JR. Errors in the evaluation of hypertension *Am Heart J* 51:776 1956
- 401 SCHROEDER, H A The effect of 1 hydrazinophthalazine and hexamethonium on hypertension *J Lab & Clin Med* 38:949 1951
- 402 SCHROEDER, H A. Control of hypertension by hexamethonium and



1 hydrazinophthalazine Preliminary observations *Arch Int Med* 89 523 1952

- 403 SCHROEDER H A MORROW J D AND PERRY H M JR Studies on the control of hypertension by Hyphex I Effects on blood pressure *Circulation* 8 672 1953
- 404 PERRY H M JR SCHROEDER, H A AND MORROW J D Studies on the control of hypertension by Hyphex IV Levels of the agents in urine and blood *Am J M Sc* 228 403 1954
- 405 SCHROEDER H A MORROW J D., AND PERRY H M JR Studies on the control of hypertension by Hyphex V Effects on the course of the malignant stage *Circulation* 10 321 1954
- 406 PERRY H M JR. AND SCHROEDER H A Studies on the control of hypertension VI Some evidence for reversal of the process during hexamethonium and hydralazine therapy *Circulation* 13 528 1956
- 407 PERRY H M JR AND SCHROEDER H A Studies on the control of hypertension VII Effects of ganglionic blockade combined with hydralazine on the malignant stage complicated by renal azotemia *Circulation* 14 105 1956
- 408 SCHROEDER, H A Hypertension in *Current Therapy* edited by Conn H F Philadelphia Saunders 1952 pp 162 167
- 409 SCHROEDER H A MORROW J D AND PERRY H M., JR. Medical control of hypertension by Hyphex *Proc A.M.A Scientific Session June 1953*
- 410 SCHROEDER H A Hypertension in *Current Therapy* edited by Conn H F Philadelphia Saunders 1954 pp 187 196
- 411 SCHROEDER H A The treatment of arterial hypertension Veterans Administration Technical Bulletin TB 10 102 1954
- 412 SCHROEDER H A AND PERRY H M JR Hexamethonium chloride and 1 hydrazinophthalazine (Hyphex) in malignant hypertension *Am J Med*, 16 607 1954
- 413 SCHROEDER H A AND PERRY H M JR. Medical management of hypertension *Proc Second World Congress of Cardiology and Am Heart A* 1954 p 89
- 414 SCHROEDER H A Why not control hypertension by drugs? *Clin Research Proc* 3 1 1955
- 415 PERRY H M., JR. AND SCHROEDER H A The use of pentolinium tartrate with and without hydralazine in the treatment of severe human hypertension *New England J Med* 252 1057 1955
- 416 PERRY H M JR AND SCHROEDER H A Studies on the control of hypertension VIII Effects on the course of the benign stage In preparation
- 417 PERRY H M JR AND SCHROEDER H A Evidence for reversal of

- the hypertensive process when blood pressure is controlled by drugs. *Circulation* 12:759 1955
418. SCHROEDER, H. A. AND PERRY H. M., JR. Clinical Conference: The treatment of hypertension with modern drugs. *Circulation* 13:98 1956
419. SCHROEDER, H. A. Management of arterial hypertension. *Am J Med.* 17:540 1954
420. SMITHWICK, R. H. BUSH R. D., KINSEY D., AND WHITELOW G. P. Hypertension and associated cardiovascular disease. *JAMA*, 160 1023 1956
421. WHITE, P. D. Severe hypertension—study of one hundred patients with cardiovascular complications. *JAMA* 160 1077 1956
422. CLARKE, N. E., CLARKE, C. N., AND MOSHER, R. E. The "in vivo" dissolution of metastatic calcium. An approach to atherosclerosis. *Am J M Sc* 229 142 1955
423. LEE, R. E. SELIGMANN A. M. GOESEL, D., FULTON L. A. AND CLARK, M. A. Reserpine-hydralazine combination therapy of hypertensive disease with hydralazine in doses generally below the "toxic range." *Ann Int Med.* 44 456 1956
424. MEYER, R. Antistune and related imidazoles. *Ann New York Acad Sc* 50 1161 1950
425. WILKINSON E. L., BACKMAN H., AND HECHT H. H. Cardiovascular and renal adjustments to a hypotensive agent (1 hydrazinophthalazine). *J Clin Investigation* 31:872 1952.
426. REURI F. C. Renal hyperemia induced in man by a new phthalazine derivative. *Proc Soc Exper Biol & Med* 73 10<sup>th</sup> 1950
427. MARKS P. A., REYNELL, P. C., AND BRADLEY S. E. Hemodynamic effects of 1 hydrazinophthalazine in the dog, with special reference to circulating splanchnic blood volume. *Am J Physiol.* 183 144 1955
428. PICK, R., STAMLER J. RODBARD S. AND KATZ L. N. Inhibition of coronary atheromatosis in cholesterol fed chicks receiving estrogens. *Circulation* 4 468 1951
429. PICK, R., STAMLER, J., RODBARD S., AND KATZ L. N. Estrogen induced regression of coronary atherosclerosis in cholesterol fed chicks. *Circulation* 6:858 1952
430. RIVIN A. U. AND DIMITROFF S. P. The incidence and severity of atherosclerosis in estrogen treated males and in females with a hypoestrogenic or a hyperestrogenic state. *Circulation* 9 533 1954
431. WILKINS S. L. The resorption of arterial atheromatous deposits in wasting disease. *Am J Path.* 23:93 1947
432. MEISTER, A. Metabolism of glutamine. *Physiol Rev.* 36 103 1956

- 433 NOBLE N L BOUCEK R J KAO K T AND PARTIN H C Hexosamine concentration in normal and atheromatous human aortic connective tissue *Federation Proc* 15 463 1956
- 434 MCGLODY D H OLSEN N S AND FIELD L A pressor material produced by the action of pepsin on casein *J Biol Chem* 210 299 1956
- 435 POFENOE E A AND DU VIGNEAUD V A partial sequence of amino acids in performic acid-oxidized vasopressin *J Biol Chem* 206 353 1954
- 436 MEIER R TRIPOD J AND BRÜNI C Änderung der blutdrucksenken den Wirkung von Apresolin und Nepresol durch Reaktion mit Serumbestandteilen *Arch exper Path u Pharmacol* 273 338 1954
- 437 SCHULER W AND MEIER R Releasing action of metals on the hydrazine inhibited enzymatic oxidation of cadaverine *Arch Exper Path*, 223 169 1954
- 438 TRIPOD J AND MEIER R Détermination et classification pharmacodynamique de l'action vasculaire périphérique de l'Apresoline du Nepresol et du Serpasil *Arch internat pharmacodyn* 99 101 1954
- 439 SAIFER A AND KAMMERER O F Photometric determination of total cholesterol in plasma or serum by a modified Liebermann Burchard reaction *J Biol Chem* 164 657 1946
- 440 BRONTE STEWART B KEYS A AND BROCK J F Serum cholesterol diet and coronary heart disease An interracial survey in the Cape Peninsula *Lancet* 2 1103 1955
- 441 OFFENHEIM F Review of one hundred autopsies of Shanghai *Chinese Chinese M J* 39 1067 1925
- 442 SCHLITTLER E MACPHILLAMY H B DORFMAN L FURLENMEIER A HUERNER C F, LUCAS R. MUELLER J M SCHWYZER R. AND ST ANDRE A F Chemistry of rauwolfia alkaloids including reserpine *Ann New York Acad Sc* 39 1 1954
- 443 KATZ L N Current trends in atherosclerosis research. *Circulation Research* 4 123 1956
- 444 BRAGDON J H AND HAVEL R J *In vivo* effect of anti heparin agents on serum lipids and lipoproteins *Am J Physiol* 177 128 1954
- 445 OPDYKE, D F, AND OTT W H Influence of source of cholesterol grade of cottonseed oil and breed on experimental avian atherosclerosis *Proc Soc Exper Biol & Med* 85 414 1954
- 446 SCHROEDER H A A practical method for the reduction of plasma cholesterol in man *J Chronic Dis* 4 461 1956
- 447 ECKEY E W *Vegetable Fats and Oils* New York Reinhold 1954
- 448 BRONTE STEWART B ANTONIS A EALES L AND BROCK J F Effects of feeding different fats on serum cholesterol level *Lancet* 1 521

# INDEX

## A

- $\alpha_2$ -globulins 69 76-77
  - from beef 76
  - from hogs 76
  - from horses, 16
  - in liver 69
- Abdominal
  - aorta 244
  - lymphosarcoma 61
  - scars 257
- Abnormal
  - hair in cattle 175
  - trace metals in man 116-185 206
- Abraham J 311
- Abrams M L, 314
- Abreu B E., 302
- Absence of kidneys 60
- Acetate 83 92 208 224 225 292 294
- Acetal lipid 221
- Acetaldehyde 83 92
- Acetic acid 224
- Acetoacetic acid, 224
- Acetonyl mercaptan 99
- Acetyl acetone 158
- Acetyl amino 162
- Acetyl choline (quaternary ammonium compound) 40-41
- Aching 257
- Achor R W P 302
- Acid
  - content in urine 59 236 288
  - esters of cholesterol 217
  - foods 198
  - renal cortex, 58-59
- Ackerman N W 299
- Acridine 164
- ACTH 164
- Actomyosin 149
- Acute infections 70 183
- Acute nephritis 10
- Actions of adrenergic blocking agents in man table on 48
- Actomyosin 234
- Acute vasospastic states 77
- Acyl Co-enzyme A dehydrogenase 147 148 230
  - copper flavinoid in 147
- Adams E., 318
- Addison's disease 134 136
- Adenoma in adrenal cortex 11
- Adipoin 163
- Adipose tissue trace metals in estimate of 170-171
- Adrenalin 157
- Adrenals 4 6-7 11 40 49-50 109-110 125 132 140 170-171 176-183 194 196-197 199 224 241 243 276 286 291 292
  - aluminum in 176-183
  - barium in 180
  - cadmium in 196
  - cholesterol in 224
  - cortex 11 49-50 109-110 125 132 140 243 276 291 292
  - adenoma in 11
  - in hypertension 138
  - overactivity of 139
  - relation of to medulla 133-135
  - hyperfunction 276
  - mechanisms 132 140
    - clinical findings of 135
  - steroids 133-134

- as cause of hypertension 133
- as result 136-139 291
- tumors 243
- zona glomerulosa 292
- dysfunction 241
- effect of experimental nephro-  
genic hypertension on 133
- hyperplasia 136
- lead in 176-183 194
- medulla 40\*
- trace metals in 125 170-171 176-  
183 194 196
- Adrenalectomy 138 140 276
- bilateral 276
- Adrenalectomized rats urinary ex-  
tracts in 138
- Adrenocortical factor summary  
291 292
- Adrenocorticotrophic hormone  
(ACTH) 136
- Adrenergic agent 109
- Adrenergic blocking agents com-  
ment on 49 50
- Adrenergic blockade of vasoactive  
peptides (rabbit aortic strip)  
110
- Aerated water metals in 197
- Aerobic metabolism 50
- Africa
  - hypertension in 25
  - natives 182 185 194
  - tissues metals in 194
- Aftergood L. 323
- Agitated depressive psychosis 34
- Agmon J. 214 322
- Ag P-dimethylamino-benzalrhoda-  
mine 163
- Agranulocytosis 151 161
- Ahrens E H Jr 323
- $\alpha$  ketoglutaric carboxylase 148
- Alanine 63 76 195
- Alaskan esquimaux lipids of 209
- Albumin 6-7 112 190 195 248  
269-271
- Albuminuria 112 190 248 269-  
271
- Alcohol 144 149 193 222
- Aldehyde 77 149 152
- oxidase 152
- Aldosterone 136-139 286 291 292
- Aldosteronism 136
- Alexander H L. 161 164 316
- Alexander W M 302
- Albrink W S 318
- Alfin Slater R B 323
- Aliphatic compounds 103
- Alkaline 149 152 157
- phosphatase 152 157
- Alkalosis 134-138
- Allalouf D. 214 322
- Allen R P 310 320
- Allergy 166 202
- Alpha lipoproteins 236
- Alrose Chemical Co 106
- Altschule M D 306 319
- Aluminum 68 105 143 145-147  
167 176-183 191 199
- in adrenals 176-183
- in animal tissues 191
- in aorta 176-183
- in brain 191
- in heart 176-183 191 199
- in kidney 191
- in liver 191
- in lungs 176-183 191
- in plant tissues 191
- in prostate 176 183
- in spleen 191
- in stomach 176-183
- in thyroid 176-183
- phenylalanine complex 105
- toxicity of 191
- Amblyopia 270
- $\alpha$  mercaptopropionic acid 98
- American Indians hypertension  
among 25
- American Negroes hypertension  
among 25

- Amine oxidase—see Monamine oxidase  
 Amino acids, 31 37 96 97 98 99 110 120 132  
   143-144 154 161 162 167 187  
   188 193 197 206 224 286-290  
   decarboxylation of 64 157 228  
   by kidney 84  
   deamination of 31 37 59 67 124  
   14 94 110 188  
   theory of, 62 72  
   in vasoactive peptides chart on 76  
   metabolism 67 224  
   renal tubular reabsorption of 193  
 Aminoaciduria cadmium 193 229  
 Amino- $\alpha$  mercaptobenzothiazole 99  
 Amino grouping (primary secondary tertiary cyclic tertiary) 143  
 Aminoguanidine  $\text{HCO}_2$  87 97  
 Aminopeptidase 197  
 Aminopyrine 161 167 187  
 Aminothiazole 162  
 Ammonia 97 103 133 153 155  
   286-299  
   in urine 288-289  
 Ammoniated mercury freckle cream  
   action of 153  
 Ammonium  
   chloride 97  
   compounds 133  
   nitrogen 103  
 Amphetamine (Benzedrine) 31 63  
   273  
 Amyloidosis 219 231 270  
 Androgens 138  
 Androgenic overproduction 138  
 Anaerobic decarboxylation 37 38  
   50 62 286  
 Anaesthetized rats 93-109  
   effect of intravenous sulphhydryl  
   compounds on the diastolic  
   pressures of 98  
   effect of intravenous EDTA on  
   diastolic blood pressure of  
   96-109  
 Anaesthesia peripheral vasoconstriction under 38  
 Analgesic agents 156-162  
 Analysis of metals 163  
   some reagents for 163  
 Anaphylactic shock 166  
 Anatomical causes of renal ischemia  
   78-82  
 Anatomic chemistry of phospholipids 234  
 Anderson J T. 3, 3 325  
 Andrus S B 321  
 Anemia 93 117 164 1, 4 175  
   aplastic 164  
   hypochromic, 175  
   in infancy 175  
 Aneurysms 243  
 Angina pectoris, 204 219 257 273  
   275 277 281 283  
   syndrome 204  
 Angiotonin (constrictor peptide)  
   58 66-67 69 74 94 110  
 Animals  
   atherosclerosis in 280  
   ataxic 175  
   blood protein obtained from  
   1273  
   fat 233 278-279 293  
   tissues  
     aluminum in 191  
     nickel in 190  
 Anionic elements 151  
 Anitschkow N 320  
 Ankle edema 231  
 Anorexia 174 175  
 Ansoylen (pentolinium) 43  
 Antiadrenal hormones 110  
 Antibiotics 63 167 164 243 264  
   bacterial resistance to 64  
 Anticoagulant 236  
 Antidiuretic properties 2  
 Antiemetic action 35

- Antimetabolites 186 200
- Antihistamines 87 161
- Antihypertensive tranquilizing  
drugs 36-38 69 74 82 109  
comment on 36-38
- Anti Lewisite British (BAL) 93
- Antipyrine 162
- Antipyretics 162
- Antiseptic chelating agents 157
- Anti thyroid drugs 94 153 161 162
- Antituberculous hydrazides 91
- Antimony 144 151 161 167 180  
192 199  
in animals 199  
in insecticides 199  
in rubber 199  
in solders 199  
in tin foil 199
- Antonchak N 313
- Anuria 51
- Anxiety 20 31 66 244 249 285
- Apathy 262
- Aplastic anemia 164
- Apoplexy 5 11 252
- Apoplectic stroke 252
- Apotransaminase 59
- Appendix malignant carcinoid of  
serotonin in 32
- Appetite loss of 262
- Apresoline blockade of pherentasin  
111
- Arachidonic acid 226 229 292 294  
foods containing 228  
synthesis 229
- Ariboflavinosis 175 206
- Arginine 63 74 76 148 149 152
- Arginine ATP transphorylase 149
- Argyria 200
- Army combat rations B<sub>6</sub> in 121
- Arsenic 83 131 151 153 161 167  
180 192 199  
in the skin 153  
compounds 161
- Arterenone 92
- Arterial  
blood primary amines in 59 69  
constriction 119  
disease organic  
extra renal 79 81  
intra renal 81  
hypertension 3 11 18 23 81 149  
284 285  
basic or constitutional factors  
of 18 25  
case histories of 4 11  
environment and heredity in  
20 25  
in dogs 84  
in rats 84  
psychic manifestations of cause  
of 284 285  
seen as sign of disturbed hemo-  
dynamics 3  
lesions 206  
mash 87 92  
obstruction 212  
thrombosis 53  
walls sodium content of 125
- Arteries  
cholesterol in 209  
coronary 25 204 209 210 213  
235 236 269  
hardening of 210  
hyalin degeneration of 128  
lipids in 206 208 213 214 216-  
217 230 234 236  
of the brain structure of 16  
retina 15-16
- Arteriolar  
nephrosclerosis 7 11 13 128 129  
139 245 269 216 286  
sequence of development of 13  
spasm 6
- Arterioles  
hyalinization of 12  
thickening of 128
- Arteritis in dogs from fat 210

- Atherogenic ultra-centrifugal lipoproteins 36  
 Atheromata 13<sup>o</sup> 19<sup>o</sup> 20<sup>o</sup> 213-214  
     24<sup>o</sup> 915  
     cholesterol filled 132  
     of the renal artery 242<sup>o</sup> 945  
 Arthralgia 19 94 112 113 20<sup>o</sup> 231  
 Arthritis Marie Strumpell 231  
     rheumatoid 19  
 Arvidsson U B 212 216A 324  
 Aschoff L 211 3<sup>o</sup> 1  
 Ascidia Vanadium in 187  
 Asparagine 63  
 Aspartic acid 63 74 16 988  
 Aspergillus niger metal in 18<sup>o</sup>  
 Astatine 151  
 Asthma 20  
 Asthenia 970  
 Asymptomatic duodenal obstruction 8 2<sup>o</sup> 270  
 Asystolic arterial pressure gradients (examples) 14  
 Ataxia 34 17<sup>o</sup>  
     in animals 17<sup>o</sup>  
 Atherosclerosis  
     abnormal trace metals as contributing cause of 192  
     among Kirghiz nomads 209  
     bilateral renal 80  
     cadmium as contributing cause of 192  
     case history of 9-10  
     cerebral 210  
     chromium as contributing cause of 192  
     clinical implications of 236-237  
     coronary 213 23<sup>o</sup>  
     effect of sex in 23<sup>o</sup> 236  
     clearing factor of 236  
     etiological factors of 20<sup>o</sup>  
     expected results in treatment of 281 283  
     gangrene in 90<sup>o</sup>  
     in animals 230  
     in China 13 203 210  
     dogs 20<sup>o</sup>  
     rabbits 210  
     rats 20<sup>o</sup> 210  
     in the aorta 183 210 23<sup>o</sup> 236 2<sup>o</sup> 1  
     lead as contributing cause of 19<sup>o</sup> 191  
     lesions of 206 237  
     mechanisms in 203 237  
     method of treatment of 2<sup>o</sup> 8-281  
     more frequent than hypertension 211  
     occlusion of the renal artery 80  
     pathogenetic factors in 20<sup>o</sup> 208  
     preliminary approach to the treatment of 277 283  
     renal 238  
     some common denominators of hypertension and 208 211  
     summary on 29<sup>o</sup> 296  
     tin as contributing cause of 192  
     Vitamin B<sub>6</sub> and 207 237  
     Western civilization and 203  
 Atherosclerotic plaques 80 127  
 ATPase 149 15<sup>o</sup>  
 Atocopherol 221  
 Atropine 110  
 Aureomycin 157  
 Aurintricarboxylic acid 200  
 Auscultation 270  
 Autonephrectomy 82  
 Autonomic blocking agent 41 43  
     3 265  
 Autonomic nerves 4  
 Autopsies 7-8 11 2<sup>o</sup> 53 80 169  
     179-180 203-204 273  
     sclerous at 203  
 Aide sodium 84 150  
 Azide 81 150  
 Azotemia 12 16 49 52 53 60-61  
     81 11 13<sup>o</sup> 241 248 2<sup>o</sup> 3 25  
     25<sup>o</sup> 256 269-271 273-27<sup>o</sup>  
     chart on progress in 273





- Benodaine (Pipetoxan) 49  
 Benzene rings 49  
 Benzedrine (Amphetamine) 31  
 Benzodioxanes, 48-50 60  
 Benzoin-oxime 163  
 Benzyl 71  
 Benzylamine derivatives of 45  
 Benzylthiopseudourea hydrochloride 10<sup>o</sup>  
 Bernhart F W 31<sup>o</sup>  
 Bernheim F., 31 184 186 234 301 317  
 Bernheim M L C., 184 186 234 317  
 Bernini metal and 176  
 Berry R. L. 300  
 Bersworth F C 3<sup>o</sup>4  
 Bertrand D 317  
 Beryllium 144 150-151 159 167 180 200  
   poisoning 200  
 Beta globulin 2.0  
 Beta lipoproteins 236  
 Beveridge J M R., 323  
 Bhadrakom S 303  
 Bibliography of the literature on the minor elements and their relation to plant and animal nutrition 316  
 Bicarbonate 286  
 Biehl J P 309  
 Bifurcating arteries 79 20<sub>o</sub>  
 Bifurcation of the aorta 20<sub>o</sub>  
 Bilateral  
   adrenalectomy 276  
   hydronephrosis 61  
   papilledema 270  
   renal arteriolar sclerosis 8<sup>o</sup>  
   renal arteriosclerosis 80  
 Bioassay 214  
 Biochem J 64  
 Biochemical alterations in blood vessels 4  
 Biopsies 81 128 231  
 Bing R J 303  
 Binger C. A 299  
 Binion J 312  
 Bis (diethylthiocarbamyl) disulfide (antabuse) 162  
 Bismuth 151 153 161 164 167 179 185 199  
   in the kidneys 199  
   in the liver 199  
   in the lungs 1.9  
   in the skin 153  
 Black M M., 310  
 Blackman S S Jr 79-80 308  
 Bladder 170-171 176 183 194 241  
   trace metals in 1.0-171 1.6-183 194  
 Blascho H 303  
 Bleeding 251  
 $\beta$ -lipoproteins 217 236  
 Block 215  
 Blocking actions  
   autonomic 2<sup>o</sup><sub>o</sub>  
   clinical implications of 50-54  
   in vivo 92  
   on rabbit's arterial strip 9<sup>o</sup> 93  
 Blood cholesterol 211 217 223-228  
   levels examples of in healthy male subjects 216A  
   levels in man effect of various fats on 22<sub>o</sub>-228  
 Blood  
   clotting of 155  
   dyscrasias 161  
   flow femoral 48  
   flow mesenteric 48  
   flow renal 48 208  
   lipids in 206 213 216  
   metastatic calcium in vessels 29<sub>o</sub>  
   normal cholesterol levels in chart on 212  
   pressure  
     depression of by drugs 30  
     examples of adequate control of 255

- Azotemic hypertension 60-61  
     chart on 61  
 Azotemic individuals 52  
 Aorta 7 9 38 78 79 109 128 170-  
     171 176 180-181 183 197 199-  
     200 203 205 208 210 216 218  
     235-236 238-239 242 244 283  
     atherosclerosis in 183 210 235-  
     236 251  
     abdominal 244  
     arterial plaques 128 216  
     arteriography 242  
     bifurcation of 205  
     cholesterol in 203  
     coarctation of 239 244  
     depressor nerves of 38  
     elasticity of 238  
     phosphorous in 216  
     stenosis of 218  
     strip rabbit 109  
     trace metals in 170 171 176-183  
         194 196 199-200  
         aluminum in 176-183  
         barium in 180 200  
         cadmium in 196  
         lead in 176 183 194 199  
         tin in 181 199  
 Aortography 79 242
- B**
- Backman H 327  
 Bacteria 65 153 157 173 175 242  
     264  
     in the colon 65 175  
     in the rumen 175  
     in the urine 242  
 Bacterial chelating agents 157  
     flora 65  
     oxalacetic carboxylase 153  
     resistance to antibiotics 264  
 Baer J E 303 310  
 Balar J 143 145 315  
 Bailey P 300  
 Baker B M Jr 301  
     Baking powders 191  
     BAL (dimercaptopropanol) 83-85  
         95 99 106-108 161 162 165 200  
     Balch H E 323  
     Baldwin E F 306  
     Ball J D 299  
     Ballinger J 80 308  
     Banthine 165  
     Barbiturates 164  
     Barbituric acid 165  
     Barcroft H 306  
     Barium 92 150 167 180 183 200  
         in adrenal 180  
         in aorta 180 200  
         in bone 180  
         in gastrointestinal tract 180  
         in lungs 180  
         in thyroid 180  
     Barley 172  
     Barnes Hospital 270  
     Baroreceptor changes 39  
     Barr D P 220-221 322 323  
     Barrett H M 317 318  
     Basic chemical reactions in vitro 92  
     Basic or constitutional factors of ar-  
         terial hypertension 18 25  
     Bass A C 314  
     Bauman E J 315  
     Bays R P 25 299  
     B. Coli 157  
     Beans  
         lima 280  
         soy 280  
     Beechnut oil 227  
     Beef  
          $\alpha$  globulins from 76  
         livers 173  
         rib roast 278  
         serum 76  
     Beer 198  
     Beiler J M 302  
     Bell E T 308 313 321  
     Benditt E P 302  
     Benjamin M R 324

Burchard 219 216A  
 Bush R. D., 397  
 Bush sickness in cattle 174  
 Butt E. M. 316  
 Butter 173 223 225 226 278 280  
   composition of 223  
 Buttermilk 980  
 Butyric dehydrogenase 229  
 Buxton J. 309  
 Byers S. O. 370  
 Byron F. B. 309

## C

C<sup>14</sup>-carboxyl labeled acetate 189  
 Cachexia 173  
 Cadaverine 63  
 Cadmium 99 93 107 193 123 10  
   113 144 151 153 155 161 167  
   173 176 181 183 194 197 199  
   200 209 288 290 993  
   as contributing cause of athero-  
     sclerosis 199  
   as contributing cause of hyper-  
     tension 199  
   as a toxic metal 19  
   in adrenal 196  
   in aorta 196  
   in brain 196  
   in heart 196  
   in intestine 196  
   in kidneys 193 134 176 181 183  
     196-197 199 290  
   in liver 176-183 196  
   in pancreas 176-183 196  
   in spleen 196  
   in stomach 196  
   in tissues 183 196  
     muscle 196  
   in thyroid 176-183 196  
   in urine 193 200  
   in vegetables 198  
   nephritis 93 161  
   plated vessels 198  
   poisoning 9 196 198

ice trays as cause of 196  
 Calcium 91 107 118 127 141 150  
   153 232 290-281  
   citrate chelate 155  
   disodium ethylenediamine tetra-  
     acetate (Calcium Versenate)  
     91 232 280-281  
   in bone 281  
   ionized 281  
   ions 118  
   metastatic 281  
   salts 107  
 Calvin M., 142 157 314 318  
 Campbell K. N., 300  
 Camphor 53  
 Candy metal in 193  
 Canned soups B. in 280  
 Cannon W. B. 301  
 Carbon (C<sup>14</sup> carbonyl) 83 99 91  
   113 145-144 147 148 150 12  
   162 164 197 199 223 288  
 Carbon atoms 293  
 Carbon dioxide 197  
 Carbamide 162  
 Carbazone 164  
 Carbonated beverages cadmium in  
   194 199  
 Carbonic anhydrase 94 147 148 150  
   19 288  
 Carbonyl binding 113  
 Carbonyl linkage 291  
 Carbonyl reagent 83 92  
 Carboxypeptidase 71 148  
 Carcinoma of prostate 218-219  
 Card B. Y., 318  
 Cardiovascular disease 7 9-13 20  
   40 48 59 110-111 125 141 209  
   210 216 249 253 26 270-271  
   27 277 294  
   and trace metals 141 902  
   as inherited trait 20  
   decompensation 263  
   enlargement 10  
   failure 175

- graph 27 29  
 in atherosclerosis 20,  
 lability of 244  
 pyruvate 93 113  
 urea nitrogen 271  
 uremic 60  
 vasoactive substances found in  
   73  
 vessels trace metals in 125  
 viscosity 3-4 111  
 Bloor 212 216A  
 Blurring of vision 7 3,  
 $\beta$  naphthoquinoline 163  
 Bobb F C 316  
 Bock R M 319  
 Bogdansk: D F 301  
 Bone 151 171 175 180 193 191 281  
   affections in pigs from beryllium  
     174  
   affections in rabbits 174  
   barium in 180  
   calcium in 281  
   lead in 193 194  
   marrow cytochrome oxidase ac-  
     tivity of 175  
   phosphatase low 174  
   strontium in 180  
 Bordley J III 301  
 Boric acid 165  
 Boron 144 167 176 183 190 199  
   in spleen 176 183  
 Borrus J C 302  
 Bose J P 212 216A 324  
 Boucek R J 328  
 Bourque J E 320  
 Bovine globulin 288  
   serum albumin 151  
 Bowman D K 316  
 Bowen W J 319  
 Boyd E M 213 215 322  
 Boyd T C 212 216A 324  
 Boyle A J 324  
 Bozian R C 324  
 Brachial bed 14 15  
 Bradford W L 320  
 Bradley S E 327  
 Bradycardia 19 34 39 50  
 Bragdon J H 328  
 Brain 16 30 31 65 125 132 170-  
   171 176-183 191 193 194 196  
   197 206 219 227 228 284  
   arteries of 16 132  
   effect of on vasomotor tone 30  
   extract cholesterolytic effect of  
     227 228  
   lesions 31  
   trace metals in 125 170 171 176-  
     183 191 193 194 196  
   aluminum in 191  
   cadmium in 196  
   lead in 176-183 194  
   silver in 193  
   tumors 219 244  
   vascular tumor of 219  
 Brandt W L 313  
 Brannon E S 307  
 Brass 196  
 Braun Menendez E 80 242 304  
   308 313  
 Braunschweig L W 303  
 Bread 280  
 Breast metastatic carcinoma of  
   218 219  
 Bridges W C 30,  
 Britain adults in 172  
 Broca P 300  
 Brock J F 328  
 Brod J 308  
 Brodie B B 301  
 Bromine 151  
 Bronchial asthma 16,  
 Bronte Stewart B 212 328  
 Brown H H 324  
 Bruni C 328  
 Brust A A 303  
 B subtilis 157  
 Bullous eruptions 16,  
 Bumpus F M 307  
 Bunting H 318  
 Burch G E 315

Burchard 21° 216A  
 Bush R D 3°7  
 Bush sickness in cattle 174  
 Bull E M 316  
 Butter 173 223 225-226 278 2°0  
   composition of 225  
 Buttermilk 260  
 Butyric dehydrogenase 229  
 Buxton J 302  
 Byers S O 3°0  
 Byron F B 309

## C

C-carboxyl-labeled acetate 189  
 Cachexia 175  
 Cadaverine 63  
 Cadmium 9° 95 107 1°3 1°5 130  
   143 144 151 153 155 161 167  
   173 176 181 183 194 197 199  
   2°0 2°2 283 290 293  
   as contributing cause of atherosclerosis 165  
   as contributing cause of hypertension 19°  
   as a toxic metal 193  
   in adrenal 196  
   in aorta 196  
   in brain 196  
   in heart 196  
   in intestine 196  
   in kidneys 123 154 176 181 183  
     196-197 199 290  
   in liver 176-183 196  
   in pancreas 176-183 196  
   in spleen 196  
   in stomach 196  
   in tissues 183 196  
     muscle 196  
   in thyroid 176-183 196  
   in urine 195 200  
   in vegetables 199  
   nephritis 95 161  
   plated vessels 193  
   poisoning 95 196 198

ice trays as cause of 196  
 Calcium 91 107 118 127 141 150  
   155 232 2°0-281  
   citrate thia c 155  
   disodium ethylenediamine tetraacetate (Calcium Versenate)  
     91 2 2 280-281  
   in bone 281  
   ionized 281  
   ions 118  
   metastatic 281  
   salts 107  
 Calvin M 14° 157 314 318  
 Campbell A N 300  
 Camphor 53  
 Candy metal in 198  
 Canned soups B in 2°0  
 Cannon W B 304  
 Carbon (CN carbonyl) 85 92 94  
   113 143-144 147 148 150 15°  
   16° 164 197 199 223 288  
 Carbon atoms 223  
 Carbon dioxide 197  
 Carbamide 162  
 Carbazone 164  
 Carbonated beverages cadmium in  
   197 199  
 Carbonic anhydrase 91 147 148 150  
   15° 288  
 Carbonyl binding 113  
 Carbonyl linkage 291  
 Carbonyl reagent 85 92  
 Carboxypeptidase 71 148  
 Carcinoma of prostate 218-219  
 Card B Y 318  
 Cardiovascular disease 7 9 13 20  
   40 48 52 110-111 1°5 141 202  
   210 246 249 253 265 270 271  
   2°5 277 294  
   and trace metals 141 202  
   as inherited trait 20  
   decompensation 26,  
   enlargement 10  
   failure 175

- graph 27 29  
 in atherosclerosis 205  
 lability of 214  
 pyruvate 93 113  
 urea nitrogen 271  
 uremic CO  
 vasoactive substances found in  
   73  
 vessels trace metals in 125  
 viscosity 34 111  
 Bloor 212 216A  
 Blurring of vision 7 35  
 $\beta$  naphthoquinoline 163  
 Bobb F C 316  
 Bock R M 319  
 Bogdanski D I 301  
 Bone 151 174 175 180 193 194 281  
   affections in pigs from beryllium  
     174  
   affections in rabbits 174  
   barium in 180  
   calcium in 281  
   lead in 193 194  
   marrow cytochrome oxidase ac-  
     tivity of 175  
   phosphatase low 174  
   strontium in 180  
 Bordley J III 301  
 Boric acid 165  
 Boron 144 167 176 183 190 199  
   in spleen 176-183  
 Borrus J C 302  
 Bose J P 212 216A 324  
 Boucek R J 328  
 Bourque J E 320  
 Bovine globulin 288  
   serum albumin 151  
 Bowman D A 316  
 Bowen W J 319  
 Boyd E M 213 215 322  
 Boyd T C 212 216A 324  
 Boyle A J 324  
 Bozian R C 324  
 Brachial bed 14 15  
 Bradford W L 320  
 Bradley S E 327  
 Bradycardia 19 34 39 50  
 Bragdon J H 328  
 Brain 16 30-31 65 125 132 170-  
   171 176-183 191 193 194 196-  
   197 206 219 227 228 284  
   arteries of 16 132  
   effect of on vasomotor tone 30  
   extract cholesterolytic effect of  
     227 228  
   lesions 31  
   trace metals in 125 170-171 176  
     183 191 193 194 196  
   aluminum in 191  
   cadmium in 196  
   lead in 176-183 194  
   silver in 193  
   tumors 219 244  
   vascular tumor of 219  
 Brandt W L 313  
 Brannon E S 307  
 Brass 196  
 Braun Menendez E 80 242 304  
   308 313  
 Braunschweig L W. 303  
 Bread 280  
 Breast metastatic carcinoma of  
   218 219  
 Bridges W C 305  
 Britain adults in 172  
 Broca P 300  
 Brock J F 328  
 Brod J 308  
 Brodie B B 301  
 Bromine 151  
 Bronchial asthma 165  
 Bronte Stewart B 212 328  
 Brown H H 324  
 Brun C 328  
 Brust A A 303  
 B subtilis 157  
 Bullous eruptions 165  
 Bumpus F M 307  
 Bunting H 318  
 Burch G E 315

- function of oxygen tension 64  
 on substances with metal binding properties selectively affecting arterial hypertension 84  
 Cheese 173 223 278 280  
   cottage 280  
   fat free 780  
 Cheilosis 120 131 231  
 Chelating agents 83-91 95 103  
   142 207 206 230 237 234 237  
   231 288-289 291 293  
   antiseptic, 157  
   bactericidal 157  
   drugs as 153-166  
   examples of chart on 162 163  
   fungicidal 157  
   normal and abnormal metals in chart on 146  
 Chelating compounds simple 154-155  
 Chelation principles of 143-146  
 Chemical structures of Yohimbine and Reserpine 248  
 Chemical sympathectomy 275  
 Chemosis 120 131 231  
 Chemotherapy 275-276  
 Chestnuts 171 173  
 Chickens 174 222 2 9  
 Chicken fat, 279  
 Child C. G., 298  
 Children stillborn 124  
 Chills, 34 188  
 China atherosclerosis in 13 203 210  
 China coronary thrombosis in 204  
 China hypertension in 20 203  
 Chloral hydrate 165  
 Chloramphenicol, 162 164  
 Chlorides 59 74 197 198  
 Chlorides in water 197 198  
 Chlorisondamine (Ecolid) 41 43 253 261  
 Chlorophyll porphyrin of 147  
 Chlorpromazine 34 35 51 164  
   chart on incidence of side reactions and toxic effects in normotensive patients, 34 35  
   effects of on system 35  
 Chocolates 173 198  
 Cholesterol 128 132 184 186 188-189 207 211 214 216-225 227 229 235 277 292 293 295  
   aortic, 208  
   digitonide 189  
   esterified 216-223 233  
     acid esters of 217  
     esters nature of 216-223  
   exogenous intestinal absorption of 221 222  
   fitted atheromata 132  
   hepatic, 208  
   in adrenal 224  
   in arteries 209  
   in blood 223 224  
   in kidneys 128  
   in liver 224  
   in rats 207 224  
   in serum 208 221  
   lowering foods essential fatty acid content of 227  
   metabolism of 208 224  
   phospholipid ratio 221  
   plasma 210  
   relation of to dietary fats 223-225  
   synthesis by liver 183  
   synthesis of from acetate 184  
   synthesis possible pathway of chart on 224  
 Cholesterolylus 94  
 Choline aside 89 93  
 Choline esters, 41  
 Choline oxidase 151 152 197  
 Cholinergic drugs 52  
   response to in injections 52  
 Cholinergic stimulation 47  
 Cholinesterase 92  
 Chromatograms 77



- hypertrophy 7 9 11 13 195
  - status 240
  - strain 277
- cardioaccelerator nerves 52
- cardiomegaly 270 271
- cardiovascular cardiac output 48
  - 110 111
- cardiovascular reflexes 52
- Cardiovascular effects of Protovera-  
trine and Ganglionic blocking  
agents in man chart on 40
- Cardiovascular renal diseases 294
- Cargill W H 301
- Carleton A B 310
- Carnosinase 148 152 197
- Carotene 221
- Carotid arteries 38
- Carotid sinus
  - ablation of 38
  - reflex 38 39 50 52
  - wall hardening of 38
- Casein 75 87 92
- Castleman B 309
- Catabolism of lipids 234
- Catechol amines 30 49 57 60 147
  - 244
  - in urine 214
- Catecholic oxidation 147
- Cationic elements 151
- Cattell McK 310
- Cattle 175 279 280
  - abnormal hair in 175
  - grazing on copper deficient pas-  
tures 175
  - muscle fibres of 280
- Central obesity example of 137
- Cephalin 227 228
- Cephalin cholesterol flocculation  
112
- Cereals 172 280
- Cerebral atherosclerosis 210
- Cerebral arterial narrowing 238
- Cerebral arterial rupture 7
- Cerebral edema 36 56 238 263 264
- Cerebral hemorrhage 7 274 277
- Cerebral interneurone transmission  
36
- Cerebral ischemia 38 264
- Cerebral mechanisms 30-33
- Cerebral monamine oxidase 235
- Cerebral thrombosis 219 240 274
- Cerebral vascular accident 245 275  
285
- Cerebral vascular disease 281
- Cerebral vascular lesions 244
- Cerebroactive amines 191
- Cerebrospinal fluid pressure 264
- Ceruloplasmin 147 148 173
- Cesum 167 185
- Chaikoff I L 323
- Changes occurring with time in  
methods for therapy of hyper-  
tension 264
- Change in several metals with age  
(P P M Ash) chart on 124
- Charts
  - on affinities of various common  
trace metals for chelation by  
different active groups 145
  - on azotemic hypertension 61
  - on cardiovascular effects of Pro-  
toveratrine and Ganglionic  
blocking agents in man 40
  - on comparative doses of gangli-  
onic blocking agents 43
  - on comparison of properties of  
animal hypertension and  
human pherentasin 71
  - on effect of metal ions on two  
enzyme systems (guinea pig)  
126
  - on inactivation of pherentasin by  
metal ions and metal binding  
agents 70
  - on metabolism of serotonin 37
  - on normal and abnormal metals  
in chelates 146
  - on relative rate of oxidation as a

- Comment on adrenergic blocking agents 49-50  
 Comment on antihypertensive drugs (tranquillizing drugs) 36-38  
 Comment on hypertension 23  
 Comment on secondary effects of hypertension 17  
 Comparison of serum lipids cholesterol and lipid phosphorus in the old and new Yemenite immigrants in Israel 214  
 Comparative doses of ganglionic blocking agents chart on 45  
 Complex of factors in the human disease introduction 3-4  
 Congenital malformations 243  
 Congestive heart failure 63 70 75 199 245 245 250-251  
 Conjunctivitis 94  
 Conn H F 376  
 Connell W F 373  
 Constriction of renal artery 103  
 Constrictor primary amines in the pulmonary circuit 68  
 Convulsions 108 121 131  
 Cork M J 318  
 Cooper A R. 318  
 Copper 12 83 103-106 113 142 144 147 148 150-151 155 155 157 159 161 167 169 171 175 179 181 193 200 207 207 223 239 234 239  
   binding agents 1 3  
   catalyst 223  
   chelates 104  
   deficiency 175  
     in cattle grazing pastures 175  
   enzymes 103 148 193  
   flavonoid in acyl-coenzyme A-dehydrogenase 147  
   in hemoglobin formation 173  
   in liver 181  
   poisoning 173  
   tyrosine 105  
 Corcoran A C. 212 216A 301 310 315 320 324  
 Corley R W. 302  
 Corn 225 226 279-280  
   composition of 225  
   oil 226 279  
 Cornea vascularization of 175  
 Corned beef 278  
 Cornwell D G. 325  
 Coronary atherosclerosis 213 235-236  
 Coronary arterial disease 23 201 209-210 236 269  
 Coronary arterial narrowing 238  
 Coronary occlusion 3 9 240 245 273 281  
 Coronary sclerosis 209-210  
 Coronary thrombosis 25 201  
   in No China 201  
 Corrosion of hot water heaters 197  
 Cortisone 11 53 136 157 164  
 Costello R L. 317  
 Cottage cheese 280  
 Cotter P T 305  
 Cottonseed 225-226 279  
   composition of 225  
   oil 226 279  
 Cotton wool exudate 273  
 Council on pharmacy and chemistry 303  
 Courson D B 312  
 Cowdry E V. 370  
 Cows 75 226  
   hypertension in 75  
 Cox A J Jr 318  
 Cortico-hypothalamic activity 285  
 Cortex acidity of 28-59 289 290  
 Cortex of the kidney 287  
 Cortical steroids 291  
 C-28 G. 374  
 Cream 278 280  
 Credner K. 303  
 Crisco hydrogenated oils in 227  
 Crises treatment of 263-276

- Chromium 107 142 143 146 153  
 154 159 161 167 179 181 184  
 189 192 200 207 208 234 292  
 as contributing cause of athero-  
 sclerosis 192  
 chlorides 107  
 hepatic 207  
 in liver 189  
 in lungs 188 189  
 in urine 189  
 in vegetables 189  
 in ion 143 159  
 in potassium sulfate 184  
 Chronic arterial hypertension mech-  
 anisms of some of the effects  
 of 13 17  
 Chronic arterial hypertension de-  
 gree of peripheral vasospasm  
 in 13 15  
 Chronic metal poisoning 173  
 Chronic renal ischemia 290  
 Chronic ulcerative colitis 33  
 Chronic vasospasm 74  
 Chymotrypsin 71  
 Chylomicrons 217 236  
 Cider 198  
 Circle of Willis 209 219  
 Cirrhosis of the liver 172  
 Citrate 161 172  
 Citric acid 162 198  
 Citrous drink 199  
 Clark C T 302  
 Clark H E 297  
 Clark M A 327  
 Clarke C N 281 327  
 Clarke N E 281 327  
 Clarkson T W 199 318  
 Claudication 283  
 Clawson B J 321  
 Clinical chronic hypertension ex-  
 amples of 4 11  
 Clinical findings of adrenocortical  
 mechanisms 135-139  
 Clinical implications  
 in use of blocking agents 50-54  
 of factors influencing hyperten-  
 sion 130-135 139-140  
 of hypertension 22 25  
 of mechanisms in atherosclerosis  
 236-237  
 of nephrogenic effector mecha-  
 nisms 110 115  
 of trace metals and disease 200-  
 202  
 Clinical observations on nephro-  
 genic effector mechanisms 55-68  
 Clitoris enlarged 138  
 Clostridium welchii 157  
 Clotting of blood 155  
 Cloves 171  
 Clute O L 321  
 Coarctation of the aorta 239 244  
 Cobalt 72 104 105 142 144 147 153  
 157 167 169 171 174 175 181  
 187 196 201 237  
 as vasodilator 172  
 deficiency in soil 174 175  
 excreted in urine 172  
 in liver 181  
 phenylamine complexes 109  
 Cocaine 110  
 Cochran K W 319  
 Cochrane G C 323  
 Cocoa 171 173 278  
 Coconut 278  
 Codeine 169  
 Coenzyme deficiency 127  
 Coffee 172 173 198  
 Cohen B M 299  
 Cohn A E 220 299  
 Cohn method (fraction 10) 220  
 Collagen diseases 112 202  
 Colon bacteria in 65 175  
 Colonic tone 52  
 Colowick S P 315  
 Coma 264 271  
 Comens P 298 311

- Diamine oxidase (histaminase) 50  
     63 86  
 Diamox 167  
 Diaphoresis 34  
 Diastolic pressure 3 8 78 107 203  
     908 237 239 246 248 251 255-  
     256 962  
     effects of metal ions on 107  
 Diastolic hypertension 78 203 208  
     246 256  
 Diastolic normotension 239 250  
 Diarrhea 33-34 174  
 Dianne 162  
 Dibenamine (derivative of benzyl-  
     amine) 45 47 50-51 110  
     derivatives 50  
     vomiting induced by 51  
 Dibenzylamine 48  
 Dicarboxylic acids, 160  
 "Diencephalic blush" 32 66 285  
 "Diencephalic discharge" 45  
 Dietary experiments on rats 121  
 Dietary experiments on monkeys  
     121  
 Dietary factors altering plasma  
     cholesterol in man 226  
 Dietary fats relation of to choles-  
     terol 223-225  
 Dietary salt 130 266 291  
     restriction of 291  
 Dietary sodium 259  
 Diets use of 10-11  
 Diffuse dysrhythmias in electroen-  
     cephalograms 32  
     roentgenologic changes in the  
     lungs 53  
 Digitalis 160 268-270  
 Dihydrazinoquinazoline 86-87  
 Dihydroergotamine 110  
 Dihydrogen metal 100  
 Dihydrogenated ergot alkaloids 48  
 Dihydroxyphenylalanine (DOPA)  
     62 87 90 92 123 196 1 0 137  
     149 154 207  
 Dihydroxyphenylserine 45  
 Dilantin 53  
 Dilator substances, 68  
 Dimercaptopropanol (BAL) 83-85  
     90 99  
 Dimethyl glyoxime 163  
 Dimitroff S P., 327  
 Dinitrophenol 161 165  
 Dinitro-diphenylamine sulfoxide  
     163  
 Dinning J S 312  
 Diocaine 165  
 Diphenyl 89 163  
     carbazide 163  
     thiocarbazone 163  
 Diphosphothiamin 148  
 Dipyrindyl 158  
 Disseminated lupus 122  
 Disodium dihydrogen versenate 96  
 Distension of the intestines 257  
 Dithiol 163  
 Dithiooxalate 163  
 Divalent metal disodium ethylene  
     diamine tetra acetate 105  
 Dixon W E., 300  
 Dizziness 34  
 D lysergic acid diethylamide effects  
     of on system 35  
 DOCA (desoxycorticosterone) 125  
     127 133-134 136 291  
 Dock W., 370  
 Dorfman I 328  
 Doga  
     arterial hypertension in 84  
     arteritis in 210  
     atherosclerosis in 200  
     experiments upon 58-62  
     Grollman's experiments with 60  
     lesions in 16  
     nephrectomized 16 60  
     neurogenic hypertension in 1, 3  
     polycythemia in 172  
     renal hypertension in 47 66 73  
     106 108 133

- Croxatto H 305  
 Croxatto R 305  
 Crude amine oxidase injections of  
     in rats 66  
 Cullen C F 34 302  
 Cupferron 163  
 Cupric ion 143 151  
 Curariform paralysis 41-42  
 Curran G L 181 189 207 315  
     317 321 324  
 Cushing's syndrome 11 135-136  
 Cyanide 150 155 165 187  
 Cylindruria 270  
 Cysteamine 98  
 Cysteine 63 70-71 85 92 99 106  
     186-187  
 Cystine 76 103  
 Cystitis chronic 219  
 Cytochromes 59 147 175 229  
     oxidase 59 175 229  
     activity of the bone marrow  
         175
- D
- Dairy products 172 190 295  
 Dammin G J 297  
 Dandruff 120 207  
 Davidson N W 324  
 Davies D F 297 305-307 313  
 Davies J N P 299 301  
 Davignon A 314  
 Davis A K 314  
 Davis N G 318  
 Dawes G S 302  
 Day P L 312  
 De U N 212 216A 324  
 Debilitating diseases 216  
 Decamethonium (curariform drug)  
     44  
 Decarboxylation 60 63 73 77 149  
     189 207 288 290-291  
     enzymes 65  
     inhibition 291  
     of amino acids 288  
         of a terminal carboxyl 75  
 Decholin 165  
 De Eds F 318  
 Defecatory reflex 52  
 Deficiency of vitamin B<sub>6</sub> 90 120  
     121 202 206-207 209 211 216  
     226 229 235 237 288  
 Degree of peripheral vasospasm in  
     chronic hypertension 13-15  
 Dehydrocholesterol 225  
 Dehydrogenases 149  
 Dehydrogenation of PFA 184  
 Dehydropeptidase 148  
 Delirium tremens 52  
 Demerol 164  
 Dennis E G 306  
 Densitometric photoelectric record  
     ing 169  
 Depigmentation 153 175  
 Depression of blood pressure by  
     drugs 30  
 Depression mental 264  
 Depression psychosis 51  
 Depression reaction 66  
 Derivatives of benzylamine 45  
 Derivatives of ergot 49  
 Derivatives of imidazole 49  
 Derivatives of phenethylamine 45-  
     47  
 Dermatitis 35 190 202 206  
     seborrheic 202 206  
 Desoxypyridoxine 120 131 210  
 Desoxycorticosterone (DOCA) 125  
     127 133 134 136 291  
     acetate 125 127  
 Destruction of pressor substances  
     117  
 De Suto-Nagy G I 320  
 Deuel H J Jr 225-228 322-323  
 Dexter L 306 308  
 Deysach L J 315  
 Diabetes 137 204 218 226 232  
     gangrene 204  
     melitus 204 238

- rhythmias in 3°
- Electrolyte abnormality 7° 12° 197 139
- Electrolyte imbalance theory of 1, 3-197
- Electrophoresis 220
- Elliott, D F 308
- Elliott, H C Jr 31°
- Elvehjem C. A 31° 316
- Emaciation 174
- Emboli to the renal artery 24°
- Emerson G A 391
- Emesis 971
- Emotional tension 249 983
- Emphysema 219
- Enamels antunony in 199
- Encephalitis, 31
- Encephalopathy (wet brain) 263
- Endocrine organs 4
- Enlarged clitoris 138
- Enlarged heart 8 211
- Enolase 149
- Enuresis, 7 271
- Environment and heredity in arterial hypertension 20-23
- Enzootic marasmus 174
- Enzymatic deficiencies 20°
- Enzymatic reactions 87 91
- Enzyme systems effect of metal ions on (guinea pig) 1°6
- Epinephrine 40 49 57 58 63 73 9° 93 133-134 285 289
- Epistaxis 33 249
- Equanil (2 methyl 2 n propyl 1 3-propanedioldicarbamate) effects of on system 36
- Ergot, derivatives of 49
- Ergotamine 93
- Esbach's reagent 193
- Esophagus keratinization of in rats 173
- Esoteric mechanisms 4
- Essential metals in foodstuffs 171 1, 6
- Essential metals, sources and turn over of 171 174
- Essential metals in man 166-1, 6
- Essential metals in man chart on 169-171
- Esterified cholesterol 216
- Estrogens 236
- Etamon 242
- Ethanol 144
- Ether 163
- Ethyl (guanylmecapto) acetate hydrochloride 101
- Ethylenediamine tetra acetate (ED TA) 83 93 101 106 126 131 144 150 157 159 16° 1, 6 189 193 196 201 230 231 234 2°0 283 29°
- Ethylene linkages 222
- Ethyl mercaptans 103 187
- Ethyl thiopseudourea group 103
- Etiological factors of atherosclerosis 205 231
- Euphoria 90
- Eustachian tube of ear 52
- Evaluation of patient for drug therapy 239 240
- Exacerbation of peptic ulcer 31
- Examples of inhibition of metallo enzymes by metals 152
- Examples of some mammalian metalloenzymes 148 149
- Exanthemata 165
- Excessive drive 285
- Excessive drowsiness 31
- Excessive flushing 31
- Excessive proteinuria 159
- Excessive vasomotor tone 133
- Excitability 191
- Exfoliative dermatitis 163
- Exogenous cholesterol intestinal absorption of 2°1 222
- Expected results in treatment of atherosclerosis 281 283
- Experimental animals urinary ab

- renal venous blood of 69 70  
 renin 73  
 serial renal biopsies in 81  
 tremors in 53  
 unilateral renal ischemia in 82  
 with no kidneys 118  
 Domar G 319  
 DOPA (dihydroxyphenylalanine)  
   62 87 90 92 123 126 150 152  
   149 154 207  
 Dorsalis pedis arteries 78  
 Doyle A E 300  
 Dreams vivid 34  
 Dried fruit zinc in 198  
 Drowsiness excessive 34 264  
 Drug reactions 161 166  
 Drugs acting as nephrogenic mechanisms 82 109  
 Drugs as chelating agents 155 166  
 Drugs specific use of 248 267  
 Drugs tolerance to the action of 264  
 Drug therapy evaluation of patient for 259 240  
 Drugs used to remove metals 162  
 Drury D F 309  
 Drury D R 313  
 Dry mouth 35  
 Dubach Reubenia S 160  
 Du Bois A P 319  
 Du Bois P H 298  
 Duck 278  
 Duff G L 320  
 Duncan G G 321  
 Duodenal ulcer 19  
 Dustan H P 310 320  
 Dutra F P 300  
 Du Vigneaud V 328  
 Dyspnea 8 231 240 268 270  
  
 E  
 Ear eustachian tube 52  
 Easy bruisability 157  
 Eckstein D 80 308  
 Ecolid (chlorisondamine) 43  
 Eczema 165 190  
 Edema 35 263 264 270  
   cerebral 263 264  
   pulmonary 263  
 Eder H A 220 322  
 Edinger E F Jr 303  
 EDTA (ethylenediamine tetraacetate) 83 93 104 106 126 131  
   144 150 157 159 162 176 189  
   193 196 201 230-231 234 280  
   283 292  
   complex 126  
 Effect of antihypertensive agents on neurogenic effector mechanisms 109  
 Effect of arterial hypertension on personality 20  
 Effect of blood levels of total cholesterol 213 216  
 Effect of experimental nephrogenic hypertension on adrenals 133  
 Effect of intravenous EDTA on diastolic blood pressure of anaesthetized rats 96-109  
 Effect of metal ions on the diastolic pressures 98 107  
 Effect of metal binding and antihypertensive agents upon two renal enzyme systems (guinea pig) 88-89 126  
 Effect of repeated administration of pyridoxal hydrochloride upon excretion of 4 pyridoxic acid 90-91  
 Eggs 87 92 173 221 280  
   albumin of 87 92  
   dried 173  
 Eight hydroxyquinoline 70 71 84  
   89 104 157 163 164 230 234  
 Ek J 305  
 Electric cookers 198  
 Electrocardiograms 6 204 241 252  
   269 270 283  
 Electroencephalograms diffuse dys

Frukey R. W., 393  
 Frogs, polycythemia in 172

Fruhgt., 68

Fruits 179 198

Fruits juice of 198

Frying fats 278

Fulton L. A. 327

Fundi oculi lesions in 15-16

Fungicidal chelating agents, 157

Fungicides 173

Furchgott, R. F., 47 303

experiments of 47

Furlenmeier A. 398

Furman R. H., 220 322

Futcher P. H. 305 314 325

## G

Gainsborough 913 215

Galen W. P. 312

Gallates 163

Gallium 167 1,9 191

in the lungs 179 191

Gallstones metals in 173

Galvanized zinc 196 198

Gamma globulins 150

Ganglionic blocking agents 51 54

105 122 239 244 246-248 252

257 259 264 266 274 275

parenteral 263

summary on 53-54

Ganglionic blockade combined

therapy with hydralazine 260-

263 266

Ganglionic blockade disease 53

Ganglionic blockade table on side

effects of 59

Gangrene

atherosclerotic 205

diabetic 204

senile 204

Gardner 213 215

Garn 215

Gasoline tetra-ethyl lead in 194

Gastrointestinal disturbances 33

1,2 173 180 190 198 249 251  
 276

Gastrectomy 249

Gastric hyperacidity 33

Gastric juice 52

Gastroenteritis 1,3 198 276

acute 199

Gastrointestinal tract, barium in  
 180

Gaudino M., 314

Gaunt R., 313

Gelatin 173 198

Gellhorn E., 300

Generalized vasospasm exact causes  
 of not known 4

Genest J., 314

Gertler 215

Ghose A. C., 212 216A 321

Gibbons J. E. 301

Gifford R. W., Jr., 302

Gilman A. L., 48 303 310

Glass B., 315 318

Glazer H. S. 311

Globulin

bovine 288

hog 7 288

horse 288

Glomerular capsule thickening of,  
 81

Glomerular filtration 6

Glomerular obstruction (nephritis  
 and glomerulosclerosis) 11 79  
 198 129 213 245

Glomerulonephritis in childhood  
 11

Glossopharyngeal nerve 39

Glucose 80 97

Glutamic acid 63 76 106 288

Glutamic decarboxylase 229

Glutamic dehydrogenase 229

Glutamic transferase 152

Glutamine 62-63 190 286 288  
 290

Glutathione 85 92 97 187



- normalities in 58  
 Experimental compounds 95 109  
 Experimental steroid hypertension 133  
 Experiments upon dogs 58 62  
 Experiments upon hypertensive rats 59  
 Extracellular fluid 118 134  
   ratio in 118  
 Extrinsic asthma 19  
 Exudative lesions 247  
   retinitis 241 248  
 Eye 52
- F
- Factors influencing the conversion of neurogenic to nephrogenic hypertension 116 140  
 Farnsworth E B 305  
 Farris E J 300  
 Fastiolo J C 304 308  
 Fatigue 34  
 Fat role of in atherosclerosis 211  
 Fat ingested type of 222 228  
 Fatty acids 184 189 192 207 217  
   220 222 224 226 227 229 234  
   235 278 292 294  
   deficiency of 229 293  
   deficiency of comparison with pyridoxine deficiency in rats 229  
   esters 216 293  
   foods 221 278  
   foods list of 278  
   hepatic desaturation of 217  
   in phospholipids 207 220  
   metabolism 147  
   synthesis of from acetate 184  
   unsaturated 224  
 Fellows E J 31 301  
 Femoral blood flow 48  
 Femoral palpation of arteries 244  
 Ferric cyanide 163  
 Ferns E B Jr 299 303  
 Ferrous iron 72 104 107 159 196  
 Fever 113 188 231 257  
 Fibromyomata (pelvic tumors) 243  
 Fibrosis in intima 128 218  
 Field L 328  
 Filhos L C 321  
 Fish 172 173 199 223 225 227 279  
   fat 223  
   oils 223 225 279  
 Fish G W 309  
 Fishback H R 300  
 Fitzpatrick T B 315  
 Flasher J 309  
 Flavin adenine nucleotide 147 148  
 Flavokinaic 149  
 Fluoride 187  
 Fluorine 144 145 151  
 Fluoroscopic examination of the heart 241  
 Flushing excessive 34 66 94  
 Flynn J P 300  
 Foland W D 314 316  
 Folic acid 158  
 Food processing and metals 196  
 Foodstuffs essential metals in 171 176 198  
 Foodstuffs zinc found in 198  
 Forbes R M 170 201 318  
 Foreman H 315 316  
 Fournau 49  
 Fragile bones 175  
 Frank H A 306  
 Frank M H 307  
 Frant S 318  
 Frederickson A F 319  
 Fredga A 319  
 Freeman G 80 308  
 Freeman N E 300  
 Friberg L 318  
 Friedman B 80 308  
 Friedman M 205 210 231 237 320  
 Friedman S M 305

- Hay fever 19  
 Haynes F W 306  
 Heart trace metals in 1,0 171  
 Hepatic amine oxidase 6,3  
 Hepatic cholesterol 208  
 Hepatic chromium 207  
 Hepatic lesions 195  
 Hepatic metabolism effect of tran-  
   sitional metal ions on in rats  
   184  
 Hepatic synthesis 297  
 Hepatitis 51 161 164  
 Hepatocellular damage 235  
 Hepatomegaly 3,3 112  
 Headaches severe 7 66 91  
 Heart burn 35  
 Heart disease rheumatic 219  
 Hearts enlarged 8 241  
 Heart failure 3 8 11 2,3 65 ,0 73  
   181 199 238 243 245 2,0 2,1  
   266 273-269 297  
   congestive 6 70 73 199 243  
   245 2,0-2,1  
   due to ventricular strain 268  
   hypertensive 238  
 Heart fluoroscopic examination of  
   241  
 Heart, trace metals in 1,0-171 1,6-  
   183 191 196 199  
   aluminum in 1,6 183 191 199  
   cadmium in 196  
 Heart, strontium in 199  
 Hecht H H 327  
 Hedrick J T., 32,3  
 Heller H 300  
 Heffner S 300  
 Helmer O M 301 307 32,3  
 Hematuria microscopic 112  
 Hemiplegia 21,3  
 Hemochromatosis 153  
 Hemocuprein 147 148  
 Hemocyanins 148  
 Hemodialysis 118  
 Hemodynamics of hypertension 13  
 Hemoglobin 173 270  
   formation copper in 173  
 Heme 147  
 Hemorrhage 3 8 13 16 241 242  
   247 219 268-271 274 277  
   cerebral 271 277  
   in the ocular fundi 268  
 Hemorrhagic lesions 247  
 Hemorrhagic retinitis 15 16 241  
   248 270 271  
   and exudative retinitis patho-  
   genesis of 15 16  
 Heparin 236  
 Heredity and environment in ar-  
   terial hypertension 20,2 28,3  
 Hess, W R., 299  
 Hexanoic acids 229 291  
 Hexanoic synthesis 229  
 Hexamethonium chloride (C<sub>6</sub>) 41  
   43 53 56 101 103 250 2,3  
   2,3 256 2,8 261 265-268 2 0  
   271  
   effect of as compared with penta-  
   pyrrolidinium bitartrate in  
   malignant hypertension 258  
   intramuscular 265  
 Hexamethonium ion 53 ,6 101  
   103  
   urinary excretion of 101  
 Hexamethylenebis (2 (guanylmethyl-  
   capto) ethyl) dimethylammon-  
   ium chloride dihydrochloride  
   102  
 Hexavalent molybdenum 150  
 Hexokinase 149  
 Hexosamine 216  
 Hexosediphosphatase 149  
 Heymans C., 299 302  
 Hickham J B 301  
 High metabolic activity organs of  
   4  
 Hillman C C., 18 298  
 Hines E. A Jr 18 20 298  
 Hunke J A M 30,3

- Glycine 63 76 148 152 158 195 288  
 Glycosuria 244  
 Glycylglycine 148 152 158  
 Glycylleucine dipeptidase 148 152  
 Glycerophosphates 163 172  
 Glyceryl tristearate 222  
 Goebel D 327  
 Gofman J W 220 221 322  
 Gold 143 144 151 153 161 167 179 192 193 200  
   in the lungs 179  
   in the skin 153  
   salts 161  
 Gold H 310  
 Goldblatt H 80 297 308  
 Goldenberg M 306  
 Goldman M L 297 298 301 305 306 309 313 320  
 Goldstein E 321  
 Goldstein G 307  
 Goldstein M S 314  
 Goodhart R S 316  
 Goodman L S 48 303  
 Goosefat 278  
 Graffagnino P N 34 302  
 Graham L 307  
 Granulocytopenia 51  
 Grape juice 199  
 Graph on blood pressure (case history) 24  
 Green D E 319  
 Green D M 305  
 Green J H 39 220 303  
 Greene D G 306  
 Greenberg L D 206 321  
 Green vegetables 172 173  
 Gressel G C 298  
 Grey hair 202  
 Griffin O R 321  
 Griffith C G 169 199 316  
 Grollman A 60 305  
   experiments with dogs 60  
 Gropper A L 325  
 Gross F 87 309  
 Guanidine HCl 87 92 163  
 Guanidine carbonate 163  
 Gubier Clark J 160  
 Gubner R 215 299  
 Gudaitis A 312  
 Guinea pigs  
   polycythemia in 172  
   tissues of 186  
 Gurd F R V 314 315  
 Gyorgy P 311
- H
- Habitual repetitive stimuli theory of 117  
 Hack M H 322  
 Hager T 218 219  
 Hair  
   arsenic in 199  
   grey 202  
   loss of 120  
   sulfur in 151  
 Halide sub group 151  
 Halogen 144  
 Hallucinations reserpine 52  
 Hamburgers 278  
 Hamilton J G 315  
 Handler F P 312  
 Hansen H T 319  
 Hanson N O 302  
 Hardening of the arteries 240  
 Hardwick D F 305  
 Harris S A 311  
 Harris S B 318  
 Harrison H E 318  
 Hart E B 316  
 Hartley G Jr 80 308  
 Havel R J 328  
 Hawaiian sugar plantation workers atherosclerosis among 209  
   hypertension among 209  
 Hawkins V R 311 318  
 Hawthorne E W 298

- in peanut butter 227 228
- H drovus, 150
- Hydronephrosis 213 216
- Hydroxide 130
- Hydroxybenzoic acids, 136
- Hydroxyamine, 70
- Hydroxyl ion, 143 143
- Hydroxyquinoline, 70-71 84, 89  
104, 157 163-164 230 234  
sulfonic acid, 89
- Hydroxysyringine, 209
- Hydroxytryptophan 62, 149
- Hyperaldosteronism, 133 140 222  
secondary 156 231
- Hypercholesterolemia, 207 237 232
- Hyperkeratosis in pigs, 173  
rats 130
- Hypernatremia, 134
- Hyperpyrexia, 53
- Hyperreflexia, 52 53
- Hypertension—see Angiotonin
- Hypertension  
adrenal cortex in, 138  
steroids as cause of 133  
among American Indians 25  
among American Negroes 20  
among Hawaiian sugar planta-  
tion workers 209  
arterial 142 239 231 264 280  
290  
arterial psychic manifestations  
of 281 285  
azotemic 60  
cadmium as contributing cause  
of 192  
cerebral role in 31 33  
changes occurring with time in  
therapy of 264  
clinical implications of, 22 25  
130 135 139 140  
comment on 25  
diastolic 78 203 208 246 256  
hemodynamics of, 13  
in Africa 25  
in China 25 203  
in Uganda, 25  
killing factor in 67  
malignant, 204 256 253 250  
250-253 270-273  
charts on case histories of, 255  
257 258 270-273  
effect of penicillamine  
bitartrate in as compared  
with that of hexamethoni-  
um chloride 233  
neurogenic 129 250  
seen as form of generalized vaso-  
spasm, 4  
severe benign 256 253 260 261  
some common denominators of  
atherosclerosis and, 208-211  
systolic, 203 240  
therapy of, 233 276  
office practice in, 240-243  
practical methods for modern  
therapy of 233 276  
general rules for 233 276  
results expected 268-274  
what to do if a patient is not  
doing well 264 267  
unilateral renal 81 82
- Hypertensive heart failure 238
- Hypertensive kidney 133-139
- Hypertensive patients effect of oral  
hydralazine on total fasting  
plasma cholesterol in 235  
serum sodium of 120
- Hypertensive rats 59 81 95 106  
120 197 133 210  
experiments upon 29  
significant effects on diastolic  
blood pressure of EDTA  
metal chelates and ion in  
106  
sodium intake in 127
- Hypertensive states evaluation of  
generalized vasospasm in 245
- Hypertensive vascular disease chart

- Hirsch J 323  
 Hirsch J G 85 318  
 Hirschhorn B 298  
 Hirsutism 137 138  
 Histidine 62 63 74 76 87 149  
     158 195  
 Histamine 62 66 86 87 90 92 93  
     115 149 285 291  
 Histaminase 86 90 92 149 291  
     effect of metals and binding  
     agents on 86  
 Hochberg M 312  
 Hodgman C D 93  
 Hogs  
      $\alpha_2$  globulins from 71 76 288  
     bone affections in 174  
     hyperkeratosis in 175  
     hypertension in 75  
     renin 71 73 74 76  
     vasopressin from 76  
 Holland C M Jr 312  
 Holley H L 312  
 Hollow viscus 257  
 Holman R L 210 321  
 Holman R T 322  
 Holtz P G 303  
 Honey 173 198  
 Hoobler S W 300 302 305  
 Hopkins E L 298  
 Hormones  
     antiadrenal 140  
     concerned with salt 136 137  
     concerned with sex 136 137  
     concerned with sugar 136 137  
     steroid 221  
 Horses 74 76 174 175 288  
      $\alpha_2$  globulins from 76 288  
     hypertension in 75  
     serum 74 76  
 Hospital diet 121  
 Hospital patients 244 276  
 Hot water heaters corrosion of 197  
 Hove E 316  
 Huebner C F 328  
 Hueper W C 322  
 Human milk 173  
 Human renin 73 75  
 Human tissues trace metals in  
     280 281 285  
 Hunter M 325  
 Humoral component of sustained  
     hypertension 78  
 Humoral pressor substances 67  
 Hyalin degeneration of the small  
     arteries 128  
 Hyalineization of the arterioles 12  
 Hydantoins 161 163 165  
     hydantoic acid 165  
 Hydrated cyst of kidneys 242  
 Hydralazine 43 70 71 78 82 87  
     90 91 101 104 106 111 115  
     122 126 132 133 163 164 184  
     186 188 190 193 230 232 246  
     248 250 253 255 268 270 271  
     289 290  
     as used in reduction of pervana  
     date 188  
     binding 184  
     combined therapy with ganglionic  
     blockade 260 263  
     disease (collagen) 113 115 122  
     257 259 261  
     examples of 261  
     mortality in 115  
     parenteral 263  
     use of 257 263  
 Hydrazides 87 88 106 108 291  
     inhibition of histaminase by 87  
 Hydrazine SO 87  
 Hydrazino isoquinoline HCl 88  
 Hydrocortisone 136 138  
 Hydrogenated shortening 278  
 Hydrogenated vegetable oils 227  
     278 279  
     in cottonseed 227  
     in Crisco 227  
     in margarine 227  
     in olive oil 227

- Inversine (mecamylamine) 41 43  
     270  
 Iodine 151  
 Ionized calcium 281  
 Iproniazid (isonicotinic isopropyl  
     hydrazide) 83 89-90 110  
 Iron 83 141 142 147 153 157 167  
     175 187 196 201  
     ingested, 175  
     in the skin 155  
 Irritability 194  
 Irwin D A 317  
 Ischemia 15 16 56 58-61 69 73  
     79 87 118 133 139 239 264  
     284 286 290  
     cerebral, 264  
     in kidneys 58-61 69 73 79 82,  
         133 284 290  
     in rabbits 82  
     removal of 59-60  
     renal organic 127 139 286 288-  
         289  
 Isoamylamine 62 97 130 285  
 Isocitric, 149  
 Isolated rabbit aorta 47 69 72  
 Isoleucine 74 76  
 Isoniazid (isonicotinic acid hydra-  
     zide) 83 86 89 91 170 181  
     167 164  
 Isopropanol 144  
 Isopropyl 83  
 Israel comparison of serum lipids  
     cholesterol and lipid phospho-  
     rus in the old and new immi-  
     grants in 214  
 Ives M., 312  
 Ivy A. C., 323
- J
- Jackson D E., 317  
 Jackson R. S 188 324  
 Jahn J J 323  
 Jam metal in 198  
 Janeway T C. 299
- Jarrold, T., 311  
 Jason R. S 298  
 Jaundice 35  
 Jeffers W J 300  
 Jensen W K., 371  
 Johnson A D 303  
 Johnson C. A., 307  
 Johnson K. D., 322  
 Johnson L. L., 312  
 Jones R. J., 373  
 Juxta glomerular apparatus 69 129
- K
- Kabza T C 302  
 Kahn J R., 80 307 308  
 Kammerer O F., 378  
 Kanof A., 310  
 Kao R T 328  
 Kaplan N D 315  
 Karviner F 323  
 Katz, L. N., 215 304 320 323 327  
     378  
 Katzenstein R., 298  
 Keith N M 241 247 325  
 Kench J E., 195 318  
 Keraunization in sheep 175  
 Keraunization of the esophagus in  
     rats 175  
 Kerwin T D 319  
 Keto acid carboxylases 148  
 Ketogluconic acid, 163  
 Keys A., 212 215 322 325 378  
 Keys M H 212 215 216A 324  
 Kidneys 4 6 8 16 50 57-62 64  
     66 68-69 72 74 79 81 83 95  
     117 123 125 128 137 133 133-  
     139 151 161 170-171 176-183  
     187 191 193 194 196-197 199  
     200 206 209 219 242 244 273  
     276 286  
     absence of 60  
     amino acids decarboxylated by  
         50 64  
     cholesterol emboli in 128

on case history of 262

Hyperthyroidism 219

Hyperthermia 34

Hypertrophy muscular 138 241

Hypocalcemic tetany 281

Hypochromic anemia 175

Hypokalemia 154 158

Hyponatremia 259

Hypophyseal tumors 243

Hypoplasia 242 243

Hypothalamus 30 33 36 72 259  
285

blocking agents of 36 259

injury to 31

lateral 36

posterior 36 285

relationship of to stalk of pitui-  
tary 72

vascular lesions in 32 33

Hypothesis of nephrogenic effector  
mechanisms 56-57

Hypothetical interactions of metals  
fatty acids and pyridoxal 291

Hypoxia 68

## I

Ice cubes 198

Ice trays as source of cadmium  
poisoning 196

Ikawa M 315

Imidazole

binding 150

derivatives of 49

groups 151

rings 49

Impaired growth 174

Indians American hypertension  
among 25

Iodine internal standard 169

Infants 121 123 175 180 183 190  
194

anemia in 175

food 121

stillborn 190

tissues trace metals in, 123 180-  
183 194

lead in 194

Infections 183 276

acute 183

Inferior vena cava obstruction 219

Ingested iron 175

Inhaled dust 172

Inhibition of histaminase by hydra-  
zides 87

Insecticides 173 198 199

antimony in 199

Insoluble metallic salts 164

Insomnia 35 66 249

Insulin 6 232

Insull W Jr 523

Intermittent occlusion of the renal  
artery 242

Interpretations and summary of  
mechanisms of hypertension  
281 296

Interstitial pulmonary fibrosis from  
hexamethonium 53

Intestines 65 170 171 181 194 196  
257

amine oxidase 65

distension of 257

trace metals in 170 171 181 194  
196

cadmium 196

lead 194

titanium 181

Intima 128 204 207 216 235 237

injury to 205 207 235

pyridoxine and 206

thickening of 128

ulcerated found in autopsies 204

Intracranial pressure 31

Intrarenal enzymatic mechanisms  
118-132

vasodilatation 58

Intravenous pyelography 8 242

- in spleen 176-183 193
- in stomach 176-183
- in tissues 193
  - African 193
  - infantile 193
- pipes 196
- poisoning, 161
- salts 194
- Leary T 322
- Leathin 216 226-227
- Lee R. E., 327
- Le Goff J M 316
- Legumes 172 280
- Lehmann J H., 305
- Lehninger A. L., 317
- Leiter L., 80 08
- Leloir L. F 304 308
- Lemieux G 314
- Lemonade cadmium in 193
- L-E phenomenon 113
- Leriche's syndrome 238 282
- Lerner A B 153 315
- Lesions
  - arterial, 203 206 237
  - at the mucocutaneous junctions 173 16
  - cerebral vascular 244
  - exudative 247
  - found in kidneys 81
  - hemorrhagic, 247
  - in dogs 16
  - in fundi oculi 15 16
  - of brain 31
  - organic, 129
  - pre atherosclerotic, 293
  - pustular 231
  - renal inflammatory 243
  - sub intimal 293
  - traumatic, 242
  - vascular inflammatory 243
- Lethargy 271
- Leucine 62-63 74 76 143 152 197
  - aminopeptidase 148 152
- Leukemia myeloid, 218
- Leukopenia 112 131 161 164
- Levere A H 304
- Levine R., 314
- Levitt M F., 314
- Levy R. L. 18 293
- Lewin E., 85 318
- Lewis L. A., 220 313 320 324
- Lewis U J 312
- Lewis W H., Jr 322
- Lieberman Butchard 210 2164
- Lima beans 280
- Lin T M 323
- Linderholm H., 319
- Linoleate 217 233 278 279
- Linoleic acid foods containing 228
- Linolenic acid 204 222 227 228
  - 234 279 292 294 295
- Linseed oil 227
- Lipemic serum 236
- Lipids 206 213-214 216-217 230
  - 234 236
  - catabolism of 234
  - in the blood 206 213 216
  - in the liver 230
  - plasma 217
  - phosphorus 214
- Lipoproteins 210 216 220 221 235
  - 236 277
  - alpha 236
  - atherogenic ultra-centrifugal 236
  - beta 26
  - separated by various techniques
    - comparison of 220
- Lipotropic agent 207
- Lisa J R 80 308
- Lithiasis 243
- Liver 4 50 63 65 68-69 172 174
  - 176-183 186 188 189 191 193
  - 194 196 199 206-208 224 230
  - 295
  - $\alpha_2$  globulins in 69
  - cholesterol in 188 224
  - cholesterol synthesis by 183
  - cirrhosis of 172



- chronically diseased 8  
 constriction of 66  
 cortex of 287  
 hemorrhages in 16  
 hypertensin in 138 139  
 ischemic 58 61 69 73 79 82  
     133 281 290  
 lesions found in 81  
 nephrosclerotic 259  
 oxidative metalloenzymes in 125  
 oxygen consumption of 59  
 polycystic 212 271  
     hydatid cyst of 242  
 removal of 61  
 salt losing 125  
 trace metals in 83 121 123 154  
     176 183 191 193 194 196-  
     197 199 290  
     aluminum 191  
     bismuth 199  
     cadmium 123 154 176 183 196  
         197 199 290  
     chromium 183  
     lead 176 183 194  
     mercury 199  
     metalloenzymes 83 121 123  
     molybdenum 179  
     nickel 181 183  
     silver 183 193  
     tin 183  
     titanium 181 183  
 Killing factor in hypertension 67  
 Kim C 300  
 Kinsell L W 227 323  
 Kinsey D 304 327  
 Kirghiz nomads atherosclerosis  
     among 209  
 Kirk E 3-2  
 Kleeman I 318  
 Klein R 318  
 Klemperer P 80 308  
 Klotz I W 318  
 Koellr E S 310  
 Kohlstaedt K G 304 307  
 Kohn H 1 64 303  
 Kohn E 314  
 Kollf W J 324  
 Konzett H 306  
 Koppanyi T 310  
 Kornerup 215  
 Korotkoff sounds 239  
 Kraye O 302  
 Krebs cycle 154  
 Krinsky N I 325  
 Kriss J 305 313  
 Kuczynski B 321  
  
 L  
 L 5 vinyl 2 thio oxazolidone 162  
 Laas E 80 308  
 Lactic acid 85 92 198  
 Laipply T C 308  
 Lamb 278 279  
 Lambert E H 300  
 Landis E 314  
 Langdon R G III 224 323  
 Lanthanum 159 167 180  
     in spleen 180  
 Lard 173 278  
 Larsen N P 321  
 Lateral hypothalamus 36  
 Laxative 257  
 Lead 143 146 159 161 167 176  
     183 192 194 196-197 199 202  
     as contributing cause of athero-  
         sclerosis 192 194  
     in adrenal 176-183 193  
     in aorta 176 183 193 199  
     in bladder 176 183 193  
     in bone 193  
     in brain 176 183 193  
     in intestines 193  
     in kidney 176 183 193  
     in liver 176 183 193  
     in lungs 193  
     in muscle 193  
     in pancreas 176-183 193  
     in prostate 193

- Man essential trace metals in 166-176  
     chart on 170  
 Man sodium intake in 127  
 Manganese 72 74 77 83 107 142  
     147 151 153 154 157 167 169  
     171 172 174 179 181 186-187  
     196 200 201 \*07 \*08 234 237  
     89 297  
     *in urine* 172 200  
     ion 107 134  
     lack of in rabbits, 174  
     peptidase 77 239  
 Mann G V 391  
 Mann J J G 31 301  
 Manometric reflex 240  
 Maple sugar 171 198  
 Marasmus enzootic, 174  
 Margarine 173 223 227 278  
 Marie Strumpell arthritis 231  
 Marks P A 397  
 Marrus J 80 308  
 Marsh W H., 307  
 Marshall J 306  
 Marston H R 171 316  
 Martell A E 14 151 314 \*24  
 Martin G J., 392  
 Martindale W E., 210 311  
 Mason G M C. 313  
 Mayer G., 323  
 Masus M 319  
 McCorkle W C. 316  
 McCubbin J W 39 303  
 McDaniel, A. K., 316  
 McElroy W D 315 318  
 McGill H C., Jr 321  
 McGlory D H 398  
 McLean P D 300  
 Meats 179 278  
     processed, 278  
 Mecamylamine (Inversine) 41 43  
     32 33 253 261 270  
     intoxication 32  
 Mechanisms of some of the effects  
     of chronic arterial hypertension 13 17 203 237  
 Medoff H S 300  
 Medulla relation of to adrenal cortex 133 135  
 Medulla tumors of 243  
 Meier R. 86 87 309 397 328  
 Meilman E., 302  
 Meister A., 69 327  
 Melanin 133 202  
     pigmentation 153  
 Melnick D 312  
 Mendoza H C., 324  
 Mendelian dominant vascular reaction to stress at 235  
 Menhard E. M., 299 305 307 310  
 Menopause 6 7 235 236  
 Menstrual abnormalities 137 138  
 Menes 10 137 138  
 Mental depression 264  
 Menthol, 165  
 Mercaptans 84 85 89 99 97 99  
     110 147 150 151 162 191  
 Mercaptalbumin 147 151 191  
 Mercaptoethyl hydrogen (carboxymethylmercapto) succinate 99  
 Mercaptoimidazole 162  
 Mercaptopropionate 110  
 Mercaptopropionic acid 89 99  
 Mercaptopyruvic acid (ammonium salt) 97  
 Mercaptosuccinic acid 99  
 Merck Index of Chemicals and Drugs 316  
 Mercurhydrin 164  
 Mercurial diuretics 164  
 Mercury 72 83 123 130 143 144  
     150 153 154 161 193 199 210  
     268  
     in kidneys 199  
     in the skin 153  
 Merrill A. J., 307  
 Mesenteric blood flow 48  
 Metacortandren 136

- fat 230
- lipid in 230
- oxidation of aldehydes by 174
- proteins 186
- rabbits 208
- trace metals in 69 125 170 174
  - 176 183 186 188 189 191 193
  - 194 196 199 208 224 230
- aluminum 191
- bismuth 199
- cadmium 176 183 196
- chromium 189
- cobalt 181
- copper 181
- lead 176 183 193 194
- molybdenum 179 181
- nickel 181
- silver 199
- Lobar pneumonia 218 219
- Lobotomy prefrontal 33
- Locus of action of pressor substances 77 78
- Lorente de N6 R 314
- Loss of appetite 262
- Loss of hair 120
- Loss of Ti in urine 93
- Low sweat salt, 137
- Loyke H F 302
- Lucas R 328
- Lumbodorsal sympathectomy 81
  - 275
- Lungs 53 67-68 170 171 176-183
  - 187 189 191 194
- diffuse roentgenologic changes in 53
- possible role of in nephrogenic effector mechanisms 67 68
- trace metals in 53 67 68 170-171
  - 176-183 187 189 191 194
- aluminum 176 183 191
- barium 180
- bismuth 179
- gallium 179 191
- gold 179
- in infants chromium 188 189
- lead 194
- thallium 179
- titanium 176-183
- vanadium 68 180
- Lupus erythematosus disseminated
  - 112 114 243
- urinary trace metal concentrations in 114
- Lupus like syndrome 94
- Lyons R H 300
- Lyophilized angiotonin 92
- Lysine 63 76 195
- M
- MacBryde C M 297 313
- MacCamy E T 300
- Mackler B 319
- MacPhillamy H B 328
- Magee M 315
- Magenta tongue 231
- Magnesium 105 118 127 134 141
  - 143 147 151 257
- citrate 257
- Mahler H R 319
- Mahoney L E 306
- Main renal artery obstructive lesions of 16 81
- Malaise 257 264 271
- Male sexual potency 52
- Malformation of the tibio meta tarsal joint 174
- Malignant carcinoid of the appendix serotonin in 32
- Malignant hypertension 89 254
  - 256 260 266 268 270-273
- case history of 89
- charts on case histories of 263
  - 270 273
- with uremia 270 272
- Malignant tumors 19 202
- Man and Peters 215
- Man abnormal trace metals in 176-183

- Morrison D B 317  
 Morrison J L 307  
 Morrison L M 322  
 Morrison M 311  
 Morrow J D 101 303 306  
 Mortality in hydralazine disease 115  
 Mortality rates of patients subjected to surgical sympathectomy and chemotherapy chart on 275  
 Mosher R E 281 327  
 Moshkowitz, L. 80 308  
 Moss W G., 300  
 Movat H Z 321  
 Moy R H 300  
 Mucocutaneous junctions lesions at 173 176  
 Mucopolysaccharides 293  
 Mucous colitis 251  
 Mucous membranes inflammation of 231  
 Mueller J 314  
 Mueller J F 311  
 Mueller J M 308  
 Mull J W 317  
 Muller J C. 301  
 Munoz J M 301 308  
 Muscle 72 78 138 140-171 181 191 196  
   stimulant 72  
   trace metals in 170-171 181 194 196  
     cadmium 196  
     lead 194  
     tin 181  
     titanium 181  
 Muscular arteries volume of blood in 78  
 Muscular hypertrophy 138  
 Musher C W 321  
 Mushrooms vanadium in 185  
 Mustard 227  
 Mutton 278  
 Myalgia 34  
 Myeloid leukemia 218  
 Myers and Wardell 212 2164  
 Myers G B 324  
 Myers V C. 317  
 Mylon E. 298  
 Myocardial fibrosis 269  
 Myocardial infarction 204 218 219 241 275  
 Myocardium narrowing of arteries to 132  
 Myoglobin 147
- N
- Narrowing of arteries to brain 132  
 Narrowing of arteries to myocardium 130  
 Narrowing of arteries renal 130 236  
 Nasal congestion 34 249  
 Nausea 31 39 48 51 251 266 270  
 Najjar V 146 221 315 323  
 Nails  
   arsenic in 199  
   sulfur in 151  
 Necropsy 79 81 128  
 Necrotizing arteriolar lesions pathogenesis of 16 17  
 Negroes American hypertension among 25  
 Neligh R. B. 300  
 Nephrectomy 16 60 82 210 278  
 Nephrectomized dogs 16 60  
 Nephrectomized humans 80  
 Nephrogenic effector mechanisms clinical observations on 55-68  
   drugs acting on 82 109  
   hypothesis of 56-57  
 Nephritis 129  
 Nephron vascular supply to 128  
 Nephrosclerosis arteriolar 138 259 269 276-277 286  
   as result of hypertension 7 11 15 128 24 269 286  
 Nephrosis 231

- Metabolic by products of renal abnormality 73
- Metal binding agents 82
- Metal*
- cadmium as most toxic, 195
  - complexes logarithm of the stability constants of some chart on 158
  - deficiencies specific 174 176
  - deficiencies in rats 174
  - found in infants 123
  - of possible biological significance in the first transitional group 185 192
  - taken from sea water 67
  - with possible harmful effects 192 202
- Metallic content of plants 167
- Metallic salts insoluble 164
- Metalloenzyme 74 83 109 121 123 142 154
- inhibitions 151 154
  - in the kidneys 83 121 123
  - mammalian examples of 148 149
  - metals concerned with 142 150
  - sites 109
- Metalloporphyrins 147
- Metastatic calcium 281 295
- in blood 295
- Metastatic carcinoma of breast 218 219
- Metastatic fibrosarcoma 218 219
- Methionine 63 76 103
- Method of treatment of atherosclerosis 278 281
- Methoxy tryptamine 71
- Methyl 71 195 224 236 285
- histidine 195
  - linoleate 224
  - testosterone 236
- Methylated analogues 285
- Metzler D F 315
- Mice polycythemia in 172
- Michaels G D 323
- Michelson O 323
- Microcytic anemia 120
- Migratory polyarthritides 231
- Millet 227
- Milk 173 175 198 223
- production 175
- Müller G J 313
- Müller H 307
- Mineral analysis 171
- Mitchell H H 318
- Mitchell R L 316
- Mitchell W 319
- Modell W 310
- Moe G K 300
- Mohammedans dietary customs of 228 229
- Molasses 198
- Molony C J 312
- Molybdenum 142 144 147 154 167 169 171 174 175 179 180 181 195 201
- in kidney 179
  - in liver 179 181
  - poisoning 174
- Monamine oxidase 50 59 63 67 68 74 75 77 88 90 92 123 126 132 149 153 187 189 191 285 287 290 291
- cerebral 285
  - depletion of 59
- Monier Williams G W 171 198 316
- Monkeys 73 121 206 222 294
- dietary experiments on 121
  - plasma cholesterol in 294
  - pyridoxine deficiency in 206
  - renin 73
- Monoethioglycerol 99 107
- Moodiness 194
- Moore C V 174 316
- More R H 321
- Moritz A R 297
- Morphine 165
- Morrison B 303

- Ocular fundi 8 247 252 258 268-  
 269  
 hemorrhages in 268  
 Office practice in therapy of hyper  
 tension 240 243  
 Ogden E., 39 303  
 Olds M. R., 297  
 Oleate 216-217  
 Oliguria 262  
 Olive oil, 225 227  
 composition of, 225  
 Olsen N. S. 210 303 306 310 311  
 314 378  
 Oncley J. L., 325  
 O'Neal R. M. 265 297  
 Onions 151  
 Opdyke D. F., 328  
 Opium 165  
 Oppenheim F. 378  
 Oppenheimer B. S. 80 308  
 Orangeade 193  
 Ordway N. K. 318  
 Orgain E. S., 301  
 Organic intra renal arterial and ar  
 teriolar disease 79-81 127 129  
 139 241 269 286 288-289  
 Organic lesions, 129  
 Organic renal disease parenchymal  
 19  
 Organic renal ischemia 127 286  
 288-289  
 Organs of high metabolic activity  
 4  
 Ortho-phenanthroline 158  
 Oshry E., 315  
 Oster B. L., 312  
 Ott, W. H. 373  
 Ovarian tumors 244  
 Overactivity of the adrenal cortex  
 139  
 Overman R. R., 314  
 Oxalacetate 149  
 Oxalate 158  
 Oxaloacetic carboxylase 148  
 Oxalosuccinic carboxylase 148  
 Oxidation  
 as a function of oxygen tension  
 chart on relative rate of, 64  
 of aldehydes by the liver 174  
 of cysteine 184 186  
 to its sulfonic acid 184  
 of double bond in PFA, 184  
 of phospholipid fatty acid 184  
 of the amine residues 64-65  
 of thioglycolic acid, 184  
 Oxidative deamination 62  
 Oxidative metalloenzymes in kid  
 ney 125  
 Oxidized glutathione 103  
 Oxygenated Ringer's solution 109  
 Oximes, 163  
 Oxygen 59 144 145 155 200  
 Oxygen consumption of the kidney  
 59  
 Oxytocin 72 76  
 Oysters 173  
 Ozone 85
- P
- Pace M. G., 297  
 Page L. H. 39 212 213 215 216A,  
 220 300 301 303 304 310 313  
 370 322 374  
 Palladium 144  
 Palm oil 278  
 Palmitate 216-217  
 Palpation of the femoral arteries  
 244  
 Pamaquine 164  
 P-aminobenzoic acid 162  
 P-aminophenol 187  
 P-aminosalicylic acid, 162  
 Pancreas 4 170-171 176-183 194  
 196-197 232 249  
 perforation in 249  
 trace metals in 1,0 171 176-183  
 194 196  
 cadmium 176-183 196

- Nephrotic syndrome 159 219  
 Nephrotoxicity 35 123 288  
 Nephrotoxic metal 123 288  
 Nervousness 60 219 262 285  
 Nervous tissue 4  
 Neuritis 131  
 Neurogenic effector mechanisms 26  
     115  
     clinical implications of 110 115  
     hypothesis of 26  
     introduction to 26  
 Neurogenic effector substances ef-  
     fect of antihypertensive agents  
     on 109  
 Neurogenic hypertension 128 255  
     in dogs 38 128  
 Neurogenic vasospasm 127 128 285  
 Neumann C 309  
 Neville J B 320  
 Nichols C W Jr 323  
 Nickel 72 83 104 105 107 125 142  
     144 155 159 161 167 179 180-  
     187 190 193 200 202 207  
     arginine complex 107  
     catalyst 223  
     chelates 104  
     in kidneys 181 186  
     in liver 181 186  
     in tissues 183 190  
         animal tissue 190  
         plant tissue 190  
     in urine 190  
 Nicotine 41  
 Nightmares 35 219  
 Ninhydrin 71  
 Niobium 180  
 Nitrite 163  
 Nitrogen 16 83 144 145 155 174  
     196 200 248 269 284  
     chelators 155  
     in the soil 174  
     ligands 196  
     retention 16  
     valence of 284  
 Nitroindoles effects of on system  
     35 36  
 Nitroprusside 84  
 Nitroso groups 161 165  
 Nitrous acid 71  
 Noble N L 328  
 Nocturia 240  
 Nonhemolytic staphylococcus 8  
 Nord F F 315 319  
 Norepinephrine 27 44 46 50 52  
     57 66 69 92 96 98 109 110  
     134 135 188 289  
     infusion of 44  
     response to in injections 52  
     sensitivity from salt 151  
     structural formulae of 46-47  
 Normal blood viscosity 3-4  
 Normal cholesterol levels in blood  
     211 217  
     chart on 212  
 Normotension 96 276  
     in rats 96  
 Note I W 261  
 Novalgin 164  
 Novurone 164  
 Nowaczynski W 314  
 Nowak J G 299 300  
 N-propanol 144  
 Nuts fatty acids in 172 173 226-227  
     280
- O
- Oatmeal 171  
 Obesity 10 11 137 138 226  
     central example of 137  
 Obsessive compulsive traits 4 20 31  
 Obstructive lesions of the main  
     renal artery 81  
 O-carboxyl hydroxyl group 157  
 Octahedralchelate 146  
 Octanoate oxidation 229

- under anaesthesia 33  
 Peritoneal dialysis 60  
 Perma Kleer 84 104  
 Perosis, 174  
 Perry B F., 317  
 Perry H M Jr 24 85 101 103  
     107 111 160 183 215 231 233  
     265 267 270 77° 297 301 303  
     305 307 309 311 317 319 320  
     324 325 327  
 Personality effect of arterial hy-  
     pertension on 20  
 Peristanate 184  
 Peters R. A 215 310  
 Peterson D W., 323  
 Petroleum formation of 185 187  
 Pervanadate 107 183  
     reduction of by hydralazine 188  
 Pervanadyl 92  
 PFA  
     dehydrogenation of 184  
     oxidation of double bond in 184  
 Pharmacological effects of vana-  
     dium 188  
 Phenacetylurea 162  
 Phenethylamine  
     complexes 45-47  
     derivatives of 45-47  
 Phenobarbital 6-7  
 Phenolic oxidases 147 173  
 Phentolamine (Regitine) 48-49 244  
 Phenol red (PSP) 211  
 Phenothianes 164  
 Phenurone 164  
 Phenylalanine 74 76  
 Phenylbutazone 161 162  
 Phenyl diazine 88  
 Phenyl hydrazine 85  
 Pheochromocytomata 39 45 49 60  
     173 244 267  
 Phentetate 66-75 77 97 109 111  
     137 288 289  
     apresoline blockade of 111  
     in rats 110  
 Philips F S 310  
 Phosphate 117 148 149 151 229  
     esterification of 229  
 Phosphatases 148 149 151  
 Phosphoenolpyruvate to ADP 149  
 Phosphoglucomutase 149 152  
 Phosphogluconic acid, 149  
 Phospholipids 184 186 192 207  
     217 220 227 235 236 234  
     anatomic chemistry of 284  
     fatty acids in 184 207 220  
     oxidation of 184  
     of plasma 217  
 Phosphonate 145  
 Phosphorus 144 199  
 Phosphotungstic acid 269  
 Phthalazine 83  
 Physiological alterations in vascu-  
     lar volume 78  
 Pick, R. 327  
 Pickering G W 20 21 119 298 299  
 Pigmentation 153 173  
     melanin 153  
 Pigs 75 174 175  
     bone affections in 174  
     hyperkeratosis in 174  
     hypertensin in 75  
 Pijoan M J 300  
 Pines K L., 306  
 Piperoxan (Benodaine) 49  
 Pitressin 72 92 93 110  
 Pitt Rivers R 318  
 Pituitary 77 77° 136  
     basophilism 136  
     posterior 57  
     relationship of stalk of to hypo-  
         thalamus 72  
 Pituitrin 72  
 Placenta 181 190 191  
 Placental membrane 181  
 Plants 167 174 190 191 221  
     metallic content of, 167  
     sterols of 221  
     tissues 174 190-191



- lead 176 183 194  
*Pancreatic loss of zinc*, 232  
*Pantetheine* 99 148  
*Pantothenic acid* 148  
*Papain* 71  
*Papilledema* 8 242 270 271 273  
     *bilateral* 270  
*Papular eruptions* 120  
*Para aminohippurate* 6  
*Para amino salicylic acid* 164  
*Paraesthesias* 94 283  
*Paralytic diseases* 175 283  
*Paralytic episodes* 283  
*Paranoid depression* 249  
*Parasympatholysis* 33 51 52 251  
     257  
*Parasympathetic overactivity* 33  
     251  
*Paravertebral ganglia* 39  
*Paredrine* 163  
*Parenchymal disease* 286  
*Parenchymal tissues* 69  
*Parenteral ganglionic blocking*  
     *agents* 263  
*Parenteral hydralazine* 263  
*Parkinson's disease* 34 172 218  
*Parmelee A H* 312  
*Partial constriction of main artery*  
     16  
*Partin H C* 328  
*Partridge J W* 323  
*Paterson J G* 318  
*Pathogenesis of atherosclerosis* 205  
     208  
     *hemorrhagic and exudative reu-*  
         *nitis* 15 16  
     *necrotizing arteriolar lesions* 16  
         17  
*Pathogenetic factors in atheroscle-*  
     *rosis* 203 208  
*Pathologic alterations* 12 13  
*Patwardhan V N* 323  
*Paulson S F* 303  
*Peanut oil* 227 278 279  
*Peart W S* 74 308  
*Peas* 280  
*Pedicle tumors of* 243  
*Peek N F* 323  
*Pelvic tumors (fibromyomata)* 243  
*Pendiomide* 41  
*Penicillin* 157 162 164  
*Pentamethonium* 41 43  
*Pentapyrrolidinium bitartrate ex-*  
     *ample of effect of as compared*  
     *with that of hexamethonium*  
     *chloride in malignant hyperten-*  
     *sion* 258  
*Pentolinium (Ansolsen)* 41 43  
     233 255-256 261 263 267  
*Pentolinium bitartrate* 253 255  
     261 263  
*Pentyl thiopseudourea propionate*  
     102  
*Pepper* 171  
*Pepsin* 71 75 76  
*Pepsitensin (pressor peptide)* 75 76  
*Peptic ulcer* 19 20 22 33 34  
     *exacerbation of* 34  
     *psychotherapy of* 22  
*Peptide*  
     *amines* 67 74 75 77 147 287  
     *decarboxylases* 74 287  
     *splitting* 147  
*Perera G A* 246-247 323  
*Perforation in the pancreas* 249  
*Perfusion experiments* 68  
*Perinephritis* 242  
*Peripheral arterial bed* 67  
*Peripheral blood flow* 111  
*Peripheral circulatory profile* 66  
*Peripheral metabolic abnormalities*  
     31 32  
*Peripheral neuritis* 90 94 120  
*Peripheral pressure* 132  
*Peripheral resistance* 48 125  
*Peripheral vascular disease* 33 66  
     281 282  
*Peripheral vasoconstriction* 33 66

- in rats 45-46
- Principles of chelation 143 146
- Priscoline (tolazoline) 49
- Privine 95
- Procaine 97 161 164
  - amide 161
  - salt of  $\beta$  mercaptopropionic acid 97
- Processed meats 278
- Proctus 251
- Prolidase 148 152
- Proline, 74 76
- Prostate
  - carcinoma of, 218 219
  - trace metals in 170 171 176-183 194
    - aluminum 176-183
    - lead 194
    - titanium 176-183
- Prostatic hypertrophy 219 243 257
- Prostatic obstruction 60-61 257
- Prosthetic group 146
- Prostagmine, 52
- Proteins 7<sup>n</sup> 73 157 195 281
  - in urine 195
  - obtained from renal tissue or animal blood 72 73
- Proteinuria 159 176 195 244
  - excessive 159
- Proteolytic enzymes 69 148 287
- Protoveratrine 33 39 50-51 55 246 251 257 259 266
  - vomiting induced by 51
- Provitamin D 225
- Prunus 35
- Pyro W R., 50,*
- Pseudomonas pyocyaneus* 157
- Pseudopeptidase activity 74
- Pseudothiohydantoin 101
- Psychic manifestations of arterial hypertension 284 285
- Psychosomatic disorders 20
- Psychosomatic influences 251
- Psychosomatic summary 284 285
- Psychotherapy 6 22 23
  - of peptic ulcer 22
- Ptoxis 52
- Pulmonary circuit constrictor primary amines in 63
- Pulmonary circulation 67-68
- Pulmonary edema 265
- Pulmonary fibrosis, 195 219
- Pulmonary insufficiency 218 219
- Pulmonary lesions 112
- Pure Food and Drug administration 278
- Purkhold, A., 300
- Pustular lesions 231
- Pyclography intravenous 242
- Pyelonephritis (scar) 11 12 79 129 242 243 245 246 270 273
  - during pregnancy 11 12
- Pyloric obstruction 23
- Pyrexia 265 271
- Pyrophosphate 187
- Pyocyaneus 157
- Pyonephrosis 243
- Pyribenzamine 110
- Pyridazine 261
- Pyridine 85 155 16<sup>n</sup> 163 165
  - bases 85
  - compound 165
  - thiocyanate 163
- Pyridoxal Po., 149 217 228 229 234 291
  - acids 206
  - conversion of to its metabolite 4 pyridoxic acid 90
  - deficiency 210 293
  - enzymes 62 87 130 176 283
  - hydrochloride 91 237
  - isoniazid 89 90
    - complex in urine 90
  - metalloenzyme 293
  - phosphate 59 130 147
- Pyridoxine 131 176 206 237 278 280 293
  - deficiency 176

- aluminum in 191
- nickel in 190
- Plasma chlorides 262
- Plasma cholesterol 93 112 210  
215 226 231 233 277 280 282  
292 294
- change in with oral EDTA table  
on 281
- effect of intravenous EDTA on  
232
- effect of regimen on 282
- in man dietary factors altering  
226
- in monkeys on pyridoxine defi-  
cient diets 294
- levels effects of oral hydralazine  
and intravenous EDTA on  
231
- levels variations of in Western  
countries 215
- Plasma enzymes 75 77
- Plasma levels 221
- Plasma lipids 217 235 236
- Plasma phospholipids of 217
- Plasma proteins 4 101
- Plethora 15
- Pletscher A 301
- Pleuritis 112
- Phytic acid 163
- Pneumonia Iobar 218 219
- Poisoning in rats 195
- Polioomyelitis hypertension with 31
- Polyaminocarboxylic acid resin 84  
104
- Polyarteritis 161 231 243  
migratory 231  
nodosa 243
- Polycythemia 172 239  
in dogs 172  
in frogs 172  
in guinea pigs 172  
in mice 172  
in sheep 172
- Polycystic kidneys 242 245 271
- Polypeptidases 67 87 92 148
- Polyphenol oxidase 45 92
- Polyphosphate 158
- Polyuna 10 240
- Pollard A E 312
- Pool J L 301
- Popenoe E A 328
- Pork 278 295
- Porphyrin 147 172 187  
chelate 172  
structure 147
- Possible competitions between ab-  
normal and essential trace  
metals 150 155
- Posterior hypothalamus 36 285
- Posterior pituitary 57  
factor of pressor substances 72
- Potassium 118 127 134 141 151  
163  
ethyl xanthate 163  
gluconate 163  
thiocarbonate 163
- Poultry 279
- Pre atherosclerotic lesions 293
- Prefrontal lobotomy 33
- Pregnancy 10 70 121 133 244 263  
toxemia of 70 133 244 263
- Prehypertensive state 246-248
- Premenopausal women 235 236
- Presidon 161
- Pressor  
action in rats 69  
amines 58 69  
substance 58 60 61 69 72 74  
77 78  
destruction of 117  
locus of action of 77 78  
posterior pituitary factor of 72
- Pre systolic gallop 271
- Pyridoxal amino acid 130
- Primary amines 30 32 36 44-46 50  
59 65 67 73 75 90 92 109  
188 284 286 288 290 291  
in arterial blood 59

- 20 22  
 Reagents for analysis of metals 163  
 Red blood cells 4 15  
 Refined sugar 143  
 Refrigerator trays cadmium plated 198  
 Regimen effect on plasma cholesterol 282  
 Register U D 312  
 Regitine (phentolamine) 49 60 110 244  
 Reiser M 299  
 Reiss O K 323  
 Reitman H J 34  
 Removal of kidneys 59 61 ischemic, 59-60  
 Removal of tumor 128  
 Renal abnormalities, 69 73 79 metabolic by products of 73  
 Renal amino acid metabolism 190 291  
 Renal amino acid oxidase 63 60  
 Renal arteries 7 80 108 127 130 132 200 242 243 286 287 atheromata of 242 243 constriction of 108 130 132 286 diminution of the calibre of 243 emboli to 242 external compression of, 243 intermittent occlusion of 242 obstruction mechanical theory of 127 130 stenosis of 80 thrombosis of 242  
 Renal atherosclerosis 238  
 Renal biopsies 81 231 in dogs 81 punch 231  
 Renal blood flow 4 44 48 74 208  
 Renal circulation effects of nervous discharges upon 57-67  
 Renal damage 69  
 Renal deaminase 63  
 Renal decarboxylase 63  
 Renal deficiency 191  
 Renal disease 4 16 51 79 139 241 243 269 246 291 cardiovascular 294 organic 139 241 269 parenchymal 79 unilateral 276  
 Renal disturbances 285 291  
 Renal enzymes 61 88 89 208 mechanisms 208 systems (guinea pig) effect of metal binding and antihypertensive agents upon 88-89  
 Renal excretion of 13 metals before during and after intravenous EDTA 160  
 Renal function 246  
 Renal hypertension in dogs 47 66 69 70 73 106 108 133 venous blood of 69 70  
 Renal hypertension in rats 101 104 105 transient effect of dimercaptopropanol (BAL) on systolic pressure of 101  
 Renal ischemia 13 39 57 60 63 64-66 70 78 82 117 119 177 129 139 208 285 287 290 anatomical cause of 78 82 chronic 290 organic 288 289  
 Renal lesions 19 243 inflammatory 243  
 Renal oxygen consumption 39  
 Renal parenchyma 242  
 Renal plasma flow 6 93 111 289  
 Renal pressor mechanisms 73  
 Renal ptosis 242  
 Renal sodium wastage 291  
 Renal tissue protein obtained from 72 73  
 Renal tubular reabsorption amino acids 195  
 Renal tumors 247

- in monkeys 206
- in man chart on various effects of 131
- Pyridoxylidene metal amino complexes 105
- Pyrocatechol 163
- Pyruvate 85 92 113
  - in blood 113
- Pyruvic acid oxidase 148
- Q**
- Quastel J H 31 301
- Quaternary ammonium 41
- Quaternary nitrogenous compounds 32
- Quinacrine 164
- Quinaldinate 163
- Quinidine 164
- Quinine 164 166
- Quinoline acid 164
- Quinolol 163
- Quotane 165
- R**
- Raab W 299 300
- Rabbits
  - atherosclerosis in 210
  - bone affections in 174
  - experiments with 109 110 207 222 230
  - hypertension in 81
  - ischemic kidneys in 82
  - lack of manganese in 174
  - livers in 208
  - poisoning in 195
  - renin 74 76
  - vasoconstriction in 188
- Rabinowitch I M 212 216A 324
- Radial arteries 78
- Radioactivity 189
- Radio rubidium 151
- Radiotherapy 61
- Radium 150
- Rain water 198
- Ramey E R 314
- Rapid weight gain 137
- Rare earths 159
- Raska S B 304
- Ratio in extracellular fluids 118
- Ratio of ammonia to citric acid 59
- Rats
  - adrenalectomized urinary extracts in 138
  - anaesthetized 95
  - arterial hypertension in 84
  - atherosclerosis in 205 210
  - cholesterol in 207 230
  - dietary experiments on 121
  - effect of transitional metal ions on hepatic metabolism in 184
  - fatty acid in 189
  - hepatic synthesis in effect of trace metals on 292
  - hyperkeratosis in 175
  - hypertension in 81 95 104 105 120 133 210
  - renal 104 105
  - injections of crude amine oxidase in 66
  - keratinization of the esophagus in 173
  - lipid synthesis in 186
  - liver 153
  - metal deficiency in 174
  - normotensive 96
  - phenentasin in 110
  - plasma levels in 222
  - poisoning in 195
  - polycythemia in 172
  - pressor action in 69
  - primary amines in 45 46
- Rauwolfia drugs 8
- Ray A C 212 324
- Ray C T 315
- Ray T W 315
- Reaction to stress by vasospasm 18

- diets 259 263 269  
 hormones concerned with 156-157  
 intake 10-11  
 losing kidney 125  
 retaining hormone 136  
 restriction 137 140  
 Samaan A., 299  
 Saphir O 80 308  
 Sapirstein L. A 313  
 Saslow G 298  
 Scandium, 191  
 Scars (pyelonephritis) 129 132 273  
   during pregnancy 11 12  
 Schalet O 306  
 Scharzenbach 106  
 Schiff base 206  
 Schizophrenic like states 35  
 Scleroderma 201  
 Sclerosis 56 80 116 201 203 209-  
   210 242  
   coronary 209 210  
   in autopsies 203  
 Sclerotic arteries 56  
 Schlittler E., 218 328  
 Schlossmann H., 303  
 Schneider J A., 302  
 Schoenheimer R. 216 322  
 Schreiner A. W., 318  
 Schroeder H. A., 24 85 101 105  
   107 111 160 215 218 219 231  
   233 241 242 262 267 270 272  
   275 297 299 301 303-307 309-  
   314 317 319 320 324 327  
 Schubert, J 155 314  
 Schuler W 86-87 309 328  
 Schwyzer R 328  
 Schwarz H J 307  
 Schwartz P L., 218 219 317  
 Scrimshaw N S 25 299  
 Scrotal inflammation 231  
 Scurvy 226  
 Sea foods 199  
 Sea water 166 180 193  
   metals taken from, 67  
   percentage of trace metals in  
   chart on 168  
 Searle N Z., 315  
 Seborrhaic dermatitis 131 202 206  
 Secondary amine 41  
 Secondary effects of hypertension,  
   comment on 17  
 Sedative drugs 23 33 249  
 Sedormid 164  
 Seed oils 280  
 Seidlin S M., 315  
 Selenium 151 174  
   poisoning 174  
 Seligmann A M., 327  
 Selling L. S 301  
 Selling P H 301  
 Selye H., 313  
 Semicarbazide HCl 70 87 92 131  
   165  
 Semmons E., 317  
 Senile gangrene 204  
 Sequence of development of arterio-  
   lar nephrosclerosis 13  
 Sequestrene 106 157 164  
 Sequestering groups 164  
 Serine 76 190  
   excretion 190  
 Serotonin (derivative of trypto-  
   phane) 32 38 69 68 92, 110  
   130 285  
   antagonists 33 38  
   chart on metabolism of 37  
   its effects on system 36  
   producing tumor 32  
 Serpasil (reserpine) 33 35 50-51  
   89 246-252 264  
   chart on effect of 250  
 Serum  
   albumin 196  
   beef 76  
   cholesterol in 208 221  
   horse 74 76  
   lipids 214 218-219 236  
   lipids iodine number of before

- Renin (renal proteolytic enzyme)  
     58 66 69 71 73 77 110 286  
     287  
     hog 71 73 74 76  
 Rennick B R. 300  
 Renzi A A 313  
 Reserpine (serpasil) 33 35 50 51  
     89 246 252 264  
     chart on effect of 230  
     chart on incidence of side reactions and toxic effects in normotensive patients 31 35  
     chemical structure of 248  
     use of 248 251  
 Resistance of the glomerulus 128  
 Respiration 172 229  
 Respiratory tract 245  
 Response to injected cholinergic drugs 52  
 Response to injected norepinephrine 52  
 Restlessness 194  
 Retina arteries of 15 16  
 Retinitis 246 248 270 271  
     exudative 247 248  
     hemorrhagic 247 248 270 271  
 Retinoscopy 241  
 Reubi F C 304 305 327  
 Reynell P C. 327  
 Rhenium 151  
 Rheumatic heart disease 219  
 Rheumatic fever 156  
 Rheumatoid arthritis 19  
 Rhinitis 94 257  
 Rib cage roentgenograms of 244  
 Riboflavin 147 149 158  
 Rice 172 262  
 Rice diet 262  
 Richards A B 302  
 Richardson G O 80 308  
 Rickets 151  
 Richter D 303  
 Rietman H H 302  
 Rinehart J F 206 321  
 Ringer's solution oxygenated 109  
 Ravin A V 327  
 Robertson C W 299  
 Rodahl K 212 216A 321  
 Rodhard S 327  
 Rodriguez Minon J L 324  
 Roentgen 241  
 Roentgenograms 244 269-270  
 Roentgenograms of the rib cage 244  
 Roentgenologic examination 271  
 Roh C E 306  
 Roman Catholic church dietary customs of 228 229  
 Ronzoni E 313  
 Root beer 198  
 Rosenblueth A 304  
 Rosenman R H 320 324  
 Rowley D A 302  
 Rowntree L G 314  
 Rubber antimony in 199  
 Rubenic acid 163  
 Rubin M 321  
 Ruegamer W R 312  
 Rumen bacteria in 175  
 Russ E M 220 322  
 Russian Orthodox church dietary customs of 228 229  
 Ruthenium 180  

S

 Saifer A 328  
 Salad dressings 280  
 Salicylaldehyde-5 sulphonie acid 158  
 Salicylates 161  
 Salicylic acid 156 157 162  
 Salicylic acid derivatives of 157  
 Saline liquids 198  
 Saline solution intravenous hypertonic 262  
 Salivary secretion 52  
 Salmon W D 316  
 Salt 10 11 125 133 156-157 139  
     140 259 268 269  
     deficiency 159

- diets 259 263-269  
 hormones concerned with 136-137  
 intake 10-11  
 losing kidney 123  
 retaining hormone 136  
 restriction 137 140  
 Samaan A., 299  
 Saphir O., 80 303  
 Sapirstein L. A. 313  
 Saslow G. 293  
 Scandium 191  
 Scars (pyelonephritis) 129-137 273  
   during pregnancy 11 12  
 Schalet O. 306  
 Scharzenbach 106  
 Schiff base 206  
 Schizophrenic like states 35  
 Scleroderma 201  
 Sclerosis 56 80 116 201 203 209-  
   210 242  
   coronary 209 210  
   in autopsies 203  
 Sclerotic arteries 56  
 Schlattler E. 248 308  
 Schlossmann H. 303  
 Schneider J. A., 02  
 Schoenheimer R. 216 322  
 Schreiner A. W., 318  
 Schroeder H. A., 74 85 101 105  
   107 111 160 215 218 219 231  
   233 251 257 262 267 270-272  
   275 297 299 301 303-307 309-  
   314 317 319-370 324 327  
 Schubert J. 155 314  
 Schuler W., 86-87 309 323  
 Schwyzer R., 323  
 Schwarz, H. J. 307  
 Schwartz P. I., 218-219 317  
 Scrimshaw N. S., 25 299  
 Scrotal inflammation 231  
 Scurvy 226  
 Sea foods 199  
 Sea water 166 185 193  
   metals taken from 67  
   percentage of trace metals in  
   chart on 163  
 Searle N. Z., 315  
 Seborrheic dermatitis 131 202 206  
 Secondary amine 41  
 Secondary effects of hypertension,  
   comment on 17  
 Sedative drugs 23 33 249  
 Sedormid 164  
 Seed oils 280  
 Seidlin S. M., 315  
 Selenium 151 174  
   poisoning 174  
 Seligmann A. M. 377  
 Selling, L. S. 301  
 Selling P. H., 301  
 Selye H., 313  
 Semicarbazide HCl 70 87 92, 131  
   165  
 Semmons, E., 317  
 Senile gangrene 204  
 Sequence of development of arterio-  
   lar nephrosclerosis 13  
 Sequestrene 106 157 164  
 Sequestering groups 164  
 Serine 76 195  
   excretion 193  
 Serotonin (derivative of trypto-  
   phane) 32 38 62 68 92 110  
   130 285  
   antagonists 33 38  
   chart on metabolism of 37  
   its effects on system 36  
   producing tumor 32  
 Serpasil (reserpine) 33 35 50 51  
   89 246 252 264  
   chart on effect of 250  
 Serum  
   albumin 196  
   beef 76  
   cholesterol in 208 221  
   horse 74 76  
   lipids 214 218-219 236  
   lipids iodine number of before



- and after oral B. 218  
 lipids iodine numbers of in  
   white patients 219  
 proteins 87  
   serum sickness pattern 164  
 sodium of hypertensive patients  
   125  
 thymol turbidity of 112  
 Sesame oil 279  
 Severe benign hypertension 258  
 Severe headaches 7  
 Sex 52 133 136-137 235 236  
   adrenal hormones concerned with  
     136 137  
   effect of in atherosclerosis 235  
     236  
   immunity to coronary disease 236  
   potency (male) 52  
 Shackman N H 311  
 Sharp and Dohme 270  
 Shaw C W 312  
 Sheep  
   keratinization in 175  
   polycythemia in 172  
 Shell fish 173 193 279  
 Shermer A 303  
 Shipley R E 307  
 Shobe F O 298  
 Shock 34 65 70  
 Shore P A 301  
 Shorr E. 303 304 314 320 322  
 Shoulder 278  
 Shrinkage of tumor 61  
 Shumway N P 307  
 Side effects of ganglionic blockade  
   table on 52  
 Side effects of two metal binding  
   antihypertensive drugs chart  
   on 94  
 Siegal E 315  
 Silva T F 304  
 Silver 83 143 144 151 153 159  
   167 179 181 192 193 199 200  
   in brain 193  
   in kidney 193  
   in liver 199  
   in skin 153 200  
   in urine 193  
 Silver S L 301  
 Silverstone F 299  
 Simple chelating compounds 154  
   155  
 Sinclair H M 302 309  
 Singh I 311 317  
 Singh S I 311 317  
 Sjoerdsma A 301  
 Skeggs L T Jr 307  
 Skeleton trace metals in 170 171  
 SKF 1298A (epinephrine like sub  
   stance) 47  
 SKF 690A (epinephrine like sub  
   stance) 47  
 Skim milk 280  
 Skin 94 120 121 133 153 170 171  
   188 200 206  
   diseases 188  
   lesions 94 120 121  
   thin 138  
   trace metals in 153 170 171 200  
     arsenic 153  
     bismuth 153  
     gold 153  
     iron 153  
     mercury effects on 153  
     silver 153 200  
 Slinger W 318  
 Slipped tendon 174  
 Smirk F H 300  
 Smith E L 307 318 319  
 Smith Emil 146  
 Smith H W 309  
 Smith M K 324  
 Smithwick R H 275 299 304 309  
   327  
 Snapper I 203 209 297 320  
 Snell A M 314  
 Snell E E 147 230 313 315  
 Soda water 198

- Sodium 59 83 89 94 95 99 105  
   108 118 125 127 134 135 141  
   186-188 244 246-247 259 261  
   262 286 288-289 291  
 amylal 244 246-247  
   release test, 244  
 azide ( $\text{NaN}_3$ ) 83 89 95 259 261  
 content of arterial walls, 125  
 cyanide 89  
 dietary 259  
 intake in hypertensive rats 127  
 intake in man 127  
 loss by kidneys 291  
 metavanadate 186 188  
 nitroprusside 83 89 94  
 pertitanate 187  
 potassium 291  
 thiocyanate 89 106 108  
 S-sulf deficiency in 173 175  
   cobalt, 174 175  
   nitrogen 174  
 Solder's antimony in 199  
 Soley M H 315  
 Sollmann T 91 310  
 Solomon C., 80 308  
 Soluble complexes of thiocyanates  
   in water 95  
 Soluble salts 91  
 Somogyi zinc method 257 269  
 Somogyi zinc precipitate 269  
 Soups  
   canned 193 280  
   meat 193 280  
 Sources and turnover of essential  
   metals 171 174  
 Soybeans 171 186 227 279 280  
   lecithin 186  
   meal made of 171  
   oil from 279 280  
 Spackman D H 318-319  
 Spasm 242  
 Spatula, 63  
 Specific metal deficiencies 244 246  
 Specific nephrogenic effector sub-  
   stances 68 71  
 Specific use of drugs 33 38-39 41  
   54 248 267  
   used in therapy of hypertensive  
     patients 33 41 54  
   used in therapy of as effecting  
     ganglia 41 54  
   used in therapy of effecting caro-  
     tid sinus 38-39  
 Speer F D., 310  
 Spence E. R., 312  
 Spinal fracture 218  
 Spitznagel J 309  
 Splanchnic bed 65  
 Splanchnic blood flow 41  
 Spleen 4 140 171 146 183 191 192  
   194 196  
   trace metals in 170 171 146-183  
     191 192 194 196  
 aluminum 191  
 boron 146-183  
 cadmium 196  
 lanthanum 180  
 lead 146 183 191  
 van 181 192  
 Splenomegaly 112  
 Squalene ( $\text{C}_{30}\text{H}_{50}$ ) 224 225 292  
 Stamler J 215 303 327  
 St. Andre A F., 308  
 Stanley M 314  
 Staphylococcus aureus 157  
 Stare F J 321  
 Starling E. H 300  
 Starvation 226  
 Stearate 210 216-217  
 Stearic acid 222  
 Steele J M 299 304 325  
 Steiner A 323  
 Steiner R. L. 314  
 Steiner R. S 316  
 Stewart, C F., 80 212 308  
 Stewed apples 193  
 Steyermark, P., 314  
 Stenosis of renal arteries 80

- Steroids 139 221  
 Steroid hormones 221  
 Stillbirths 124 180 190  
 Stock C C 303 306  
 Stocken L A 310 316  
 Stomach  
   trace metals in 170-171 176 183  
     196  
   aluminum 176-183  
   cadmium 196  
   lead 176 183  
 Stomatitis 231  
 Streptococcus hemolyticus 157  
 Streptomycin 161 162  
 Stress reaction to 18 19  
 Strong F M 312  
 Strong J P., 321  
 Strontium 15 151 167 180 183 199  
   in bone 180  
   in heart muscle 199  
   in tissues 180  
 Stroud W D 18 298  
 Structural formulae of norepineph-  
   rine 46 47  
 Subcutaneous injection 263  
 Subintimal lesions 293  
 Substances with metal binding prop-  
   erties selectively affecting ar-  
   terial hypertension chart on  
   84  
 Substitution of one element for  
   another 150 151  
 Substrates 75  
 Succinate 165  
 Succinic acid 198  
   dehydrogenase 59 92 152 197  
     229  
   oxidase 229  
 Succinyl choline 44  
 Suet 173  
 Sugar 133 136 157 173 193  
   hormones concerned with 136-  
     157  
   refined 173 198  
 Suicidal tendencies from reserpine  
   35 51 249  
 Sulfur 84 85 87 103 113 125 143  
   145 150 151 154 161 162 165  
   185 187 194 196-197 200 261  
   291  
   compounds  
     sulfanilamide 150  
     sulfanilic acid 165  
     sulfide 150  
     sulfobromophthalein 165  
   sulfonamides 131 161 162  
   sulfonate 143  
   sulfonic acid 186-187  
   sulfhydryl 113 143  
     binding 84 154 197 291  
     enzymes 185 194  
   groups 85 103 125 150-151  
     153 161 165  
   linkages 87  
   in hair 151  
   in nails 151  
 Sulzberger M B 310  
 Summary and interpretations of hy-  
   pertension 284 296  
 Summary of properties of hydrala-  
   zine other than cardiovascular  
   92 93  
 Summary on atherosclerosis 292 296  
 Summary on ganglionic blocking  
   agents 53 54  
 Surgical sympathectomy 55 257  
   274 276  
 Surtshin S 325  
 Sustained hypertension humoral  
   component of 78  
 Sustained normotension 55  
 Sustained pressor principle 72 73  
   Swayback in sheep 175  
 Sweating 52 66  
 Sweet W H 300  
 Sweetbreads 278  
 Swiller A I 311  
 Sympathetic nerve endings 44-45

Sympathetic nervous mechanisms through ganglia 39 54  
 Sympatholytic drugs response to 55  
 Sympathomimetic amines 50  
 Sympathotonic people diseases subject to 19  
 Synaptic transmission 32  
 Syncope 31 270  
 Synthesis of cholesterol from acetate 184  
 Synthesis of fatty acids from acetate 184  
 Syphilis 188 243  
 Systolic hypertension 203 240  
 Systolic pressure 253 255 262 263  
 Szent-Györgyi A. 117 311

## T

Table on actions of adrenergic blocking agents in man 43  
 Table on side effects of ganglionic blockade 52  
 Tachycardia 7 34 35 48 93 127 239 265  
 Tachypnea sign of ganglionic blockade disease 53 265  
 Tallow 278  
 Tanning 209  
 Tapazole 99 161 162  
 Tappan D. V. 312  
 Taqumi A. C., 308  
 Tartaric acid 198  
 Tartrate 158  
 Taylor B. 308  
 Taylor H. L., 325  
 Taylor R. D. 300 310 313  
 Tea 171 173  
 "Teart, 174  
 Technetium, 151  
 Teitelbaum S. 317  
 Tellurium 151  
 Terminal carboxyl 75 77  
   decarboxylation of 75

Terpenes 224  
 Terramycin 157  
 Tertiary amines 46  
 Tertiary compounds 32  
 Testis trace metals in 10-171  
 Testicular tumors 244  
 Testosterone 236  
 Tetravalent nitrogen 40-41 44  
 Tetraethenoid acids, 228  
 Tetra-ethyl ammonium chloride (Etamon) 6 9 43 242  
 Tetra ethyl ammonium ion 8 41 56  
 Tetra-ethyl lead in gasoline 191  
 Tetrasodium pyrophosphate 84 89  
 Tetrathiodiacetic acid 101  
 Tetrahedral chelates 144 146  
 Thallium 167 180  
 Theory of depletion of vascular substances 117 118  
 Theory of electrolyte imbalance 125 127  
 Theory of habitual repetitive stimuli 117  
 Theory of local vitamin B deficiency 120-121  
 Theory of mechanical renal arterial obstruction 127 130  
 Therapeutic pressure as secret of successful therapy 264  
 Therapy of hypertension office practice in 240-243  
   practical methods for 238 276  
   general rules for 238 276  
   results expected 268 274  
   successful continuous therapeutic pressure as secret of 261  
 Thiazazole 167 165  
 Thiamine 147  
 Thickening of glomerular capsule 81  
 Thickening of the walls of the arterioles 128  
 Thin skin 133

- Thiocarbonylhydrazide 89  
 Thiocyanate 83 84 91 93 150 163  
     164 259  
     in water soluble complexes of 93  
     ion 83 91  
 Thioether 143  
 Thioglycolic acid 97 184 186 187  
     oxidation of 184 187  
     hepatic 187  
 Thio hydroxy propane 99  
 Thiol 162 165  
 Thiosemicarbazide 87 92 101 108  
     157 161 162  
 Thiouracil 131 161 162  
 Thiourea 162 163  
 Thomas C B 20 298  
 Thomas W A 265 297  
 Thromboangitis obliterans 243  
 Thrombocytopenia induced by qui-  
     nine 166  
 Thrombocytopenic purpura 164  
 Thrombosis cerebral 274  
 Thrombosis of the renal artery 242  
 Thompson C 311  
 Thompson J E 301  
 Thompson R H S 310 316  
 Thompson W R 322  
 Threefoot S 315  
 Three hydroxy 3 methyl gluteric  
     acid 224  
 Threonine 76 195  
 Thymol turbidity of serum 112  
 Thyroid 4 151 170 171 176 183  
     197  
     trace metals in 170 171  
         aluminum 176 183  
         barium 180  
         cadmium 176 183 196  
 Tibio metatarsal joint malforma-  
     tion of '74  
 Tin 83 113 125 143 144 146 167  
     179 181 183 186 192 199  
     as contributing cause of athero-  
     sclerosis 192  
     in aorta 181 199  
     in muscle 181  
     in spleen 181 192  
     in tissues 183 192  
     in urine 192  
 Tin foil antimony in 199  
 Tipton I H 68 124 169 179 180  
     182 185 187 191 199 314 316  
 Tissues  
     injury of local 48  
     trace metals in 180 183 192 193  
         cadmium 183  
         lead 193  
         nickel 183  
         strontium 180  
         tin 183 192  
         titanium 183  
 Titanium 68 125 142 143 159 167  
     176 187 202  
     in intestines 181  
     in kidneys 181  
     in lungs 176 183  
     in muscle 181  
     in prostate 176-183  
     in tissues 183  
 Tobian L Jr 312  
 Tolazoline (Priscoline) 48 49  
 Tolerance to the action of drugs  
     264  
 Toluene dithiol 163  
 Tolybiguanide 104  
 Toman J E P 301  
 Tomarelli R M 312  
 Tomatoes 173 193  
 Tongue 231 278  
     inflamed 231  
 Toor M 212 214 216A 322  
 Toxemia of pregnancy 39 70 133  
     244 263  
 Toxic effects 111 112 165 172 191  
 Toxicity of aluminum 191  
 Toxicity of manganese 172  
 Toxic skin reactions 165  
 Trace metals

- abnormal 209  
 and cardiovascular disease 141  
 209  
 and pyridoxal 229-235  
 clinical implications of 200-202  
 essential concentrations of in  
 man 167 169-171  
 chart on 140  
 found in sea water ‰ chart on  
 162  
 in man probable roles of chart  
 on 167  
 in adipose tissue 140 171  
 in adrenal 123 140 171 146 183  
 191 196  
 in aorta 140-171 176-183  
 in bladder 170 171 176-183 191  
 in blood vessels 125  
 in brain 123 170 171 146-183  
 191 193 194 196  
 in heart, 140 171  
 in intestines 140 171 181 191  
 196  
 in kidney 83 121 123 125 154  
 170-171 176-183 191 193 194  
 196 197 199 200  
 in liver 69 143 170-174 176 183  
 186 188-189 191 193 194 196  
 199 203 224 230  
 in lungs 53 67-68 170 171 176  
 183 187 189 191 194  
 in muscle 170 171 181 191 196  
 in pancreas 170 171 176 183 191  
 196  
 in prostate 170 171 176-183 191  
 in skeleton 170 171  
 in skin 153 170-171 200  
 in spleen 170-171 176-183 191  
 197 194 196  
 in stomach 170-171 176-183 196  
 in testis 170 171  
 in thyroid 170-171  
 in tissues 140 171 180 185 220-  
 281 285  
 from uncivilized peoples 182  
 183  
 infants 180 183  
 in urine 101 113 122 123 168  
 172 189-190 192 193 195 200  
 imbalance 121 123 237  
 Tranquilizers 33 285  
 Tranquilizing action of reserpine  
 33  
 Transaminase 149 283  
 Transient effect of dimercaptopro-  
 panol (BAL) on systolic pres-  
 sure of renal hypertensive rat  
 101  
 Transition from intermittent to  
 permanent vasospasm 116-140  
 metals as cause of 144  
 Transphorylase 149  
 Trauma 246  
 Traumatic lesions 242  
 Treatment of atherosclerosis pre-  
 liminary approach to 277 "83  
 Treatment of crises 263 "76  
 Tremulousness 34  
 Tremors in dogs 53  
 Tri-decyl mercaptan 99  
 Triglycerides 222  
 Trimethaphan camphor sulfonate  
 structural formulae of 42  
 Tripod J 87 309 328  
 Trisodium EDTA 281  
 Trithione (SKF 1717) 102 107  
 Trivalent iron 105  
 Trujillo T T. 316  
 Trypsin 71  
 Tryptamine 62 83 126 130  
 Tryptophane 36 37 62  
 Tsaltas T T 323  
 Tuberculosis 90 188  
 Tucker H F 316  
 Tulpule P G \*23  
 Tumors 19 31 32 61 148 202  
 247 244  
 adrenal cortical 243

brain 241  
 hypophyseal 243  
 malignant 19 202  
 medullary 243  
 ovarian 244  
 pedicle 243  
 pelvic 243  
 removal of 128  
 renal 242  
 serotonin producing 32  
 shrinkage of 61  
 testicular 244  
 Tungsten 154 193  
 Turner K. B. 323  
 Tyramine 45 62 92 130 285 289  
   oxidase 64  
 Tyrosinase (copper) 71 74 110  
   148 152 153 289  
 Tyrosine 62 74 76 190  
 Type of fat ingested 222 228

## U

Uganda hypertension in 25  
 Uhl H. S. M. 324  
 Ulcers 19 20 22 33 34 204 249 251  
   duodenal 19  
   peptic, 19 20 22 33 34  
 Ulceration 204 251  
   of the intima found in autopsies  
   204  
 Uncivilized peoples trace metals in  
   tissues from 182 185  
 Undenfriend S. 301 302  
 Ungerleider 215 299  
 Unilateral renal disease 80 82 276  
 Unilateral renal hypertension 81 82  
 Unilateral renal ischemic dogs 82  
 Unilateral narrowing 80  
 Unmyelinated fibres 134 135  
 Uracils 163  
 Uranium 210  
 Urecholine 52  
 Uremia 8 16 248 258 262 269  
   272

malignant hypertension with  
   chart on 270 272  
 Uremic pneumonitis 53  
 Ureteropelvic junction kink in 11  
 Urethral catheter use of 61  
 Uricase 149  
 Urinalysis 241  
 Urinary abnormalities in experi-  
   mental animals 58  
 Urinary ammonia 63 286 288 289  
 Urinary bladder tone 52  
 Urinary extracts in adrenalecto-  
   mized rats 139  
 Urinary losses 259  
 Urinary sediment 79  
 Urinary tract disorders of 243  
 Urine  
   acid in 59 174 286 288  
   NH<sub>4</sub> acid ratio 286  
   albumin in 6-7  
   bacteria in 242  
   blood in 60  
   catechol amines in 27 244  
   excretion of in normotensive and  
   hypertensive states 101 122  
   • 172 186 188  
   cobalt 172  
   hexamethonium ion 101  
   manganese 172  
   vanadium 188  
   loss of Ti in 93  
   protein in 160 195  
   pyridoxal isoniazid complex in  
   90  
   trace metals in 101 113 122 123  
   168 172 186 189 190 192 193  
   195 200  
   cadmium 195 200  
   chromium 189  
   manganese 200  
   nickel 190  
   silver 193  
   tin 192 193  
   vasoactive substances found in 73

- volume 160 241  
   concentration test, 241  
 Urticaria 19 165  
 Uterine prolapse 245  
   V  
 Vagal stimulation, 39  
 Valine 74 76  
 Vallee B L, 315 319  
 Vanadium 67-68 83 142 144 150  
   159 167 180 183 185 188 191  
   197 208 285 292  
   acetate 186  
   deficiency 183 285  
   evidence for its being essential  
     trace metal, 187 188  
   in the lungs 68 180  
   in therapy of degenerative cardi-  
     ovascular diseases 191  
   pharmacological effects of 188  
   urinary output of, 188  
 Vanadyl ion 153  
 Van Slyke D D 322  
 Various effects of pyridoxine in  
   man chart on 131  
 Vasa vasorum 205  
 Vascular constriction 72  
 Vascular disease cerebral 284  
   peripheral 281 282  
 Vascular hyperreactivity 138  
 Vascular lesions 32 33 56 119 133  
   243  
   in the hypothalamus 32 33  
   inflammatory 243  
 Vascular substances theory of de-  
   pletion of 117 118  
 Vascular tumor of brain 219  
 Vascular volume physiological al-  
   terations in 78  
 Vascularization of the cornea 175  
 Vasoactive amines 60 291  
 Vasoactive peptides 60 76 110  
   adrenergic blockade of 110  
   amino acids in chart on 76  
 Vasoactive polypeptide 69  
 Vasoactive substances found in  
   blood, 73  
 Vasoactive substances found in  
   urine 73  
 Vasoconstriction 49 50 57 189  
   in rabbits 188  
 Vasodilatation 3 41  
 Vasodilating drug 41  
 Vasoexcitator material (VEM) 58-59  
   73 78  
 Vasomotor tone effect of brain on  
   30  
 Vasomotor tone excessive 135  
 Vasopressin 72 76  
   from hogs 16  
 Vasospasm 3 18 20 22 55 77 215  
   lability of 215  
   reaction to stress by 18 20 22  
 Vasospastic states acute 77  
 Veal 279  
 Vegetables 172 185 190 198 222  
   223 226-227 233 277  
   cadmium in 198  
   chromium in 185  
   fats 222 223 226-227 233 277  
   oils 190 222  
 VEM (vaso-excitator material) 58 59  
   73 78  
 Venous pressure 52 69  
 Ventricular strain heart failure  
   due to 268  
 Versene (see EDTA) 157  
 Vertigo 270  
 Vier M 315  
 Vilter R. W. 309 311 318  
 Vinegar 193  
 Vinogradov A P 168 316  
 Viscus hollow 257  
 Vision blurred 7 35  
 Vitamins, A 221  
   B 90 95 119 121 131 194 197  
   202 206-207 209 211 216  
   226 227 229 230 234 235 237



- 280 283 288 293  
 deficiency of 90 120 121 202  
     206 207 209 211 216 226  
     229 235 237 288  
 theory of 120 121  
 selected annotated bibliogra-  
     phy 324  
*B<sub>12</sub>* 147 172 175  
*Vivanco F* 324  
*Vivid dreams* 34 35  
*Volhard F* 302  
*Volume of blood in muscular ar-*  
*teries* 78  
*Vomiting* 34 39 48 51 251 252  
     270  
*Von Euler U S* 300  
  
     W  
*Wackstein M* 312  
*Wachsch, H* 319  
*Wagener H P* 241 247 325  
*Wakerlin G E* 306 307 320  
*Waldron J M* 321  
*Walker A R P* 212 216A 324  
*Walker J* 316  
*Walker J J* 300  
*Walnuts* 227 280  
*Walter C W* 300  
*Walter H* 303  
*Wardell* 212 216A  
*Washing machines* 198  
*Water metals in*  
     aerated 197 198  
     carbonated 197 198  
     chlorinated 197 198  
*Waters L L* 298 320  
*Waxy exudates* 275  
*Weakness* 174 262 264  
*Weaver L C* 302  
*Weight gain rapid* 137  
     loss 190  
*Weiland H* 319  
*Weiskrantz L* 301  
*Weissbach H* 301 302  
  
*Weller J M* 305  
 "Wet brain" (encephalopathy) 263  
*Wheat germ* 173  
*Whiskey* 199  
*White blood cells* 7  
*White flour* 172  
*White P D.* 18 275 298 327  
*Whitlaw G P* 327  
*Whole milk* 278 280  
*Whole wheat flour* 171  
*Wilens S L* 320 327  
*Wilkinson C F Jr* 324  
*Wilkinson E L* 327  
*Williams A H* 297 298  
*Williams A W* 299  
*Williams D I* 310  
*Williams R P J* 146 158 315  
*Willis circle of* 205 219  
*Wilson C* 309  
*Wilson R H* 318  
*Wilson W A Jr* 301  
*Windaus A* 322  
*Wine* 198  
*Winternitz M C* 298  
*Wire netting* 198  
*Wissler R W* 320  
*Witten P W* 322  
*Wohl M G* 316  
*Wolfe K M* 305 307  
*Women menstrual irregularities in*  
     137  
*Women premenopausal* 235 236  
  
     X  
*Xanthine* 64 149 152 154 174 282  
     oxidase 64 152 154 174  
*Xanthomatosis* 282  
  
     Y  
*Yalow A A* 315  
*Yohimbine* 33 35 248  
     chemical structure of 248  
     its effects on system 35  
*Yeakey E. H* 300

- Yeast 1,3  
 Yule C. L. 81 309
- Z
- Zack B 3 4  
 Zawolski E J 303  
 Zeller W W 34 309  
 Zinc 79 84 94 95 101 105 107  
     113 170 123 125 131 142 144  
     147 150 151 153 154 157 159  
     161 167 169 171 173 175 1,6  
     181 193 195 201 259 288  
 chelates 104  
 coating, 196  
 deficiency 95 170 131 175-176  
 foil 198  
 in foods 198  
 metalloprotein 150  
 poisoning 199  
 reagent 84 94
- Zirconium 160  
 Zinner N., 315  
 Zlathis A., 324  
 Zona glomerulosa 133 292  
 Zondek S G., 298  
 Zucker M B 303  
 Zweifach B W., 303 304 310 314  
     320 322



*This Book*  
**MECHANISMS OF HYPERTENSION**

*By*  
**HENRY ALFRED SCHROEDER M D F.A.C.P**

*was set, printed and bound by The George Banta Company, Inc of Menasha, Wisconsin The engravings were made by The Northwestern Engraving Company of Menasha, Wisconsin The page trim size is  $5\frac{1}{2} \times 8\frac{1}{2}$  inches The type page is  $23 \times 39$  picas The type face is Linotype Baskerville, set 11 point on 13 point The text paper is 70 lb White Winnebago Eggshell The cover is Roxite LS Vellum, 5x75, 11 M, Two tone Black*



*With THOMAS BOOKS careful attention is given to all details of manufacturing and design It is the Publisher's desire to present books that are satisfactory as to their physical qualities and artistic possibilities and appropriate for their particular use THOMAS BOOKS will be true to those laws of quality that assure a good name and good will*



